<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article id="CD007031" article-type="systematic-review" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="iso-abbrev">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3102</journal-id><journal-id journal-id-type="pmc-domain">cochrev</journal-id><journal-id journal-id-type="publisher-id">14651858</journal-id><journal-title-group><journal-title>The Cochrane Database of Systematic Reviews</journal-title></journal-title-group><issn pub-type="epub">1469-493X</issn><issn-l>1361-6137</issn-l><publisher><publisher-name>John Wiley and Sons, Inc. and the Cochrane Library</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8932084</article-id><article-id pub-id-type="pmcid-ver">PMC8932084.1</article-id><article-id pub-id-type="pmcaid">8932084</article-id><article-id pub-id-type="pmcaiid">8932084</article-id><article-id pub-id-type="pmid">18425977</article-id><article-id pub-id-type="doi">10.1002/14651858.CD007031</article-id><article-id pub-id-type="publisher-id">CD007031</article-id><article-id pub-id-type="other">CD007031</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Asthma, chronic ‐ pharmacotherapy</subject><subject>Child health</subject><subject>Lungs &amp; airways</subject></subj-group></article-categories><title-group><article-title>Ciclesonide versus other inhaled steroids for chronic asthma in children and adults</article-title></title-group><contrib-group><contrib id="d24e171" contrib-type="author" corresp="yes"><name name-style="western"><surname>Manning</surname><given-names initials="P">Pat</given-names></name><address><email>pjmanning@eircom.net</email></address><xref ref-type="aff" rid="CD007031-aff-0001"/></contrib><contrib id="d24e175" contrib-type="author"><name name-style="western"><surname>Gibson</surname><given-names initials="PG">Peter G</given-names></name><xref ref-type="aff" rid="CD007031-aff-0002"/></contrib><contrib id="d24e179" contrib-type="author"><name name-style="western"><surname>Lasserson</surname><given-names initials="TJ">Toby J</given-names></name><xref ref-type="aff" rid="CD007031-aff-0003"/></contrib><contrib id="d24e189" contrib-type="editor"><collab collab-type="editors">Cochrane Airways Group</collab></contrib></contrib-group><aff id="CD007031-aff-0001"><institution>Bon Secours Hospital</institution><institution content-type="dept">Consultants Clinic</institution><addr-line>Glasnevin</addr-line><city>Dublin</city><country>Ireland</country><postal-code>9</postal-code></aff><aff id="CD007031-aff-0002"><institution>John Hunter Hospital</institution><institution content-type="dept">Department of Respiratory and Sleep Medicine</institution><addr-line>Locked Bag 1</addr-line><city>Hunter Mail Centre</city><state>NSW</state><country>Australia</country><postal-code>2310</postal-code></aff><aff id="CD007031-aff-0003"><institution>St George's, University of London</institution><institution content-type="dept">Community Health Sciences</institution><addr-line>Cranmer Terrace</addr-line><addr-line>Tooting</addr-line><city>London</city><country>UK</country><postal-code>SW17 ORE</postal-code></aff><author-notes><corresp>Pat Manning, Consultants Clinic, Bon Secours Hospital, Glasnevin, Dublin, 9, Ireland. <email>pjmanning@eircom.net</email>.</corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>4</month><year>2008</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2008</year></pub-date><pub-date pub-type="update"><day>29</day><month>3</month><year>2009</year></pub-date><volume>2008</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">332739</issue-id><elocation-id>CD007031</elocation-id><pub-history><event event-type="pmc-release"><date><day>23</day><month>04</month><year>2009</year></date></event><event event-type="pmc-live"><date><day>19</day><month>03</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-10-08 18:25:20.027"><day>08</day><month>10</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2010 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CD007031.pdf"/><abstract><title>Abstract</title><sec id="CD007031-sec-0001"><title>Background</title><p>Inhaled corticosteroids (ICS) are an integral part of asthma management, and act as an anti‐inflammatory agent in the airways of the lung. These agents confer both significant benefit in terms of symptom management and improvement in lung function, but may also cause harm in terms of local and systemic side‐effects. Ciclesonide is a novel steroid that is metabolised to its active component in the lung, making it a potentially useful for reducing local side effects.</p></sec><sec id="CD007031-sec-0002"><title>Objectives</title><p>To assess the efficacy and adverse effects of ciclesonide relative to those of other inhaled corticosteroids in the management of chronic asthma.</p></sec><sec id="CD007031-sec-0003"><title>Search methods</title><p>We searched the Cochrane Airways Group register of trials with pre‐defined terms. Additional searches of PubMed and Clinicalstudyresults.org were undertaken. The literature searches for this review are current up to June 2007.</p></sec><sec id="CD007031-sec-0004"><title>Selection criteria</title><p>Randomised parallel or crossover studies were eligible for the review. We included studies comparing ciclesonide with other steroids both at nominally equivalent dose or lower doses of ciclesonide.</p></sec><sec id="CD007031-sec-0005"><title>Data collection and analysis</title><p>Two review authors independently assessed trial quality and extracted data. Study authors were contacted for additional information. Adverse effects information was collected from the trials.</p></sec><sec id="CD007031-sec-0006"><title>Main results</title><p>Twenty one trials involving 7243 participants were included. Equal daily doses of ciclesonide and beclomethasone (BDP) or budesonide (BUD) gave similar results for peak expiratory flow rates (PEF), although forced vital capacity (FVC) was higher with ciclesonide. Data on forced expired volume in one second (FEV1) were inconsistent. Withdrawal data and symptoms were similar between treatments. Compared with the same dose of fluticasone (FP), data on lung function parameters (FEV1, FVC and PEF) did not differ significantly. Paediatric quality of life score favoured ciclesonide. Candidiasis was less frequent with ciclesonide, although other side‐effect outcomes did not give significant differences in favour of either treatment. When lower doses of ciclesonide were compared to BDP or BUD, the difference in FEV1 did not reach significance but we cannot exclude a significant effect in favour of BDP/BUD. Other lung function outcomes did not give significant differences between treatments. Paediatric quality of life scores did not differ between treatments. Adverse events occurred with similar frequency between ciclesonide and BDP/BUD. Comparison with FP at half the nominal dose was undertaken in three studies, which indicated that FEV1 was not significantly different, but was not equivalent between the treatments (per protocol: ‐0.05 L 95% confidence intervals ‐0.11 to 0.01).</p></sec><sec id="CD007031-sec-0007"><title>Authors' conclusions</title><p>The results of this review give some support to ciclesonide as an equivalent therapy to other ICS at similar nominal doses. The studies assessed low doses of steroids, in patients whose asthma required treatment with low doses of steroids. At half the dose of FP and BDP/BUD, the effects of ciclesonide were more inconsistent The effect on candidiasis may be of importance to people who find this to be problematic. The role of ciclesonide in the management of asthma requires further study, especially in paediatric patients. Further assessment against FP at a dose ratio of 1:2 is a priority.</p></sec></abstract><abstract abstract-type="plain-language-summary"><title>Plain language summary</title><p><bold>Ciclesonide versus other inhaled steroids for chronic asthma in children and adults</bold></p><p>Inhaled corticosteroids, such as budesonide, beclomethasone or fluticasone, which have been available for many years, have proven to be an important therapy for controlling the inflammation caused by asthma. They are given usually twice daily, and are recommended therapy in international guidelines for most asthmatics. However, the currently available inhaled corticosteroids can be associated with significant side‐effects, including local effects in the upper airways such as hoarseness and oral candida (thrush infection). Ciclesonide is a new steroid which is reported to make less of the active steroid available until the drug reaches the lung on inhalation, which could reduce the likelihood of throat symptoms. This findings of this review of 21 trials (7243 participants) do not allow certainty about the relative efficacy of ciclesonide compared to older inhaled corticosteroids, especially at higher doses. The results of the review to date do not indicate whether ciclesonide provides a significantly more useful safety profile that other inhaled corticosteroids at similar equivalent doses. However, the finding of lower oral candidiasis in patients treated with ciclesonide compared to fluticasone may be important for those patients who experience oral thrush with their current ICS. In addition, further studies in children are required to obtain data on the side‐effect profile of ciclesonide in this population.</p></abstract><kwd-group kwd-group-type="mesh"><kwd>Adult</kwd><kwd>Child</kwd><kwd>Humans</kwd><kwd>Administration, Inhalation</kwd><kwd>Androstadienes</kwd><kwd>Androstadienes/therapeutic use</kwd><kwd>Anti-Asthmatic Agents</kwd><kwd>Anti-Asthmatic Agents/therapeutic use</kwd><kwd>Asthma</kwd><kwd>Asthma/drug therapy</kwd><kwd>Beclomethasone</kwd><kwd>Beclomethasone/therapeutic use</kwd><kwd>Budesonide</kwd><kwd>Budesonide/therapeutic use</kwd><kwd>Chronic Disease</kwd><kwd>Fluticasone</kwd><kwd>Pregnenediones</kwd><kwd>Pregnenediones/therapeutic use</kwd><kwd>Randomized Controlled Trials as Topic</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="status-note"><p>Edited (no change to conclusions)</p></notes></front></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ocul Pharmacol Ther</journal-id><journal-id journal-id-type="iso-abbrev">J Ocul Pharmacol Ther</journal-id><journal-id journal-id-type="pmc-domain-id">1160</journal-id><journal-id journal-id-type="pmc-domain">joph</journal-id><journal-id journal-id-type="publisher-id">jop</journal-id><journal-title-group><journal-title>Journal of Ocular Pharmacology and Therapeutics</journal-title></journal-title-group><issn pub-type="ppub">1080-7683</issn><issn pub-type="epub">1557-7732</issn><publisher><publisher-name>Mary Ann Liebert, Inc.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9041290</article-id><article-id pub-id-type="pmcid-ver">PMC9041290.1</article-id><article-id pub-id-type="pmcaid">9041290</article-id><article-id pub-id-type="pmcaiid">9041290</article-id><article-id pub-id-type="pmid">32678687</article-id><article-id pub-id-type="doi">10.1089/jop.2019.0150</article-id><article-id pub-id-type="publisher-id">10.1089/jop.2019.0150</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Effect of Particle Size and Viscosity of Suspensions on Topical Ocular Bioavailability of Budesonide, a Corticosteroid</article-title><alt-title alt-title-type="left-running-head">Vooturi et al.</alt-title><alt-title alt-title-type="right-running-head">Corticosteroid Bioavailability from Ophthalmic Suspensions</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Vooturi</surname><given-names initials="S">Sunil</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bourne</surname><given-names initials="D">David</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Panda</surname><given-names initials="JJ">Jiban Jyoti</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Choi</surname><given-names initials="S">Stephanie</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="H">Hyewon</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yandrapu</surname><given-names initials="SK">Sarath K.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Kompella</surname><given-names initials="UB">Uday B.</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="corr1" ref-type="corresp"/></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.</aff><aff id="aff2"><label><sup>2</sup></label>US Food and Drug Administration, Silver Spring, Maryland, USA.</aff><aff id="aff3"><label><sup>3</sup></label>Chemical Biology Unit, Institute of Nano Science and Technology, Punjab, India.</aff><aff id="aff4"><label><sup>4</sup></label>Mylan Pharmaceuticals, Morgantown, West Virginia, USA.</aff></contrib-group><author-notes><corresp id="corr1">Address correspondence to: Dr. Uday B. Kompella, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, 12850 E. Montview Boulevard, C238-V20, Aurora, CO 80045, USA <email>uday.kompella@cuanschutz.edu</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2020</year><string-date>July/August 2020</string-date></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2020</year></pub-date><volume>36</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">362773</issue-id><fpage>404</fpage><lpage>409</lpage><history><date date-type="received"><day>02</day><month>12</month><year>2019</year><string-date>Received: December 2, 2019</string-date></date><date date-type="accepted"><day>22</day><month>5</month><year>2020</year><string-date>Accepted: May 22, 2020</string-date></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>07</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>27</day><month>04</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-06-10 06:16:56.350"><day>10</day><month>06</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>Copyright 2020, Mary Ann Liebert, Inc., publishers</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Mary Ann Liebert, Inc., publishers</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jop.2019.0150.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="jop.2019.0150.pdf"/><abstract><sec id="S019"><title>Purpose:</title><p>To determine the effect of particle size and viscosity of suspensions on topical ocular bioavailability of budesonide, a corticosteroid drug.</p></sec><sec id="S020"><title>Methods:</title><p>Budesonide microparticle and nanoparticle (MP and NP) suspensions were prepared with or without homogenization and microfluidization. Using different grades of hydroxyl propyl methyl cellulose, low viscosity NP (NP-LV) and low and high viscosity MP (MP-LV and MP-HV) were prepared. Suspensions were characterized for particle size, viscosity, and osmolality. Budesonide suspensions were administered topically to rabbits and aqueous humor was collected and analyzed for budesonide. Budesonide C<sub>max</sub>, t<sub>max</sub>, and the area under the concentration time curve (AUC <sub>(0–6h)</sub>) values were determined. The geometric mean ratio of AUC and bioequivalence was evaluated using a bootstrap method.</p></sec><sec id="S021"><title>Results:</title><p>The particle sizes for NP and MP were ∼700 and 2,000 nm. The viscosities for low and HV formulations were ∼5 and 50 cP. The geometric mean budesonide C<sub>max</sub> values for the suspensions NP-LV, MP-LV, and MP-HV were 0.22, 0.22, and 0.31 μg/g, t<sub>max</sub> values were 0.67, 0.60 and 0.53 h, and AUC<sub>0–6h</sub> values were 0.72, 0.53, and 0.95 μg h/g, respectively. Bootstrap analysis indicated that the 90% confidence intervals of the geometric mean ratio of AUC<sub>0–6h</sub> values were 1.00–1.74 (MP-HV vs. NP-LV), 0.57–0.96 (MP-LV vs. NP-LV), and 0.45–0.70 (MP-LV vs. MP-HV).</p></sec><sec id="S022"><title>Conclusions:</title><p>The 3 budesonide suspensions assessed in this study were not bioequivalent. Results suggested that an increase in viscosity improves the bioavailability of budesonide from the microsuspension formulation.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>drug delivery</kwd><kwd>ocular delivery</kwd><kwd>nanoparticles</kwd><kwd>microparticles</kwd><kwd>nanosuspensions</kwd><kwd>bioavailability</kwd><kwd>and bioequivalence</kwd></kwd-group><counts><fig-count count="1"/><table-count count="5"/><ref-count count="18"/><page-count count="6"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article><article id="CD003530" article-type="systematic-review" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="iso-abbrev">Cochrane Database Syst Rev</journal-id><journal-id journal-id-type="pmc-domain-id">3102</journal-id><journal-id journal-id-type="pmc-domain">cochrev</journal-id><journal-id journal-id-type="publisher-id">14651858</journal-id><journal-title-group><journal-title>The Cochrane Database of Systematic Reviews</journal-title></journal-title-group><issn pub-type="epub">1469-493X</issn><issn-l>1361-6137</issn-l><publisher><publisher-name>John Wiley and Sons, Inc. and the Cochrane Library</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8717128</article-id><article-id pub-id-type="pmcid-ver">PMC8717128.1</article-id><article-id pub-id-type="pmcaid">8717128</article-id><article-id pub-id-type="pmcaiid">8717128</article-id><article-id pub-id-type="pmid">11869673</article-id><article-id pub-id-type="doi">10.1002/14651858.CD003530</article-id><article-id pub-id-type="publisher-id">CD003530</article-id><article-id pub-id-type="other">CD003530</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group><subject>Asthma, chronic ‐ pharmacotherapy</subject><subject>Child health</subject><subject>Lungs &amp; airways</subject></subj-group></article-categories><title-group><article-title>Beclomethasone versus budesonide for chronic asthma</article-title></title-group><contrib-group><contrib id="d23e173" contrib-type="author" corresp="yes"><name name-style="western"><surname>Adams</surname><given-names initials="NP">Nick P</given-names></name><address><email>Nick.Adams@wash.nhs.uk</email><email>nadams2002@btinternet.com</email></address><xref ref-type="aff" rid="CD003530-aff-0001"/></contrib><contrib id="d23e177" contrib-type="author"><name name-style="western"><surname>Bestall</surname><given-names initials="JC">Janine C</given-names></name><xref ref-type="aff" rid="CD003530-aff-0002"/></contrib><contrib id="d23e181" contrib-type="author"><name name-style="western"><surname>Jones</surname><given-names initials="P">Paul</given-names></name><xref ref-type="aff" rid="CD003530-aff-0003"/></contrib><contrib id="d23e192" contrib-type="editor"><collab collab-type="editors">Cochrane Airways Group</collab></contrib></contrib-group><aff id="CD003530-aff-0001"><institution>Worthing &amp; Southlands NHS Trust</institution><institution content-type="dept">Respiratory Medicine</institution><city>Worthing</city><country>UK</country></aff><aff id="CD003530-aff-0002"><institution>Leeds Institute of Health Sciences, Faculty of Medicine and Health, University of Leeds</institution><institution content-type="dept">Academic Unit of Psychiatry and Behavioural Sciences</institution><addr-line>Charles Thackrah Building</addr-line><addr-line>101 Clarendon Road</addr-line><city>Leeds</city><state>West Yorkshire</state><country>UK</country><postal-code>LS2 9LJ</postal-code></aff><aff id="CD003530-aff-0003"><institution>St George's Hospital Medical School</institution><institution content-type="dept">Cardiovascular Medicine</institution><addr-line>Cranmer Terrace</addr-line><city>London</city><country>UK</country><postal-code>SW17 0RE</postal-code></aff><pub-date pub-type="epub"><day>21</day><month>1</month><year>2002</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2002</year></pub-date><pub-date pub-type="update"><day>8</day><month>12</month><year>2014</year></pub-date><volume>2002</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">335243</issue-id><elocation-id>CD003530</elocation-id><pub-history><event event-type="pmc-release"><date><day>21</day><month>01</month><year>2003</year></date></event><event event-type="pmc-live"><date><day>04</day><month>01</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-03 14:25:14.387"><day>03</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="CD003530.pdf"/><abstract><title>Abstract</title><sec id="CD003530-sec-0001"><title>Background</title><p>Beclomethasone dipropionate (BDP) and budesonide (BUD) are used widely in the treatment of chronic asthma. The two drugs have different in vitro pharmacokinetic characteristics. It is unclear whether this translates into clinically significant differences in efficacy or safety when treating children and adults with chronic asthma.</p></sec><sec id="CD003530-sec-0002"><title>Objectives</title><p>To assess clinical outcomes in studies which have compared inhaled BDP and BUD in the treatment of chronic asthma.</p></sec><sec id="CD003530-sec-0003"><title>Search methods</title><p>We searched the Cochrane Airways Group Trial Register (1999) and reference lists of articles. We contacted trialists and pharmaceutical companies for additional studies and searched abstracts of major respiratory society meetings (1997‐1999).</p></sec><sec id="CD003530-sec-0004"><title>Selection criteria</title><p>Prospective, randomised trials comparing BDP to BUD in the treatment of chronic asthma. Two reviewers independently assessed articles for inclusion and methodological quality.</p></sec><sec id="CD003530-sec-0005"><title>Data collection and analysis</title><p>One reviewer extracted data; authors were contacted to clarify missing information. Quantitative analyses where undertaken using Review Manager 4.0.3 with MetaView 3.1.</p></sec><sec id="CD003530-sec-0006"><title>Main results</title><p>24 studies met the criteria for inclusion (1174 participants). Methodological quality was variable. A meta‐analysis of crossover studies did not demonstrate a significant difference between BDP and BUD for FEV1, morning PEF, evening PEF, asthma symptoms or rescue beta2 agonist use, over a dose range of 400 to 1000 mcg/d. The majority of crossover trials had significant design flaws related to a lack of washout and/or failure to exclude carryover effects so the results must be viewed with caution. A single crossover study with adequate washout showed that BUD 400 mcg/d delivered via Turbohaler dry powder inhaler (DPI) may be more effective than BDP 400 mcg/d delivered via Rotahaler DPI in reducing histamine bronchial hyper‐responsiveness: Weighted Mean Difference (WMD) 0.43 log10 PC20 FEV1 (95% Confidence Intervals (CI) 0.05, 0.81 log10 PC20 FEV1). A meta‐analysis of two parallel group, dose down‐titration studies (231 patients) showed that less BUD delivered via a Turbohaler DPI was required to maintain control in adults asthmatics compared to BDP delivered via metered dose inhaler with or without a spacer: WMD 444 mcg/d (95% CI 332, 556 mcg/d).</p></sec><sec id="CD003530-sec-0007"><title>Authors' conclusions</title><p>There is limited high quality randomised controlled trial data comparing the relative efficacy of BDP and BUD. Current guidelines (BTS 1997; GINA 1995; NHLBI 1997) assume BDP and BUD to have equal efficacy, such that for each defined level of asthma severity, the recommended doses BDP and BUD are the same. Although there is some data to suggest that BUD via Turbohaler is more effective than BDP via either Rotahaler or MDI (with and without spacer), these comparisons are confounded by use of different delivery devices, and are not sufficient to warrant a change in guideline recommendations.</p></sec></abstract><abstract abstract-type="short"><title>Plain language summary</title><p><bold>The effects of beclomethasone or budesonide for chronic asthma</bold></p><p>Beclomethasone and budesonide are commonly used to treat people with asthma in the long‐term. Despite the large amount of research which has been conducted with these two steroids, very little can be concluded as to how effective they are, because the quality of the research to date has not been strong enough. The available research does not therefore provide a clear answer as to whether beclomethasone or budesonide are better for treating asthma.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta><notes notes-type="status-note"><p>Edited (no change to conclusions), comment added to review</p></notes></front></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Bone Marrow Transplant</journal-id><journal-id journal-id-type="iso-abbrev">Bone Marrow Transplant</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Bone marrow transplantation</journal-title></journal-title-group><issn pub-type="ppub">0268-3369</issn><issn pub-type="epub">1476-5365</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9512089</article-id><article-id pub-id-type="pmcid-ver">PMC9512089.1</article-id><article-id pub-id-type="pmcaid">9512089</article-id><article-id pub-id-type="pmcaiid">9512089</article-id><article-id pub-id-type="manuscript-id">NIHMS1828545</article-id><article-id pub-id-type="pmid">31953533</article-id><article-id pub-id-type="doi">10.1038/s41409-020-0786-8</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1828545</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1828545</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>A Prospective Evaluation on the Interaction of Fluconazole and Voriconazole on Serum Concentrations of Budesonide in Patients Treated for Gastrointestinal GVHD</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Hughes</surname><given-names initials="TE">Thomas E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stansfield</surname><given-names initials="L">Lindsay</given-names></name><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kumar</surname><given-names initials="P">Parag</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Worthy</surname><given-names initials="T">Tat’Yana</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tian</surname><given-names initials="X">Xin</given-names></name><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Childs</surname><given-names initials="RW">Richard W.</given-names></name><xref rid="A4" ref-type="aff">4</xref></contrib></contrib-group><aff id="A1"><label>1</label>Clinical Center, Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA</aff><aff id="A2"><label>2</label>Verastem Oncology, Needham, Massachusetts</aff><aff id="A3"><label>3</label>Otsuka Pharmaceutical Development and Commercialization, Inc. Rockville, MD</aff><aff id="A4"><label>4</label>Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA</aff><aff id="A5"><label>5</label>Office of Biostatistics Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA</aff><author-notes><corresp id="CR1"><bold>Corresponding author</bold>: Thomas E. Hughes, PharmD, Clinical Center, Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA, Address: National Institutes of Health Clinical Center, Pharmacy Department, 10 Center Drive, Building 10, Room 1C-240, MSC 1196, Bethesda, MD 20892-1196, <email>thughes@cc.nih.gov</email>, Phone: 301-451-0495 Fax: 301-496-0210</corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>17</day><month>1</month><year>2020</year></pub-date><volume>55</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">417923</issue-id><fpage>1085</fpage><lpage>1092</lpage><pub-history><event event-type="nihms-submitted"><date><day>11</day><month>08</month><year>2022</year></date></event><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>26</day><month>09</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-13 16:25:14.970"><day>13</day><month>06</month><year>2024</year></date></event></pub-history><permissions><license><license-p>This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1828545.pdf"/><abstract id="ABS1"><p id="P12">The gastrointestinal (GI) tract is commonly affected by acute and chronic graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT). For patients developing GI GVHD, non-absorbable corticosteroids such as budesonide may be used alone to reduce the risk of systemic corticosteroid toxicities or combined with systemic steroids to enhance clinical responses and to allow more rapid tapering of systemic corticosteroid doses. This prospective cross-over study was conducted to evaluate what effect two commonly used antifungal agents, fluconazole and voriconazole, would have on the trough (Cmin) and peak (Cmax) levels of budesonide in adult patients who had undergone allo-HSCT who subsequently developed clinical GI GVHD. Fifteen subjects were enrolled and nine completed the study and were evaluable. When co-administered with budesonide, voriconazole significantly increased the geometric mean of budesonide Cmin and Cmax levels by 8.52 and 6.63 fold respectively. The cohort to evaluate the interaction with fluconazole did not meet accrual goals to reach definitive conclusions. In conclusion, this prospective study demonstrated that when patients with GI GVHD are treated with budesonide concurrently with voriconazole, the systemic concentrations of budesonide increase substantially which could increase the risk of steroid-associated toxicities.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P13">The gastrointestinal (GI) tract is commonly affected by acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD) in patients who have undergone allo-HSCT. As first line therapy, patients are treated with systemic corticosteroids, which produce complete response rates in 35 percent of patients.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Although short courses of steroids are preferred to minimize adverse effects, GI GVHD if often difficult to treat, can have a negative impact on quality of life and nutrition status, and may require protracted treatment before resolving. Non-absorbable corticosteroids, such as beclomethasone or budesonide, act locally on the GI tract and have been utilized by clinicians to minimize the deleterious effects of systemic corticosteroid exposure.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Beclomethasone dipropionate has been evaluated in multiple clinical trials for the management of GI GHVD.<sup><xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R8" ref-type="bibr">8</xref></sup> Despite some positive clinical results from these trials, an FDA approved commercial product of beclomethasone has not been developed for use in GI GVHD.</p><p id="P14">Budesonide (Entocort® EC, AstraZeneca, Wilmington, DE) is an FDA-approved oral topical corticosteroid for the treatment of mild to moderate active Crohn’s disease involving the ileum and/or the ascending colon, and for maintenance of clinical remission of mild to moderate Crohn’s disease involving the ileum and/or the ascending colon for up to 3 months. It has a high ratio of topical-to-systemic activity with minimally active metabolites, and undergoes extensive first-pass metabolism. Since both intestinal GVHD and Crohn’s disease seem to share a similar pathogenic background and given the clinical trial experience with beclomethasone dipropionate, budesonide has been increasingly used following allo-HSCT to treat GI GVHD. In this context, budesonide is sometimes given alone or combined with systemic corticosteroids (e.g. methylprednisolone) in an effort to improve clinical response and allow for more rapid tapering of systemic corticosteroid doses.<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup></p><p id="P15">First-pass metabolism of budesonide is mediated mostly by the cytochrome P450 (CYP450) enzyme system. Although the liver is the major site of CYP450-mediated metabolism, the enterocytes of the intestinal epithelium are also an important site for drug metabolism. Budesonide undergoes significant metabolism by CYP enzymes, specifically the CYP3A4 isoenzyme, with substantial first-pass metabolism.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup> It has also been demonstrated that the extent of intestinal CYP3A4 expression has an impact on budesonide pharmacokinetics.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> The potential for greater systemic availability of orally administered budesonide exists when it is given concurrently with triazole antifungals, which are commonly prescribed for prophylaxis or treatment of fungal infections after transplantation and are known inhibitors of CYP3A4.</p><p id="P16">In a randomized, open-label, crossover pharmacokinetic study in eight healthy men, ketoconazole, a potent inhibitor of CYP3A4, was given concomitantly with or separated by 12 hours from budesonide. The mean AUC for budesonide was increased by 6.5 times when it was given concomitantly with ketoconazole and 3.8 times when the two were separated by 12 hours.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> This trial provided important evidence that a potent inhibitor of CYP3A4 could have a significant impact on budesonide systemic exposure.</p><p id="P17">Fluconazole and voriconazole are two commonly utilized triazoles for antifungal prophylaxis and are moderate and strong inhibitors of CYP3A4, respectively, In a retrospective analysis of 60 patients who received an allogeneic SCT, El Fakih et al. identified 5 patients with acute or chronic GVHD who were continued on budesonide with an azole antifungal agent (fluconazole or voriconazole) following the completion of a course of systemic steroids. Although no subject had received systemic steroids for at least 21 days, all 5 patients were found to have suppression of plasma cortisol levels as well as the onset of iatrogenic Cushing’s syndrome with weight gain, facial mooning, central obesity and glucose intolerance.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> Similar drug interaction reports have been published involving other patient populations. A case report documented an adult female with Crohn’s disease who developed iatrogenic Cushing syndrome following 13 weeks of concomitant therapy with oral voriconazole and budesonide. Remarkably, two months after voriconazole was discontinued, the prominent Cushingoid features in this patient markedly regressed despite the continuation of budesonide therapy.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> A case report of Cushing’s syndrome was also reported following the combination of the antiretroviral agent, ritonavir (a strong CYP3A4 inhibitor) and oral budesonide in an HIV positive patient treated for lymphocytic colitis.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> Case reports of iatrogenic Cushing’s syndrome following the combination of various strong CYP3A4 inhibitors including ritonavir<sup><xref rid="R18" ref-type="bibr">18</xref>–<xref rid="R23" ref-type="bibr">23</xref></sup>, itraconazole<sup><xref rid="R23" ref-type="bibr">23</xref>–<xref rid="R25" ref-type="bibr">25</xref></sup> and clarithromycin<sup><xref rid="R24" ref-type="bibr">24</xref></sup> with inhaled budesonide have also been reported.</p><p id="P18">None of the drug interaction case reports noted above evaluated the impact of the triazole antifungal or other CYP3A4 inhibiting drug on systemic budesonide levels. There are also no prospective studies evaluating the effects of triazole antifungal agents on budesonide’s pharmacokinetics in patients who have undergone allo-HSCT. Here we conducted a study with the primary objective to determine the effects of two commonly used triazole antifungal agents (fluconazole and voriconazole) on the trough (Cmin) and peak (Cmax) of budesonide in patients who have undergone allo-HSCT and received treatment with budesonide to treat GI GVHD.</p></sec><sec id="S2"><title>Methods</title><p id="P19">Adult and pediatric subjects (≥ 13 years of age and ≥ 49 kg) who were enrolled into a research protocol that included bone marrow, cord blood, haplo-cord or peripheral blood stem cell transplantation at the National Institutes of Health Clinical Center and had been diagnosed with GI GVHD were recruited into this protocol. Written informed consent was obtained in accordance with the Declaration of Helsinki for research under protocols approved by the Institutional Review Board of the National Heart, Lung and Blood Institute (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://Clinicaltrials.gov" ext-link-type="uri">Clinicaltrials.gov</ext-link> ID: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01950507" ext-link-type="uri">NCT01950507</ext-link>). Inclusion into the trial required a clinical diagnosis of GI GVHD requiring treatment with budesonide and systemic corticosteroids as determined by the research subject’s primary medical team. For the purpose of this trial, the grade of GI GVHD for study eligibility was one of a severity requiring therapy with systemic corticosteroids (grade II-IV). Confirmatory data supporting the GVHD diagnosis such as tissue biopsy results were documented but not required for eligibility. Eligible subjects had to be candidates for antifungal therapy and have liver transaminase values (alanine aminotransferase and aspartate aminotransferase) less than 5 times the upper limit of normal. Exclusion criteria included: pregnancy or breast feeding, concomitant use of other CYP3A4 inhibiting or inducing medications or foods, an inability to take oral medications, allergies or contraindications to budesonide, fluconazole, voriconazole or micafungin, a poor performance status (ECOG PS ≥ 4, Lansky PS ≤ 30), a psychiatric disorder or mental deficiency that could interfere with the subject’s ability to comply with study procedures or requirements, an inability to provide informed consent, major anticipated illness or organ failure, a current documented or suspected invasive fungal infection, intensive care unit subjects, or Child-Pugh Class C hepatic impairment.</p><p id="P20">A longitudinal cohort design was chosen to allow each subject to serve as his or her own control to minimize the variation in the individual pharmacokinetics of budesonide that can occur from subject to subject and to answer the research questions posed with fewer research subjects. Subjects meeting inclusion criteria that were consented onto the trial were enrolled into one of three cohorts based upon the subject’s current antifungal prophylaxis (or lack thereof) at the time of study enrollment and the primary medical team’s preference for continued antifungal coverage after the initiation of budesonide and systemic corticosteroids. The protocol trial period was 14 days long, with each research subject receiving 7 days of budesonide concurrently with a triazole (fluconazole or voriconazole) and 7 days of budesonide without the triazole antifungal. In all three cohorts, a budesonide Cmin and Cmax were measured on day 7 and day 14 of the protocol at the 9 am scheduled budesonide dose in the presence and absence of concurrent fluconazole or voriconazole (see <xref rid="F1" ref-type="fig">Figure 1</xref>). The budesonide Cmin was drawn 15 min (± 30 min) prior to the 9 am budesonide dose and the Cmax was drawn 4.5 hours (± 30 min) after the 9 am budesonide dose. A four day forward window was allowed (i.e. pharmacokinetic assessments could be drawn on day 11 and 18 if necessary), but there had to be at least 7 days between the collection of budesonide serum samples. A voriconazole Cmin sample was also taken after 7 days of voriconazole dosing in those patients assigned to a voriconazole cohort. The echinocandin antifungal micafungin, which does not impact CYP3A4 drug metabolism, could be initiated for antifungal prophylaxis if desired by the primary medical team as an alternative non-azole antifungal agent during the study periods. Following completion of the 14 day study period, continuation of an antifungal agent was at the discretion of the primary medical team. The primary medical team was provided the pharmacokinetic analysis of budesonide levels to aid in decision making regarding the continued use of antifungal prophylaxis while patients were receiving budesonide.</p><p id="P21">During the trial period, budesonide (Entocort® EC) was administered at a dose of 3 mg orally three times daily (9am, 4pm, 10pm). Fluconazole was dosed at 400 mg orally once daily at 9am. Subjects enrolled in cohort 1 who were initiated on voriconazole received a loading dose of 400 mg orally every 12 hours for 2 doses, then 200 mg orally every 12 hours at 9am and 9pm. Subjects enrolled in cohort 2 continued their current dose of voriconazole if the dose was 200 mg orally every 12 hours or higher. If their dose was less than 200 mg, the dose was advanced upwards to 200 mg every 12 hours. Oral dosing of fluconazole and voriconazole was preferred, but if a research subject was unable to take the triazole agent orally, the equivalent dose (1:1 oral: intravenous) could be administered by intravenous infusion. Micafungin was dosed as 100 mg as an intravenous infusion once daily at 9am. If a patient was discharged during the trial period, a micafungin dose of 200 mg to 300 mg as an intravenous infusion administered two to three times weekly was permitted. A one-hour drug administration window was permitted for all study drugs, except on the days of pharmacokinetic sampling when a 30 minute window was allowed. Dose modifications of fluconazole for renal impairment (creatinine clearance &lt; 50 ml/min) were required. Subjects who developed grade 3 or higher hepatic impairment (ALT and/or AST &gt; 5–20 × ULN) during the trial period that required the discontinuation of the triazole antifungal agent were removed from the protocol. Additional criteria for removal from the protocol included: any grade 3 or 4 toxicity not expected to occur as a consequence of the allo-HSCT and thought to be related to the medications in the study, subject preference, PI or primary medical team’s discretion, evidence during the study of a presumptive, probable, or proven invasive fungal infection or required treatment with a prohibited interacting medication that was deemed to significantly impact the study’s objectives, and for which there was no reasonable substitute.</p><p id="P22">Budesonide samples were analyzed by a commercial laboratory (Mayo Clinic Laboratories) using a Liquid Chromatography Tandem Mass Spectrometry assay. The detection limit of the assay (negative cutoff concentration) was 0.10 mcg/dl. Duplicate samples were obtained for both the Cmin and Cmax time points. For three subjects, the duplicate samples were sent for analysis to confirm results. In these subjects, the two results were averaged for reporting purposes. For assay results that were reported as undetectable, a result of 0.05 mcg/dl was used (one half of the stated detection limit). Voriconazole trough samples were also analyzed by a commercial laboratory (Mayo Clinic Laboratories) using a Liquid Chromatography Tandem Mass Spectrometry assay.</p></sec><sec id="S3"><title>Statistical analysis</title><p id="P23">We calculated that a sample size of 6 subjects is required to provide 90% power to detect a 2-fold difference in the budesonide Cmax and Cmin before and after azole administration for each cohort at the significant level of 0.05 using a two-sided paired t-test for each of the two primary comparisons. Because both cohort 1 and cohort 2 evaluated the same drug interaction between voriconazole and budesonide, the two cohorts were combined for analysis with an accrual goal of six subjects. The goal for accrual for cohort 3 (interaction between fluconazole and budesonide) was also set at six subjects but stopped prematurely due to poor accrual. Descriptive statistics, including mean, SD, geometric mean and geometric mean ratio were used to summarize each cohort and drug interaction. The data analysis was performed using R statistical software Version 3.6.1 (R Foundation for Statistical Computing) and P-values less than 0.05 were considered statistically significant.</p></sec><sec id="S4"><title>Results</title><p id="P24">Fifteen subjects were enrolled into the study from February 2014 to July 2017. Nine evaluable subjects completed the study and six subjects did not complete the study. Amongst the subjects not completing the study, two voluntarily withdrew, three were withdrawn due to hepatic transaminase elevations requiring discontinuation of the triazole antifungal agent, and one was withdrawn due to clinical decompensation requiring transfer to the intensive care and discontinuation of budesonide. The nine evaluable subjects were evenly distributed among the three cohorts with six subjects in the voriconazole cohorts (three subjects each in cohort 1 and 2) and three subjects in the fluconazole cohort (cohort 3). The characteristics of the nine evaluable subjects are provided in <xref rid="T1" ref-type="table">Table 1</xref>.</p><p id="P25">Individual and averaged budesonide levels for subjects in voriconazole cohorts 1 and 2 and the fluconazole cohort 3 are provided in <xref rid="T2" ref-type="table">Tables 2</xref> and <xref rid="T3" ref-type="table">3</xref> respectively. Plots showing budesonide Cmax and Cmin values for individual subjects in cohorts and 1 and 2 in the absence or presence of voriconazole are shown in <xref rid="F2" ref-type="fig">figure 2</xref>. The mean budesonide Cmin without concurrent voriconazole was 0.16 ± 0.15 mcg/dl, which increased to 1.03 ± 0.24 mcg/dl (<italic toggle="yes">P</italic>=0.0009) when dosed concurrently with voriconazole (geometric mean ratio 8.52 [90% CI 4.64 to 15.66]). The mean budesonide Cmax without concurrent voriconazole was 0.23 ± 0.21 mcg/dl, which increased to 1.27 ± 0.77 mcg/dl when dosed concurrently with voriconazole (geometric mean ratio 6.63 [90% CI 3.15 to 13.94]). The mean voriconazole trough level in the voriconazole cohorts was 0.67 mcg/ml (range 0.1 mcg/mL to 1.9 mcg/mL). For the fluconazole cohort, the mean budesonide Cmin without concurrent fluconazole was not different compared to that with fluconazole, however there was a significant increase in mean budesonide Cmax when dosed concurrently with fluconazole compared to Cmax when dosed without fluconazole (mean ±SD, 0.68 ± 0.16 vs. 0.16 ± 0.08, geometric mean ratio 4.38 with 90% CI, 2.12–9.06, <italic toggle="yes">P</italic>=0.027, <xref rid="T3" ref-type="table">Table 3</xref>).</p></sec><sec id="S5"><title>Discussion</title><p id="P26">This is the first prospective study providing pharmacokinetic data to demonstrate the impact of voriconazole on budesonide serum concentrations when budesonide is used to treat GI GVHD. When co-administered with budesonide, voriconazole significantly increased the geometric mean of budesonide Cmin and Cmax levels by 8.52 and 6.63 fold respectively. Published clinical practice guidelines on therapeutic drug monitoring of antifungal agents recommend voriconazole trough levels be maintained at &gt; 1 mcg/ml (1 mg/L), particularly in patients with invasive fungal infections.<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> It is important to consider the increases in systemic budesonide exposure associated with voriconazole were readily apparent in our study population despite the majority of subjects having voriconazole troughs below this recommended guideline threshold (mean trough level of 0.67 mcg/mL). Because our study was conducted in patients receiving concomitant systemic corticosteroid therapy, we were unable to attribute any systemic corticosteroid related toxicity to systemic exposure to budesonide. However, this study provides confirmatory evidence that triazole antifungals, particularly those that are strong inhibitors of CYP3A4 such as voriconazole, significantly increase systemic exposure to budesonide, potentially increasing the risk for systemic toxicities associated with corticosteroid use. Studies conducted in patients with endogenous Cushing’s syndrome have demonstrated a correlation with elevated cortisol levels and risk of opportunistic infections.<sup><xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref></sup> Sarlis et al. established that a cortisol level that exceeded 43.1 mcg/dl was predictive of severe infections with a positive predictive value of 57.7%.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> The budesonide Cmin and Cmax values that we observed with concomitant voriconazole in this study (1.03 mcg/dl and 1.27 mcg/dl, respectively) are likely comparable to the cortisol threshold value established by the Sarlis study. A bioequivalence study of budesonide in asthma patients demonstrated a systemic potency ratio of 9.2 (milligrams of prednisone equivalent to 1 mg of budesonide).<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Given that the dose equivalency of prednisone to hydrocortisone is 4 fold (prednisone 5 mg equivalent to 20 mg of hydrocortisone), the potency ratio of hydrocortisone (and cortisol) to budesonide may be as high as 37. Thus, although we cannot correlate cortisol levels to budesonide levels exactly, if we assume this potency ratio of 37, the elevated budesonide levels we observed with concomitant voriconazole could be comparable to cortisol levels in the range of 38 to 47 mcg/dl, where an increased risk for opportunistic infections has previously been established. This increased risk is particularly important to consider when budesonide is being used as the sole corticosteroid to manage GI GVHD, with the intent to purposely avoid toxicities associated with systemic corticosteroid exposure.</p><p id="P27">Data from our study support both the pharmacokinetic data in healthy volunteers treated with the combination of ketoconazole and oral budesonide,<sup><xref rid="R14" ref-type="bibr">14</xref></sup> as well as anecdotal clinical case reports demonstrating an increase in systemic corticosteroid effects when azole antifungal agents are used concurrently with oral budesonide.<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup> Data on budesonide levels from individual subjects comparing Cmin to Cmax results sometimes showed unexpected Cmin levels that were higher than Cmax. The Entocort® EC (budesonide) product labeling states that time to peak concentration can vary in individual patients between 30 and 600 minutes.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> We chose the Cmax time point of 4.5 hours (270 minutes) for our study based on pharmacokinetic data provided in the healthy volunteer pharmacokinetic drug interaction study with ketoconazole and budesonide.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> In this trial with 8 subjects, the time to a maximum budesonide concentration (Tmax) ranged from 180 to 360 minutes when ketoconazole and budesonide were given concomitantly, with a mean Tmax of 261 minutes. Similarly, the Tmax ranged from 90 to 540 minutes when budesonide was given alone, with the mean Tmax occurring at 292 minutes. Since the Tmax mean values occurred at similar time points, we expected that the Cmax would occur at similar time points for subjects in our study during both sampling periods. In circumstances where the measured Cmin levels were higher than Cmax, it is likely that the true Cmax was not obtained due to variations in the Tmax for individual subjects. However, since our paired analysis separately compared the means of our chosen Cmin and Cmax values, we were able to demonstrate the effect of voriconazole increasing both these values. Because only 3 subjects in our study were able to complete the fluconazole cohort, our analysis had only limited statistical power to interpret the effects of fluconazole on budesonide Cmin and Cmax levels. Nevertheless, for these 3 subjects, we observed a significant increase in Cmax values with fluconazole treatment (Cmax mean of 0.16 mcg/dl off fluconazole to 0.68 mcg/dl with concomitant fluconazole).</p><p id="P28">In conclusion, this prospective study establishes that voriconazole, when given to patients with GI GVHD receiving budesonide, significantly increases systemic concentrations of budesonide. Based on these data, it is reasonable to assume other strong CYP3A4 inhibitors, such as posaconazole, would have a similar effect. Before combining azoles with budesonide, this interaction should be carefully considered as the substantial increases in budesonide levels observed in this study could increase the risk of patients developing corticosteroid-induced toxicities such as diabetes, hypertension, and opportunistic infections. Further, systemic exposure to higher levels of budesonide could suppress the adrenal access in patients not being treated with concomitant systemic steroids, placing them at risk for adrenal insufficiency should budesonide be abruptly discontinued. For patients where budesonide is specifically being utilized to avoid risks associated with systemic steroid exposure, use of alternative antifungal agents that do not inhibit CYP3A4 should be considered.</p></sec></body><back><ack id="S7"><title>Acknowledgements:</title><p id="P30">The authors gratefully acknowledge the contributions of Juan Gea-Banacloche, MD for his assistance in the initial design of the protocol, Jaydira Del Rivero, MD for her assistance in the review of the final manuscript, and to all the research subjects who participated in the trial. This research was supported [in part] by the Intramural Research Program of the NIH, National Heart, Lung, and Blood Institute.</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P31"><bold>Conflict of Interest</bold>: The authors have no conflicts of interest to report.</p></fn><fn fn-type="COI-statement" id="FN3"><p id="P32"><bold>Declarations of interest</bold>: none</p></fn></fn-group><sec sec-type="data-availability" id="S6"><title>Data availability:</title><p id="P29">All data generated or analyzed during this study are included in this published article.</p></sec><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ibrahim</surname><given-names>RB</given-names></name>, <name name-style="western"><surname>Abidi</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Cronin</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Lum</surname><given-names>LG</given-names></name>, <name name-style="western"><surname>Al-Kadhimi</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Ratanatharathorn</surname><given-names>V</given-names></name>, <etal/>
<article-title>Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease</article-title>. <source>Biol Blood Marrow Transplant</source>
<year>2009</year>; <volume>15</volume>:<fpage>395</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">19285626</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2008.12.487</pub-id><pub-id pub-id-type="pmcid">PMC3809114</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Baeher</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Bouvier</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Hockenbery</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Gooley</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Stern</surname><given-names>JG</given-names></name>, <etal/>
<article-title>Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease</article-title>. <source>Transplantation</source>
<year>1995</year>; <volume>60</volume>:<fpage>1231</fpage>–<lpage>1238</lpage>.<pub-id pub-id-type="pmid">8525516</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McDonald</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Bouvier</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hockenbery</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Stern</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Gooley</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Farrand</surname><given-names>A</given-names></name>, <etal/>
<article-title>Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: A randomized, controlled trial</article-title>. <source>Gastroenterology</source>
<year>1998</year>; <volume>115</volume>:<fpage>28</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">9649455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0016-5085(98)70361-0</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Iyer</surname><given-names>RV</given-names></name>, <name name-style="western"><surname>Hahn</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Roy</surname><given-names>HN</given-names></name>, <name name-style="western"><surname>Battiwalla</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>B</given-names></name>, <etal/>
<article-title>Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease</article-title>. <source>Biol Blood Marrow Transplant</source>
<year>2005</year>; <volume>11</volume>:<fpage>587</fpage>–<lpage>592</lpage>.<pub-id pub-id-type="pmid">16041308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2005.04.008</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Castilla</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Perez-Simon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sanchez-Guijo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Diez-Campelo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ocio</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Perez-Persona</surname><given-names>O</given-names></name>, <etal/>
<article-title>Oral beclomethasone dipropionate for the treatment of gastrointestinal acute graft-versus-host disease (GVHD)</article-title>. <source>Biol Blood Marrow Transplant</source>
<year>2006</year>; <volume>12</volume>:<fpage>936</fpage>–<lpage>941</lpage>.<pub-id pub-id-type="pmid">16920559</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2006.05.010</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Miura</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Narimatsu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Kami</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kusumi</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Matsumura</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Yuji</surname><given-names>K</given-names></name>, <etal/>
<article-title>Oral beclomethasone dipropionate as an initial treatment of gastrointestinal acute graft-versus-host disease after reduced-intensity cord blood transplantation (letter)</article-title>. <source>Bone Marrow Transplant</source>
<year>2006</year>; <volume>38</volume>:<fpage>577</fpage>–<lpage>579</lpage>.<pub-id pub-id-type="pmid">16953206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1705489</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hockenbery</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Cruickshank</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rodell</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Gooley</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schuening</surname><given-names>FG</given-names></name>, <name name-style="western"><surname>Rowley</surname><given-names>SD</given-names></name>, <etal/>
<article-title>A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease</article-title>. <source>Blood</source>
<year>2007</year>; <volume>109</volume>:<fpage>4557</fpage>–<lpage>4563</lpage>.<pub-id pub-id-type="pmid">17244684</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2006-05-021139</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Villanueva</surname><given-names>FN</given-names></name>, <name name-style="western"><surname>Perez-Simon</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Caballero-Velazquez</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Sanchez-Guijo</surname><given-names>FF</given-names></name>, <name name-style="western"><surname>Canizo</surname><given-names>CC</given-names></name>, <etal/>
<article-title>Oral beclomethasone dipropionate for the treatment of gastrointestinal chronic graft-versus-host disease</article-title>. <source>Biol Blood Marrow Transplant</source>
<year>2009</year>; <volume>15</volume>:<fpage>1331</fpage>–<lpage>1336</lpage>.<pub-id pub-id-type="pmid">19747642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbmt.2009.05.018</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Andree</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Hilgendorf</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Leithaueuser</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Junghanss</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Holzhueter</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Loddenkemper</surname><given-names>C</given-names></name>, <etal/>
<article-title>Enteral budesonide in treatment for mild and moderate gastrointestinal chronic GVHD</article-title>. <source>Bone Marrow Transplant</source>
<year>2008</year>; <volume>42</volume>:<fpage>541</fpage>–<lpage>546</lpage>.<pub-id pub-id-type="pmid">18641680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2008.209</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bertz</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Afting</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kreisel</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Duffner</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Greinwald</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Finke</surname><given-names>J</given-names></name>. <article-title>Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD</article-title>. <source>Bone Marrow Transplant</source>
<year>1999</year>; <volume>24</volume>:<fpage>1185</fpage>–<lpage>1189</lpage>.<pub-id pub-id-type="pmid">10642806</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bmt.1702055</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jonsson</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Astrom</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>P</given-names></name>. <article-title>Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver</article-title>. <source>Drug Metab Dispos</source>
<year>1994</year>; <volume>23</volume>(<issue>1</issue>):<fpage>137</fpage>–<lpage>142</lpage>.<pub-id pub-id-type="pmid">7720517</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="book"><part-title>Product information</part-title>. <source>Entocort EC (budesonide)</source>. <publisher-loc>Wilmington, DE</publisher-loc>: <publisher-name>AstraZeneca</publisher-name>. <month>December</month>
<year>2011</year>.</mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ufer</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dilger</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Leschhorn</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Daufresne</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Mosyagin</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Rosenstiel</surname><given-names>P</given-names></name>, <etal/>
<article-title>Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: A possible role of intestinal CYP3A4 expression</article-title>. <source>Clin Pharmacol Ther</source>
<year>2008</year>; <volume>84</volume>(<issue>1</issue>):<fpage>43</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">18322448</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.clpt.6100505</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Seidegard</surname><given-names>J</given-names></name>
<article-title>Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration</article-title>. <source>Clin Pharmacol Ther</source>
<year>2000</year>; <volume>68</volume>(<issue>1</issue>):<fpage>13</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">10945311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2000.106895</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>El Fakih</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Obi</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Scholoff</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Carrum</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kamble</surname><given-names>RT</given-names></name>. <article-title>Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles (letter)</article-title>. <source>Bone Marrow Transplant</source>
<year>2012</year>; <volume>47</volume>:<fpage>1370</fpage>–<lpage>1371</lpage>.<pub-id pub-id-type="pmid">22327133</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/bmt.2012.17</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jones</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Chastain</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Wright</surname><given-names>PW</given-names></name>. <article-title>Iatrogenic Cushing syndrome secondary to a probable interaction between voriconazole and budesonide</article-title>. <source>Pharmacotherapy</source>
<year>2014</year>; <volume>34</volume>(<issue>7</issue>):<fpage>e116</fpage>–<lpage>e119</lpage> (doi:<pub-id pub-id-type="doi">10.1002/phar.1432</pub-id>)<pub-id pub-id-type="pmid">24757038</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Frankel</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Packer</surname><given-names>CD</given-names></name>. <article-title>Cushing’s syndrome due to antiretroviral-budesonide interaction (letter)</article-title>. <source>Ann Pharmacother</source>
<year>2011</year>; <volume>45</volume>:<fpage>823</fpage>–<lpage>824</lpage>.<pub-id pub-id-type="pmid">21558486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1P731</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gray</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Roux</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Carrihill</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>M</given-names></name>. <article-title>Adrenal suppression and Cushing’s syndrome secondary to ritonavir and budesonide (letter)</article-title>. <source>S Afr Med J</source>
<year>2010</year>; <volume>100</volume>(<issue>5</issue>):<fpage>296</fpage>–<lpage>297</lpage>.<pub-id pub-id-type="pmid">20460021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7196/samj.3848</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kedem</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Shahar</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hassoun</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Pollack</surname><given-names>S</given-names></name>. <article-title>Iatrogenic Cushing’s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient</article-title>. <source>J Asthma</source>
<year>2010</year>; <volume>47</volume>(<issue>7</issue>):<fpage>830</fpage>–<lpage>831</lpage>.<pub-id pub-id-type="pmid">20653496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/02770903.2010.485666</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yoganathan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>David</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>K</given-names></name>. <article-title>Cushing’s syndrome with adrenal suppression induced by inhaled budesonide due to a ritonavir drug interaction in a woman with HIV infection</article-title>. <source>Int J STD AIDS</source>
<year>2012</year>; <volume>23</volume>(<issue>7</issue>):<fpage>520</fpage>–<lpage>521</lpage>.<pub-id pub-id-type="pmid">22844010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1258/ijsa.2011.011408</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Colpitts</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>TB</given-names></name>, <name name-style="western"><surname>Tahhan</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Boggs</surname><given-names>JP</given-names></name>. <article-title>Iatrogenic Cushing syndrome in a 47-year-old HIV-positive woman on ritonavir and inhaled budesonide</article-title>. <source>J Int Assoc Provid AIDS Care</source>
<year>2017</year>; <volume>16</volume>(<issue>6</issue>):<fpage>531</fpage>–<lpage>534</lpage>.<pub-id pub-id-type="pmid">29108449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2325957417736612</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Veilleux</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>EG</given-names></name>. <article-title>Rebound adrenal insufficiency after withdrawal of ritonavir in a 65-year-old man using inhaled budesonide</article-title>. <source>CMAJ</source>
<year>2017</year>; <volume>189</volume>(<issue>37</issue>):<fpage>E1188</fpage>–<lpage>E1191</lpage>. doi: <pub-id pub-id-type="doi">10.1503/cmaj.170415</pub-id>.<pub-id pub-id-type="pmid">28923796</pub-id><pub-id pub-id-type="pmcid">PMC5602498</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Blondin</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Beauregard</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Serri</surname><given-names>O</given-names></name>. <article-title>Iatrogenic Cushing Syndrome in patients receiving inhaled budesonide and itraconazole or ritonavir: Two cases and literature review</article-title>. <source>Endocrine Practice</source>
<year>2013</year>; <volume>19</volume>(<issue>6</issue>):<fpage>e138</fpage>–<lpage>e141</lpage>.<pub-id pub-id-type="pmid">23807527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4158/EP13122.CR</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>De Wachter</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Malfroot</surname><given-names>A</given-names></name>, <name name-style="western"><surname>De Schutter</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Vanbesien</surname><given-names>J</given-names></name>, <name name-style="western"><surname>De Schepper</surname><given-names>J</given-names></name>. <article-title>Inhaled budesonide induced Cushing’s syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450</article-title>. <source>J Cyst Fibros</source>
<year>2003</year>; <volume>2</volume>(<issue>2</issue>):<fpage>72</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">15463853</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1569-1993(03)00022-5</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bolland</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Bagg</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Lucas</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Ticehurst</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>PN</given-names></name>. <article-title>Cushing’s Syndrome due to interaction between inhaled corticosteroids and itraconazole</article-title>. <source>Ann Pharmacother</source>
<year>2004</year>; <volume>38</volume>(<issue>1</issue>):<fpage>46</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">14742792</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1345/aph.1D222</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ashbee</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Barnes</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Gorton</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hope</surname><given-names>WW</given-names></name>. <article-title>Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology</article-title>. <source>J Antimicrobial Chemother</source>
<year>2014</year>; <volume>69</volume>(<issue>5</issue>):<fpage>1162</fpage>–<lpage>1176</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jac/dkt508</pub-id><pub-id pub-id-type="pmcid">PMC3977608</pub-id><pub-id pub-id-type="pmid">24379304</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chau</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>DCM</given-names></name>, <name name-style="western"><surname>van Hal</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Urbancic</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Trubiano</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Cassumbhoy</surname><given-names>M</given-names></name>, <etal/>
<article-title>Consensus guidelines for optimizing antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014</article-title>. <source>Internal Medicine Journal</source>
<year>2014</year>; <volume>44</volume>:<fpage>1364</fpage>–<lpage>1388</lpage>.<pub-id pub-id-type="pmid">25482746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imj.12600</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Tucker</surname><given-names>WS</given-names></name>. <article-title>Opportunistic infections in endogenous Cushing’s syndrome</article-title>. <source>Ann Int Med</source>
<year>1984</year>; <volume>101</volume>:<fpage>334</fpage>–<lpage>338</lpage>.<pub-id pub-id-type="pmid">6331781</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-101-3-334</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sarlis</surname><given-names>NJ</given-names></name>, <name name-style="western"><surname>Chanock</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Nieman</surname><given-names>LK</given-names></name>. <article-title>Cortisolemic indices predict severe infections in Cushing Syndrome due to ectopic production of adrenocorticotropin</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2000</year>; <volume>85</volume>:<fpage>42</fpage>–<lpage>47</lpage>.<pub-id pub-id-type="pmid">10634361</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jcem.85.1.6294</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Toogood</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Baskerville</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jennings</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lefcoe</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Johansson</surname><given-names>SA</given-names></name>. <article-title>Bioequivalent doses of budesonide and prednisone in moderate and severe asthma</article-title>. <source>J Allergy Clin Immunol</source>
<year>1989</year>; <volume>84</volume>:<fpage>688</fpage>–<lpage>700</lpage>.<pub-id pub-id-type="pmid">2681331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/0091-6749(89)90297-2</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1:</label><caption><p id="P33">Study cohort design</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1828545-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p id="P34">Plots of budesonide Cmax and Cmin values in the absence or presence of voriconazole (Cmax and Cmin values in mcg/dl)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihms-1828545-f0002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p id="P35">Patient characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Subject number</th><th align="left" valign="top" rowspan="1" colspan="1">Age</th><th align="left" valign="top" rowspan="1" colspan="1">Sex</th><th align="center" valign="top" rowspan="1" colspan="1">Transplant regimen</th><th align="left" valign="top" rowspan="1" colspan="1">Enrollment date post-transplant</th><th align="left" valign="top" rowspan="1" colspan="1">Cohort</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">43</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">RIC, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+29</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">RIC, Haplo-cord</td><td align="center" valign="top" rowspan="1" colspan="1">+104</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">67</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Myeloablative, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+37</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">42</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Myeloablative, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+70</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">33</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">Nonmyeloablative, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+190</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">46</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Myeloablative, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+27</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">28</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Myeloablative, Haploidentical PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+124</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">44</td><td align="center" valign="top" rowspan="1" colspan="1">M</td><td align="center" valign="top" rowspan="1" colspan="1">RIC, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+28</td><td align="center" valign="top" rowspan="1" colspan="1">3</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="center" valign="top" rowspan="1" colspan="1">F</td><td align="center" valign="top" rowspan="1" colspan="1">Myeloablative, MRD PBSCT</td><td align="center" valign="top" rowspan="1" colspan="1">+28</td><td align="center" valign="top" rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P36">Abbreviations: RIC: reduced intensity conditioning; MRD: matched related donor; PBSCT: peripheral blood stem cell transplant; Haplo-cord: combined haploidentical &amp; cord-blood transplant.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p id="P37">Budesonide and voriconazole levels in evaluable subjects</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><th colspan="6" align="center" valign="top" style="border-bottom: solid 1px" rowspan="1">Voriconazole cohorts (cohorts 1 and 2)</th></tr><tr><th colspan="5" align="center" valign="top" style="border-bottom: solid 1px" rowspan="1">Budesonide level</th><th align="center" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">Voriconazole level</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1">Subject Number</th><th align="center" valign="top" rowspan="1" colspan="1">Cmin (mcg/dl) (off voriconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmax (mcg/dl) (off voriconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmin (mcg/dl) (on voriconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmax (mcg/dl) (on voriconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmin (mcg/mL)</th></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0.205</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">2.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">0.915</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">7</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.885</td><td align="center" valign="top" rowspan="1" colspan="1">0.905</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="center" valign="top" rowspan="1" colspan="1">0.44</td><td align="center" valign="top" rowspan="1" colspan="1">0.62</td><td align="center" valign="top" rowspan="1" colspan="1">1.4</td><td align="center" valign="top" rowspan="1" colspan="1">1.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11</td><td align="center" valign="top" rowspan="1" colspan="1">0.15</td><td align="center" valign="top" rowspan="1" colspan="1">0.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.81</td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">1.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td><td align="center" valign="top" rowspan="1" colspan="1">1.9</td></tr></tbody><tbody><tr><th colspan="6" align="center" valign="top" style="border-bottom: solid 1px;border-top: solid 1px" rowspan="1">Budesonide levels in Fluconazole cohort (cohort 3)</th></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Cmin (mcg/dl) (off fluconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmax (mcg/dl) (off fluconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmin (mcg/dl) (on fluconazole)</th><th align="center" valign="top" rowspan="1" colspan="1">Cmax (mcg/dl) (on fluconazole)</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.19</td><td align="center" valign="top" rowspan="1" colspan="1">0.84</td><td rowspan="3" align="left" valign="top" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">9</td><td align="center" valign="top" rowspan="1" colspan="1">0.13</td><td align="center" valign="top" rowspan="1" colspan="1">0.11</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="center" valign="top" rowspan="1" colspan="1">0.52</td><td align="center" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">0.05</td><td align="center" valign="top" rowspan="1" colspan="1">0.69</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p id="P43">Budesonide level analysis for voriconazole and fluconazole cohorts</p></caption><table frame="hsides" rules="none"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><th colspan="7" align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Voriconazole cohorts (cohorts 1 and 2)</th></tr><tr><th align="left" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="bottom" rowspan="1">Cmin (mcg/dl)</th><th align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="bottom" rowspan="1">Cmax (mcg/dl)</th><th align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" style="border-bottom: solid 1px;border-right: solid 1px" rowspan="1" colspan="1"/><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">off voriconazole</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">on voriconazole</th><th align="center" valign="top" style="border-bottom: solid 1px;border-right: solid 1px" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">off voriconazole</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">on voriconazole</th><th align="center" valign="top" style="border-bottom: solid 1px" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><td align="left" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1">Mean ± SD</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.16± 0.15</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.03± 0.24</td><td rowspan="3" align="center" valign="top" style="border-right: solid 1px" colspan="1">0.0009</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.23± 0.21</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.27± 0.77</td><td rowspan="3" align="center" valign="top" colspan="1">0.0037</td></tr><tr><td align="left" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1">Geometric mean</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.12</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.01</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.17</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.13</td></tr><tr><td align="left" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1">Geometric mean ratio (90% CI)</td><td colspan="2" align="center" valign="bottom" rowspan="1">8.52 (4.64–15.66)</td><td colspan="2" align="center" valign="bottom" rowspan="1">6.63 (3.15–13.94)</td></tr></tbody><tbody><tr><th colspan="7" align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1">Fluconazole cohort (cohort 3)</th></tr><tr><th align="left" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="bottom" rowspan="1">Cmin (mcg/dl)</th><th align="center" valign="bottom" style="border-right: solid 1px" rowspan="1" colspan="1"/><th colspan="2" align="center" valign="bottom" rowspan="1">Cmax (mcg/dl)</th><th align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="bottom" style="border-bottom: solid 1px;border-right: solid 1px" rowspan="1" colspan="1"/><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">off fluconazole</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">on fluconazole</th><th align="center" valign="bottom" style="border-bottom: solid 1px;border-right: solid 1px" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">off fluconazole</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">on fluconazole</th><th align="center" valign="bottom" style="border-bottom: solid 1px" rowspan="1" colspan="1">
<italic toggle="yes">P</italic>
</th></tr><tr><td align="left" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1">Mean ± SD</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.23± 0.25</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.10± 0.08</td><td rowspan="3" align="center" valign="top" style="border-right: solid 1px" colspan="1">0.60</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.16± 0.08</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.68± 0.16</td><td rowspan="3" align="center" valign="top" colspan="1">0.027</td></tr><tr><td align="left" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1">Geometric mean</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.15</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.08</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.15</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" valign="middle" style="border-right: solid 1px" rowspan="1" colspan="1">Geometric mean ratio (90% CI)</td><td colspan="2" align="center" valign="bottom" rowspan="1">0.52 (0.023–11.90)</td><td colspan="2" align="center" valign="bottom" rowspan="1">4.38 (2.12–9.06)</td></tr></tbody></table></table-wrap></floats-group></article><article id="jcph6131" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">379</journal-id><journal-id journal-id-type="pmc-domain">blackwellopen</journal-id><journal-id journal-id-type="publisher-id">JCPH</journal-id><journal-title-group><journal-title>Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0091-2700</issn><issn pub-type="epub">1552-4604</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Wiley Open Access Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11771711</article-id><article-id pub-id-type="pmcid-ver">PMC11771711.1</article-id><article-id pub-id-type="pmcaid">11771711</article-id><article-id pub-id-type="pmcaiid">11771711</article-id><article-id pub-id-type="pmid">39263900</article-id><article-id pub-id-type="doi">10.1002/jcph.6131</article-id><article-id pub-id-type="publisher-id">JCPH6131</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants: A Randomized Phase 1 Study</article-title><alt-title alt-title-type="left-running-head">Prokopienko et al</alt-title></title-group><contrib-group><contrib id="jcph6131-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Prokopienko</surname><given-names initials="AJ">Alexander J.</given-names></name><degrees>PharmD, PhD</degrees><xref rid="jcph6131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>alexander.prokopienko@takeda.com</email></address></contrib><contrib id="jcph6131-cr-0002" contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="J">Junyao</given-names></name><degrees>PhD</degrees><xref rid="jcph6131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jcph6131-cr-0003" contrib-type="author"><name name-style="western"><surname>Yajnik</surname><given-names initials="V">Vijay</given-names></name><degrees>MD</degrees><xref rid="jcph6131-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="jcph6131-cr-0004" contrib-type="author"><name name-style="western"><surname>Baratta</surname><given-names initials="M">Mike</given-names></name><degrees>MAHCPM</degrees><xref rid="jcph6131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jcph6131-cr-0005" contrib-type="author"><name name-style="western"><surname>Desai</surname><given-names initials="NK">Nirav K.</given-names></name><degrees>MD</degrees><xref rid="jcph6131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jcph6131-cr-0006" contrib-type="author"><name name-style="western"><surname>Richmond</surname><given-names initials="CA">Camilla A.</given-names></name><degrees>MD</degrees><xref rid="jcph6131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="jcph6131-cr-0007" contrib-type="author"><name name-style="western"><surname>Suri</surname><given-names initials="A">Ajit</given-names></name><degrees>PhD</degrees><xref rid="jcph6131-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jcph6131-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Takeda Development Center Americas, Inc.</institution>
<city>Cambridge</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><aff id="jcph6131-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Takeda Pharmaceuticals USA, Inc.</institution>
<city>Lexington</city>
<named-content content-type="country-part">MA</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Corresponding author</bold>:<break/>Alexander J. Prokopienko, 125 Binney St, Cambridge, MA 02142<break/> Email: <email>alexander.prokopienko@takeda.com</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2025</year></pub-date><volume>65</volume><issue seq="90">2</issue><issue-id pub-id-type="pmc-issue-id">480624</issue-id><issue-id pub-id-type="doi">10.1002/jcph.v65.2</issue-id><fpage>217</fpage><lpage>225</lpage><history><date date-type="received"><day>12</day><month>4</month><year>2024</year></date><date date-type="accepted"><day>22</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>01</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-01-31 10:25:44.370"><day>31</day><month>01</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2024 Takeda Pharmaceuticals USA, Inc. <italic toggle="yes">The Journal of Clinical Pharmacology</italic> published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JCPH-65-217.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:JCPH-65-217.pdf"/><abstract><title>Abstract</title><p>Budesonide oral suspension (BOS) is a swallowed corticosteroid indicated for 12‐week therapy in eosinophilic esophagitis with minimal systemic exposure following administration. We aimed to assess the relative bioavailability of a single dose of BOS administered under fasting and fed (high‐fat/high‐calorie meal) conditions. Healthy adult volunteers (N = 20) were enrolled in an open‐label, single‐center, crossover study and were randomized (1:1) to receive a single oral dose of BOS 2.0 mg under fasting or fed conditions, with a 48‐h washout period before crossover to the alternative conditions. Serial plasma samples were collected before and up to 24 h after dosing. Pharmacokinetic (PK) parameters were calculated from plasma budesonide concentration–time profiles by noncompartmental analysis. The mean peak budesonide concentration (C<sub>max</sub>) was ∼13% lower under fed than under fasting conditions (604.1 vs 692.9 pg/mL). Areas under the concentration–time curves from dosing to the last measurable budesonide concentration and from dosing to infinity were ∼26% higher and ∼27% higher under fed than fasting conditions (3529 vs 2811 pg h/mL and 3892 vs 3075 pg h/mL, respectively). The median time to peak plasma budesonide concentration was significantly longer (∼1 h) under fed than fasting conditions (2.516 vs 1.286 h, <italic toggle="yes">P</italic> &lt; .001). Safety and tolerability were also assessed throughout the study; all adverse events were mild or moderate in severity. Despite slight differences in budesonide PK parameters between fed and fasting conditions, the effect of food on systemic exposure to budesonide (BOS formulation) is not expected to be clinically meaningful.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jcph6131-kwd-0001">budesonide oral suspension</kwd><kwd id="jcph6131-kwd-0002">eosinophilic esophagitis</kwd><kwd id="jcph6131-kwd-0003">food‐effect study</kwd><kwd id="jcph6131-kwd-0004">pharmacokinetics</kwd><kwd id="jcph6131-kwd-0005">swallowed corticosteroids</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>Takeda Development Center Americas, Inc.</funding-source></award-group></funding-group><counts><fig-count count="2"/><table-count count="3"/><page-count count="9"/><word-count count="5743"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.2 mode:remove_FC converted:27.01.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="jcph6131-sec-0010"><title>Introduction</title><p>Eosinophilic esophagitis (EoE) is a chronic, immune‐mediated disease characterized by esophageal dysfunction and eosinophilic inflammation of the esophageal mucosa.<xref rid="jcph6131-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref>, <xref rid="jcph6131-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> Over time, the prevalence and incidence of EoE have rapidly increased in the United States and are now estimated at approximately 55.4 and 10.8 per 100,000 person‐years, respectively.<xref rid="jcph6131-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> Symptoms of EoE have a significant impact on the health‐related quality of life of affected individuals and their families.<xref rid="jcph6131-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jcph6131-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jcph6131-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref> Although both children and adults may be diagnosed with EoE,<xref rid="jcph6131-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref> adult patients may present with dysphagia (i.e., difficulty swallowing), esophageal stricture, and food impaction, while symptoms in pediatric patients include feeding difficulty, vomiting, heartburn, and regurgitation.<xref rid="jcph6131-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jcph6131-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jcph6131-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>
</p><p>Clinical guidelines for adult and pediatric patients with EoE strongly recommend swallowed topical corticosteroids, with conditional recommendations for proton pump inhibitors and/or dietary modifications in place of no treatment.<xref rid="jcph6131-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref>, <xref rid="jcph6131-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Swallowed topical corticosteroids are preferred over systemic corticosteroids, owing to the well‐characterized adverse effects of systemically absorbed corticosteroids (e.g., glaucoma, secondary adrenal insufficiency, and cushingoid features).<xref rid="jcph6131-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref>, <xref rid="jcph6131-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref>
</p><p>Budesonide oral suspension (BOS) is an immediate‐release, swallowed corticosteroid that was optimized as a viscous thixotropic suspension.<xref rid="jcph6131-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jcph6131-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jcph6131-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> BOS 2.0 mg twice daily (b.i.d.) is approved by the US Food and Drug Administration (FDA) for 12‐week use in pediatric and adult patients aged 11 years and older with EoE; BOS 2.0 mg b.i.d. is not indicated for treatment beyond 12 weeks and additional data on long‐term efficacy and safety are needed.<xref rid="jcph6131-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Before BOS was approved by the US FDA for EoE, patients' only options for swallowed corticosteroids were the off‐label use of specialty compounded or home‐made preparations, and even sometimes off‐label use of metered dose inhalers.<xref rid="jcph6131-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</p><p>Pharmacokinetic (PK) data for BOS have been reported in a phase 1 study in healthy adults, a phase 2 dose‐ranging study in pediatric and adolescent patients with EoE, and a population PK analysis (various formulations) in pediatric and adult patients with EoE and in healthy adults.<xref rid="jcph6131-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jcph6131-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jcph6131-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Budesonide has high glucocorticoid activity with minimal systemic exposure following oral administration and absorption in healthy individuals, owing to an 80% to 90% first‐pass hepatic metabolism and a plasma clearance of approximately 0.9 to 1.8 L/min.<xref rid="jcph6131-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>Several food‐effect studies have reported PK data for enteric‐coated, delayed‐release capsule and extended‐release tablet formulations of budesonide (which are approved by the FDA for patients with inflammatory bowel disease).<xref rid="jcph6131-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jcph6131-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jcph6131-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jcph6131-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Although differences in PK parameters have been reported for these formulations when administered under fasting conditions compared with fed conditions, these differences were generally not considered to be clinically meaningful.<xref rid="jcph6131-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jcph6131-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jcph6131-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jcph6131-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</p><p>Until now, the impact of food intake on budesonide bioavailability has not been formally investigated for BOS. In this phase 1 study, we assessed the relative bioavailability of budesonide after a single dose of BOS 2.0 mg under fasting and fed (high‐fat/high‐calorie meal) conditions in healthy adult volunteers. The safety and tolerability of BOS were also evaluated under these conditions.</p></sec><sec id="jcph6131-sec-0020"><title>Methods</title><sec id="jcph6131-sec-0030"><title>Study Design and Population</title><p>This study was conducted in healthy adult volunteers at a single center in the United States (Celerion, Lincoln, NE) in February 2023. The protocol and informed consent forms were reviewed and approved by the local institutional review board (Advarra, Columbia, MD, USA). All participants provided informed consent before the start of any study‐specific procedures. The study was conducted according to the study protocol, the ethical principles in accordance with the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use's Harmonised Tripartite Guideline for Good Clinical Practice, and all local or regional regulatory requirements.</p><p>This open‐label, single‐dose, randomized, two‐period, two‐sequence, two‐way crossover study aimed to assess the effect of food on the PK profile of budesonide after a single oral dose of BOS 2.0 mg (0.2 mg/mL in a volume of 10 mL) in healthy adults. The study was designed (Figure <xref rid="jcph6131-fig-0001" ref-type="fig">1</xref>) in accordance with FDA guidance for food‐effect bioavailability studies.<xref rid="jcph6131-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p><fig position="float" fig-type="Figure" id="jcph6131-fig-0001" orientation="portrait"><label>Figure 1</label><caption><p>Study design. <sup>a</sup>In each treatment period, participants received a single oral dose of BOS 2.0 mg under fasting or fed (high‐fat/high‐calorie meal) conditions on day 1, according to the randomization schedule. <sup>b</sup>PK sampling was carried out pre‐dose and up to 24 h after dosing in each period. <sup>c</sup>All participants who received BOS returned to the study site approximately 3 days after the last dose of BOS for follow‐up procedures and to determine if any adverse events had occurred since the last study visit. BOS, budesonide oral suspension; PK, pharmacokinetic.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="JCPH-65-217-g001.jpg"/></fig><p>In period 1, participants were randomly assigned to receive a single oral dose of BOS 2.0 mg under fasting or fed (high‐fat/high‐calorie meal) conditions, followed by a washout period of at least 48 h. In period 2, participants were crossed over to receive a single oral dose of BOS 2.0 mg under the alternative fasting or fed conditions. For fasting conditions, participants were required to fast overnight for at least 10 h and up to at least 4 h after dosing. For fed conditions, participants were required to fast overnight for at least 10 h until 30 min pre‐dose, when they were given a high‐fat/high‐calorie breakfast (∼50% fat, 800 to 1000 calories), which was consumed entirely within 30 min. Water was restricted within 1 h of dosing but was allowed after each mouth rinse (∼240 mL, 30 min post‐dose) or ad libitum at all other times. This was consistent with the prescribing information for BOS 2.0 mg b.i.d. and guidance during clinical studies, which advised “do not eat or drink for 30 minutes after taking BOS.”<xref rid="jcph6131-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jcph6131-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jcph6131-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jcph6131-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> This guidance was implemented to ensure optimal coating of the esophageal mucosa with BOS and to enhance budesonide exposure at the site of action. All participants who received BOS returned to the study site approximately 3 days after the last dose of BOS for follow‐up procedures and to determine if any adverse events (AEs) had occurred since the last study visit.</p><p>Eligible participants were aged 19 to 55 years with a body mass index (BMI) of ≥18.0 to ≤32.0 kg/m<sup>2</sup>. Individuals with a history or presence of a clinically significant medical or psychiatric condition or disease, in the opinion of the investigator or designee, were excluded from the study. Prior concomitant medications (including prescription and nonprescription medications, herbal remedies, or vitamin supplements) were prohibited. Individuals were also excluded if they had received an injectable corticosteroid in the 12 weeks before the first BOS dose; had received any other forms of corticosteroid (e.g., inhaled, nasal, or oral) in the 30 days before the first BOS dose; or had ingested any drugs known to be moderate or strong inducers of cytochrome P450 3A4 enzymes and/or P‐glycoprotein, in the 28 days before the first BOS dose. Hormone replacement therapy was permitted, including thyroid hormone replacement medication if the participant had been on the same stable dose for at least the immediate 3 months before the first BOS dose. After the first BOS dose, acetaminophen administration (up to 2.0 g per 24 h) was permitted at the discretion of the investigator. Full inclusion and exclusion criteria are available in Supplemental Material <xref rid="jcph6131-supitem-0001" ref-type="supplementary-material">S1</xref>.</p></sec><sec id="jcph6131-sec-0040"><title>Study Endpoints</title><p>For the primary PK endpoints, the following parameters were examined: maximum observed concentration (C<sub>max</sub>); area under the concentration–time curve from 0 h to the time of the last quantifiable concentration (AUC<sub>last</sub>); and area under the concentration–time curve from 0 h to infinity (AUC<sub>∞</sub>), calculated using the observed value of the last quantifiable concentration.</p><p>PK parameters analyzed as secondary endpoints were: area under the concentration–time curve from 0 to 12 h (AUC<sub>0‐12</sub>); lag time to the first quantifiable concentration (t<sub>lag</sub>); time to the first occurrence of C<sub>max</sub> (t<sub>max</sub>); area under the concentration–time curve from the last quantifiable concentration to infinity (AUC<sub>extrap%</sub>), calculated using the observed value of the last quantifiable concentration and expressed as a percentage of AUC<sub>∞</sub>; terminal disposition phase half‐life (t<sub>1/2z</sub>); apparent clearance after extravascular administration (CL/F), calculated using the observed value of the last quantifiable concentration; and apparent volume of distribution during the terminal disposition phase after extravascular administration (V<sub>z</sub>/F), calculated using the observed value of the last quantifiable concentration.</p><p>Safety endpoints included the incidence of treatment‐emergent AEs (TEAEs) and their severity, seriousness, and causality, as well as the incidence of clinically significant abnormal values for vital signs and clinical laboratory evaluations.</p></sec><sec id="jcph6131-sec-0050"><title>PK Assessments</title><p>Plasma samples for PK analysis were collected pre‐dose and up to 24 h post‐dose in each period. Post‐dose collections occurred every 15 min up to 30 min after dosing; every 30 min up to 4 h after dosing; every 1 h from 4 to 6 h after dosing; every 2 h from 6 to 12 h after dosing; and at 24 h after dosing. Plasma budesonide concentrations were listed and summarized by PK sampling time and treatment using descriptive statistics. Samples were measured using liquid chromatography/tandem mass spectrometry assay at QPS Netherlands BV (Groningen, the Netherlands; analytical range for budesonide: 20‐5000 pg/mL). PK parameters of budesonide were calculated from the individual concentration–time profiles from all evaluable participants using noncompartmental analysis methods in Phoenix WinNonlin (v8.3.4). All calculations were based on actual post‐dose sampling times. PK parameters were not calculated for participants with fewer than three consecutive post‐dose time points with quantifiable concentrations. Further details of the human PK assay are included in Supplemental Material <xref rid="jcph6131-supitem-0001" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="jcph6131-sec-0060"><title>Safety Assessments</title><p>Safety was evaluated by the incidence, severity, and relationship(s) of TEAEs, as well as changes from baseline in clinical laboratory results, vital signs, and 12‐lead electrocardiograms. TEAEs were defined as AEs that started or worsened following administration of the first dose of BOS and until the follow‐up visit approximately 3 days after the last dose of BOS. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA; v25.1). Clinically significant laboratory values and vital signs were reported as AEs, as applicable.</p></sec><sec id="jcph6131-sec-0070"><title>Statistical Analyses</title><p>For plasma budesonide C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>∞</sub>, it was estimated that 18 participants would need to enroll and complete all treatment periods of the study to provide 80.0%, 85.0%, and 80.0% power to test for bioequivalence between dosing under fasting and fed conditions. This assumed a true mean ratio of 1.0 with intraparticipant coefficients of variation of 21.8%, 21.0%, and 21.8%, respectively, using the criteria of a 90% CI within 0.80 to 1.25. In total, 20 participants were enrolled to allow for a dropout rate of 10%. All 20 participants complied sufficiently with the protocol and displayed an evaluable PK profile, and were thus included in the PK analyses.</p><p>A linear mixed‐effects model was applied to natural logarithm (ln)‐transformed C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>∞</sub>, with treatment, period, and sequence as fixed effects, and participant within sequence as a random effect. Point estimates and their associated 90% CIs were constructed for the difference between treatment groups (fed − fasting). The point estimates and their associated 90% CIs were then back transformed to provide point estimates and 90% CIs for the ratios of fed to fasting. Geometric least‐squares means (LSMs) were calculated by exponentiating the LSMs derived from the linear mixed‐effects model. Geometric least‐squares mean ratios (GMRs) were calculated as: 100*value for fed conditions/value for fasting conditions. Intraparticipant percent coefficients of variation (CV%) were calculated as: 100*(√(exp[MSE] − 1)), where MSE was defined as the residual variance from the linear mixed‐effects model.</p><p>Analyses of t<sub>lag</sub> and t<sub>max</sub> were performed by nonparametric Wilcoxon signed‐rank tests. The median differences (fed − fasting) and 90% CIs were estimated using the Hodges–Lehmann method and Walsh averages. The t<sub>lag</sub> and t<sub>max</sub> parameters were not ln‐transformed, and the comparison of interest was the same as in the linear mixed‐effects model. All statistical analyses were conducted using SAS Version 9.4.</p></sec></sec><sec id="jcph6131-sec-0080"><title>Results</title><sec id="jcph6131-sec-0090"><title>Baseline Characteristics and Patient Disposition</title><p>In total, 20 participants were enrolled and completed the study. The majority of participants were female (60% [12/20]), White (55% [11/20]), and not Hispanic or Latino (85% [17/20]) (Table <xref rid="jcph6131-tbl-0001" ref-type="table">1</xref>). Participants had a mean age of 35.7 years and a mean BMI of 27.6 kg/m<sup>2</sup>.</p><table-wrap position="float" id="jcph6131-tbl-0001" content-type="Table" orientation="portrait"><label>Table 1</label><caption><p>Baseline Demographics and Clinical Characteristics</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">
<p>Baseline Demographic/Clinical Characteristic</p>
</th><th align="center" rowspan="1" colspan="1">
<p>Period 1: Fasting</p>
<p>Period 2: Fed</p>
<p>(n = 10)</p>
</th><th align="center" rowspan="1" colspan="1">
<p>Period 1: Fed</p>
<p>Period 2: Fasting</p>
<p>(n = 10)</p>
</th><th align="center" rowspan="1" colspan="1">
<p>Overall</p>
<p>(N = 20)</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Sex, n (%)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">7 (70.0)</td><td align="center" rowspan="1" colspan="1">5 (50.0)</td><td align="center" rowspan="1" colspan="1">12 (60.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Male</td><td align="center" rowspan="1" colspan="1">3 (30.0)</td><td align="center" rowspan="1" colspan="1">5 (50.0)</td><td align="center" rowspan="1" colspan="1">8 (40.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Race, n (%)</bold>
<xref rid="jcph6131-tbl1-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">American Indian or Alaska Native</td><td align="center" rowspan="1" colspan="1">1 (10.0)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asian</td><td align="center" rowspan="1" colspan="1">2 (20.0)</td><td align="center" rowspan="1" colspan="1">0 (0.0)</td><td align="center" rowspan="1" colspan="1">2 (10.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Black or African American</td><td align="center" rowspan="1" colspan="1">1 (10.0)</td><td align="center" rowspan="1" colspan="1">2 (20.0)</td><td align="center" rowspan="1" colspan="1">3 (15.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multiple</td><td align="center" rowspan="1" colspan="1">1 (10.0)</td><td align="center" rowspan="1" colspan="1">2 (20.0)</td><td align="center" rowspan="1" colspan="1">3 (15.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">White</td><td align="center" rowspan="1" colspan="1">5 (50.0)</td><td align="center" rowspan="1" colspan="1">6 (60.0)</td><td align="center" rowspan="1" colspan="1">11 (55.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Ethnicity, n (%)</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hispanic or Latino</td><td align="center" rowspan="1" colspan="1">2 (20.0)</td><td align="center" rowspan="1" colspan="1">1 (10.0)</td><td align="center" rowspan="1" colspan="1">3 (15.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not Hispanic or Latino</td><td align="center" rowspan="1" colspan="1">8 (80.0)</td><td align="center" rowspan="1" colspan="1">9 (90.0)</td><td align="center" rowspan="1" colspan="1">17 (85.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age, years, mean (SD)</bold>
</td><td align="center" rowspan="1" colspan="1">38.6 (9.5)</td><td align="center" rowspan="1" colspan="1">32.7 (10.0)</td><td align="center" rowspan="1" colspan="1">35.7 (10.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Min, max</td><td align="center" rowspan="1" colspan="1">26, 55</td><td align="center" rowspan="1" colspan="1">22, 53</td><td align="center" rowspan="1" colspan="1">22, 55</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>BMI, kg/m<sup>2</sup>, mean (SD)</bold>
</td><td align="center" rowspan="1" colspan="1">27.5 (2.9)</td><td align="center" rowspan="1" colspan="1">27.6 (2.7)</td><td align="center" rowspan="1" colspan="1">27.6 (2.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Height, cm, mean (SD)</bold>
</td><td align="center" rowspan="1" colspan="1">165.4 (10.7)</td><td align="center" rowspan="1" colspan="1">169.0 (11.5)</td><td align="center" rowspan="1" colspan="1">167.2 (11.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Weight, kg, mean (SD)</bold>
</td><td align="center" rowspan="1" colspan="1">76.0 (15.4)</td><td align="center" rowspan="1" colspan="1">79.5 (14.5)</td><td align="center" rowspan="1" colspan="1">77.8 (14.7)</td></tr></tbody></table><table-wrap-foot><fn id="jcph6131-tbl1-note-0001"><p>BMI, body mass index; n, number of patients; N, total number of patients.</p></fn><fn id="jcph6131-tbl1-note-0002"><label>a</label><p>Participants reporting two or more races are summarized under “Multiple,” not under the individual race category.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>Ten participants each were randomly assigned to receive a single oral dose of BOS 2.0 mg under fasting or fed (high‐fat/high‐calorie meal) conditions; this was followed by a crossover to the alternative conditions. Baseline demographics were generally similar for the two treatment groups, with a minor difference noted in the mean age of participants. For those who first received BOS under fasting conditions, the mean age was 38.6 years. For participants who first received BOS under fed conditions, the mean age was 32.7 years.</p></sec><sec id="jcph6131-sec-0100"><title>PK Parameters</title><p>Plasma budesonide concentration–time profiles for all participants were well characterized following administration under fasting and fed conditions (Figure <xref rid="jcph6131-fig-0002" ref-type="fig">2</xref>). In total, 16/20 participants (80%) under fasting conditions and 15/20 participants (75%) under fed conditions had quantifiable plasma budesonide concentrations at 0.25 h post‐dose. Quantifiable plasma budesonide concentrations were observed for all participants up to 10 h post‐dose under fasting conditions. At 12 h post‐dose, 18/20 participants (90%) had quantifiable budesonide concentrations under fasting conditions, and all participants had quantifiable concentrations under fed conditions. Only 4/20 participants (20%) under fasting conditions and 10/20 participants (50%) under fed conditions had quantifiable plasma budesonide concentrations at 24 h post‐dose.</p><fig position="float" fig-type="Figure" id="jcph6131-fig-0002" orientation="portrait"><label>Figure 2</label><caption><p>Arithmetic mean plasma budesonide concentrations over time after a single oral dose of BOS 2.0 mg under fasting and fed conditions in healthy participants on linear (a) and semi‐logarithmic (b) scales. BOS, budesonide oral suspension.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="JCPH-65-217-g002.jpg"/></fig><p>The geometric mean plasma budesonide C<sub>max</sub> was slightly lower under fed conditions than under fasting conditions (604.1 vs 692.9 pg/mL) (Table <xref rid="jcph6131-tbl-0002" ref-type="table">2</xref>). The geometric mean plasma budesonide AUC<sub>last</sub> and AUC<sub>∞</sub> were slightly higher under fed conditions than under fasting conditions (3529 vs 2811 pg h/mL and 3892 vs 3075 pg h/mL, respectively). Plasma budesonide C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>∞</sub> were approximately 13% lower, 26% higher, and 27% higher, respectively, under fed conditions than under fasting conditions.</p><table-wrap position="float" id="jcph6131-tbl-0002" content-type="Table" orientation="portrait"><label>Table 2</label><caption><p>Summary of Budesonide PK Parameters Following a Single Dose of BOS 2.0 mg Under Fasting and Fed Conditions in Healthy Participants</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">PK parameter</th><th align="center" rowspan="1" colspan="1">Fasting (n = 20)<xref rid="jcph6131-tbl2-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" rowspan="1" colspan="1">Fed (n = 20)<xref rid="jcph6131-tbl2-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>C<sub>max</sub>, pg/mL</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric mean (geometric CV%)</td><td align="center" rowspan="1" colspan="1">692.9 (54.4)</td><td align="center" rowspan="1" colspan="1">604.1 (46.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric LS mean ratio, % (90% CI)<xref rid="jcph6131-tbl2-note-0004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td><td align="center" colspan="2" rowspan="1">87.18 (74.80 to 101.61)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AUC<sub>last</sub>, pg·h/mL</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric mean (geometric CV%)</td><td align="center" rowspan="1" colspan="1">2811 (57.5)</td><td align="center" rowspan="1" colspan="1">3529 (52.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric LS mean ratio, % (90% CI)</td><td align="center" colspan="2" rowspan="1">125.54 (113.85 to 138.41)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AUC<sub>∞</sub>, pg·h/mL</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric mean (geometric CV%)</td><td align="center" rowspan="1" colspan="1">3075 (57.0)</td><td align="center" rowspan="1" colspan="1">3892 (47.1)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric LS mean ratio, % (90% CI)</td><td align="center" colspan="2" rowspan="1">126.56 (116.60 to 137.36)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AUC<sub>0‐12</sub>, pg·h/mL</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Geometric mean (geometric CV%)</td><td align="center" rowspan="1" colspan="1">2728 (53.0)</td><td align="center" rowspan="1" colspan="1">3208 (42.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>t<sub>lag</sub>, h</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (min, max)</td><td align="center" rowspan="1" colspan="1">0.33 (0.26, 0.56)</td><td align="center" rowspan="1" colspan="1">0.31 (0.25, 0.53)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median difference (90% CI)<xref rid="jcph6131-tbl2-note-0005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td><td align="center" colspan="2" rowspan="1">0.003 (−0.041 to 0.049)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>t<sub>max</sub>, h</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median (min, max)</td><td align="center" rowspan="1" colspan="1">1.29 (0.55, 2.57)</td><td align="center" rowspan="1" colspan="1">2.52 (1.01, 6.03)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Median difference (90% CI)</td><td align="center" colspan="2" rowspan="1">0.884 (0.472 to 1.285)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>AUC<sub>extrap%</sub>, %</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arithmetic mean (SD)</td><td align="center" rowspan="1" colspan="1">8.455 (4.734)</td><td align="center" rowspan="1" colspan="1">9.006 (7.272)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>t<sub>1/2z</sub>, h</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arithmetic mean (SD)</td><td align="center" rowspan="1" colspan="1">4.457 (1.435)</td><td align="center" rowspan="1" colspan="1">4.933 (1.388)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>CL/F, L/h</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arithmetic mean (SD)</td><td align="center" rowspan="1" colspan="1">744.2 (406.0)</td><td align="center" rowspan="1" colspan="1">565.8 (262.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>V<sub>z</sub>/F, L</bold>
</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arithmetic mean (SD)</td><td align="center" rowspan="1" colspan="1">4358 (2155)</td><td align="center" rowspan="1" colspan="1">3686 (1175)</td></tr></tbody></table><table-wrap-foot><fn id="jcph6131-tbl2-note-0001"><p>AUC<sub>∞</sub>, area under the concentration–time curve from 0 h to infinity, calculated using the observed value of the last quantifiable concentration; AUC<sub>0‐12</sub>, area under the concentration–time curve from 0 to 12 h; AUC<sub>extrap%</sub>, area under the concentration–time curve from the last quantifiable concentration to infinity, calculated using the observed value of the last quantifiable concentration, expressed as a percentage of AUC<sub>∞</sub>; AUC<sub>last</sub>, area under the concentration–time curve from 0 h to the time of the last quantifiable concentration; BOS, budesonide oral suspension; CI, confidence interval; CL/F, apparent clearance after extravascular administration, calculated using the observed value of the last quantifiable concentration; C<sub>max</sub>, maximum observed concentration; CV%, percentage coefficient of variation; LS, least‐squares; n, number of patients; PK, pharmacokinetic; t<sub>1/2z</sub>, terminal disposition phase half‐life; t<sub>lag</sub>, lag time to the first quantifiable concentration; t<sub>max</sub>, time to the first occurrence of C<sub>max</sub>; V<sub>z</sub>/F, apparent volume of distribution during the terminal disposition phase after extravascular administration, calculated using the observed value of the last quantifiable concentration.</p></fn><fn id="jcph6131-tbl2-note-0002"><label>
<sup>a</sup>
</label><p>Fasting participants were those who received BOS 2.0 mg under fasting conditions in either period 1 or period 2 of the study.</p></fn><fn id="jcph6131-tbl2-note-0003"><label>
<sup>b</sup>
</label><p>Fed participants were those who received BOS 2.0 mg under fed conditions in either period 1 or period 2 of the study.</p></fn><fn id="jcph6131-tbl2-note-0004"><label>
<sup>c</sup>
</label><p>Geometric LS means were calculated by exponentiating the LS means derived from the linear mixed‐effects model. Geometric LS mean ratios were calculated as: 100*LS mean for fed conditions/LS mean for fasting conditions.</p></fn><fn id="jcph6131-tbl2-note-0005"><label>
<sup>d</sup>
</label><p>Median differences (fed versus fasting conditions) and 90% CIs were estimated using the Hodges–Lehmann method and Walsh averages.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap><p>The geometric mean plasma budesonide AUC<sub>0‐12</sub> was slightly higher under fed conditions than under fasting conditions (3208 vs 2728 pg h/mL) (Table <xref rid="jcph6131-tbl-0002" ref-type="table">2</xref>). The median t<sub>lag</sub> of plasma budesonide was similar following each treatment condition (fasting: 0.328 h; fed: 0.308 h; <italic toggle="yes">P</italic> = .906). The median t<sub>max</sub> of plasma budesonide was significantly longer by approximately 1 h under fed conditions compared with under fasting conditions (2.516 vs 1.286 h; <italic toggle="yes">P</italic> = .001). The arithmetic mean t<sub>1/2z</sub> of plasma budesonide was similar under each condition, whereas the arithmetic mean plasma budesonide CL/F and V<sub>z</sub>/F were lower under fed conditions than under fasting conditions (565.8 vs 744.2 L/h and 3686 vs 4358 L, respectively).</p><p>The plasma budesonide concentration–time profile (linear scale) with standard deviation values is included in Supplemental Materials <xref rid="jcph6131-supitem-0001" ref-type="supplementary-material">S3</xref>.</p></sec><sec id="jcph6131-sec-0110"><title>Safety</title><p>In total, 10 TEAEs were reported by 7 participants (35%) in the study (fasting: n = 2; fed: n = 5) (Table <xref rid="jcph6131-tbl-0003" ref-type="table">3</xref>). All TEAEs were mild in severity, except for one event of headache of moderate severity after BOS administration under fasting conditions. There were no deaths or serious AEs, and there were no TEAEs leading to study drug discontinuation or study withdrawal. The most frequently observed TEAEs were headache (n = 3, 15%) and vessel puncture site pain (n = 2, 10%). Three participants (15%) reported at least one TEAE considered by the investigator to be related to the study drug: headache (m [number of events] = 2], diarrhea (m = 1), and musculoskeletal chest pain (m = 1). One patient received acetaminophen (1.0 g) for a TEAE of headache, which was considered by the investigator to be related to the study drug. There were no treatment‐related trends noted in the incidence of TEAEs or in laboratory or vital sign data.</p><table-wrap position="float" id="jcph6131-tbl-0003" content-type="Table" orientation="portrait"><label>Table 3</label><caption><p>Summary of TEAEs by System Organ Class, and Preferred Term Following a Single Dose of BOS 2.0 mg Under Fasting and Fed Conditions in Healthy Participants</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">
<p>n (%)</p>
</th><th align="center" rowspan="1" colspan="1">
<p>Overall</p>
<p>(N = 20)</p>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>At least one TEAE</bold>
</td><td align="char" rowspan="1" colspan="1">7 (35.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>No TEAEs</bold>
</td><td align="char" rowspan="1" colspan="1">13 (65.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Gastrointestinal disorders</bold>
</td><td align="char" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diarrhea</td><td align="char" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>General disorders and sampling‐related conditions</bold>
<xref rid="jcph6131-tbl3-note-0003" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" rowspan="1" colspan="1">4 (20.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vessel puncture site bruise</td><td align="char" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vessel puncture site pain</td><td align="char" rowspan="1" colspan="1">2 (10.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Vessel puncture site swelling</td><td align="char" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Musculoskeletal and connective tissue disorders</bold>
</td><td align="char" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Musculoskeletal chest pain</td><td align="char" rowspan="1" colspan="1">1 (5.0)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nervous system disorders</bold>
</td><td align="char" rowspan="1" colspan="1">3 (15.0)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Headache</td><td align="char" rowspan="1" colspan="1">3 (15.0)</td></tr></tbody></table><table-wrap-foot><fn id="jcph6131-tbl3-note-0001"><p>AE, adverse event; BOS, budesonide oral suspension; n, number of patients; N, total number of patients; SOC, system organ class; TEAE, treatment‐emergent adverse event.</p></fn><fn id="jcph6131-tbl3-note-0002"><p>If a participant had at least two AEs within a SOC or preferred term, the participant was counted only once within each SOC or preferred term. The same participant may appear in different categories.</p></fn><fn id="jcph6131-tbl3-note-0003"><label>
<sup>a</sup>
</label><p>TEAEs associated with administration site conditions included those arising from collection of blood samples for PK analysis.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="jcph6131-sec-0120"><title>Discussion</title><p>In this study, the data demonstrate that there is no clinically meaningful impact of food on systemic exposure to budesonide (BOS formulation) or on its safety and tolerability. This highlights the potential for BOS administration in a fasting or fed state. However, patients with EoE should wait at least 30 min before eating or drinking after taking BOS to ensure optimal budesonide exposure in the esophagus.<xref rid="jcph6131-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jcph6131-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> The lack of a clinically meaningful food effect, and the convenience of BOS as a swallowed corticosteroid specifically designed for EoE with thixotropic properties following oral administration,<xref rid="jcph6131-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="jcph6131-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> may improve treatment adherence in patients with EoE. This is further supported by the fact that increasing regimen complexity may lower adherence to orally administered drugs,<xref rid="jcph6131-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> and is of particular importance given that adherence to EoE medications is often reported to be poor.<xref rid="jcph6131-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jcph6131-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> Further, our findings may support the real‐world administration of BOS 2.0 mg b.i.d. after consuming food. Increasing flexibility regarding when BOS can be administered may reduce the burden on a population of patients who often already adapt their eating behaviors to manage their disease.<xref rid="jcph6131-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</p><p>In our study, PK parameters determining the peak exposure (C<sub>max</sub>) and the extent of exposure (AUC<sub>last</sub> and AUC<sub>∞</sub>) were approximately 13% lower, 26% higher, and 27% higher under fed conditions than under fasting conditions. During a previous study in healthy adult volunteers receiving a single dose of BOS 2.0 mg under fasting conditions, plasma budesonide C<sub>max</sub>, AUC<sub>last</sub>, and AUC<sub>∞</sub> values were higher than those under fed conditions in our study (1063 vs 604.1 pg/mL, 4527 vs 3529 pg h/mL, 4254 vs 3892 pg h/mL, respectively).<xref rid="jcph6131-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref> Plasma budesonide C<sub>max</sub> was also higher in adult patients (aged 18‐55 years) with EoE receiving BOS 2.0 mg b.i.d. in a previous study under fed conditions (914.8 pg/mL)<xref rid="jcph6131-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref> compared with the equivalent readout from our study (604.1 pg/mL). However, it should be noted that slightly different BOS formulations were used in each of these studies; the current study used the commercialized formulation of BOS.<xref rid="jcph6131-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> Overall, this indicates that the decreased C<sub>max</sub>, the increased t<sub>max</sub>, and the slightly increased systemic exposure to BOS in our study under fed conditions compared with fasting conditions is not expected to be clinically meaningful.</p><p>When considering the similarities in the mean t<sub>1/2z</sub> of plasma budesonide under each condition in our study (fasting: 4.457 h; fed: 4.933 h), food is not expected to affect the accumulation of BOS when given as a single 2.0 mg oral dose. These values for the mean t<sub>1/2z</sub> of plasma budesonide are consistent with data from a study in healthy adults in which the effect of food administration on the accumulation of BOS was not evaluated.<xref rid="jcph6131-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</p><p>The effect of food intake on PK parameters has also been investigated for other budesonide formulations. Plasma budesonide C<sub>max</sub> decreased by 27% in healthy adults when budesonide extended‐release tablets (indicated for the induction of remission in patients with active, mild‐to‐moderate ulcerative colitis) were co‐administered with a high‐fat meal, than under fasting conditions.<xref rid="jcph6131-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> The mean absorption lag time was 2.4 h longer under fed conditions than under fasting conditions for this formulation,<xref rid="jcph6131-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> whereas the t<sub>lag</sub> was similar under each treatment condition in our study. In line with the approximately 1 h longer t<sub>max</sub> observed under fed conditions than under fasting conditions in our study, t<sub>max</sub> was 3.0 and 2.3 h longer in healthy adult volunteers receiving budesonide controlled‐release capsules and budesonide enteric‐coated, delayed‐release capsules, respectively, under fed conditions compared with fasting conditions.<xref rid="jcph6131-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jcph6131-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> By contrast, a food‐effect study evaluating PK parameters for an orally disintegrating tablet formulation of fluticasone propionate (3.0 mg b.i.d.) had slightly different results, showing an approximately 21% increase in the plasma C<sub>max</sub> when co‐administered with a high‐fat/high‐calorie meal, than under fasting conditions.<xref rid="jcph6131-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> Moreover, when compared with fasting conditions, fed participants who received this disintegrating tablet formulation of fluticasone propionate had reduced AUC<sub>last</sub> and AUC<sub>∞</sub> (548.9 vs 775.0 pg h/mL and 587.9 vs 1044.3 pg h/mL, respectively), and the t<sub>max</sub> was 5 h shorter.<xref rid="jcph6131-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</p><p>During the current study, BOS was well tolerated under both fasting and fed conditions in healthy adult volunteers. There were no TEAEs considered related to budesonide that led to study drug discontinuation or study withdrawal, and all TEAEs were mild or moderate in severity. Although previous studies did not consider the impact of food intake on the safety and tolerability of BOS, their safety data are consistent with those reported in the current study.<xref rid="jcph6131-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="jcph6131-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jcph6131-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="jcph6131-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="jcph6131-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</p><p>In terms of limitations, the PK profile of BOS when taken <italic toggle="yes">during</italic> a meal was not examined in this study and therefore we were unable to determine the effect of concomitant food/liquid and BOS administration. In addition, patients with EoE typically have substantial physiological changes in the esophagus compared with individuals without EoE;<xref rid="jcph6131-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> and because our study was conducted in healthy adults, differences in the pathophysiology of the esophagus should be considered when applying these findings to clinical practice. Despite this, it should be noted that a population PK analysis of various budesonide formulations found no significant differences between systemic PK parameters for healthy individuals compared with patients with EoE.<xref rid="jcph6131-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</p><p>Strengths of this study include the randomized design, which minimized assignment bias, the comprehensive PK assessment, and the robust study design that adhered to FDA guidance for food‐effect studies.<xref rid="jcph6131-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</p></sec><sec id="jcph6131-sec-0130"><title>Conclusions</title><p>This study provides key information for patients, showing that BOS 2.0 mg can be taken without dietary restrictions before dosing. It also presents data on the safety and tolerability of BOS under fasting and fed conditions. Importantly, the decrease in C<sub>max</sub>, the increase in t<sub>max</sub>, and the slight increase in systemic exposure to budesonide under fed conditions compared with fasting conditions are not expected to be clinically meaningful based on these results and prior studies with BOS.<xref rid="jcph6131-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jcph6131-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jcph6131-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</p></sec><sec sec-type="COI-statement" id="jcph6131-sec-0150"><title>Conflicts of Interest</title><p>Alexander J. Prokopienko, J.W., Ajit Suri, Mike Baratta, Nirav K. Desai, and Camilla A. Richmond are employees of Takeda Development Center Americas, Inc., and are stockholders of Takeda Pharmaceutical Company Limited. Vijay Yajnik is an employee of Takeda Pharmaceuticals USA, Inc., and is a stockholder of Takeda Pharmaceutical Company Limited.</p></sec><sec id="jcph6131-sec-0160"><title>Funding</title><p>This study was funded by Takeda Development Center Americas, Inc.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="jcph6131-supitem-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>Supporting information</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="JCPH-65-217-s001.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="jcph6131-sec-0140"><title>Acknowledgments</title><p>Medical writing support was provided by Joshua Dow, PhD, and Joanna L Donnelly, PhD, of PharmaGenesis London, London, UK, and was funded by Takeda Pharmaceuticals USA, Inc.</p></ack><sec sec-type="data-availability" id="jcph6131-sec-0180"><title>Data Availability Statement</title><p>The data sets, including the redacted study protocol, redacted statistical analysis plan, and individual participant data supporting the results reported in this article, will be made available within 3 months from the initial request to researchers who provide a methodologically sound proposal. The data will be provided after their de‐identification, in compliance with applicable privacy laws, data protection, and requirements for consent and anonymization.</p></sec><ref-list id="jcph6131-bibl-0001"><title>References</title><ref id="jcph6131-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jcph6131-cit-0001">
<string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Liacouras</surname>
<given-names>CA</given-names>
</string-name>, <string-name name-style="western">
<surname>Molina‐Infante</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference</article-title>. <source>Gastroenterology</source>. <year>2018</year>;<volume>155</volume>(<issue>4</issue>):<fpage>1022</fpage>‐<lpage>1033.e1010</lpage>.<pub-id pub-id-type="pmid">30009819</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2018.07.009</pub-id><pub-id pub-id-type="pmcid">PMC6174113</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jcph6131-cit-0002">
<string-name name-style="western">
<surname>Collins</surname>
<given-names>MH</given-names>
</string-name>, <string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Katzka</surname>
<given-names>DA</given-names>
</string-name>, <string-name name-style="western">
<surname>Hirano</surname>
<given-names>I</given-names>
</string-name>, <string-name name-style="western">
<surname>Williams</surname>
<given-names>J</given-names>
</string-name>, <string-name name-style="western">
<surname>Lan</surname>
<given-names>L</given-names>
</string-name>. <article-title>Budesonide oral suspension significantly improves eosinophilic esophagitis histology scoring system results: analyses from a 12‐week, phase 2, randomized, placebo‐controlled trial</article-title>. <source>Am J Surg Pathol</source>. <year>2019</year>;<volume>43</volume>(<issue>11</issue>):<fpage>1501</fpage>‐<lpage>1509</lpage>.<pub-id pub-id-type="pmid">31498177</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/PAS.0000000000001361</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jcph6131-cit-0003">
<string-name name-style="western">
<surname>Hahn</surname>
<given-names>JW</given-names>
</string-name>, <string-name name-style="western">
<surname>Lee</surname>
<given-names>K</given-names>
</string-name>, <string-name name-style="western">
<surname>Shin</surname>
<given-names>JI</given-names>
</string-name>, et al. <article-title>Global incidence and prevalence of eosinophilic esophagitis, 1976–2022: a systematic review and meta‐analysis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2023</year>;<volume>21</volume>(<issue>13</issue>):<fpage>3270</fpage>‐<lpage>3284.e3277</lpage>.<pub-id pub-id-type="pmid">37331411</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2023.06.005</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jcph6131-cit-0004">
<string-name name-style="western">
<surname>van Rhijn</surname>
<given-names>BD</given-names>
</string-name>, <string-name name-style="western">
<surname>Smout</surname>
<given-names>AJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Bredenoord</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Disease duration determines health‐related quality of life in adult eosinophilic esophagitis patients</article-title>. <source>Neurogastroenterol Motil</source>. <year>2014</year>;<volume>26</volume>(<issue>6</issue>):<fpage>772</fpage>‐<lpage>778</lpage>.<pub-id pub-id-type="pmid">24602119</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/nmo.12323</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jcph6131-cit-0005">
<string-name name-style="western">
<surname>Safroneeva</surname>
<given-names>E</given-names>
</string-name>, <string-name name-style="western">
<surname>Coslovsky</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Kuehni</surname>
<given-names>CE</given-names>
</string-name>, et al. <article-title>Eosinophilic oesophagitis: relationship of quality of life with clinical, endoscopic and histological activity</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2015</year>;<volume>42</volume>(<issue>8</issue>):<fpage>1000</fpage>‐<lpage>1010</lpage>.<pub-id pub-id-type="pmid">26271642</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.13370</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jcph6131-cit-0006">
<string-name name-style="western">
<surname>Mukkada</surname>
<given-names>V</given-names>
</string-name>, <string-name name-style="western">
<surname>Falk</surname>
<given-names>GW</given-names>
</string-name>, <string-name name-style="western">
<surname>Eichinger</surname>
<given-names>CS</given-names>
</string-name>, <string-name name-style="western">
<surname>King</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western">
<surname>Todorova</surname>
<given-names>L</given-names>
</string-name>, <string-name name-style="western">
<surname>Shaheen</surname>
<given-names>NJ</given-names>
</string-name>. <article-title>Health‐related quality of life and costs associated with eosinophilic esophagitis: a systematic review</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2018</year>;<volume>16</volume>(<issue>4</issue>):<fpage>495</fpage>‐<lpage>503.e498</lpage>.<pub-id pub-id-type="pmid">28655543</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2017.06.036</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jcph6131-cit-0007">
<string-name name-style="western">
<surname>Furuta</surname>
<given-names>GT</given-names>
</string-name>, <string-name name-style="western">
<surname>Katzka</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Eosinophilic esophagitis</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>(<issue>17</issue>):<fpage>1640</fpage>‐<lpage>1648</lpage>.<pub-id pub-id-type="pmid">26488694</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra1502863</pub-id><pub-id pub-id-type="pmcid">PMC4905697</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jcph6131-cit-0008">
<string-name name-style="western">
<surname>Rossetti</surname>
<given-names>D</given-names>
</string-name>, <string-name name-style="western">
<surname>Isoldi</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Oliva</surname>
<given-names>S</given-names>
</string-name>. <article-title>Eosinophilic esophagitis: update on diagnosis and treatment in pediatric patients</article-title>. <source>Paediatr Drugs</source>. <year>2020</year>;<volume>22</volume>(<issue>4</issue>):<fpage>343</fpage>‐<lpage>356</lpage>.<pub-id pub-id-type="pmid">32519266</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40272-020-00398-z</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jcph6131-cit-0009">
<string-name name-style="western">
<surname>Hirano</surname>
<given-names>I</given-names>
</string-name>, <string-name name-style="western">
<surname>Chan</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Rank</surname>
<given-names>MA</given-names>
</string-name>, et al. <article-title>AGA institute and the joint task force on allergy‐immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis</article-title>. <source>Gastroenterology</source>. <year>2020</year>;<volume>158</volume>(<issue>6</issue>):<fpage>1776</fpage>‐<lpage>1786</lpage>.<pub-id pub-id-type="pmid">32359562</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2020.02.038</pub-id><pub-id pub-id-type="pmcid">PMC9473154</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jcph6131-cit-0010">
<string-name name-style="western">
<surname>Dougherty</surname>
<given-names>T</given-names>, <suffix>Jr.</suffix>
</string-name>, <string-name name-style="western">
<surname>Stephen</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Borum</surname>
<given-names>ML</given-names>
</string-name>, <string-name name-style="western">
<surname>Doman</surname>
<given-names>DB</given-names>
</string-name>. <article-title>Emerging therapeutic options for eosinophilic esophagitis</article-title>. <source>Gastroenterol Hepatol (N Y)</source>. <year>2014</year>;<volume>10</volume>(<issue>2</issue>):<fpage>106</fpage>‐<lpage>116</lpage>.<pub-id pub-id-type="pmid">24803874</pub-id>
<pub-id pub-id-type="pmcid">PMC4011375</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0011">
<collab collab-type="authors">Takeda Pharmaceuticals America Inc</collab>
. <article-title>Highlights of prescribing information, EOHILIA 2024</article-title>. US FDA. Accessed May 31, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213976s000lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213976s000lbl.pdf</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jcph6131-cit-0012">
<string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Katzka</surname>
<given-names>DA</given-names>
</string-name>, <string-name name-style="western">
<surname>Collins</surname>
<given-names>MH</given-names>
</string-name>, et al. <article-title>Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis</article-title>. <source>Gastroenterology</source>. <year>2017</year>;<volume>152</volume>(<issue>4</issue>):<fpage>776</fpage>‐<lpage>786.e775</lpage>.<pub-id pub-id-type="pmid">27889574</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.gastro.2016.11.021</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jcph6131-cit-0013">
<string-name name-style="western">
<surname>Hirano</surname>
<given-names>I</given-names>
</string-name>, <string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Gupta</surname>
<given-names>SK</given-names>
</string-name>, et al. <article-title>Safety of an investigational formulation of budesonide (budesonide oral suspension) for eosinophilic oesophagitis: an integrated safety analysis of six phase 1–3 clinical trials</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2023</year>;<volume>57</volume>(<issue>10</issue>):<fpage>1117</fpage>‐<lpage>1130</lpage>.<pub-id pub-id-type="pmid">36890134</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.17430</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jcph6131-cit-0014">
<string-name name-style="western">
<surname>Reed</surname>
<given-names>CC</given-names>
</string-name>, <string-name name-style="western">
<surname>Fan</surname>
<given-names>C</given-names>
</string-name>, <string-name name-style="western">
<surname>Koutlas</surname>
<given-names>N</given-names>
</string-name>, et al. <article-title>Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis</article-title>. <source>HSOA J Gastroenterol Hepatol Res</source>. <year>2018</year>;<volume>7</volume>(<issue>1</issue>):<fpage>2509</fpage>‐<lpage>2515</lpage>.<pub-id pub-id-type="pmid">29608193</pub-id>
<pub-id pub-id-type="pmcid">PMC5875939</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jcph6131-cit-0015">
<string-name name-style="western">
<surname>Gupta</surname>
<given-names>SK</given-names>
</string-name>, <string-name name-style="western">
<surname>Hill</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Vitanza</surname>
<given-names>JM</given-names>
</string-name>, et al. <article-title>Pharmacokinetics of budesonide oral suspension in children and adolescents with eosinophilic esophagitis</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>2022</year>;<volume>75</volume>(<issue>2</issue>):<fpage>186</fpage>‐<lpage>191</lpage>.<pub-id pub-id-type="pmid">35666852</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MPG.0000000000003482</pub-id><pub-id pub-id-type="pmcid">PMC9278710</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jcph6131-cit-0016">
<string-name name-style="western">
<surname>Song</surname>
<given-names>IH</given-names>
</string-name>, <string-name name-style="western">
<surname>Finkelman</surname>
<given-names>RD</given-names>
</string-name>, <string-name name-style="western">
<surname>Lan</surname>
<given-names>L</given-names>
</string-name>. <article-title>A pharmacokinetic bridging study to compare systemic exposure to budesonide between budesonide oral suspension and ENTOCORT EC in healthy individuals</article-title>. <source>Drugs R D</source>. <year>2020</year>;<volume>20</volume>(<issue>4</issue>):<fpage>359</fpage>‐<lpage>367</lpage>.<pub-id pub-id-type="pmid">33057953</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40268-020-00324-1</pub-id><pub-id pub-id-type="pmcid">PMC7691405</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jcph6131-cit-0017">
<string-name name-style="western">
<surname>Song</surname>
<given-names>IH</given-names>
</string-name>, <string-name name-style="western">
<surname>Rodgers</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Hayes</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Farrell</surname>
<given-names>C</given-names>
</string-name>. <article-title>A population pharmacokinetic analysis of budesonide oral suspension in children and adults with eosinophilic esophagitis and healthy adult volunteers</article-title>. <source>Am J Gastroenterol</source>. <year>2020</year>;<volume>115</volume>:<fpage>S220</fpage>.</mixed-citation></ref><ref id="jcph6131-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jcph6131-cit-0018">
<string-name name-style="western">
<surname>Lundin</surname>
<given-names>P</given-names>
</string-name>, <string-name name-style="western">
<surname>Naber</surname>
<given-names>T</given-names>
</string-name>, <string-name name-style="western">
<surname>Nilsson</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Edsbacker</surname>
<given-names>S</given-names>
</string-name>. <article-title>Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2001</year>;<volume>15</volume>(<issue>1</issue>):<fpage>45</fpage>‐<lpage>51</lpage>.<pub-id pub-id-type="pmid">11136277</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2036.2001.00910.x</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jcph6131-cit-0019">
<string-name name-style="western">
<surname>Edsbacker</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Bengtsson</surname>
<given-names>B</given-names>
</string-name>, <string-name name-style="western">
<surname>Larsson</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>A pharmacoscintigraphic evaluation of oral budesonide given as controlled‐release (Entocort) capsules</article-title>. <source>Aliment Pharmacol Ther</source>. <year>2003</year>;<volume>17</volume>(<issue>4</issue>):<fpage>525</fpage>‐<lpage>536</lpage>.<pub-id pub-id-type="pmid">12622761</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2036.2003.01426.x</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0020"><label>20</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0020">
<collab collab-type="authors">Salix Pharmaceuticals, Inc., a division of Bausch Health US, LLC</collab>
. <article-title>Uceris® (budesonide) extended‐release tablets</article-title>. Prescribing information. <year>2020</year>. Accessed May 31, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203634s007lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203634s007lbl.pdf</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0021"><label>21</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0021">
<collab collab-type="authors">AstraZeneca</collab>
. <article-title>Entocort EC (budesonide) delayed‐release capsules</article-title>. Prescribing information. <year>2020</year>. Accessed May 31, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021324s023lbl.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021324s023lbl.pdf</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0022">
<collab collab-type="authors">US Food and Drug Administration</collab>
. <article-title>Assessing the effects of food on drugs in INDs and NDAs — clinical pharmacology considerations. Guidance for industry</article-title>. <year>2022</year>. Accessed May 31, <year>2024</year>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070241.pdf" ext-link-type="uri">https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070241.pdf</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0023">
<collab collab-type="authors">ClinicalTrials.gov</collab>
. <article-title>An extension study to evaluate maintenance of efficacy and long‐term treatment effect of oral budesonide suspension (OBS) in adults and adolescents with eosinophilic esophagitis (EoE) (ORBIT2)</article-title>. Accessed May 31, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrials.gov/study/NCT02736409" ext-link-type="uri">https://www.clinicaltrials.gov/study/NCT02736409</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0024">
<collab collab-type="authors">ClinicalTrials.gov</collab>
. <article-title>Continuation study with budesonide oral suspension (BOS) for adolescent and adult subjects with eosinophilic esophagitis (EoE)</article-title>. Accessed May 31, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT03245840" ext-link-type="uri">https://clinicaltrials.gov/ct2/show/study/NCT03245840</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jcph6131-cit-0025">
<string-name name-style="western">
<surname>Glowczewski</surname>
<given-names>A</given-names>
</string-name>, <string-name name-style="western">
<surname>Krogulska</surname>
<given-names>A</given-names>
</string-name>. <article-title>Formulations of topical steroids in eosinophilic esophagitis ‐ current treatment and emerging possibilities</article-title>. <source>J Clin Med</source>. <year>2022</year>;<volume>11</volume>(<issue>5</issue>):<fpage>1454</fpage>.<pub-id pub-id-type="pmid">35268544</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm11051454</pub-id><pub-id pub-id-type="pmcid">PMC8910832</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jcph6131-cit-0026">
<string-name name-style="western">
<surname>Hirano</surname>
<given-names>I</given-names>
</string-name>, <string-name name-style="western">
<surname>Collins</surname>
<given-names>MH</given-names>
</string-name>, <string-name name-style="western">
<surname>Katzka</surname>
<given-names>DA</given-names>
</string-name>, et al. <article-title>Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2022</year>;<volume>20</volume>(<issue>3</issue>):<fpage>525</fpage>‐<lpage>534.e510</lpage>.<pub-id pub-id-type="pmid">33887475</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2021.04.022</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jcph6131-cit-0027">
<string-name name-style="western">
<surname>Vinther</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Christensen</surname>
<given-names>M</given-names>
</string-name>, <string-name name-style="western">
<surname>Christensen</surname>
<given-names>HR</given-names>
</string-name>. <article-title>The importance of convenience for patient adherence to drug treatments ‐ an overview of secondary literature</article-title>. <source>Clin Ther</source>. <year>2015</year>;<volume>37</volume>(<issue>8</issue>):<fpage>E95</fpage>‐<lpage>E96</lpage>.</mixed-citation></ref><ref id="jcph6131-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jcph6131-cit-0028">
<string-name name-style="western">
<surname>Haasnoot</surname>
<given-names>ML</given-names>
</string-name>, <string-name name-style="western">
<surname>Safi</surname>
<given-names>S</given-names>
</string-name>, <string-name name-style="western">
<surname>Bredenoord</surname>
<given-names>AJ</given-names>
</string-name>. <article-title>Poor adherence to medical and dietary treatments in adult patients with eosinophilic esophagitis</article-title>. <source>Am J Gastroenterol</source>. <year>2022</year>;<volume>117</volume>(<issue>9</issue>):<fpage>1412</fpage>‐<lpage>1418</lpage>.<pub-id pub-id-type="pmid">35973155</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000001850</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jcph6131-cit-0029">
<string-name name-style="western">
<surname>Alexander</surname>
<given-names>R</given-names>
</string-name>, <string-name name-style="western">
<surname>Alexander</surname>
<given-names>JA</given-names>
</string-name>, <string-name name-style="western">
<surname>Ravi</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Measurement of observed eating behaviors in patients with active and inactive eosinophilic esophagitis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2019</year>;<volume>17</volume>(<issue>11</issue>):<fpage>2371</fpage>‐<lpage>2373</lpage>.<pub-id pub-id-type="pmid">30557737</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2018.12.011</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0030"><label>30</label><mixed-citation publication-type="miscellaneous" id="jcph6131-cit-0030">
<collab collab-type="authors">ClinicalTrials.gov</collab>
. <article-title>A study in adolescents and adults with eosinophilic esophagitis (EoE) measuring histologic response and determine if reduction in dysphagia is achieved (NCT02605867)</article-title>. Accessed May 31, 2024. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT02605837" ext-link-type="uri">https://classic.clinicaltrials.gov/ct2/show/NCT02605837</ext-link>
</mixed-citation></ref><ref id="jcph6131-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jcph6131-cit-0031">
<string-name name-style="western">
<surname>Comer</surname>
<given-names>GM</given-names>
</string-name>, <string-name name-style="western">
<surname>Bush</surname>
<given-names>MA</given-names>
</string-name>, <string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Marino</surname>
<given-names>MT</given-names>
</string-name>. <article-title>Effect of food intake and body position on the pharmacokinetics of swallowed APT‐1011, a fluticasone orally disintegrating tablet, in healthy adult volunteers</article-title>. <source>J Clin Pharmacol</source>. <year>2020</year>;<volume>60</volume>(<issue>6</issue>):<fpage>734</fpage>‐<lpage>743</lpage>.<pub-id pub-id-type="pmid">31943257</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jcph.1572</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jcph6131-cit-0032">
<string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Collins</surname>
<given-names>MH</given-names>
</string-name>, <string-name name-style="western">
<surname>Katzka</surname>
<given-names>DA</given-names>
</string-name>, et al. <article-title>Long‐term treatment of eosinophilic esophagitis with budesonide oral suspension</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2022</year>;<volume>20</volume>(<issue>7</issue>):<fpage>1488</fpage>‐<lpage>1498.e1411</lpage>.<pub-id pub-id-type="pmid">34182150</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2021.06.020</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jcph6131-cit-0033">
<string-name name-style="western">
<surname>Dellon</surname>
<given-names>ES</given-names>
</string-name>, <string-name name-style="western">
<surname>Katzka</surname>
<given-names>DA</given-names>
</string-name>, <string-name name-style="western">
<surname>Collins</surname>
<given-names>MH</given-names>
</string-name>, et al. <article-title>Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2019</year>;<volume>17</volume>(<issue>4</issue>):<fpage>666</fpage>‐<lpage>673.e668</lpage>.<pub-id pub-id-type="pmid">29902649</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2018.05.051</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jcph6131-cit-0034">
<string-name name-style="western">
<surname>Gupta</surname>
<given-names>SK</given-names>
</string-name>, <string-name name-style="western">
<surname>Vitanza</surname>
<given-names>JM</given-names>
</string-name>, <string-name name-style="western">
<surname>Collins</surname>
<given-names>MH</given-names>
</string-name>. <article-title>Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2015</year>;<volume>13</volume>(<issue>1</issue>):<fpage>66</fpage>‐<lpage>76.e63</lpage>.<pub-id pub-id-type="pmid">24907502</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cgh.2014.05.021</pub-id></mixed-citation></ref><ref id="jcph6131-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jcph6131-cit-0035">
<string-name name-style="western">
<surname>Lim</surname>
<given-names>AW</given-names>
</string-name>, <string-name name-style="western">
<surname>Talley</surname>
<given-names>NJ</given-names>
</string-name>, <string-name name-style="western">
<surname>Walker</surname>
<given-names>MM</given-names>
</string-name>, <string-name name-style="western">
<surname>Storm</surname>
<given-names>G</given-names>
</string-name>, <string-name name-style="western">
<surname>Hua</surname>
<given-names>S</given-names>
</string-name>. <article-title>Current status and advances in esophageal drug delivery technology: influence of physiological, pathophysiological and pharmaceutical factors</article-title>. <source>Drug Deliv</source>. <year>2023</year>;<volume>30</volume>(<issue>1</issue>):<elocation-id>2219423</elocation-id>.<pub-id pub-id-type="pmid">37344759</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/10717544.2023.2219423</pub-id><pub-id pub-id-type="pmcid">PMC10286676</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="pmc-domain-id">3335</journal-id><journal-id journal-id-type="pmc-domain">tardis</journal-id><journal-id journal-id-type="publisher-id">TAR</journal-id><journal-title-group><journal-title>Therapeutic Advances in Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1753-4658</issn><issn pub-type="epub">1753-4666</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12901903</article-id><article-id pub-id-type="pmcid-ver">PMC12901903.1</article-id><article-id pub-id-type="pmcaid">12901903</article-id><article-id pub-id-type="pmcaiid">12901903</article-id><article-id pub-id-type="pmid">41677208</article-id><article-id pub-id-type="doi">10.1177/17534666261417149</article-id><article-id pub-id-type="publisher-id">10.1177_17534666261417149</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bednarczyk</surname><given-names initials="A">Artur</given-names></name><aff id="aff1-17534666261417149">Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca Pharma Poland, Warsaw, Poland</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4660-5040</contrib-id><name name-style="western"><surname>Aurivillius</surname><given-names initials="M">Magnus</given-names></name><aff id="aff2-17534666261417149">Respiratory and Immunology, Global Patient Safety, Biopharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jassal</surname><given-names initials="M">Mandeep</given-names></name><aff id="aff3-17534666261417149">Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA</aff><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shah</surname><given-names initials="M">Mihir</given-names></name><aff id="aff4-17534666261417149">Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA</aff><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Raphiou</surname><given-names initials="I">Ibrahim</given-names></name><aff id="aff5-17534666261417149">Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Durham, NC, USA</aff><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petullo</surname><given-names initials="D">David</given-names></name><aff id="aff6-17534666261417149">Respiratory and Immunology, Biometrics, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="J">John</given-names></name><aff id="aff7-17534666261417149">Respiratory and Immunology, Biometrics, Biopharmaceuticals R&amp;D, AstraZeneca, Gaithersburg, MD, USA</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Heijer</surname><given-names initials="M">Maria</given-names></name><aff id="aff8-17534666261417149">Integrated Bioanalysis, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Gothenburg, Sweden</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sychowicz</surname><given-names initials="K">Klementyna</given-names></name><aff id="aff9-17534666261417149">Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca Pharma Poland, Warsaw, Poland</aff><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Collison</surname><given-names initials="K">Kathryn</given-names></name><aff id="aff10-17534666261417149">Respiratory and Immunology, Clinical Operations, Biopharmaceuticals R&amp;D, AstraZeneca, Durham, NC, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Silva</surname><given-names initials="C">Carlos</given-names></name><aff id="aff11-17534666261417149">Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Reddy</surname><given-names initials="J">Jitendar</given-names></name><aff id="aff12-17534666261417149">Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&amp;D, AstraZeneca, Cambridge, UK</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="D">David</given-names></name><aff id="aff13-17534666261417149">Parexel, Glendale, CA, USA</aff><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Goldwater</surname><given-names initials="R">Ronald</given-names></name><aff id="aff14-17534666261417149">Parexel, Baltimore, MD, USA</aff><role content-type="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gillen</surname><given-names initials="M">Michael</given-names></name><aff id="aff15-17534666261417149">Creek Lane PK, LLC, Waterford, VA, USA</aff><role content-type="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patel</surname><given-names initials="M">Mehul</given-names></name><xref rid="corresp1-17534666261417149" ref-type="corresp"/><aff id="aff16-17534666261417149">Respiratory &amp; Immunology, Clinical Development, Biopharmaceuticals R&amp;D, AstraZeneca, Academy House, 136 Hills Road, Cambridge CB2 8PA, UK</aff><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-17534666261417149">
<email>mehul.patel1@astrazeneca.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>2</month><year>2026</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2026</year></pub-date><volume>20</volume><issue-id pub-id-type="pmc-issue-id">503708</issue-id><elocation-id>17534666261417149</elocation-id><history><date date-type="received"><day>18</day><month>6</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>1</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>02</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>14</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-14 00:25:14.907"><day>14</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s), 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_17534666261417149.pdf"/><abstract><sec id="section1-17534666261417149"><title>Background:</title><p>Hydrofluoroolefin-1234ze (HFO-1234ze) is a next-generation propellant with 99.9% lower global warming potential (GWP) than hydrofluoroalkane-134a (HFA-134a).</p></sec><sec id="section2-17534666261417149"><title>Objectives:</title><p>We report systemic and lung exposure bioequivalence for budesonide/glycopyrrolate/formoterol fumarate (BGF) components with HFO-1234ze versus HFA-134a.</p></sec><sec id="section3-17534666261417149"><title>Design:</title><p>These phase I, randomized, double-blind, single-dose, 3-way cross-over trials in healthy adults included three phases (screening; three single-dose treatment periods with 3- to 7-day washouts; follow-up).</p></sec><sec id="section4-17534666261417149"><title>Methods:</title><p>Participants were randomized to four BGF inhalations (160/9/4.8 µg/actuation) with test (HFO-1234ze) or reference (HFA-134a) treatments in one of three sequences, with HFA-134a administered during two of the three treatment periods. For lung exposure, oral activated charcoal was administered before and after treatment. Bioequivalence was considered established if the 90% confidence interval (CI) for the geometric mean ratio (GMR) was within 80%–125% (or expanded limits, if appropriate) for maximum plasma concentration (Cmax), area under the plasma concentration–curve from time zero to the last quantifiable concentration (AUClast) and AUC from time zero to infinity (AUCinf; US approach only).</p></sec><sec id="section5-17534666261417149"><title>Results:</title><p>Bioequivalence criteria were met across BGF components. The 90% CI for the GMR was within 80%–125% (or expanded limits) for HFO-1234ze versus HFA-134a, for systemic (GMR: Cmax, 85.41–99.29; AUClast, 95.74–102.48; AUCinf, 90.72–102.58) and lung (GMR: Cmax, 93.39–104.24, AUClast, 97.02–107.76; AUCinf, 101.45–112.22) exposure. No serious adverse events were reported.</p></sec><sec id="section6-17534666261417149"><title>Conclusion:</title><p>Total systemic and lung exposure to all BGF components met bioequivalence criteria for HFO-1234ze versus HFA-134a, with no new or unexpected safety findings. The near-zero GWP HFO-1234ze propellant is a viable replacement for HFA-134a.</p></sec><sec id="section7-17534666261417149"><title>Trial registration:</title><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05569421">NCT05569421</ext-link> (clinicaltrials.gov/study/<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05569421">NCT05569421</ext-link>) and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05477108">NCT05477108</ext-link> (clinicaltrials.gov/study/<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05477108">NCT05477108</ext-link>).</p></sec></abstract><kwd-group><kwd>bioequivalence</kwd><kwd>COPD</kwd><kwd>global warming potential</kwd><kwd>hydrofluoroolefin-1234ze</kwd><kwd>next-generation propellant</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-17534666261417149"><funding-source id="funding1-17534666261417149">
<institution-wrap><institution>AstraZeneca</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100004325</institution-id></institution-wrap>
</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2026</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section8-17534666261417149"><title>Introduction</title><p>Many people living with respiratory diseases, such as chronic obstructive pulmonary disease (COPD) or asthma, require the use of pressurized metered dose inhalers (pMDIs) for delivery of therapies,<sup><xref rid="bibr1-17534666261417149" ref-type="bibr">1</xref><xref rid="bibr2-17534666261417149" ref-type="bibr"/>–<xref rid="bibr3-17534666261417149" ref-type="bibr">3</xref></sup> particularly in those unable to use dry powder inhalers due to reduced inspiratory flow.<sup><xref rid="bibr2-17534666261417149" ref-type="bibr">2</xref>,<xref rid="bibr4-17534666261417149" ref-type="bibr">4</xref></sup> Additionally, some therapies, either alone or in combination, are only available for delivery by pMDIs.<sup>
<xref rid="bibr2-17534666261417149" ref-type="bibr">2</xref>
</sup> In pMDIs, propellants are used to atomize respiratory medications, enabling their inhalation and delivery to the lungs.<sup>
<xref rid="bibr3-17534666261417149" ref-type="bibr">3</xref>
</sup> However, currently marketed pMDI propellants, such as hydrofluoralkane-134a (HFA-134a), are greenhouse gases with global warming potential (GWP),<sup><xref rid="bibr5-17534666261417149" ref-type="bibr">5</xref>,<xref rid="bibr6-17534666261417149" ref-type="bibr">6</xref></sup> and thus, contribute to global climate change. Consequently, their phase-down is included within the scope of the Kigali Amendment of the Montreal Protocol.<sup>
<xref rid="bibr7-17534666261417149" ref-type="bibr">7</xref>
</sup> As it has been estimated that pMDIs annually contribute to 0.03% of total global greenhouse gas emissions, it is important to address any climate concerns resulting from their use.<sup>
<xref rid="bibr8-17534666261417149" ref-type="bibr">8</xref>
</sup></p><p>Triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) is indicated as a maintenance treatment for patients with COPD in multiple countries and regions.<sup><xref rid="bibr9-17534666261417149" ref-type="bibr">9</xref>,<xref rid="bibr10-17534666261417149" ref-type="bibr">10</xref></sup> In the phase III studies, ETHOS (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02465567">NCT02465567</ext-link>) and KRONOS (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02497001">NCT02497001</ext-link>),<sup><xref rid="bibr11-17534666261417149" ref-type="bibr">11</xref>,<xref rid="bibr12-17534666261417149" ref-type="bibr">12</xref></sup> BGF significantly improved lung function (KRONOS only) and reduced the annual rate of COPD exacerbations when compared with corresponding dual therapies in participants with moderate-to-very severe COPD.<sup><xref rid="bibr11-17534666261417149" ref-type="bibr">11</xref><xref rid="bibr12-17534666261417149" ref-type="bibr"/><xref rid="bibr13-17534666261417149" ref-type="bibr"/>–<xref rid="bibr14-17534666261417149" ref-type="bibr">14</xref></sup> Furthermore, in the ETHOS study, BGF was associated with a reduction in all-cause mortality versus dual therapy with glycopyrrolate/formoterol fumarate,<sup><xref rid="bibr11-17534666261417149" ref-type="bibr">11</xref>,<xref rid="bibr15-17534666261417149" ref-type="bibr">15</xref></sup> as recognized by the 2025 Global Initiative for Chronic Obstructive Lung Disease report.<sup>
<xref rid="bibr13-17534666261417149" ref-type="bibr">13</xref>
</sup></p><p>Hydrofluoroolefin-1234ze (HFO-1234ze) is in development for use as a propellant in pMDIs and has a GWP 99.9% lower than HFA-134a.<sup>
<xref rid="bibr16-17534666261417149" ref-type="bibr">16</xref>
</sup> The GWP<sub>100</sub> (a measure of the amount of atmospheric warming caused by a gas over 100 years relative to carbon dioxide (CO<sub>2</sub>)) is approximately 1530 for HFA-134a, indicating that its warming potential is 1530 times greater than that of CO<sub>2</sub>, versus 1.37 for HFO-1234ze.<sup>
<xref rid="bibr17-17534666261417149" ref-type="bibr">17</xref>
</sup> The GWP potential of HFA-134a necessitates the adoption of next-generation, low GWP propellants to mitigate the climate impacts of pMDIs while ensuring continued patient access to vital medications.<sup><xref rid="bibr5-17534666261417149" ref-type="bibr">5</xref>,<xref rid="bibr18-17534666261417149" ref-type="bibr">18</xref></sup></p><p>In a prior study, systemic exposure to the components of BGF triple therapy was comparable for HFO-1234ze relative to HFA-134a,<sup>
<xref rid="bibr19-17534666261417149" ref-type="bibr">19</xref>
</sup> and as such, further studies were conducted. Here, we report on the evaluation of total systemic exposure and of lung exposure (using charcoal block) bioequivalence, in two separate studies, for each of the three constituent components of BGF (160/9/4.8 μg per actuation with four inhalations as a single dose) delivered with HFO-1234ze as the propellant versus HFA-134a as the propellant.</p><p>The primary objective of the separate studies was to assess and compare total systemic exposure (total systemic exposure study) and lung exposure (lung exposure study) bioequivalence of budesonide, glycopyrrolate (measured from plasma as the glycopyrronium analyte), and formoterol following pMDI delivery of BGF with HFO-1234ze versus with HFA-134a. Secondary objectives included characterizing the pharmacokinetic (PK) profiles of budesonide, glycopyrronium, and formoterol and assessing safety and tolerability profiles following administration of BGF with HFO-1234ze versus with HFA-134a.</p></sec><sec sec-type="methods" id="section9-17534666261417149"><title>Methods</title><sec id="section10-17534666261417149"><title>Study designs and treatment</title><p>Both the total systemic exposure study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05569421">NCT05569421</ext-link>) and lung exposure study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05477108">NCT05477108</ext-link>) were phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over studies in healthy volunteers assessing the PK, safety, and tolerability of BGF (160/9/4.8 μg per actuation with four inhalations as a single dose) when formulated with the test propellant HFO-1234ze versus the reference propellant HFA-134a. The systemic exposure study was performed at the Parexel Early Phase Clinical Unit (Glendale, CA, USA) from October 2022 to April 2023. The lung exposure study was performed at the Parexel Early Phase Clinical Unit at the Harbour Hospital (Baltimore, MD, USA) from July 2022 to April 2023. Consolidated Standards of Reporting Trials (CONSORT) guidelines were consulted during preparation of this manuscript.<sup>
<xref rid="bibr20-17534666261417149" ref-type="bibr">20</xref>
</sup></p><p>In both studies (<xref rid="fig1-17534666261417149" ref-type="fig">Figure 1</xref>), following a screening period of up to 28 days, eligible participants were randomized 1:1:1 to one of three treatment sequences (ABB, BAB, BBA). Each participant received a single dose of BGF formulated with HFO-1234ze (Treatment A) or HFA-134a (Treatment B; referenced/marketed product, administered on two occasions) in each of the 3-day treatment periods; each period was separated by a washout of 3–7 days. Each dose was administered on day 1 of each treatment period as four actuations of BGF 160/9/4.8 μg, with each actuation taking place within 30 s of the previous actuation. The total dose administered after the four inhalations, was higher than the approved therapeutic dose<sup><xref rid="bibr9-17534666261417149" ref-type="bibr">9</xref>,<xref rid="bibr10-17534666261417149" ref-type="bibr">10</xref></sup> to allow for reliable calculation of the PK parameters and to ensure glycopyrronium levels were not below the level of quantification. A healthcare provider observed dosing to ensure the required number of actuations were administered and that the full dose was inhaled. In the lung exposure study, participants received 10 g of oral activated charcoal (approximately 48 mL) immediately before and after dosing, and at 1 and 2-h post-dosing to block gastrointestinal absorption and enable an estimate of lung deposition. The charcoal block method for eliminating the gastrointestinal absorption component of inhaled drugs has been widely used and accepted by regulatory authorities.<sup><xref rid="bibr21-17534666261417149" ref-type="bibr">21</xref>,<xref rid="bibr22-17534666261417149" ref-type="bibr">22</xref></sup> In particular, this and similar regimens of charcoal administration have been used with inhaled budesonide,<sup><xref rid="bibr23-17534666261417149" ref-type="bibr">23</xref>,<xref rid="bibr24-17534666261417149" ref-type="bibr">24</xref></sup> formoterol,<sup><xref rid="bibr24-17534666261417149" ref-type="bibr">24</xref>,<xref rid="bibr25-17534666261417149" ref-type="bibr">25</xref></sup> and glycopyrronium.<sup>
<xref rid="bibr26-17534666261417149" ref-type="bibr">26</xref>
</sup></p><fig position="float" id="fig1-17534666261417149" orientation="portrait"><label>Figure 1.</label><caption><p>Study design for the total systemic exposure and lung exposure studies.</p><p>In the lung exposure study, participants received 10 g of oral activated charcoal (approximately 48 mL) immediately before dosing with study treatment, immediately after administration of study treatment, and at 1- and 2-h post-dose. Treatment A: BGF HFO-1234ze 160/9/4.8 µg per actuation, four inhalations as a single dose (test formulation). Treatment B: BGF HFA-134a 160/9/4.8 µg per actuation, four inhalations as a single dose (reference formulation).</p><p>BGF, budesonide/glycopyrrolate/formoterol fumarate; HFA-134a, hydrofluoroalkane-134a; HFO-1234ze, hydrofluoroolefin-1234ze.</p></caption><alt-text>A diagram depicting a clinical study comparing the effects of BGF HFO-1234ze and HFA-134a formulations over three periods with washout periods</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666261417149-fig1.jpg"/></fig><p>At screening, on admission, and pre-dose on day 1 of each treatment period, participants were instructed on inhalation technique using an AIM Aerosol Inhalation Trainer Device (Model 4500; Vitalograph Inc, Lenexa, KS, USA), and placebo pMDIs were used to demonstrate that participants had adequate pMDI technique. Participants resided in the study facility from the morning of the day before the first dose of the first treatment period (day 1), through all treatment and washout periods, and were discharged on day 2 of treatment Period 3. Each treatment was administered following an overnight fast of ⩾8 h, with a meal given 4 h after dosing. Water consumption was allowed until 1 h before dosing and from 2 h after dosing. A final safety follow-up call occurred within 3–7 days following administration of the final dose of treatment Period 3.</p></sec><sec id="section11-17534666261417149"><title>Study populations</title><p>In accordance with the inclusion criteria, in both studies, the populations were healthy, nonsmoking male and female adults aged 18−60 years who had suitable veins for cannulation or venipuncture, agreed to adhere to the reproductive restrictions, had a body mass index (BMI) 18−35 kg/m<sup>2</sup>, weighed ⩾50 kg to ⩽120 kg, had a forced expiratory volume in 1 s (FEV<sub>1</sub>) of ⩾80% of the predicted normal value and an FEV<sub>1</sub>/forced vital capacity (FVC) &gt; 70%, based on height, age and ethnicity, and who demonstrated proper inhalation technique and were able to properly use the pMDI device after training.</p><p>Key exclusion criteria included previous receipt of BGF formulated with HFO-1234ze and histories of any significant respiratory disorders (including SARS-CoV-2 infection, COPD, asthma, idiopathic pulmonary fibrosis or a severe course of COVID-19). Additional exclusion criteria included a history or presence of gastrointestinal, hepatic, or renal diseases that may interfere with drug absorption, metabolism, distribution, excretion, or any clinically significant disease or disorder that, in the opinion of the investigator, may either put the participant at risk or influence the study results.</p></sec><sec id="section12-17534666261417149"><title>Endpoints</title><p>The primary PK endpoints were the maximum plasma concentration (Cmax (both studies)), the area under the plasma concentration–time curve (AUC) from time zero to infinity (AUCinf, (US approach only)), and the AUC from time zero to the last quantifiable concentration (AUClast (both studies)). Secondary PK endpoints included time to Cmax, the terminal rate constant estimated by log-linear least squares regression of the terminal part of the concentration–time curve, the half-life associated with terminal slope of a semi-logarithmic concentration–time curve, and the mean residence time of the unchanged drug in the systemic circulation from time zero to infinity.</p><p>Safety and tolerability endpoints included adverse events (AEs) and serious adverse events (SAEs), vital signs (including systolic and diastolic blood pressure, pulse rate, body temperature, and respiratory rate), resting 12-lead electrocardiogram (ECG), physical examination, and laboratory assessments (including hematology, clinical chemistry, and urinalysis). AEs were reported by preferred term and system organ class using Medical Dictionary for Regulatory Activities (MedDRA: version 26.0 for the systemic exposure study and version 25.1 for the lung exposure study, Herndon, VA) and were summarized according to severity and relatedness to treatment, as determined by the investigator. AEs leading to the discontinuation of study treatment were also documented.</p></sec><sec id="section13-17534666261417149"><title>Assessments</title><p>To assess PK endpoints, blood samples were collected pre-dose, at 2, 5, 10, 20, 30, and 45 min post-dose, and at 1, 2, 4, 8, 12, and 24 h post-dose on day 1 of each treatment period. Plasma extracted from whole blood samples was used for the assessment of budesonide, glycopyrronium, and formoterol. Analyses were conducted by LabCorp Early Development Laboratories Limited (Harrogate, UK) using validated high-performance liquid chromatography tandem mass spectrometry assays, on behalf of the study sponsor similar to as previously reported.<sup>
<xref rid="bibr27-17534666261417149" ref-type="bibr">27</xref>
</sup></p><p>The bioanalytical methods were validated according to regulatory guidance, with a lower limit of quantification (LLOQ) in plasma of 5.0 pg/mL for budesonide and 1.0 pg/mL for glycopyrronium and formoterol, intra- and inter-assay precision (reported as coefficient of variation (CV)), well below ⩽15% (⩽20% at LLOQ), and accuracy within the accepted ±15% (±20% at LLOQ) of the nominal concentration at all levels for all analytes. To support the accuracy and precision of measurements established with spiked quality control samples in plasma, and to verify the reliability of the reported plasma concentrations in study samples, incurred sample reanalysis was also performed for this clinical study. It was observed that 91.5% (236 of 258 for budesonide), 89.9% (241 of 268 for glycopyrronium), and 91.2% (238 of 261 for formoterol), of the repeated and original results, were within 20% of the mean of the two values, which was acceptable and within the acceptance criteria of the current regulatory guidance. All study samples were analyzed within the known stability period.</p><p>To assess safety and tolerability, AEs and SAEs were recorded from screening through follow-up (3−7 days after the final dose). Vital signs were recorded at screening, on day 1 of all treatment periods, and at 3−7 days after the early termination visit, if applicable. Twelve-lead ECGs, as well as clinical laboratory evaluations, urinalysis, and body weight measurements were recorded at screening, on day 2, treatment Period 3, and at the early termination visit, if applicable. Physical examinations were performed at screening, admission, and at discharge or the early termination visit.</p></sec><sec id="section14-17534666261417149"><title>Statistical analysis</title><p>Each study included three populations: the randomized set included all participants randomized to treatment; the safety analysis set included all participants who received ⩾1 inhalation of any treatment. In both studies, the PK analysis set included all participants in the safety analysis set who had ⩾1 primary PK parameter that was quantifiable and without any impactful protocol deviations. In the lung exposure study, the randomized set was identical to the safety analysis set.</p><p>Demographics and clinical characteristics are reported in the randomized set and summarized by treatment sequence. All PK analyses used the PK analysis set and are reported by treatment. Plasma PK parameters were estimated for budesonide, glycopyrronium, and formoterol for both treatments by non-compartmental analysis using Phoenix<sup>®</sup>, Phoenix WinNonlin: Radnor, PA; WinNonlin<sup>®</sup> Version 8.2 (or higher) and/or SAS<sup>®</sup> Version 9.4, SAS: Cary, NC (or higher)and are presented using appropriate descriptive statistics by treatment. Safety analyses were conducted in the safety analysis set and are summarized by treatment. As different MedDRA versions were used to classify AEs, specific AEs from the lung exposure study were re-assessed according to MedDRA version 26.0 and the data presented are merged across studies.</p><p>Bioequivalence was assessed between the test and reference treatments based on the PK analysis set using average bioequivalence (ABE), average bioequivalence with expanded limits (ABEL), or reference-scaled average bioequivalence (RSABE) depending on US or EU regulatory requirements. For both regulatory approaches, bioequivalence was considered established if the 90% confidence interval (CI) for the geometric mean ratio (GMR) of each PK parameter was within 80%–125% (or the expanded equivalence limits, where appropriate). Further, the acceptance criteria for GMR, and the acceptance criteria for 90% CIs of GMR had to be satisfied for each PK parameter and each analyte.</p><p>For the US regulatory approach, the GMR and its 90% CIs were estimated for Cmax, AUClast and AUCinf for budesonide, glycopyrronium, and formoterol using ABE or RSABE methods depending on the within-participant standard deviation (swr) of the reference treatment. The ABE is a linear mixed effects model, with the log-transformed PK parameter as a dependent variable, sequence and period as fixed effects and participant and treatment nested within-participant as random effects. If the swr of the reference treatment was &lt;0.294 (i.e., CV &lt; 30%), the ABE method was used, and the acceptance criteria for the 90% CIs of GMR were the fixed limits of 80%–125%. Conversely, if swr was ⩾ 0.294 (i.e., CV ⩾ 30%), the RSABE method was used,<sup>
<xref rid="bibr28-17534666261417149" ref-type="bibr">28</xref>
</sup> and bioequivalence was demonstrated if the criteria bound was ⩽ 0 and the point estimate of GMR fell between 80% and 125%. Criteria bound was defined as the 95% upper CI for <inline-formula id="inline-formula1-17534666261417149">
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="math1-17534666261417149" display="inline" overflow="scroll"><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>T</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>R</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>−</mml:mo><mml:mi>θ</mml:mi><mml:msubsup><mml:mi>S</mml:mi><mml:mrow><mml:mi>W</mml:mi><mml:mi>R</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>;</mml:mo></mml:mrow></mml:math>
</inline-formula> where <inline-formula id="inline-formula2-17534666261417149">
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="math2-17534666261417149" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:math>
</inline-formula> and <inline-formula id="inline-formula3-17534666261417149">
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="math3-17534666261417149" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:math>
</inline-formula> are the means of the ln-transformed PK parameter for test treatment and reference treatment; <inline-formula id="inline-formula4-17534666261417149">
<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="math4-17534666261417149" display="inline" overflow="scroll"><mml:mrow><mml:mi>θ</mml:mi><mml:mo>≡</mml:mo><mml:mspace width="0.25em"/><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mi>l</mml:mi><mml:mi>n</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math>
</inline-formula> is the scaled ABE limit.</p><p>For the EU regulatory approach, GMRs and their 90% CIs were estimated for Cmax and AUClast for budesonide, glycopyrronium, and formoterol using an analysis of variance model, with the log-transformed PK parameter as a dependent variable and sequence, period, treatment, and participant within sequence as fixed effects. As with the US approach, if the swr of the reference treatment was &lt;0.294, the ABE method was used for Cmax, and the acceptance limits for the 90% CIs of GMR were 80%–125%. If swr was ⩾0.294, the ABEL method was used for Cmax, and the acceptance limits for the 90% CIs of the GMR were expanded to where the upper (U) and lower (L) limits were defined as: (U, L) = <italic toggle="yes">e</italic> ± <italic toggle="yes">k</italic>·swr, where the regulatory constant <italic toggle="yes">k</italic> = 0.760. If within-participant CV exceeded 50%, then the acceptance limits were capped at 69.84% and 143.19%. For AUClast, expanded limits were not allowed, even when the CV exceeded 30%, and the ABE method was used, and the acceptance limits of the 90% CIs of the GMR were 80% to 125%. The ABE or ABEL approaches were performed via an analysis of variance model, with log-transformed PK parameter as dependent variable, sequence, period, treatment, and participant within sequence as fixed effects.<sup>
<xref rid="bibr29-17534666261417149" ref-type="bibr">29</xref>
</sup></p><p>Study sample sizes were determined for a partial replicate, three-way cross-over study based on the precision in estimating AUCinf, AUClast, and Cmax of BGF formulated with HFA-134a from previous studies.<sup><xref rid="bibr27-17534666261417149" ref-type="bibr">27</xref>,<xref rid="bibr30-17534666261417149" ref-type="bibr">30</xref><xref rid="bibr31-17534666261417149" ref-type="bibr"/><xref rid="bibr32-17534666261417149" ref-type="bibr"/>–<xref rid="bibr33-17534666261417149" ref-type="bibr">33</xref></sup> The partial replicate design was utilized to allow for expanded limits if CV exceeded 30%. In studies with higher intra-participant variability, larger absolute differences between the logarithmic means have been observed.<sup>
<xref rid="bibr34-17534666261417149" ref-type="bibr">34</xref>
</sup> As such, the studies were powered for a true GMR of 0.9.<sup>
<xref rid="bibr34-17534666261417149" ref-type="bibr">34</xref>
</sup> It was planned to randomize 108 participants in each study to achieve a minimum of 96 evaluable participants, assuming a 10% dropout rate, which was determined to provide a 90% probability of obtaining a 90% CI within the pre-specified limits of 69.84% to 143.19% for Cmax, as well as the fixed limits of 80%–125% for AUCinf and AUClast, and a GMR estimate within the bounds of 80%–125%.</p></sec></sec><sec sec-type="results" id="section15-17534666261417149"><title>Results</title><sec id="section16-17534666261417149"><title>Participant disposition</title><p>In the systemic exposure study, a total of 279 participants were screened, 108 were randomized and 107 (99.1%) participants completed the study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666261417149" ext-link-type="uri">Supplemental Figure 1</ext-link> for CONSORT diagram). In the lung exposure study, 223 participants were screened, 108 randomized; 103 (98.1%) participants completed the study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666261417149" ext-link-type="uri">Supplemental Figure 1</ext-link> for CONSORT diagram).</p></sec><sec id="section17-17534666261417149"><title>Demographics</title><p>Baseline participant demographics were generally well-balanced across treatment groups within each study (<xref rid="table1-17534666261417149" ref-type="table">Table 1</xref>). In the systemic exposure study, most participants were male (54.6%), the mean (standard deviation (SD)) age was 37.1 (10.3) years, and the mean (SD) BMI was 27.25 (3.85) kg/m<sup>2</sup>. In the lung exposure study, most participants were male (57.4%), the mean (SD) age was 38.1 (11.0) years, and the mean (SD) BMI was 26.94 (3.63) kg/m<sup>2</sup>. The distribution of participant race differed between studies, with the majority of participants in the systemic exposure study being White (55.6%) and the majority in the lung exposure study being Black (59.3%).</p><table-wrap position="float" id="table1-17534666261417149" orientation="portrait"><label>Table 1.</label><caption><p>Participant demographics by treatment sequence for the systemic exposure and lung exposure studies.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666261417149-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Study</th><th align="left" colspan="4" rowspan="1">Systemic exposure study</th><th align="left" colspan="4" rowspan="1">Lung exposure study</th></tr><tr><th align="left" rowspan="1" colspan="1">Treatment sequence</th><th align="left" rowspan="1" colspan="1">ABB<break/>(<italic toggle="yes">n</italic> = 36)</th><th align="left" rowspan="1" colspan="1">BAB<break/>(<italic toggle="yes">n</italic> = 36)</th><th align="left" rowspan="1" colspan="1">BBA<break/>(<italic toggle="yes">n</italic> = 36)</th><th align="left" rowspan="1" colspan="1">Total<break/>(<italic toggle="yes">N</italic> = 108)</th><th align="left" rowspan="1" colspan="1">ABB<break/>(<italic toggle="yes">n</italic> = 36)</th><th align="left" rowspan="1" colspan="1">BAB<break/>(<italic toggle="yes">n</italic> = 36)</th><th align="left" rowspan="1" colspan="1">BBA<break/>(<italic toggle="yes">n</italic> = 36)</th><th align="left" rowspan="1" colspan="1">Total<break/>(<italic toggle="yes">N</italic> = 108)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age, mean (SD), years</td><td rowspan="1" colspan="1">36.0 (10.0)</td><td rowspan="1" colspan="1">35.8 (9.6)</td><td rowspan="1" colspan="1">39.5 (11.2)</td><td rowspan="1" colspan="1">37.1 (10.3)</td><td rowspan="1" colspan="1">37.9 (10.5)</td><td rowspan="1" colspan="1">37.8 (11.7)</td><td rowspan="1" colspan="1">38.6 (11.1)</td><td rowspan="1" colspan="1">38.1 (11.0)</td></tr><tr><td colspan="9" rowspan="1">Sex, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1"> Male</td><td rowspan="1" colspan="1">22 (61.1)</td><td rowspan="1" colspan="1">17 (47.2)</td><td rowspan="1" colspan="1">20 (55.6)</td><td rowspan="1" colspan="1">59 (54.6)</td><td rowspan="1" colspan="1">22 (61.1)</td><td rowspan="1" colspan="1">21 (58.3)</td><td rowspan="1" colspan="1">19 (52.8)</td><td rowspan="1" colspan="1">62 (57.4)</td></tr><tr><td rowspan="1" colspan="1"> Female</td><td rowspan="1" colspan="1">14 (38.9)</td><td rowspan="1" colspan="1">19 (52.8)</td><td rowspan="1" colspan="1">16 (44.4)</td><td rowspan="1" colspan="1">49 (45.4)</td><td rowspan="1" colspan="1">14 (38.9)</td><td rowspan="1" colspan="1">15 (41.7)</td><td rowspan="1" colspan="1">17 (47.2)</td><td rowspan="1" colspan="1">46 (42.6)</td></tr><tr><td colspan="9" rowspan="1">Race, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1"> White</td><td rowspan="1" colspan="1">21 (58.3)</td><td rowspan="1" colspan="1">19 (52.8)</td><td rowspan="1" colspan="1">20 (55.6)</td><td rowspan="1" colspan="1">60 (55.6)</td><td rowspan="1" colspan="1">12 (33.3)</td><td rowspan="1" colspan="1">10 (27.8)</td><td rowspan="1" colspan="1">13 (36.1)</td><td rowspan="1" colspan="1">35 (32.4)</td></tr><tr><td rowspan="1" colspan="1"> Black/African American</td><td rowspan="1" colspan="1">8 (22.2)</td><td rowspan="1" colspan="1">8 (22.2)</td><td rowspan="1" colspan="1">10 (27.8)</td><td rowspan="1" colspan="1">26 (24.1)</td><td rowspan="1" colspan="1">21 (58.3)</td><td rowspan="1" colspan="1">24 (66.7)</td><td rowspan="1" colspan="1">19 (52.8)</td><td rowspan="1" colspan="1">64 (59.3)</td></tr><tr><td rowspan="1" colspan="1"> Asian</td><td rowspan="1" colspan="1">4 (11.1)</td><td rowspan="1" colspan="1">3 (8.3)</td><td rowspan="1" colspan="1">2 (5.6)</td><td rowspan="1" colspan="1">9 (8.3)</td><td rowspan="1" colspan="1">2 (5.6)</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">2 (5.6)</td><td rowspan="1" colspan="1">5 (4.6)</td></tr><tr><td rowspan="1" colspan="1"> Native Hawaiian/Other Pacific Islander</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"> American Indian/Alaska Native</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (0.9)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">2 (1.9)</td></tr><tr><td rowspan="1" colspan="1"> Other</td><td rowspan="1" colspan="1">2 (5.6)</td><td rowspan="1" colspan="1">5 (13.9)</td><td rowspan="1" colspan="1">4 (11.1)</td><td rowspan="1" colspan="1">11 (10.2)</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (2.8)</td><td rowspan="1" colspan="1">2 (1.9)</td></tr><tr><td colspan="9" rowspan="1">Body mass index, kg/m<sup>2</sup></td></tr><tr><td rowspan="1" colspan="1"> Mean (SD)</td><td rowspan="1" colspan="1">26.66 (3.84)</td><td rowspan="1" colspan="1">27.72 (3.99)</td><td rowspan="1" colspan="1">27.36 (3.75)</td><td rowspan="1" colspan="1">27.25 (3.85)</td><td rowspan="1" colspan="1">27.09 (3.42)</td><td rowspan="1" colspan="1">25.46 (3.19)</td><td rowspan="1" colspan="1">28.26 (3.77)</td><td rowspan="1" colspan="1">26.94 (3.63)</td></tr><tr><td rowspan="1" colspan="1"> Median (range)</td><td rowspan="1" colspan="1">26.90 (19.3–33.8)</td><td rowspan="1" colspan="1">28.35 (19.4–34.7)</td><td rowspan="1" colspan="1">27.65 (20.1–34.5)</td><td rowspan="1" colspan="1">27.65 (19.3–34.7)</td><td rowspan="1" colspan="1">27.00 (20.2–34.0)</td><td rowspan="1" colspan="1">25.55 (19.1–32.5)</td><td rowspan="1" colspan="1">27.80 (19.4–34.8)</td><td rowspan="1" colspan="1">26.85 (19.1–34.8)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-17534666261417149"><p>Treatment A: BGF HFO-1234ze 160/9/4.8 µg per actuation, four inhalations as a single dose (test formulation). Treatment B: BGF HFA-134a 160/9/4.8 µg per actuation, four inhalations as a single dose (reference formulation). In the lung exposure study, Treatments A and B were administered with oral activated charcoal to block gastrointestinal absorption.</p></fn><fn id="table-fn2-17534666261417149"><p>BGF, budesonide/glycopyrrolate/formoterol fumarate; HFA-134a, hydrofluoroalkane-134a; HFO-1234ze, hydrofluoroolefin-1234ze; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section18-17534666261417149"><title>Pharmacokinetics</title><p>Following administration, the geometric mean plasma concentration–time profiles of budesonide, glycopyrronium, and formoterol were similar across all treatments for both studies (<xref rid="fig2-17534666261417149" ref-type="fig">Figure 2</xref>), as were the individual PK measures (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666261417149" ext-link-type="uri">Supplemental Tables 1 and 2</ext-link>).</p><fig position="float" id="fig2-17534666261417149" orientation="portrait"><label>Figure 2.</label><caption><p>Geometric mean (geometric SD) plasma concentration versus nominal sampling time for each BGF component (linear scale) in the systemic (a) and lung exposure (b) studies.</p><p>BGF, budesonide/glycopyrrolate/formoterol fumarate; h, hours; HFA-134a, hydrofluoroalkane-134a; HFO-1234ze, hydrofluoroolefin-1234ze; SD, standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666261417149-fig2.jpg"/></fig></sec><sec id="section19-17534666261417149"><title>Bioequivalence</title><p>Total systemic exposure and lung exposure for each BGF analyte met bioequivalence criteria for HFO-1234ze relative to HFA-134a using both the US and EU regulatory approaches (<xref rid="fig3-17534666261417149" ref-type="fig">Figure 3</xref>), with GMRs for all BGF analytes consistent across approaches. For budesonide, RSABE was used per the US regulatory approach for Cmax in both studies as the CV was &gt;30% and RSABE was used for AUC parameters in the lung exposure study as the CV was &gt;30%, whereas ABE was used for the AUC parameters in the systemic exposure study as the CV was &lt;30%; the GMR for all measures was within 80%–125% and the criteria bound was &lt;0. ABE was used per the EU regulatory approach for AUClast, and ABEL was used for Cmax in both studies as the CV exceeded 30%, resulting in AUClast acceptable limits within 80%–125% for both studies and Cmax acceptance limit expansion of 76.64%–130.48% for the systemic exposure study and 73.29%–136.44% for the lung exposure study.</p><fig position="float" id="fig3-17534666261417149" orientation="portrait"><label>Figure 3.</label><caption><p>Geometric mean ratios (90% CI) for total systemic exposure (a) and lung exposure (b) parameters for each BGF component for HFO-1234ze relative to HFA-134a. The grey area represents the bioequivalence boundary for the GMR and 90% CIs of GMR at the fixed limits of 80%–125%. <sup>a</sup>US approach results based on ABE method for Cmax, AUClast, and AUCinf if intra-subject CV &lt; 30%, or RSABE method if intra-subject CV ⩾ 30%. When the RSABE method was used, bioequivalence was demonstrated if the criteria bound was ⩽0 together with a GMR within 80%–125%. The GMR and its 90% CIs were estimated for Cmax, AUClast, and AUCinf for budesonide, glycopyrronium, and formoterol using a linear mixed effects model, with the log-transformed PK parameter as a dependent variable, sequence and period as fixed effects, and participant and treatment nested within-participant as random effects. <sup>b</sup>EU approach results based on ABE method for Cmax if intra-subject CV &lt; 30%, or ABEL method for Cmax if intra-subject CV ⩾ 30%, and the ABE method for AUClast. GMRs and their 90% CIs were estimated for Cmax and AUClast for budesonide, glycopyrronium, and formoterol using an analysis of variance model, with the log-transformed PK parameter as a dependent variable, and sequence, period, treatment, and subject within sequence as fixed effects.</p><p>ABE, average bioequivalence; ABEL, average bioequivalence with expanded limits; AUCinf, area under the plasma concentration–time curve from time zero to infinity; AUClast, area under the plasma concentration–time curve from time zero to the time of the final quantifiable concentration; BGF, budesonide/glycopyrrolate/formoterol fumarate; CI, confidence interval; Cmax, maximum observed plasma drug concentration; CV, coefficient of variation; GMR, geometric mean ratio; HFA-134a, hydrofluoroalkane-134a; HFO-1234ze, hydrofluoroolefin-1234ze; PK, pharmacokinetic; RSABE, reference-scaled average bioequivalence.</p></caption><alt-text>Compare bioequivalence ratios (90% CI) for total systemic exposure (a) and lung exposure (b) parameters for each BGF component for HFO-1234ze relative to HFA-134a, covering budesonide, glycopyrrolonium, and formoterol. Graphs depict different approaches and conditions. Graphs show a range of values with bioequivalence boundary represented.</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666261417149-fig3.jpg"/></fig><p>For glycopyrronium, RSABE was used per the US regulatory approach for Cmax and AUC parameters in both studies as the CV was &gt;30%; the GMR for all measures was within 80%–125%, and the criteria bound was &lt;0. ABEL was used per the EU regulatory approach for Cmax in both studies as the CV exceeded 30%, resulting in Cmax acceptance limit expansion of 75.47%–132.50% for the systemic exposure study and 74.24%–134.70% for the lung exposure study. ABE was used per the EU regulatory approach for AUClast, with acceptable limits within 80% to 125% for both studies.</p><p>For formoterol, RSABE was used per the US regulatory approach for Cmax and AUC parameters in the lung exposure study as the CV was &gt;30%, whereas RSABE was only used for Cmax in the systemic exposure study as the CV was &lt;30% for AUCinf and AUClast; the GMR for all measures was within 80%–125% and the criteria bound was &lt;0. In both studies, ABE was used per the EU regulatory approach for AUClast, whereas ABEL was used for Cmax as the CV exceeded 30%. AUClast acceptable limits were within 80%–125% for both studies, and Cmax acceptance limit expansion was 79.52%–125.75% for the systemic exposure study and 74.21%–134.75% for the lung exposure study.</p></sec><sec id="section20-17534666261417149"><title>Safety and tolerability</title><p>In the systemic exposure study, 14.8% of participants experienced any AEs with BGF HFO-1234ze compared with 19.6% and 8.4%, respectively, for each replicate of BGF HFA-134a (<xref rid="table2-17534666261417149" ref-type="table">Table 2</xref>). Similar results were observed in the lung exposure study, in which 11.7% of participants experienced any AE with BGF HFO-1234ze compared with 18.1% and 3.8%, respectively, for each replicate of BGF HFA-134a (<xref rid="table2-17534666261417149" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="table2-17534666261417149" orientation="portrait"><label>Table 2.</label><caption><p>Overall summary of AEs for the systemic exposure study and lung exposure study.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666261417149-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" colspan="3" rowspan="1">Systemic exposure</th><th align="left" colspan="3" rowspan="1">Lung exposure</th></tr><tr><th align="left" rowspan="1" colspan="1">AE category, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">BGF HFO-1234ze<sup>
<xref rid="table-fn3-17534666261417149" ref-type="table-fn">a</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 108</th><th align="left" rowspan="1" colspan="1">BGF HFA-134a<break/>(Replicate 1)<sup>
<xref rid="table-fn4-17534666261417149" ref-type="table-fn">b</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 107</th><th align="left" rowspan="1" colspan="1">BGF HFA-134a<break/>(Replicate 2)<sup>
<xref rid="table-fn4-17534666261417149" ref-type="table-fn">b</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 107</th><th align="left" rowspan="1" colspan="1">BGF HFO-1234ze<sup>
<xref rid="table-fn3-17534666261417149" ref-type="table-fn">a</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 103</th><th align="left" rowspan="1" colspan="1">BGF HFA-134a<break/>(Replicate 1)<sup>
<xref rid="table-fn4-17534666261417149" ref-type="table-fn">b</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 105</th><th align="left" rowspan="1" colspan="1">BGF HFA-134a<break/>(Replicate 2)<sup>
<xref rid="table-fn4-17534666261417149" ref-type="table-fn">b</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 104</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Any AE</td><td rowspan="1" colspan="1">16 (14.8)</td><td rowspan="1" colspan="1">21 (19.6)</td><td rowspan="1" colspan="1">9 (8.4)</td><td rowspan="1" colspan="1">12 (11.7)</td><td rowspan="1" colspan="1">19 (18.1)</td><td rowspan="1" colspan="1">4 (3.8)</td></tr><tr><td rowspan="1" colspan="1"> SAE</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"> AE leading to discontinuation of study intervention</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1"> Treatment-related AE<sup>
<xref rid="table-fn5-17534666261417149" ref-type="table-fn">c</xref>
</sup></td><td rowspan="1" colspan="1">10 (9.3)</td><td rowspan="1" colspan="1">12 (11.2)</td><td rowspan="1" colspan="1">4 (3.7)</td><td rowspan="1" colspan="1">4 (3.9)</td><td rowspan="1" colspan="1">6 (5.7)</td><td rowspan="1" colspan="1">2 (1.9)</td></tr><tr><td rowspan="1" colspan="1">  Treatment-related SAE<sup>
<xref rid="table-fn5-17534666261417149" ref-type="table-fn">c</xref>
</sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn3-17534666261417149"><label>a</label><p>BGF HFO-1234ze 160/9/4.8 µg per actuation, four inhalations as a single dose, administered during one treatment period (test formulation; Treatment A).</p></fn><fn id="table-fn4-17534666261417149"><label>b</label><p>BGF HFA-134a 160/9/4.8 µg per actuation, four inhalations as a single dose, administered during one treatment period (reference formulation; Treatment B).</p></fn><fn id="table-fn5-17534666261417149"><label>c</label><p>Any AE/SAE determined by the investigator to have a possible causal link to the study intervention/investigational product.</p></fn><fn id="table-fn6-17534666261417149"><p>AE, adverse event; BGF, budesonide/glycopyrrolate/formoterol fumarate; HFA-134a, hydrofluoroalkane-134a; HFO-1234ze, hydrofluoroolefin-1234ze; SAE, serious adverse event.</p></fn></table-wrap-foot></table-wrap><p>No AEs led to treatment discontinuation (<xref rid="table2-17534666261417149" ref-type="table">Table 2</xref>), and no SAEs or deaths were reported during either study. Combined across studies, headache was the most common AE (<xref rid="table3-17534666261417149" ref-type="table">Table 3</xref>), which was reported in 2.8% of participants with HFO-1234ze and in 5.2% (replicate 1) and 0.9% (replicate 2) of participants with HFA-134a.</p><table-wrap position="float" id="table3-17534666261417149" orientation="portrait"><label>Table 3.</label><caption><p>Most frequently reported AEs (reported by ⩾ 2 participants in any treatment group) combined across both the systemic exposure study and the lung exposure study.</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666261417149-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Preferred term, <italic toggle="yes">n</italic> (%)</th><th align="left" rowspan="1" colspan="1">BGF HFO-1234ze<sup>
<xref rid="table-fn7-17534666261417149" ref-type="table-fn">a</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 211</th><th align="left" rowspan="1" colspan="1">BGF HFA-134a<break/>(Replicate 1)<sup>
<xref rid="table-fn8-17534666261417149" ref-type="table-fn">b</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 212</th><th align="left" rowspan="1" colspan="1">BGF HFA-134a<break/>(Replicate 2)<sup>
<xref rid="table-fn8-17534666261417149" ref-type="table-fn">b</xref>
</sup>
<break/><italic toggle="yes">N</italic> = 211</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">6 (2.8)</td><td rowspan="1" colspan="1">11 (5.2)</td><td rowspan="1" colspan="1">2 (0.9)</td></tr><tr><td rowspan="1" colspan="1">Catheter site bruise</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td rowspan="1" colspan="1">Cough</td><td rowspan="1" colspan="1">1 (0.5)</td><td rowspan="1" colspan="1">4 (1.9)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Dizziness</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td rowspan="1" colspan="1">Nausea</td><td rowspan="1" colspan="1">3 (1.4)</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Throat irritation</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">3 (1.4)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">1 (0.5)</td><td rowspan="1" colspan="1">3 (1.4)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Feces discolored</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Vessel puncture site bruise</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Back pain</td><td rowspan="1" colspan="1">1 (0.5)</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">0</td></tr><tr><td rowspan="1" colspan="1">Catheter site pain</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (0.5)</td><td rowspan="1" colspan="1">2 (0.9)</td></tr><tr><td rowspan="1" colspan="1">Catheter site swelling</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (1.4)</td></tr><tr><td rowspan="1" colspan="1">Dry throat</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">1 (0.5)</td></tr><tr><td rowspan="1" colspan="1">Abdominal pain</td><td rowspan="1" colspan="1">2 (0.9)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn7-17534666261417149"><label>a</label><p>BGF HFO-1234ze 160/9/4.8 µg per actuation, four inhalations as a single dose (test formulation; Treatment A).</p></fn><fn id="table-fn8-17534666261417149"><label>b</label><p>BGF HFA-134a 160/9/4.8 µg per actuation, four inhalations as a single dose (reference formulation; Treatment B).</p></fn><fn id="table-fn9-17534666261417149"><p>AE, adverse event; BGF, budesonide/glycopyrrolate/formoterol fumarate; HFA-134a, hydrofluoroalkane-134a; HFO-1234ze, hydrofluoroolefin-1234ze.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="section21-17534666261417149"><title>Discussion</title><p>The development of pMDI propellants with near-zero GWP, such as HFO-1234ze, aims to reduce the environmental impact of respiratory disease care while ensuring access to essential medicines for patients.<sup><xref rid="bibr5-17534666261417149" ref-type="bibr">5</xref>,<xref rid="bibr18-17534666261417149" ref-type="bibr">18</xref></sup> HFO-1234ze has a near-zero 100-year global warming potential (GWP<sub>100</sub> = 1.37) compared with approximately 1530 for HFA-134a (a reduction exceeding 99.9%),<sup><xref rid="bibr17-17534666261417149" ref-type="bibr">17</xref>,<xref rid="bibr35-17534666261417149" ref-type="bibr">35</xref>,<xref rid="bibr36-17534666261417149" ref-type="bibr">36</xref></sup> which translates to a substantial decrease in carbon dioxide equivalent emissions per device and overall, because pMDIs are used by the majority of patients.<sup>
<xref rid="bibr4-17534666261417149" ref-type="bibr">4</xref>
</sup> The current findings demonstrate that total systemic and lung exposure in healthy adults is bioequivalent, and that safety and tolerability profiles are comparable, when BGF is administered using near-zero GWP HFO-1234ze propellant versus HFA-134a. Taken together, the current findings demonstrate that BGF pMDI HFO-1234z represents a viable alternative propellant to HFA-134a.</p><p>PK parameters were similar for the BGF HFO-1234ze and BGF HFA-134a formulations. Analysis of total systemic and lung exposure demonstrated bioequivalence for all three BGF components (budesonide, glycopyrronium, and formoterol) with HFO-1234ze versus HFA-134a, using both US and EU regulatory approaches. Data from the systemic exposure study are consistent with a prior study, which also showed similar systemic exposure with HFO-1234ze and HFA-134a.<sup>
<xref rid="bibr19-17534666261417149" ref-type="bibr">19</xref>
</sup> However, as the previous study was not designed to specifically establish bioequivalence, the current data extend previous findings to directly verify bioequivalence not only for systemic exposure but also lung exposure. The overall PK variables observed for each component were as expected and generally comparable with previous findings of BGF in healthy adults.<sup><xref rid="bibr19-17534666261417149" ref-type="bibr">19</xref>,<xref rid="bibr27-17534666261417149" ref-type="bibr">27</xref>,<xref rid="bibr30-17534666261417149" ref-type="bibr">30</xref><xref rid="bibr31-17534666261417149" ref-type="bibr"/><xref rid="bibr32-17534666261417149" ref-type="bibr"/>–<xref rid="bibr33-17534666261417149" ref-type="bibr">33</xref></sup> Both BGF HFO-1234ze and BGF HFA-134a were also well-tolerated, with similar safety profiles observed with each propellant in both the systemic and lung exposure studies. No new or unexpected safety findings were observed following single dosing of healthy participants with either propellant.</p><p>Collectively, based on these findings, it is expected that BGF HFO-1234ze will have similar clinical characteristics to BGF HFA-134a from both efficacy and safety perspectives. In phase III studies, BGF pMDI HFA-134a has been shown to improve lung function and reduce the rate of COPD exacerbations in people with moderate-to-very severe COPD.<sup><xref rid="bibr11-17534666261417149" ref-type="bibr">11</xref><xref rid="bibr12-17534666261417149" ref-type="bibr"/>–<xref rid="bibr13-17534666261417149" ref-type="bibr">13</xref>,<xref rid="bibr37-17534666261417149" ref-type="bibr">37</xref></sup> These lung bioequivalence findings support the likelihood that the BGF HFO-1234ze formulation will have comparable efficacy to the approved BGF HFA-134a formulation in patients with COPD. Further, the systemic bioequivalence data suggest the safety profile of the HFO-1234ze formulation in clinical practice will be similar to the current HFA-134a formulation. Additional studies aim to further evaluate and confirm clinical and safety outcomes.</p><p>These studies are limited by factors generally associated with phase I studies, including their limited dosing duration, which can influence safety and tolerability evaluations, and the restriction of the study population to healthy participants without diagnosed respiratory diseases. However, inclusion of healthy participants is consistent with the conduct of other bioequivalence studies, as it minimizes daily fluctuation in lung function that can occur in participants with respiratory diseases that could potentially confound the PK comparisons between treatment.<sup><xref rid="bibr19-17534666261417149" ref-type="bibr">19</xref>,<xref rid="bibr27-17534666261417149" ref-type="bibr">27</xref>,<xref rid="bibr30-17534666261417149" ref-type="bibr">30</xref>,<xref rid="bibr38-17534666261417149" ref-type="bibr">38</xref></sup> While healthy volunteers are commonly included in phase I studies, differences in inhalation technique and lung pathology in patients with COPD may affect drug deposition and pharmacokinetics, and should be considered when interpreting these findings.<sup><xref rid="bibr39-17534666261417149" ref-type="bibr">39</xref>,<xref rid="bibr40-17534666261417149" ref-type="bibr">40</xref></sup></p></sec><sec sec-type="conclusions" id="section22-17534666261417149"><title>Conclusion</title><p>For people living with COPD who may be unable to produce the adequate inspiratory flow required to use dry powder inhalers, pMDIs are essential, as the propellants in pMDIs facilitate the inhalation and delivery of medications to the lungs. However, currently marketed pMDI propellants, such as HFA-134a, are greenhouse gases with GWP that contribute to global climate change. The current findings indicate total systemic and lung exposure to BGF components was bioequivalent when formulated with the near-zero GWP HFO-1234ze propellant compared with the currently marketed HFA-134a propellant, with no new or unexpected safety findings. These findings suggest HFO-1234ze is a viable replacement for HFA-134a for use in BGF, ensuring access to essential medicines and supporting the recently completed clinical program for the transition of BGF to the next-generation HFO-1234ze propellant. It is anticipated that initial availability of the BGF pMDI utilizing HFO-1234ze will occur in 2025.</p></sec><sec sec-type="supplementary-material" id="section23-17534666261417149" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-17534666261417149" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-doc-2-tar-10.1177_17534666261417149 – Supplemental material for Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-doc-2-tar-10.1177_17534666261417149.doc" position="float" orientation="portrait"/><p>Supplemental material, sj-doc-2-tar-10.1177_17534666261417149 for Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies by Artur Bednarczyk, Magnus Aurivillius, Mandeep Jassal, Mihir Shah, Ibrahim Raphiou, David Petullo, John Xu, Maria Heijer, Klementyna Sychowicz, Kathryn Collison, Carlos Silva, Jitendar Reddy, David Han, Ronald Goldwater, Michael Gillen and Mehul Patel in Therapeutic Advances in Respiratory Disease</p></supplementary-material><supplementary-material id="suppl2-17534666261417149" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-tar-10.1177_17534666261417149 – Supplemental material for Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-tar-10.1177_17534666261417149.docx" position="float" orientation="portrait"/><p>Supplemental material, sj-docx-1-tar-10.1177_17534666261417149 for Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies by Artur Bednarczyk, Magnus Aurivillius, Mandeep Jassal, Mihir Shah, Ibrahim Raphiou, David Petullo, John Xu, Maria Heijer, Klementyna Sychowicz, Kathryn Collison, Carlos Silva, Jitendar Reddy, David Han, Ronald Goldwater, Michael Gillen and Mehul Patel in Therapeutic Advances in Respiratory Disease</p></supplementary-material></sec></body><back><ack><p>AstraZeneca would like to thank the study participants and investigational site staff for their participation in these clinical studies. Medical writing and submission support, under the direction of the authors, was provided by Mark Bloom, PhD, and Rebecca Douglas, PhD, CMC Connect, a division of IPG Health Medical Communications, funded by AstraZeneca, in accordance with Good Publication Practice (GPP 2022) guidelines. Artificial Intelligence was not used in the development of this manuscript.</p></ack><fn-group><fn fn-type="other"><p><bold>ORCID iD:</bold> Magnus Aurivillius <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17534666261417149-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-4660-5040" ext-link-type="uri">https://orcid.org/0000-0003-4660-5040</ext-link></p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn><fn fn-type="other"><p><bold>Prior publication:</bold> Portions of the data being reported have been presented at the 2024 annual meeting of the American Thoracic Society (17–22 May 2024) and the associated abstracts published.<sup><xref rid="bibr42-17534666261417149" ref-type="bibr">41</xref>,<xref rid="bibr43-17534666261417149" ref-type="bibr">42</xref></sup></p></fn></fn-group><sec id="section25-17534666261417149"><title>Declarations</title><fn-group><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> The studies were conducted in accordance with ethical principles derived from the Declaration of Helsinki and the Council for International Organizations of Medical Sciences International Ethical Guidelines. Ethical principles were consistent with the applicable International Council for Harmonization Good Clinical Practice Guidelines, the AstraZeneca policy on Bioethics and Human Biological Samples and local laws and regulations. The conduct of the study was monitored by an independent Parexel monitor and by the study sponsor to ensure compliance with applicable regulatory requirements and good clinical practice guidelines. The study sponsor provided oversight of all study-related activities, including remote monitoring of dosing sessions, to ensure appropriate study intervention dosing and inhalation technique. The study protocol and informed consent forms were reviewed and approved by an Institutional Review Board (Advarra IRB, Columbia, MD, USA; registration number 00000971) before study initiation. Participants provided written, dated, and signed informed consent before receiving study-specific procedures.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> Not applicable.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Artur Bednarczyk:</bold> Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Visualization; Writing – review &amp; editing.</p><p><bold>Magnus Aurivillius:</bold> Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Project administration; Supervision; Validation; Visualization; Writing – review &amp; editing.</p><p><bold>Mandeep Jassal:</bold> Project administration; Visualization; Writing – review &amp; editing.</p><p><bold>Mihir Shah:</bold> Writing – review &amp; editing.</p><p><bold>Ibrahim Raphiou:</bold> Investigation; Methodology; Project administration; Resources; Supervision; Writing – review &amp; editing.</p><p><bold>David Petullo:</bold> Conceptualization; Data curation; Formal analysis; Methodology; Writing – review &amp; editing.</p><p><bold>John Xu:</bold> Data curation; Formal analysis; Writing – review &amp; editing.</p><p><bold>Maria Heijer:</bold> Formal analysis; Writing – review &amp; editing.</p><p><bold>Klementyna Sychowicz:</bold> Project administration; Supervision; Writing – review &amp; editing.</p><p><bold>Kathryn Collison:</bold> Conceptualization; Funding acquisition; Methodology; Project administration; Resources; Supervision; Writing – review &amp; editing.</p><p><bold>Carlos Silva:</bold> Formal analysis; Writing – review &amp; editing.</p><p><bold>Jitendar Reddy:</bold> Formal analysis; Methodology; Writing – review &amp; editing.</p><p><bold>David Han:</bold> Project administration; Writing – review &amp; editing.</p><p><bold>Ronald Goldwater:</bold> Data curation; Investigation; Project administration; Supervision; Writing – review &amp; editing.</p><p><bold>Michael Gillen:</bold> Conceptualization; Formal analysis; Methodology; Project administration; Supervision; Visualization; Writing – review &amp; editing.</p><p><bold>Mehul Patel:</bold> Formal analysis; Methodology; Project administration; Supervision; Writing – review &amp; editing.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by AstraZeneca.</p></fn><fn fn-type="COI-statement"><p>Artur Bednarczyk, Magnus Aurivillius, Mandeep Jassal, Mihir Shah, David Petullo, John Xu, Maria Heijer, Klementyna Sychowicz, Kathryn Collison, Carlos Silva, Jitendar Reddy, and Mehul Patel are employees of AstraZeneca and may hold stock and/or stock options in the company. Ibrahim Raphiou is currently at Research Triangle Park, NC, United States. Ronald Goldwater is an employee of Parexel, which was funded by AstraZeneca to conduct this study. Michael Gillen is a contract employee of AstraZeneca and holds stock in the company. David Han is an employee of Parexel, which was funded by AstraZeneca to conduct this study.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca’s data sharing policy described at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure" ext-link-type="uri">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ext-link>. Data for studies directly listed on Vivli can be requested through Vivli at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.vivli.org" ext-link-type="uri">www.vivli.org</ext-link>. Data for studies not listed on Vivli could be requested through Vivli at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/" ext-link-type="uri">https://vivli.org/members/enquiries-about-studies-not-listed-on-the-vivli-platform/</ext-link>. The AstraZeneca Vivli member page is also available outlining further details: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://vivli.org/ourmember/astrazeneca/" ext-link-type="uri">https://vivli.org/ourmember/astrazeneca/</ext-link>.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bibr1-17534666261417149"><label>1</label><mixed-citation publication-type="webpage">
<collab>Global Initiative for Asthma</collab>. <article-title>Global strategy for asthma management and prevention</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf" ext-link-type="uri">https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf</ext-link> (<year>2024</year>, <comment>accessed 26 November 2024</comment>).</mixed-citation></ref><ref id="bibr2-17534666261417149"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Laube</surname><given-names>BL</given-names></name>
<name name-style="western"><surname>Janssens</surname><given-names>HM</given-names></name>
<name name-style="western"><surname>de Jongh</surname><given-names>FHC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>What the pulmonary specialist should know about the new inhalation therapies</article-title>. <source>Eur Respir J</source>
<year>2011</year>; <volume>37</volume>: <fpage>1308</fpage>–<lpage>1331</lpage>.<pub-id pub-id-type="pmid">21310878</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09031936.00166410</pub-id></mixed-citation></ref><ref id="bibr3-17534666261417149"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Myrdal</surname><given-names>PB</given-names></name>
<name name-style="western"><surname>Sheth</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Stein</surname><given-names>SW.</given-names></name>
</person-group>
<article-title>Advances in metered dose inhaler technology: formulation development</article-title>. <source>AAPS PharmSciTech</source>
<year>2014</year>; <volume>15</volume>: <fpage>434</fpage>–<lpage>455</lpage>.<pub-id pub-id-type="pmid">24452499</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1208/s12249-013-0063-x</pub-id><pub-id pub-id-type="pmcid">PMC3969484</pub-id></mixed-citation></ref><ref id="bibr4-17534666261417149"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Aggarwal</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Gogtay</surname><given-names>J.</given-names></name>
</person-group>
<article-title>Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence</article-title>. <source>Expert Rev Respir Med</source>
<year>2014</year>; <volume>8</volume>: <fpage>349</fpage>–<lpage>356</lpage>.<pub-id pub-id-type="pmid">24802511</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/17476348.2014.905916</pub-id></mixed-citation></ref><ref id="bibr5-17534666261417149"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Woodcock</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Beeh</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>Sagara</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The environmental impact of inhaled therapy: making informed treatment choices</article-title>. <source>Eur Respir J</source>
<year>2022</year>; <volume>60</volume>: <fpage>2102106</fpage>.<pub-id pub-id-type="pmid">34916263</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.02106-2021</pub-id><pub-id pub-id-type="pmcid">PMC9301054</pub-id></mixed-citation></ref><ref id="bibr6-17534666261417149"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Jeswani</surname><given-names>HK</given-names></name>
<name name-style="western"><surname>Azapagic</surname><given-names>A.</given-names></name>
</person-group>
<article-title>Life cycle environmental impacts of inhalers</article-title>. <source>J Clean Prod</source>
<year>2019</year>; <volume>237</volume>: <fpage>117733</fpage>.</mixed-citation></ref><ref id="bibr7-17534666261417149"><label>7</label><mixed-citation publication-type="webpage">
<collab>United Nations Environment Programme</collab>. <article-title>The Kigali Amendment (2016): the amendment to the Montreal Protocol agreed by the Twenty-Eighth Meeting of the Parties</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ozone.unep.org/treaties/montreal-protocol/amendments/kigali-amendment-2016-amendment-montreal-protocol-agreed" ext-link-type="uri">https://ozone.unep.org/treaties/montreal-protocol/amendments/kigali-amendment-2016-amendment-montreal-protocol-agreed</ext-link> (<year>2016</year>, <comment>accessed 2025 Mar 5</comment>).</mixed-citation></ref><ref id="bibr8-17534666261417149"><label>8</label><mixed-citation publication-type="webpage">
<collab>United Nations Environment Programme</collab>. <article-title>The Montreal protocol on substances that deplete the ozone layer</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ozone.unep.org/treaties/montreal-protocol" ext-link-type="uri">https://ozone.unep.org/treaties/montreal-protocol</ext-link> (<year>2020</year>, <comment>accessed 5 June 2024</comment>).<pub-id pub-id-type="pmid">1506990</pub-id></mixed-citation></ref><ref id="bibr9-17534666261417149"><label>9</label><mixed-citation publication-type="webpage">
<collab>European Medicines Agency</collab>. <article-title>Trixeo Aerosphere</article-title>. <source>Summary of product characteristics</source>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/product-information/trixeo-aerosphere-epar-product-information_en.pdf</ext-link> (<year>2020</year>, <comment>accessed 23 Sep 2025</comment>).</mixed-citation></ref><ref id="bibr10-17534666261417149"><label>10</label><mixed-citation publication-type="webpage">
<collab>US Food and Drug Administration</collab>. <article-title>Breztri Aerosphere™ highlights of prescribing information</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9d44f9af-438a-448b-bb5c-dae506e17e49/9d44f9af-438a-448b-bb5c-dae506e17e49_viewable_rendition__v.pdf" ext-link-type="uri">https://den8dhaj6zs0e.cloudfront.net/50fd68b9-106b-4550-b5d0-12b045f8b184/9d44f9af-438a-448b-bb5c-dae506e17e49/9d44f9af-438a-448b-bb5c-dae506e17e49_viewable_rendition__v.pdf</ext-link> (<year>2022</year>, <comment>accessed 9 July 2025</comment>).</mixed-citation></ref><ref id="bibr11-17534666261417149"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rabe</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Ferguson</surname><given-names>GT</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD</article-title>. <source>N Engl J Med</source>
<year>2020</year>; <volume>383</volume>: <fpage>35</fpage>–<lpage>48</lpage>.<pub-id pub-id-type="pmid">32579807</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1916046</pub-id></mixed-citation></ref><ref id="bibr12-17534666261417149"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ferguson</surname><given-names>GT</given-names></name>
<name name-style="western"><surname>Rabe</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial</article-title>. <source>Lancet Respir Med</source>
<year>2018</year>; <volume>6</volume>: <fpage>747</fpage>–<lpage>758</lpage>.<pub-id pub-id-type="pmid">30232048</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(18)30327-8</pub-id></mixed-citation></ref><ref id="bibr13-17534666261417149"><label>13</label><mixed-citation publication-type="webpage">
<collab>Global Initiative for Chronic Obstructive Lung Disease</collab>. <year>2025</year>
<article-title>GOLD Report: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://goldcopd.org/2025-gold-report/" ext-link-type="uri">https://goldcopd.org/2025-gold-report/</ext-link> (<year>2025</year>, <comment>accessed 23 Sep 2025</comment>).</mixed-citation></ref><ref id="bibr14-17534666261417149"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Rabe</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler versus dual therapies in patients with COPD: a sub-study of the ETHOS trial</article-title>. <source>Ther Adv Respir Dis</source>
<year>2021</year>; <volume>15</volume>: 17534666211034329.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/17534666211034329</pub-id><pub-id pub-id-type="pmcid">PMC8392797</pub-id><pub-id pub-id-type="pmid">34428980</pub-id></mixed-citation></ref><ref id="bibr15-17534666261417149"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name>
<name name-style="western"><surname>Rabe</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Ferguson</surname><given-names>GT</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2021</year>; <volume>203</volume>: <fpage>553</fpage>–<lpage>564</lpage>.<pub-id pub-id-type="pmid">33252985</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202006-2618OC</pub-id><pub-id pub-id-type="pmcid">PMC7924571</pub-id></mixed-citation></ref><ref id="bibr16-17534666261417149"><label>16</label><mixed-citation publication-type="webpage">
<collab>Honeywell International I</collab>. <article-title>Honeywell and Recipharm to speed development of inhalers with a near-zero global warming potential propellant</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.honeywell.com/us/en/press/2023/08/honeywell-and-recipharm-to-speed-development-of-inhalers-with-a-near-zero-global-warming-potential-propellant" ext-link-type="uri">https://www.honeywell.com/us/en/press/2023/08/honeywell-and-recipharm-to-speed-development-of-inhalers-with-a-near-zero-global-warming-potential-propellant</ext-link> (<year>2023</year>, <comment>accessed 23 June 2025</comment>).</mixed-citation></ref><ref id="bibr17-17534666261417149"><label>17</label><mixed-citation publication-type="webpage">
<collab>Intergovernmental Panel on Climate Change</collab>. <article-title>Working Group I Sixth Assessment Report</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ipcc.ch/report/ar6/wg1/downloads/report/IPCC_AR6_WGI_Chapter_07_Supplementary_Material.pdf" ext-link-type="uri">https://www.ipcc.ch/report/ar6/wg1/downloads/report/IPCC_AR6_WGI_Chapter_07_Supplementary_Material.pdf</ext-link> (<year>2021</year>, <comment>accessed 10 June 2025</comment>).</mixed-citation></ref><ref id="bibr18-17534666261417149"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Pritchard</surname><given-names>JN.</given-names></name>
</person-group>
<article-title>The climate is changing for metered-dose inhalers and action is needed</article-title>. <source>Drug Des Devel Ther</source>
<year>2020</year>; <volume>14</volume>: <fpage>3043</fpage>–<lpage>3055</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/DDDT.S262141</pub-id><pub-id pub-id-type="pmcid">PMC7410333</pub-id><pub-id pub-id-type="pmid">32801643</pub-id></mixed-citation></ref><ref id="bibr19-17534666261417149"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Aurivillius</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Bednarczyk</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Kokot</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate triple therapy delivered using next generation propellants with low global warming potential</article-title>. <source>Pulm Pharmacol Ther</source>
<year>2023</year>; <volume>83</volume>: <fpage>102245</fpage>.<pub-id pub-id-type="pmid">37607661</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2023.102245</pub-id></mixed-citation></ref><ref id="bibr20-17534666261417149"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hopewell</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>AW</given-names></name>
<name name-style="western"><surname>Collins</surname><given-names>GS</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>CONSORT 2025 statement: updated guideline for reporting randomized trials</article-title>. <source>Nat Med</source>
<year>2025</year>; <volume>31</volume>: <fpage>1776</fpage>–<lpage>1783</lpage>.<pub-id pub-id-type="pmid">40229553</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-025-03635-5</pub-id></mixed-citation></ref><ref id="bibr21-17534666261417149"><label>21</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author">
<name name-style="western"><surname>Snell</surname><given-names>NJ</given-names></name>
<name name-style="western"><surname>Ganderton</surname><given-names>D.</given-names></name>
</person-group>
<article-title>Assessing lung deposition of inhaled medications</article-title>. <conf-name>Consensus statement from a workshop of the British Association for Lung Research, held at the Institute of Biology</conf-name>, <conf-loc>London, U.K</conf-loc>. On <conf-date>17 April 1998</conf-date>. <conf-name>Respir Med</conf-name>
<year>1999</year>; <volume>93</volume>: <fpage>123</fpage>–<lpage>133</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0954-6111(99)90302-5</pub-id><pub-id pub-id-type="pmid">10464864</pub-id></mixed-citation></ref><ref id="bibr22-17534666261417149"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chrystyn</surname><given-names>H.</given-names></name>
</person-group>
<article-title>Methods to identify drug deposition in the lungs following inhalation</article-title>. <source>Br J Clin Pharmacol</source>
<year>2001</year>; <volume>51</volume>: <fpage>289</fpage>–<lpage>299</lpage>.<pub-id pub-id-type="pmid">11318763</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2125.2001.01304.x</pub-id><pub-id pub-id-type="pmcid">PMC2014454</pub-id></mixed-citation></ref><ref id="bibr23-17534666261417149"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Thorsson</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Edsbacker</surname><given-names>S.</given-names></name>
</person-group>
<article-title>Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer</article-title>. <source>Eur Respir J</source>
<year>1998</year>; <volume>12</volume>: <fpage>1340</fpage>–<lpage>1345</lpage>.<pub-id pub-id-type="pmid">9877488</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/09031936.98.12061340</pub-id></mixed-citation></ref><ref id="bibr24-17534666261417149"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Lähelmä</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sairanen</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Haikarainen</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Equivalent lung dose and systemic exposure of budesonide/formoterol combination via Easyhaler and Turbuhaler</article-title>. <source>J Aerosol Med Pulm Drug Deliv</source>
<year>2015</year>; <volume>28</volume>: <fpage>462</fpage>–<lpage>473</lpage>.<pub-id pub-id-type="pmid">25757188</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/jamp.2014.1195</pub-id><pub-id pub-id-type="pmcid">PMC4688463</pub-id></mixed-citation></ref><ref id="bibr25-17534666261417149"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Singh</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Collarini</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Poli</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI</article-title>. <source>Br J Clin Pharmacol</source>
<year>2011</year>; <volume>72</volume>: <fpage>932</fpage>–<lpage>939</lpage>.<pub-id pub-id-type="pmid">21615456</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2011.04024.x</pub-id><pub-id pub-id-type="pmcid">PMC3244640</pub-id></mixed-citation></ref><ref id="bibr26-17534666261417149"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Leaker</surname><given-names>BR</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Nicholson</surname><given-names>GC</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Evaluation of systemic absorption and bronchodilator effect of glycopyrronium bromide delivered by nebulizer or a dry powder inhaler in subjects with chronic obstructive pulmonary disease</article-title>. <source>Respir Res</source>
<year>2019</year>; <volume>20</volume>: <fpage>132</fpage>.<pub-id pub-id-type="pmid">31253162</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12931-019-1113-z</pub-id><pub-id pub-id-type="pmcid">PMC6599298</pub-id></mixed-citation></ref><ref id="bibr27-17534666261417149"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Maes</surname><given-names>A</given-names></name>
<name name-style="western"><surname>DePetrillo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Siddiqui</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pharmacokinetics of co-suspension delivery technology budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate (BFF MDI) fixed-dose combinations compared with an active control: a Phase 1, randomized, single dose, crossover study in healthy adults</article-title>. <source>Clin Pharmacol Drug Dev</source>
<year>2019</year>; <volume>8</volume>: <fpage>223</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">29901860</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.585</pub-id><pub-id pub-id-type="pmcid">PMC6585691</pub-id></mixed-citation></ref><ref id="bibr28-17534666261417149"><label>28</label><mixed-citation publication-type="gov">
<collab>United States Food and Drug Administration</collab>. <article-title>Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA guidance for industry</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/87219/download" ext-link-type="uri">https://www.fda.gov/media/87219/download</ext-link> (<year>2021</year>, <comment>accessed 5 March 2025</comment>).</mixed-citation></ref><ref id="bibr29-17534666261417149"><label>29</label><mixed-citation publication-type="webpage">
<collab>European Medicines Agency</collab>. <article-title>Guideline on the investigation of bioequivalence</article-title>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf" ext-link-type="uri">https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf</ext-link> (<year>2010</year>, <comment>accessed 5 March 2025</comment>).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1742-7843.2009.00518.x</pub-id><pub-id pub-id-type="pmid">20070293</pub-id></mixed-citation></ref><ref id="bibr30-17534666261417149"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Darken</surname><given-names>P</given-names></name>
<name name-style="western"><surname>DePetrillo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Reisner</surname><given-names>C</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: a Phase I randomized, single-dose, crossover study in healthy adults</article-title>. <source>Pulm Pharmacol Ther</source>
<year>2018</year>; <volume>50</volume>: <fpage>11</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">29544728</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2018.03.001</pub-id></mixed-citation></ref><ref id="bibr31-17534666261417149"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Chen</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Hu</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pharmacokinetics and tolerability of budesonide/glycopyrronium/formoterol fumarate dihydrate and glycopyrronium/formoterol fumarate dihydrate metered dose inhalers in healthy Chinese adults: a randomized, double-blind, parallel-group study</article-title>. <source>Clin Ther</source>
<year>2019</year>; <volume>41</volume>: 897–909 e891.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2019.03.007</pub-id><pub-id pub-id-type="pmid">30982547</pub-id></mixed-citation></ref><ref id="bibr32-17534666261417149"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dorinsky</surname><given-names>P</given-names></name>
<name name-style="western"><surname>DePetrillo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>DeAngelis</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Relative bioavailability of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler administered with and without a spacer: results of a phase I, randomized, crossover trial in healthy adults</article-title>. <source>Clin Ther</source>
<year>2020</year>; <volume>42</volume>: <fpage>634</fpage>–<lpage>648</lpage>.<pub-id pub-id-type="pmid">32253054</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2020.02.012</pub-id></mixed-citation></ref><ref id="bibr33-17534666261417149"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dorinsky</surname><given-names>P</given-names></name>
<name name-style="western"><surname>DePetrillo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Siddiqui</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Safety and pharmacokinetics of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) in healthy adult subjects of Japanese descent</article-title>. <source>Pulm Pharmacol Ther</source>
<year>2018</year>; <volume>51</volume>: <fpage>18</fpage>–<lpage>25</lpage>.<pub-id pub-id-type="pmid">29763659</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2018.05.001</pub-id></mixed-citation></ref><ref id="bibr34-17534666261417149"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tothfalusi</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Endrenyi</surname><given-names>L.</given-names></name>
</person-group>
<article-title>Sample sizes for designing bioequivalence studies for highly variable drugs</article-title>. <source>J Pharm Pharm Sci</source>
<year>2012</year>; <volume>15</volume>: <fpage>73</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">22365089</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.18433/j3z88f</pub-id></mixed-citation></ref><ref id="bibr35-17534666261417149"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Tewari</surname><given-names>SG</given-names></name>
<name name-style="western"><surname>Bell</surname><given-names>JP</given-names></name>
<name name-style="western"><surname>Budgen</surname><given-names>N</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pressurized metered-dose inhalers using next-generation propellant HFO-1234ze(E) deposit negligible amounts of trifluoracetic acid in the environment</article-title>. <source>Front Environ Sci</source>
<year>2023</year>; <volume>11</volume>.</mixed-citation></ref><ref id="bibr36-17534666261417149"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Hargreaves</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Budgen</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Whiting</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>S60 A new medical propellant HFO-1234ze(E): reducing the environmental impact of inhaled medicines [abstract]</article-title>. <source>Thorax</source>
<year>2022</year>; <volume>77</volume>: A38–A39.</mixed-citation></ref><ref id="bibr37-17534666261417149"><label>37</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bafadhel</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rabe</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: a post-hoc analysis of data from ETHOS</article-title>. <source>Int J Chron Obstruct Pulmon Dis</source>
<year>2022</year>; <volume>17</volume>: <fpage>3061</fpage>–<lpage>3073</lpage>.<pub-id pub-id-type="pmid">36510486</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/COPD.S374670</pub-id><pub-id pub-id-type="pmcid">PMC9738173</pub-id></mixed-citation></ref><ref id="bibr38-17534666261417149"><label>38</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gimeno</surname><given-names>F</given-names></name>
<name name-style="western"><surname>van der Weele</surname><given-names>LT</given-names></name>
<name name-style="western"><surname>Koëter</surname><given-names>GH</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Variability of forced oscillation (Siemens Siregnost FD 5) measurements of total respiratory resistance in patients and healthy subjects</article-title>. <source>Ann Allergy</source>
<year>1993</year>; <volume>71</volume>: <fpage>56</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">8328715</pub-id>
</mixed-citation></ref><ref id="bibr39-17534666261417149"><label>39</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dhand</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Cavanaugh</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Skolnik</surname><given-names>N.</given-names></name>
</person-group>
<article-title>Considerations for optimal inhaler device selection in chronic obstructive pulmonary disease</article-title>. <source>Cleve Clin J Med</source>
<year>2018</year>; <volume>85</volume>: S19–S27.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3949/ccjm.85.s1.04</pub-id><pub-id pub-id-type="pmid">29494329</pub-id></mixed-citation></ref><ref id="bibr40-17534666261417149"><label>40</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mahler</surname><given-names>DA.</given-names></name>
</person-group>
<article-title>The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease</article-title>. <source>Respir Med</source>
<year>2020</year>; <volume>161</volume>: <fpage>105857</fpage>.<pub-id pub-id-type="pmid">32056720</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.rmed.2019.105857</pub-id></mixed-citation></ref><ref id="bibr42-17534666261417149"><label>41</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Raphiou</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>. <source>Am J Respiratory Critical Care Med</source>
<year>2024</year>; <volume>209</volume>: A1216.</mixed-citation></ref><ref id="bibr43-17534666261417149"><label>42</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Shah</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>. <source>Am J Respiratory Critical Care Med</source>
<year>2024</year>; <volume>209</volume>: A3824.</mixed-citation></ref></ref-list></back></article><article id="ueg270156" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">United European Gastroenterol J</journal-id><journal-id journal-id-type="iso-abbrev">United European Gastroenterol J</journal-id><journal-id journal-id-type="pmc-domain-id">2382</journal-id><journal-id journal-id-type="pmc-domain">ueg</journal-id><journal-id journal-id-type="publisher-id">UEG2</journal-id><journal-title-group><journal-title>United European Gastroenterology Journal</journal-title></journal-title-group><issn pub-type="ppub">2050-6406</issn><issn pub-type="epub">2050-6414</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12781189</article-id><article-id pub-id-type="pmcid-ver">PMC12781189.1</article-id><article-id pub-id-type="pmcaid">12781189</article-id><article-id pub-id-type="pmcaiid">12781189</article-id><article-id pub-id-type="pmid">41442229</article-id><article-id pub-id-type="doi">10.1002/ueg2.70156</article-id><article-id pub-id-type="publisher-id">UEG270156</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Luminal</subject></subj-group></article-categories><title-group><article-title>Integrated Multi‐Omic Analysis Identifies Altered Colonic Brush Border Profile as a Key Feature of Microscopic Colitis</article-title></title-group><contrib-group><contrib id="ueg270156-cr-0001" contrib-type="author" corresp="yes"><name name-style="western"><surname>Guagnozzi</surname><given-names initials="D">Danila</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6171-1901</contrib-id><xref rid="ueg270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ueg270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ueg270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><address><email>danilagua77@gmail.com</email></address></contrib><contrib id="ueg270156-cr-0002" contrib-type="author"><name name-style="western"><surname>Gonzalez‐Castro</surname><given-names initials="AM">Ana Maria</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3955-3318</contrib-id><xref rid="ueg270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ueg270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ueg270156-cr-0003" contrib-type="author"><name name-style="western"><surname>Zabana</surname><given-names initials="Y">Yamile</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4023-8868</contrib-id><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ueg270156-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ueg270156-cr-0004" contrib-type="author"><name name-style="western"><surname>Fernández‐Bañares</surname><given-names initials="F">Fernando</given-names></name><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ueg270156-aff-0005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="ueg270156-note-1001" ref-type="author-notes">
<sup>†</sup>
</xref></contrib><contrib id="ueg270156-cr-0005" contrib-type="author"><name name-style="western"><surname>Münch</surname><given-names initials="A">Andreas</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4703-581X</contrib-id><xref rid="ueg270156-aff-0006" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib id="ueg270156-cr-0006" contrib-type="author"><name name-style="western"><surname>Tristan</surname><given-names initials="E">Eva</given-names></name><xref rid="ueg270156-aff-0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib id="ueg270156-cr-0007" contrib-type="author"><name name-style="western"><surname>Lozano</surname><given-names initials="JJ">Juan‐José</given-names></name><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ueg270156-cr-0008" contrib-type="author"><name name-style="western"><surname>Sidorova</surname><given-names initials="J">Julia</given-names></name><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ueg270156-cr-0009" contrib-type="author"><name name-style="western"><surname>Lobo</surname><given-names initials="B">Beatriz</given-names></name><xref rid="ueg270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ueg270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ueg270156-cr-0010" contrib-type="author"><name name-style="western"><surname>Alonso‐Cotoner</surname><given-names initials="C">Carmen</given-names></name><xref rid="ueg270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ueg270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ueg270156-cr-0011" contrib-type="author"><name name-style="western"><surname>Exposito</surname><given-names initials="E">Elba</given-names></name><xref rid="ueg270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ueg270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="ueg270156-cr-0012" contrib-type="author"><name name-style="western"><surname>Lucendo</surname><given-names initials="AJ">Alfredo J.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1183-1072</contrib-id><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ueg270156-aff-0007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="ueg270156-aff-0008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib id="ueg270156-cr-0013" contrib-type="author"><name name-style="western"><surname>Landolfi</surname><given-names initials="S">Stefania</given-names></name><xref rid="ueg270156-aff-0009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib id="ueg270156-cr-0014" contrib-type="author"><name name-style="western"><surname>Benages</surname><given-names initials="A">Ana</given-names></name><xref rid="ueg270156-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="ueg270156-cr-0015" contrib-type="author"><name name-style="western"><surname>Llerena‐Castro</surname><given-names initials="R">Ronald</given-names></name><xref rid="ueg270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="ueg270156-cr-0016" contrib-type="author"><name name-style="western"><surname>Castillo Cejas</surname><given-names initials="MD">Maria Dolores</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0002-0838-4291</contrib-id><xref rid="ueg270156-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="ueg270156-cr-0017" contrib-type="author"><name name-style="western"><surname>Dot</surname><given-names initials="J">Joan</given-names></name><xref rid="ueg270156-aff-0010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib id="ueg270156-cr-0018" contrib-type="author"><name name-style="western"><surname>Santos</surname><given-names initials="J">Javier</given-names></name><xref rid="ueg270156-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ueg270156-aff-0003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib id="ueg270156-cr-0019" contrib-type="author"><name name-style="western"><surname>Vicario</surname><given-names initials="M">Maria</given-names></name><xref rid="ueg270156-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ueg270156-aff-0004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="ueg270156-aff-0011" ref-type="aff">
<sup>11</sup>
</xref></contrib></contrib-group><aff id="ueg270156-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Neuro‐immuno‐gastroenterology</named-content>
<institution>Vall d’Hebron Institut de Recerca</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Laboratory of Translational Mucosal Immunology</named-content>
<institution>Vall d’Hebron Institut de Recerca</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Gastroenterology Department</named-content>
<institution>University Hospital Vall d'Hebron</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBER‐EHD)</named-content>
<city>Madrid</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Gastroenterology Department</named-content>
<institution>University Hospital Mutua de Terrassa</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Gastroenterology Department</named-content>
<institution>Linköping University</institution>
<city>Linköping</city>
<country country="SE">Sweden</country>
</aff><aff id="ueg270156-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Gastroenterology Department</named-content>
<institution>Hospital General de Tomelloso</institution>
<city>Ciudad Real</city>
<country country="ES">Spain</country>
</aff><aff content-type="private-address" id="ueg270156-aff-0008">
<label>
<sup>8</sup>
</label>
<institution>Instituto de Investigación Sanitaria de Castilla‐La Mancha (IDISCAM)</institution>
<city>Toledo</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0009">
<label>
<sup>9</sup>
</label>
<named-content content-type="organisation-division">Pathology Department</named-content>
<institution>University Hospital Vall d'Hebron</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0010">
<label>
<sup>10</sup>
</label>
<named-content content-type="organisation-division">Endoscopy Department</named-content>
<institution>University Hospital Vall d'Hebron</institution>
<city>Barcelona</city>
<country country="ES">Spain</country>
</aff><aff id="ueg270156-aff-0011">
<label>
<sup>11</sup>
</label>
<named-content content-type="organisation-division">Nestlé Institute of Health Sciences</named-content>
<institution>Société Des Produits Nestlé S.A.</institution>
<institution>Nestlé Research</institution>
<city>Lausanne</city>
<country country="CH">Switzerland</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold> Danila Guagnozzi<break/>
(<email>danilagua77@gmail.com</email>)<break/>
</corresp><fn id="ueg270156-note-1001"><label>†</label><p>Deceased.</p></fn></author-notes><pub-date pub-type="epub"><day>24</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2026</year></pub-date><volume>14</volume><issue seq="20">1</issue><issue-id pub-id-type="pmc-issue-id">504585</issue-id><issue-id pub-id-type="doi">10.1002/ueg2.v14.1</issue-id><elocation-id>e70156</elocation-id><history><date date-type="rev-recd"><day>12</day><month>11</month><year>2025</year></date><date date-type="received"><day>14</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>09</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-21 04:25:13.153"><day>21</day><month>01</month><year>2026</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">United European Gastroenterology Journal</italic> published by Wiley Periodicals LLC on behalf of United European Gastroenterology.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="UEG2-14-e70156.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:UEG2-14-e70156.pdf"/><abstract><title>ABSTRACT</title><sec id="ueg270156-sec-0001"><title>Background</title><p>Microscopic colitis (MC), comprising lymphocytic colitis (LC) and collagenous colitis (CC), is an inflammatory bowel disease with increasing incidence. MC etiopathogenesis remains unknown; however, altered colonic epithelial integrity may underlie uncontrolled luminal antigen passage, triggering immuno‐inflammatory responses.</p></sec><sec id="ueg270156-sec-0002"><title>Objective</title><p>The aim of this study was to further define the involvement of the colonic epithelium in MC.</p></sec><sec id="ueg270156-sec-0003"><title>Methods</title><p>A paired transcriptomic and proteomic analysis followed by epithelial ultrastructural examination was performed on colonic biopsies from LC and CC patients, and from irritable bowel syndrome with a predominance of diarrhoea (IBS‐D) and healthy subjects (H) as control groups. The impact of budesonide therapy on the epithelial structure was also evaluated in CC.</p></sec><sec id="ueg270156-sec-0004"><title>Results</title><p>MC patients exhibited decreased expression of inter‐microvilli adhesion and actin‐bundling proteins, accompanied by increased expression of actin‐membrane connection proteins compared to both control groups. Distinct molecular differentiated CC and LC, which translated into differential ultrastructure abnormalities. The colonic microvilli in CC patients were shorter in length and fewer in number, with partial restoration following budesonide treatment, whereas LC showed a reduction solely in microvilli number. A negative correlation was found between daily stool frequency and SPATN1 and ATP8B1 protein levels in CC patients.</p></sec><sec id="ueg270156-sec-0005"><title>Conclusions</title><p>Molecular dysregulation and aberrant ultrastructure of the colonic brush border feature the colonic epithelium in LC and CC. These previously undescribed findings provide new perspectives for further defining MC pathogenesis and identifying biomarkers for diagnosis, prognosis and treatment of this debilitating and prevalent disease.</p></sec></abstract><abstract abstract-type="highlights"><title>Key Summary</title><p>
<list list-type="bullet"><list-item><p>Summarise the established knowledge on this subject</p><list list-type="simple"><list-item><label>◦</label><p>Microscopic colitis (MC) is a chronic immune‐mediated disease characterized by colonic mucosal inflammation and barrier dysfunction, but a deeper characterization of colonocytes is lacking.</p></list-item></list></list-item><list-item><p>What are the significant and/or new findings of this study?</p><list list-type="simple"><list-item><label>◦</label><p>This study is the first to MC identify molecular and ultrastructural alterations of the brush border in colonocytes in lymphocytic colitis (LC) and collagenous colitis (CC).</p></list-item><list-item><label>◦</label><p>The uniqueness of this study relies on the identification of a molecular phenotype of the brush border that differentiates from healthy controls and, notably, from the closest diarrhoeal disorder, irritable bowel syndrome with a predominance of diarrhoea.</p></list-item><list-item><label>◦</label><p>Given the fundamental role of the brush border in maintaining intestinal homoeostasis and regulating epithelial barrier function, our study sets the basis for the identification of new predictive diagnostic and/or prognostic biomarkers for both LC and CC, as well as new potential therapeutic targets.</p></list-item></list></list-item></list>
</p></abstract><kwd-group><kwd id="ueg270156-kwd-0001">brush border</kwd><kwd id="ueg270156-kwd-0002">collagenous colitis</kwd><kwd id="ueg270156-kwd-0003">lymphocytic colitis</kwd><kwd id="ueg270156-kwd-0004">microscopic colitis</kwd><kwd id="ueg270156-kwd-0005">microvilli</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>
<institution-wrap><institution>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas</institution><institution-id institution-id-type="doi">10.13039/501100015755</institution-id></institution-wrap>
</funding-source><award-id>ACCES‐16 Phase III</award-id></award-group><award-group id="funding-0002"><funding-source>
<institution-wrap><institution>AEG Foundation</institution><institution-id institution-id-type="doi">10.13039/100003558</institution-id></institution-wrap>
</funding-source><award-id>Gonzalo Miño</award-id></award-group><award-group id="funding-0003"><funding-source>
<institution-wrap><institution>Linköpings Universitet</institution><institution-id institution-id-type="doi">10.13039/501100003945</institution-id></institution-wrap>
</funding-source><award-id>Microvilli in microscopic colitis</award-id></award-group><award-group id="funding-0004"><funding-source>
<institution-wrap><institution>san carlos III</institution></institution-wrap>
</funding-source><award-id>PI17/01443</award-id><award-id>PI19/01643</award-id></award-group></funding-group><counts><fig-count count="9"/><table-count count="2"/><page-count count="15"/><word-count count="7480"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-ND</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2026</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.8 mode:remove_FC converted:08.01.2026</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="ueg270156-cit-0042">
<string-name name-style="western">
<surname>Guagnozzi</surname>, <given-names>Danila</given-names>
</string-name>, <string-name name-style="western">
<given-names>Ana M.</given-names>
<surname>Gonzalez‐Castro</surname>
</string-name>, <string-name name-style="western">
<given-names>Yamile</given-names>
<surname>Zabana</surname>
</string-name>, et al. <year>2026</year>. “<article-title>Integrated Multi‐Omic Analysis Identifies Altered Colonic Brush Border Profile as a Key Feature of Microscopic Colitis</article-title>,” <source>United European Gastroenterology Journal</source>: <elocation-id>e70156</elocation-id>. <pub-id pub-id-type="doi">10.1002/ueg2.70156</pub-id>.<pub-id pub-id-type="pmid">41442229</pub-id>
<pub-id pub-id-type="pmcid">PMC12781189</pub-id></mixed-citation>
</p></notes></front><body id="ueg270156-body-0001"><sec id="ueg270156-sec-0010"><label>1</label><title>Introduction</title><p>Microscopic colitis (MC) is an umbrella term that describes a group of inflammatory bowel diseases of the colon, causing chronic or intermittent watery diarrhoea with normal (or almost normal) endoscopic findings but characteristic histology [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>]. MC comprises two major subtypes: lymphocytic colitis (LC), marked by increased intraepithelial lymphocytes (IELs), and collagenous colitis (CC), defined by a thickened intraepithelial collagen band [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>, <xref rid="ueg270156-bib-0002" ref-type="bibr">2</xref>]. Both share significant inflammatory infiltration in the lamina propria and require histopathological diagnosis as they are clinically indistinguishable [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>, <xref rid="ueg270156-bib-0002" ref-type="bibr">2</xref>].</p><p>Since the first case was described in 1976 [<xref rid="ueg270156-bib-0003" ref-type="bibr">3</xref>], MC has shifted from being considered a rare to a common cause of chronic watery diarrhoea worldwide, especially in women over 60 years of age, significantly impacting quality of life [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>]. The incidence of MC (11.4% (95% CI, 9.2–13.6; I<sup>2</sup> = 99.7%)), is comparable to that of Crohn's disease or ulcerative colitis [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>]. The similarity of MC clinical presentation with irritable bowel syndrome with a predominance of diarrhoea (IBS‐D), and the lack of distinctive noninvasive biological biomarkers [<xref rid="ueg270156-bib-0004" ref-type="bibr">4</xref>] make MC diagnosis challenging. The differential diagnosis between MC and functional bowel disorders is particularly relevant, considering that despite having similar clinical and endoscopic manifestations, therapeutic management differs radically between the two entities. In fact, corticosteroid‐based therapy (mostly oral budesonide) is currently considered the first‐line treatment for active MC, reaching complete clinical response in 81% of the cases [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>]. However, repeated clinical relapses (61%–80%) are observed, and long‐term therapy is needed [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>, <xref rid="ueg270156-bib-0005" ref-type="bibr">5</xref>]. To date, the approach used to treat MC patients is mainly empirical, as its pathophysiology remains unknown.</p><p>MC is considered a multifactorial disease characterized by dysregulated mucosal immune responsiveness to yet undescribed luminal components [<xref rid="ueg270156-bib-0006" ref-type="bibr">6</xref>]. Although the underlying mechanisms are not yet defined, the current hypothesis supports differential innate and adaptive mucosal responsiveness linked to intestinal epithelial barrier dysfunction [<xref rid="ueg270156-bib-0005" ref-type="bibr">5</xref>, <xref rid="ueg270156-bib-0007" ref-type="bibr">7</xref>, <xref rid="ueg270156-bib-0008" ref-type="bibr">8</xref>, <xref rid="ueg270156-bib-0009" ref-type="bibr">9</xref>].</p><p>The intestinal barrier is a dynamic structure that protects the host from the external environment [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>]. The apical surface of both, enterocytes and colonocytes, is characterized by a specialized structure called the brush border [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>], which displays a highly ordered packing of microvilli. It plays a fundamental role in the transport of nutrients, water and ions, as well as in host defence. In MC, the colonic epithelium shows mild structural alterations, such as vacuolization, mucin depletion, flattening, sloughing and detachment from the sub‐epithelial collagen band without crypt architectural distortion, as described by optical microscopy techniques [<xref rid="ueg270156-bib-0002" ref-type="bibr">2</xref>, <xref rid="ueg270156-bib-0011" ref-type="bibr">11</xref>, <xref rid="ueg270156-bib-0012" ref-type="bibr">12</xref>]. Additionally, functional and structural alterations have been identified in both LC and CC, including increased paracellular permeability, altered electrolyte exchange [<xref rid="ueg270156-bib-0007" ref-type="bibr">7</xref>] and reduced expression of structural proteins (occludin and claudin‐4, ‐5 and ‐8) [<xref rid="ueg270156-bib-0008" ref-type="bibr">8</xref>].</p><p>Owing to the fundamental role of the brush border in maintaining the colonic barrier and in general homoeostasis and based on the lack of evidence of its potential involvement in disease onset and maintenance, this study aimed to investigate the molecular profile and ultrastructure of the colonic brush border in LC and CC patients to gain insight into MC pathophysiology.</p></sec><sec id="ueg270156-sec-0020"><label>2</label><title>Material and Methods</title><p>We performed a prospective, multicenter case‒control study (Figure <xref rid="ueg270156-sup-0002" ref-type="supplementary-material">S1</xref>), in Spain (University Hospital Vall d’Hebron, University Hospital Mutua Terrassa, General Hospital of Tomelloso) and Sweden (Linköping University Hospital), from 2016 to 2022. The study included adult patients with new diagnosis and active MC, healthy controls (H), and patients with active IBS‐D. MC was defined according to the guidelines [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>], and patients with IBS‐D met the Rome IV criteria [<xref rid="ueg270156-bib-0013" ref-type="bibr">13</xref>] (Table <xref rid="ueg270156-sup-0006" ref-type="supplementary-material">S1</xref>). Inclusion/exclusion criteria for cases and controls are outlined in the supplementary methods.</p><p>Active MC was defined as &gt; 3 bowel movements/day or &gt; 1 watery bowel movement/day during a 1‐week registration period (based on Bristol score [<xref rid="ueg270156-bib-0014" ref-type="bibr">14</xref>] and Hjortswang criteria [<xref rid="ueg270156-bib-0015" ref-type="bibr">15</xref>]). Clinical remission was defined as &lt; 3 bowel movements/day and no watery stools within a 1‐week period. All controls (H and IBS‐D) had no signs of pathology. All participants underwent gastroenterologist‐led evaluation covering epidemiology, risk factors, symptoms, pathology, spontaneous remission, treatment response and need of maintenance treatment.</p><sec id="ueg270156-sec-0030"><label>2.1</label><title>Sample Collection and Procedures</title><p>During endoscopy, at least 2 biopsies from multiple colonic segments were taken for routine histopathological diagnosis of MC or to confirm the absence of pathology in the control groups [<xref rid="ueg270156-bib-0001" ref-type="bibr">1</xref>]. Additionally, 6 sigmoid colon biopsies per subject were collected for transcriptomic and proteomic molecular profiling and for ultrastructural analysis as detailed in the supplementary methods.</p></sec><sec id="ueg270156-sec-0040"><label>2.2</label><title>Statistical Analysis</title><p>The statistical and bioinformatic analysis were performed using GraphPad Prism 10.5 and R [<xref rid="ueg270156-bib-0016" ref-type="bibr">16</xref>, <xref rid="ueg270156-bib-0017" ref-type="bibr">17</xref>, <xref rid="ueg270156-bib-0018" ref-type="bibr">18</xref>, <xref rid="ueg270156-bib-0019" ref-type="bibr">19</xref>, <xref rid="ueg270156-bib-0020" ref-type="bibr">20</xref>], as detailed in the supplementary methods.</p></sec></sec><sec id="ueg270156-sec-0050"><label>3</label><title>Results</title><sec id="ueg270156-sec-0060"><label>3.1</label><title>Demographic and Clinical Characteristics</title><p>We included 39 patients with MC (18 LC and 21 CC), 19 H subjects, and 18 IBS‐D patients. The clinical characteristics of all the patients in the case and the control groups are given in Tables <xref rid="ueg270156-tbl-0001" ref-type="table">1</xref> and <xref rid="ueg270156-tbl-0002" ref-type="table">2</xref>. The LC and CC groups showed no significant differences in risk factors, demographics, or clinical characteristics. No sex or age differences were found between MC subjects and H subjects, though IBS‐D patients were significantly younger than CC patients and included more women than the H group.</p><table-wrap position="float" id="ueg270156-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>Demographic characteristics and risk factors for all groups studied.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Demographic characteristics at diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">H (<italic toggle="yes">n</italic> = 19)</th><th align="center" valign="bottom" rowspan="1" colspan="1">IBS‐D (<italic toggle="yes">n</italic> = 17)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LC (<italic toggle="yes">n</italic> = 18)</th><th align="center" valign="bottom" rowspan="1" colspan="1">CC (<italic toggle="yes">n</italic> = 21)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex, % females</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>63.2% (12/19)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>94.1% (16/17)</bold>
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">72.2% (13/18)</td><td align="center" valign="top" rowspan="1" colspan="1">71.4% (15/21)</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
<bold>IBS‐D</bold> versus <bold>H</bold>
<sup>
<bold>FT</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median age, years (range)</td><td align="center" valign="top" rowspan="1" colspan="1">60 (44–73)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>45 (27‐79)</bold>
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">58 (28–83)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>65 (33–81)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
<bold>IBS‐D</bold> versus <bold>CC</bold>
<sup>
<bold>KW</bold>
</sup>
</td></tr><tr><td colspan="6" align="left" valign="top" rowspan="1">Risk factors for MC at diagnosis</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Smoking habit:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Current, %</td><td align="center" valign="top" rowspan="1" colspan="1">31.6% (6/19)</td><td align="center" valign="top" rowspan="1" colspan="1">18.8% (3/16)</td><td align="center" valign="top" rowspan="1" colspan="1">33.3% (6/18)</td><td align="center" valign="top" rowspan="1" colspan="1">30% (6/20)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Former, %</td><td align="center" valign="top" rowspan="1" colspan="1">15.8% (3/19)</td><td align="center" valign="top" rowspan="1" colspan="1">12.5% (2/16)</td><td align="center" valign="top" rowspan="1" colspan="1">33.3% (6/18)</td><td align="center" valign="top" rowspan="1" colspan="1">20% (4/20)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Any alcohol intake, %</td><td align="center" valign="top" rowspan="1" colspan="1">21.1% (4/19)</td><td align="center" valign="top" rowspan="1" colspan="1">5.9% (1/17)</td><td align="center" valign="top" rowspan="1" colspan="1">33.3% (6/18)</td><td align="center" valign="top" rowspan="1" colspan="1">28.6% (6/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Comorbidity:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Allergy diseases, %</td><td align="center" valign="top" rowspan="1" colspan="1">5.3% (1/19)</td><td align="center" valign="top" rowspan="1" colspan="1">17.6% (3/17)</td><td align="center" valign="top" rowspan="1" colspan="1">22.2% (4/18)</td><td align="center" valign="top" rowspan="1" colspan="1">14.3% (3/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Autoimmune disease, %</td><td align="center" valign="top" rowspan="1" colspan="1">5.3% (1/19)</td><td align="center" valign="top" rowspan="1" colspan="1">5.9% (1/17)</td><td align="center" valign="top" rowspan="1" colspan="1">0% (0/18)</td><td align="center" valign="top" rowspan="1" colspan="1">23.8% (5/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">Mental disorders %</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>10.5% (2/19)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">35.3% (6/17)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>44.4% (8/18)</bold>
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">19% (4/21)</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
<bold>LC</bold> versus <bold>H</bold>
<sup>
<bold>FT</bold>
</sup>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Risk drugs intake:</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">PPIs, %</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>5.3% (1/19)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>5.9% (1/17)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>38.9% (7/18)</bold>
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>33.3% (7/21)*</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0002" ref-type="table-fn">*</xref>
<bold>LC</bold> versus <bold>H</bold>, <bold>CC</bold> versus <bold>H</bold>, <bold>LC</bold> versus <bold>IBS‐D</bold>
<sup>
<bold>FT</bold>
</sup>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">NSAIDs, %</td><td align="center" valign="top" rowspan="1" colspan="1">0% (0/19)</td><td align="center" valign="top" rowspan="1" colspan="1">0% (0/17)</td><td align="center" valign="top" rowspan="1" colspan="1">11.1% (2/18)</td><td align="center" valign="top" rowspan="1" colspan="1">19.1% (4/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:15%" align="left" valign="top" rowspan="1" colspan="1">SSRIs, %</td><td align="center" valign="top" rowspan="1" colspan="1">10.5% (2/19)</td><td align="center" valign="top" rowspan="1" colspan="1">29.4% (5/17)</td><td align="center" valign="top" rowspan="1" colspan="1">33.3% (6/18)</td><td align="center" valign="top" rowspan="1" colspan="1">14.3% (3/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr></tbody></table><table-wrap-foot id="ueg270156-ntgp-0001"><fn id="ueg270156-note-0022"><p>
<italic toggle="yes">Note:</italic> The bold values indicate significant differences.</p></fn><fn id="ueg270156-note-0001"><p>Abbreviations: CC: collagenous colitis, <sup>FT</sup>: Fisher's exact test two‐sided, H: healthy subject, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, <sup>KW</sup>: Kruskal‐Wallis test with Dunn's correction for multiple comparisons, LC: lymphocytic colitis, NS: no significant difference, NSAIDs: nonsteroidal anti‐inflammatory drugs, PPIs: proton pump inhibitors, SD: standard deviation, SSRIs: selective serotonin reuptake inhibitors.</p></fn><fn id="ueg270156-note-0002"><label>
<sup>*</sup>
</label><p>
<italic toggle="yes">p</italic> = &lt; 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ueg270156-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>Clinical and histopathological characteristics of patients with CC, LC and IBS‐D.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Clinical and histopathological characteristics at diagnosis</th><th align="center" valign="bottom" rowspan="1" colspan="1">IBS‐D (<italic toggle="yes">n</italic> = 17)</th><th align="center" valign="bottom" rowspan="1" colspan="1">LC (<italic toggle="yes">n</italic> = 18)</th><th align="center" valign="bottom" rowspan="1" colspan="1">CC (<italic toggle="yes">n</italic> = 21)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Median duration of symptoms, months (range)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (6.0–180)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>6.5 (1.0‐240)</bold>
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">9.0 (1.0–96)</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
<bold>LC</bold> versus <bold>IBS‐D</bold>
<sup>
<bold>kw</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median stools/day (range)</td><td align="center" valign="top" rowspan="1" colspan="1">4.0 (1.0–6.5)</td><td align="center" valign="top" rowspan="1" colspan="1">5.3 (2.3–10)</td><td align="center" valign="top" rowspan="1" colspan="1">5.0 (2.0–12)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>Kw</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Faecal urgency, %</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>52.9% (9/17)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>88.9% (16/18)</bold>
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">81% (17/21)</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
<bold>LC</bold> versus <bold>IBS‐D</bold>
<sup>
<bold>FT</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Faecal incontinence, %</td><td align="center" valign="top" rowspan="1" colspan="1">29.4% (5/17)</td><td align="center" valign="top" rowspan="1" colspan="1">55.6% (10/18)</td><td align="center" valign="top" rowspan="1" colspan="1">61.9% (13/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abdominal pain, %</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>100% (17)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>55.5% (10/18)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>42.9% (9/21)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
<bold>CC and LC</bold> versus <bold>IBS‐D</bold>
<sup>
<bold>FT</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nocturnal diarrhoea, %</td><td align="center" valign="top" rowspan="1" colspan="1">5.9% (1/17)</td><td align="center" valign="top" rowspan="1" colspan="1">11.1% (2/18)</td><td align="center" valign="top" rowspan="1" colspan="1">33.3% (7/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Weight loss, %</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>5.9% (1/17)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">22.2% (4/18)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>33.3% (7/21)</bold>
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
<bold>CC</bold> versus <bold>IBS‐D</bold>
<sup>
<bold>FT</bold>
</sup>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median collagenous band, μm (±SD)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">20.2 (12–50)</td><td align="center" valign="top" rowspan="1" colspan="1">NA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median IELs count, (range)</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>31.5 (22‐98)</bold>
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>18.8 (0–70)</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<xref rid="ueg270156-note-0004" ref-type="table-fn">*</xref>
<bold>LC</bold> versus <bold>CC</bold>
<sup>
<bold>MW</bold>
</sup>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">Follow‐up data after diagnosis</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Spontaneous remission, %</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">38.9% (7/18)</td><td align="center" valign="top" rowspan="1" colspan="1">9.5% (2/21)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Response to budesonide treatment, %</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">100% (7/7)</td><td align="center" valign="top" rowspan="1" colspan="1">100% (17/17)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr><tr><td style="padding-left:10%" align="left" valign="top" rowspan="1" colspan="1">Maintenance treatment with budesonide, %</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">57.1% (4/7)</td><td align="center" valign="top" rowspan="1" colspan="1">47.1% (8/17)</td><td align="center" valign="top" rowspan="1" colspan="1">NS<sup>FT</sup>
</td></tr></tbody></table><table-wrap-foot id="ueg270156-ntgp-0002"><fn id="ueg270156-note-0032"><p>
<italic toggle="yes">Note:</italic> The bold values indicate significant differences.</p></fn><fn id="ueg270156-note-0003"><p>Abbreviations: CC: collagenous colitis, <sup>FT</sup>: Fisher's exact test two‐sided, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, IELs: intraepithelial lymphocytes, <sup>KW</sup>: Kruskal‐Wallis test with Dunn's correction for multiple comparisons, LC: lymphocytic colitis, <sup>MW</sup>: Mann‐Whitney two‐tailed, NA: not applicable, NS: no significant difference, SD: standard deviation.</p></fn><fn id="ueg270156-note-0004"><label>
<sup>*</sup>
</label><p>
<italic toggle="yes">p</italic> &lt; 0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="ueg270156-sec-0070"><label>3.2</label><title>Molecular Signature of the Brush Border in Microscopic Colitis</title><p>Principal component analysis separated MC (LC and CC) from control (H and IBS‐D) groups, revealing distinct gene and protein expression profiles (Figure <xref rid="ueg270156-fig-0001" ref-type="fig">1A</xref>) and no separation in gender groups were observed. Among the top enriched pathways, apical surface structures, particularly actin‐based projections, projection membrane, apical plasma membrane and brush border, identified LC and CC groups (Figure <xref rid="ueg270156-fig-0001" ref-type="fig">1B</xref>, Figure <xref rid="ueg270156-sup-0003" ref-type="supplementary-material">S2</xref> and <xref rid="ueg270156-sup-0004" ref-type="supplementary-material">S3</xref>). Notably, CC (and not LC) showed the enrichment in microvilli organization and length pathways compared to controls (Figure <xref rid="ueg270156-fig-0001" ref-type="fig">1C</xref>). A brush border signature of 28 genes showed strong mRNA‐protein correlation and network‐level interrelation (Table <xref rid="ueg270156-sup-0007" ref-type="supplementary-material">S2</xref>; Figure <xref rid="ueg270156-fig-0002" ref-type="fig">2</xref> and <xref rid="ueg270156-fig-0003" ref-type="fig">3</xref>). Therefore, this analysis allowed us to identify a differentiated brush border molecular signature in LC and CC (Figures <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>, <xref rid="ueg270156-fig-0005" ref-type="fig">5</xref>, <xref rid="ueg270156-fig-0006" ref-type="fig">6</xref> and Figure <xref rid="ueg270156-sup-0005" ref-type="supplementary-material">S4</xref>).</p><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>(A) Principal component analysis (PCA) with significant differences between case groups (LC and CC) and control groups (IBS‐D and H) for transcriptomic and proteomic analysis (<italic toggle="yes">p</italic> = 9.9e‐11 and <italic toggle="yes">p</italic> = 6.4e‐08, respectively). (B) The apical plasma membrane, cell projection membrane and brush border pathways were significantly enriched in the colonic mucosa of LC and CC patients compared with H subjects and IBS‐D patients (supervised heatmaps by setting the samples in the same order). (C) Enrichment of each pathway/GO were computed using ssgsea method showing a significantly enrichment in CCs as compared to the other study groups and represented in the corresponding supervised heatmaps. The <italic toggle="yes">p</italic> values are indicated for each comparison. CC: collagenous colitis, H: healthy subjects, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="UEG2-14-e70156-g007.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>(A). Twenty‐eight genes and proteins of the brush border signature were identified as significantly correlated at mRNA and protein expression and were significantly differentially expressed in LC and CC as compared to the control groups. (B) Protein network according to the FunCopu6 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://funcoup.org/" ext-link-type="uri">https://funcoup.org/</ext-link>) showing that most of these proteins were related to each other. CC: collagenous colitis, H: healthy subjects, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="UEG2-14-e70156-g009.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Summary of the transcriptional and posttranscriptional profiles of the brush border signature for each gene and the corresponding protein, previously identified in each comparison (CC vs. H, CC vs. IBS‐D, LC vs. H and LC vs. IBS‐D). CC: collagenous colitis, H: healthy subjects, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="UEG2-14-e70156-g005.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0004" orientation="portrait"><label>FIGURE 4</label><caption><p>Gene and protein expression of the intermicrovillar proteins, actin‐bundling proteins and actin membrane connection proteins significantly differed, as did the corresponding gene/protein correlations using the Pearson method. The <italic toggle="yes">p</italic> values are indicated for each comparison. CC: collagenous colitis, H: healthy subjects, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-7" orientation="portrait" xlink:href="UEG2-14-e70156-g002.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0005" orientation="portrait"><label>FIGURE 5</label><caption><p>Gene and protein expression of the terminal web proteins was significantly differentially expressed between all the groups studied using the Pearson method. The <italic toggle="yes">p</italic> values are indicated for each comparison. CC: collagenous colitis, H: healthy subject, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-9" orientation="portrait" xlink:href="UEG2-14-e70156-g001.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0006" orientation="portrait"><label>FIGURE 6</label><caption><p>Gene and protein expression of the markers of epithelial cell differentiation and microvillar scaffolding proteins were significantly differentially expressed between all the groups studied and the corresponding gene/protein correlations using Pearson method. The <italic toggle="yes">p</italic> values are indicated for each comparison. CC: collagenous colitis, H: healthy subject, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-11" orientation="portrait" xlink:href="UEG2-14-e70156-g003.jpg"/></fig></sec><sec id="ueg270156-sec-0080"><label>3.3</label><title>Distinctive Brush Border Signature in Lymphocytic Colitis</title><p>Analysis of the apical surface molecular pathways of the colonic mucosa in LC with respect to controls revealed significant alterations in <italic toggle="yes">actin membrane connection proteins</italic>, especially the Myosin I protein, which uses the energy from ATP hydrolysis to move along actin filaments (Figure <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>) [<xref rid="ueg270156-bib-0021" ref-type="bibr">21</xref>]. When comparing with the control groups, we observed significantly reduced expression (post‐transcriptional level) of MYO1A (critical for the actin‒membrane protein connection of the microvilli) [<xref rid="ueg270156-bib-0021" ref-type="bibr">21</xref>] and MYO1D (with a compensatory function when MY01A is not working) [<xref rid="ueg270156-bib-0019" ref-type="bibr">19</xref>] and increased expression of MYO1F (at transcriptional and posttranscriptional level) (Figure <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>). Notably, the paired gene and protein expression of some terminal web proteins and markers of epithelial cell differentiation was impaired in LC (Figures <xref rid="ueg270156-fig-0005" ref-type="fig">5</xref> and <xref rid="ueg270156-fig-0006" ref-type="fig">6</xref>). In particular, KRT20 and KRT8 were downregulated in the LC group, as well as EPCAM and MAPRE3 as compared to both control groups. Additionally, ATP8B1, IQGAP2, and SLC26A2 were downregulated in the LC group with respect to the control groups.</p><p>Considering the LC clinical phenotype, the number of IELs was positively correlated with the increased expression of the MYO1F protein (<italic toggle="yes">r</italic> = 0.65; <italic toggle="yes">p</italic> = 0.025) and negatively correlated with the reduced expression of IQGAP2, SLC26A2 and ATP8B1 proteins (<italic toggle="yes">r</italic> = −0.61, <italic toggle="yes">p</italic> = 0.038; <italic toggle="yes">r</italic> = −0.79, <italic toggle="yes">p</italic> = 0.003; <italic toggle="yes">r</italic> = −0.61, <italic toggle="yes">p</italic> = 0.035, respectively).</p></sec><sec id="ueg270156-sec-0090"><label>3.4</label><title>Distinctive Brush Border Signature in Collagenous Colitis</title><p>Subsequent analysis of the apical surface molecular pathways of the colonic mucosa in CC with respect to controls revealed a significant downregulation of proteins that constitute the intermicrovilli adhesion complex (IMAC), whose alteration was associated with a reduction in the number and length of microvilli in the colonic epithelium (Figure <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>) [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>]. More specifically, we identified a significant downregulation of ANKS4B (ankyrin), USH1C (harmonin) and CDHR5 in CC compared to both control groups, suggesting IMAC dysfunction in CC patients.</p><p>Furthermore, actin‐bundling proteins, which connect adjacent actin filaments to establish the packing arrangement, density, stiffness and unipolar organization of the actin core in microvilli, were downregulated in CC (Figure <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>) [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>]. In particular, the protein expression of PLS1 (plastin‐1) and both, the gene and the protein expression of VIL1 (vilin), were significantly lower in CC than in controls. In addition, actin‐membrane connection proteins were impaired in CC (Figure <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>) and were also identified in the LC group. The gene/protein expression of MYO1A and MYO1D was downregulated in the CC group with respect to the control groups (Figure <xref rid="ueg270156-fig-0006" ref-type="fig">6</xref>). Similarly to LC, the gene and the protein expression of MYO1F and MSN (moesin), which are part of the ERM (ezrin/radixin/moesin) protein family that connects actin from the cytoskeleton to the plasma membrane [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>], were upregulated in CC with respect to both control groups (Figure <xref rid="ueg270156-fig-0004" ref-type="fig">4</xref>).</p><p>The expression of several terminal web proteins (CLIC4, EPCAM, SPTAN1 and MAPRE3) involved in epithelial structural maintenance and the dynamics of the membrane actin cytoskeleton [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>] were reduced in CC compared to both control groups (Figure <xref rid="ueg270156-fig-0005" ref-type="fig">5</xref>). The tropomyosin (TPM) proteins TPM2 and TMP3 were upregulated in CC compared with the control groups (Figure <xref rid="ueg270156-fig-0005" ref-type="fig">5</xref>). Notably, these proteins are key for the regulation of microvilli structure, with a potential function as inhibitors of the bundling of F‐actin by VIL1 [<xref rid="ueg270156-bib-0022" ref-type="bibr">22</xref>].</p><p>Additionally, markers of epithelial cell differentiation and other microvillar scaffolding proteins were identified as impaired in CC when compared with control groups (Figure <xref rid="ueg270156-fig-0006" ref-type="fig">6</xref>). For example, keratin protein expression of intermediate filaments (KRT20 and KRT8) was downregulated as was ATP8B1, as observed in the LC group. A similar expression profile was identified for some microvillar scaffolding proteins including SLC9A3R1 (EBP50), SLC26A2 and IQGAP2. Recently, SLC9A3R1 (EBP50) has been described as a critical protein interacting with CDHR5 for proper apical polarization and IMAC assembly [<xref rid="ueg270156-bib-0023" ref-type="bibr">23</xref>]. In contrast, the protein expression of ATP6VIB2 (a vacuolar H<sup>+</sup>‐ATPase that regulates organelle‐PH) [<xref rid="ueg270156-bib-0024" ref-type="bibr">24</xref>] was significantly greater in CC than in the control groups.</p><p>Considering the CC clinical phenotype, the number of IELs was negatively correlated with the increased expression of the MYO1F protein (<italic toggle="yes">r</italic> = −0.83; <italic toggle="yes">p</italic> = 0.013) and positively correlated with the reduced expression of MAPRE3 protein (<italic toggle="yes">r</italic> = 0.79; <italic toggle="yes">p</italic> = 0.025). A negative correlation was detected between daily stool frequency and reduced levels of the SPTAN1 protein (<italic toggle="yes">r</italic> = −0.57; <italic toggle="yes">p</italic> = 0.043) and ATP8B1 protein (<italic toggle="yes">r</italic> = −0.57; <italic toggle="yes">p</italic> = 0.044) in the CC group.</p></sec><sec id="ueg270156-sec-0100"><label>3.5</label><title>Impaired Ultrastructure of the Colonic Microvilli and Their Restoration by Budesonide Treatment</title><p>Electron microscopy analysis revealed abundant and organized microvilli in H and IBS‐D, contrasting with the sparser, irregular, and shorter microvilli in LC and CC samples (Figure <xref rid="ueg270156-fig-0007" ref-type="fig">7</xref>). These observations were further confirmed by the SEM analysis of tissue sections (Figure <xref rid="ueg270156-fig-0007" ref-type="fig">7A</xref>). Microvilli abundance was significantly lower in LC (5.19/μm [3.96–6.57]) and CC (4.02/μm [2.55–5.34]) than in H (7.45/μm [6.53–8.72], <italic toggle="yes">p</italic> &lt; 0.0001) and IBS‐D (6.46/μm [5.68–8.52], <italic toggle="yes">p</italic> = 0.0010) (Figure <xref rid="ueg270156-fig-0007" ref-type="fig">7C</xref>). Similarly, CC patients had shorter microvilli (0.50μm [0.37–0.80]) than H (1.13μm [1.02–1.4], <italic toggle="yes">p</italic> = 0.0001) and IBS‐D (1.09μm [0.98–1.58], <italic toggle="yes">p</italic> = 0.0008), whereas LC patients showed no significant reduction in length (Figure <xref rid="ueg270156-fig-0007" ref-type="fig">7C</xref>). No differences in microvilli metrics were observed between LC and CC, while H and IBS‐D presented similar values. A strong positive correlation was found between microvilli number and length (<italic toggle="yes">r</italic> = 0.76 <italic toggle="yes">p</italic> &lt; 0.0001) (Figure <xref rid="ueg270156-fig-0007" ref-type="fig">7D</xref>). Despite the limited sample size, ROC curve analysis demonstrated excellent diagnostic performance of both microvilli number and length in distinguishing MC from H and IBS‐D, with sensitivity and specificity exceeding 86% and 100%, respectively (Figure <xref rid="ueg270156-fig-0007" ref-type="fig">7E</xref>). Notably, CC patients who achieved clinical remission with budesonide therapy showed recovery of the epithelial surface with the restoration of well‐structured microvilli, achieving similar microvilli number than controls (CC‐pre 4.18[2.55–5.08] vs. CC‐post 5.53[4.39–7.23]; <italic toggle="yes">p</italic> = 0.031; H 7.45/μm[6.53–8.72] vs. CC‐post, <italic toggle="yes">p</italic> = NS) and increasing microvilli length (CC‐pre 0.58[0.39–0.80] vs. CC‐post 0.74[0.55–1.09]; <italic toggle="yes">p</italic> = 0.06) although not reaching the control values (1.13μm[1.02–1.4] vs. CC‐post, <italic toggle="yes">p</italic> = NS) (Figure <xref rid="ueg270156-fig-0008" ref-type="fig">8</xref>).</p><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0007" orientation="portrait"><label>FIGURE 7</label><caption><p>Ultrastructure of the brush border colonic epithelium. (A) Representative scanning electron microscopy images of the colonic luminal surface from each experimental group (magnification at 10K). CC: collagenous colitis, H: healthy subjects, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, LC: lymphocytic colitis. (B) Representative transmission electron microscopy images of colonocyte microvilli from each experimental group (magnification at 10–15K (top) and 30–40K (bottom)). EC: epithelial cell, GC: goblet cell. (C) Quantification of the number and length of microvilli in all experimental groups. (D) Correlation analysis between number and length of microvilli in all subjects studied (<italic toggle="yes">n</italic> = 37). The <italic toggle="yes">p</italic> values are indicated for each comparison. (E) Multi‐ROC analysis for the number and length of microvilli in the CC and LC groups compared with IBS‐D group. The AUC, cutoff value, sensitivity and specificity are given.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-13" orientation="portrait" xlink:href="UEG2-14-e70156-g006.jpg"/></fig><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0008" orientation="portrait"><label>FIGURE 8</label><caption><p>Effect of budesonide on brush border ultrastructure. (A) Representative transmission electron microscopy images of the colonic epithelium before (PRE) and after (POST) induction treatment with oral budesonide (9 mg/24h for a mean of 7 weeks) in a paired group of collagenous colitis (CC) (magnification at 40K (top) and 20K (bottom)). (B) Quantification of the length of microvilli before and after treatment with oral budesonide (9 mg/24h for a mean of 7 weeks). (C) Quantification of the number of microvilli before and after treatment with oral budesonide (9 mg/24h for a mean of 7 weeks). The <italic toggle="yes">p</italic> values are indicated for each comparison.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-15" orientation="portrait" xlink:href="UEG2-14-e70156-g008.jpg"/></fig><p>In patients with MC, the microvilli number and length negatively correlated with the symptom duration (<italic toggle="yes">r</italic> = −0.44; <italic toggle="yes">p</italic> = 0.049 and <italic toggle="yes">r</italic> = −0.496; <italic toggle="yes">p</italic> = 0.002, respectively), while higher microvilli number was linked with spontaneous remission (4–08 vs. 5.44; <italic toggle="yes">p</italic> = 0.044). In CC, both microvilli number and length of microvilli positively correlated with collagen band thickness (<italic toggle="yes">r</italic> = 0.65; <italic toggle="yes">p</italic> = 0.019 and <italic toggle="yes">r</italic> = 0.57, <italic toggle="yes">p</italic> = 0.047, respectively).</p><p>In a subset of MC patients (<italic toggle="yes">n</italic> = 5 CC and <italic toggle="yes">n</italic> = 2 LC), paired omic and ultrastructural analyses revealed a positive correlation between microvilli number and MYO1A and EPCAM proteins (<italic toggle="yes">r</italic> = 0.96 <italic toggle="yes">p</italic> = 0.0028; <italic toggle="yes">r</italic> = 0.96 <italic toggle="yes">p</italic> = 0.0028, respectively). Finally, a positive correlation between microvillus length and VIL1 protein expression (<italic toggle="yes">r</italic> = 0.8 <italic toggle="yes">p</italic> = 0.035) was observed only in CC patients. No differences in microvilli number or length were observed based on sex, age, or other clinical variables.</p></sec></sec><sec id="ueg270156-sec-0110"><label>4</label><title>Discussion</title><p>This study is the first to identify impaired colonic epithelial brush border gene and protein expression, along with reduced microvilli density and length, as distinctive features of MC (Figure <xref rid="ueg270156-fig-0009" ref-type="fig">9</xref>). These abnormalities were absent in IBS‐D, despite similar clinical and endoscopic presentations. In CC, budesonide‐induced remission partially restored the microvilli structure, suggesting inflammation‐derived dysfunction. Moreover, greater alterations correlated with longer standing disease and lower spontaneous remission, highlighting the relevance of microvilli regulation in MC pathogenesis and its potential utility for biomarker development and therapeutic monitoring.</p><p>Understanding the molecular mechanisms regulating microvilli number, packing density, and function is crucial as these structures determine the absorptive and protective capacity of epithelial cells [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="ueg270156-bib-0025" ref-type="bibr">25</xref>, <xref rid="ueg270156-bib-0026" ref-type="bibr">26</xref>].</p><p>Although microvilli impairment has not been previously reported in MCs, similar abnormalities occur in chronic diarrhoeal disorders, including congenital conditions (e.g., ‘tufting’ enteropathy, microvilli inclusion disease, congenital sodium diarrhoea) and secondary causes (infections, autoimmune enteropathy, food allergy, alcohol‐related damage) [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>]. In Crohn's disease, reduced microvilli length and gene expression have been observed in ileal tissue [<xref rid="ueg270156-bib-0027" ref-type="bibr">27</xref>]. In ulcerative colitis, single‐cell RNA sequencing has shown CDHR5 downregulation in inflamed areas [<xref rid="ueg270156-bib-0028" ref-type="bibr">28</xref>], though data from macroscopic unaffected tissue are limited. These findings highlight the relevance of microvilli alterations in gastrointestinal diseases and suggest that similar mechanisms may contribute to epithelial dysfunction in MCs, warranting further investigation into their role in IBD and other inflammatory conditions.</p><p>Microvillus structure and morphogenesis are complex and not fully understood [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="ueg270156-bib-0025" ref-type="bibr">25</xref>, <xref rid="ueg270156-bib-0026" ref-type="bibr">26</xref>, <xref rid="ueg270156-bib-0028" ref-type="bibr">28</xref>, <xref rid="ueg270156-bib-0029" ref-type="bibr">29</xref>]. Each microvillus contains a core bundle of 20–40 parallel actin filaments, maintaining consistent length (1–2 μm) and width [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="ueg270156-bib-0025" ref-type="bibr">25</xref>]. Microvillus formation relies on a balance between actin polymerization and depolymerization, generating forces needed to extend the membrane [<xref rid="ueg270156-bib-0030" ref-type="bibr">30</xref>, <xref rid="ueg270156-bib-0031" ref-type="bibr">31</xref>]. When comparing CC and LC, we observed impaired expression of proteins involved in actin bundling, the IMAC complex and the actin‐membrane linkage in CC patients. Actin filaments in microvilli are organized by bundling proteins such as VIL1, ESPN, PLS1 and MISP [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="ueg270156-bib-0025" ref-type="bibr">25</xref>], which are essential for microvilli function. In patients with CC, we observed reduced expression of VIL1 and PLS1, the latter previously linked to increased sensitivity to induction of colitis [<xref rid="ueg270156-bib-0032" ref-type="bibr">32</xref>] in PLS1‐knockout mice, highlighting their role in maintaining epithelial integrity. VIL1 supports microvilli organization [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="ueg270156-bib-0025" ref-type="bibr">25</xref>, <xref rid="ueg270156-bib-0033" ref-type="bibr">33</xref>] and acts as an epithelial cell‐specific antiapoptotic protein [<xref rid="ueg270156-bib-0033" ref-type="bibr">33</xref>]. Its loss triggers mitochondrial stress and necroptosis in intestinal cells. Notably, reduced VIL1 expression correlates with increased apoptosis in patients with IBD [<xref rid="ueg270156-bib-0034" ref-type="bibr">34</xref>], potentially contributing to epithelial disruption and inflammation, underscoring its role in maintaining intestinal epithelial integrity and homoeostasis [<xref rid="ueg270156-bib-0035" ref-type="bibr">35</xref>]. However, further dedicated studies using apoptosis‐specific markers are required to elucidate whether apoptotic pathways contribute to epithelial injury in MCs.</p><p>Another key finding of this study is the altered expression of IMAC proteins in CC, including BB‐specific protocadherins (CDHR2, CDHR5), and scaffolding proteins (USH1C, ANKS4B, Myosin7b, EBP50) [<xref rid="ueg270156-bib-0023" ref-type="bibr">23</xref>, <xref rid="ueg270156-bib-0036" ref-type="bibr">36</xref>, <xref rid="ueg270156-bib-0037" ref-type="bibr">37</xref>, <xref rid="ueg270156-bib-0038" ref-type="bibr">38</xref>]. Interestingly, ANKS4B (ankyrin), downregulated in CC, is essential for intermicrovillar adhesion by linking protocadherins to the cytoskeleton via USH1C and MYO7B at the brush border tip [<xref rid="ueg270156-bib-0036" ref-type="bibr">36</xref>, <xref rid="ueg270156-bib-0037" ref-type="bibr">37</xref>, <xref rid="ueg270156-bib-0038" ref-type="bibr">38</xref>]. ANKS4B is a key scaffold protein essential for maintaining the proper localization of other IMAC components; its absence disrupts their accumulation within the brush border. Formation of the tripartite IMAC complex requires activation of ANKS4B and MYO7B by the USH1C protein [<xref rid="ueg270156-bib-0036" ref-type="bibr">36</xref>, <xref rid="ueg270156-bib-0037" ref-type="bibr">37</xref>, <xref rid="ueg270156-bib-0038" ref-type="bibr">38</xref>], all of which were downregulated in CC. Additionally, SLC9A3R1 (EBP50), another IMAC scaffolding protein, was reduced in CC. EBP50 binds CDHR5, and its loss impairs brush border assembly, leading to reduced apical IMAC proteins, in enterocyte and kidney epithelial cell models [<xref rid="ueg270156-bib-0023" ref-type="bibr">23</xref>]. The IMAC complex regulates microvillar organization, ensuring uniform microvillus length [<xref rid="ueg270156-bib-0036" ref-type="bibr">36</xref>, <xref rid="ueg270156-bib-0037" ref-type="bibr">37</xref>, <xref rid="ueg270156-bib-0038" ref-type="bibr">38</xref>], and forms a physical barrier against bacterial invasion by linking adjacent microvilli [<xref rid="ueg270156-bib-0036" ref-type="bibr">36</xref>]. Loss of these connections may create gaps that allow bacteria or luminal antigens to penetrate the epithelium [<xref rid="ueg270156-bib-0038" ref-type="bibr">38</xref>]. In fact, increased uptake of noninvasive bacteria [<xref rid="ueg270156-bib-0039" ref-type="bibr">39</xref>] has been previously observed in colonic epithelial cells in CC and IBD. Enhancing IMAC‐microvilli binding may represent a novel strategy to improve barrier function in these patients.</p><p>The core actin bundle is anchored to the enveloping plasma membrane by membrane‐actin linking proteins essential for brush border integrity, including ERM family proteins (moesin) and class I (MYO1A and MYO1D [<xref rid="ueg270156-bib-0010" ref-type="bibr">10</xref>, <xref rid="ueg270156-bib-0025" ref-type="bibr">25</xref>]), all significantly downregulated in both the CC and LC. Conversely, MYO1F was upregulated, possibly as compensation. Although its role in microvilli is unclear, MYO1F promotes macrophage‐driven inflammation [<xref rid="ueg270156-bib-0021" ref-type="bibr">21</xref>]. In colitis models, MYO1F deficiency reduces cytokine release, epithelial damage, and disease activity, while enhancing tissue repair [<xref rid="ueg270156-bib-0021" ref-type="bibr">21</xref>].</p><p>We also identified ATP8B1 and SPTAN1 downregulated in CC, in correlation with higher daily stool frequency, suggesting that disrupted epithelial cell polarity may contribute to diarrhoea in CC. Preclinical data demonstrated that ATP8B1‐depleted Caco‐2 cells show apical membrane disorganization, including disarranged apical actin cytoskeleton, microvilli loss and altered apical protein expression [<xref rid="ueg270156-bib-0040" ref-type="bibr">40</xref>].</p><p>The mechanisms underlying the alterations in the brush border molecular signature and ultrastructure in patients with MC are unclear. Dysregulation of membrane proteins such as aquaporins and epithelial sodium channels has been previously reported in CC patients [<xref rid="ueg270156-bib-0006" ref-type="bibr">6</xref>, <xref rid="ueg270156-bib-0041" ref-type="bibr">41</xref>], highlighting the presence of polarization defects in the colonic epithelial cells in these patients. Moreover, epithelial injury is not simply a passive finding but likely pivotal to symptom production in MC patients, as previously reported by the strong association between the low aquaporin8 expression and the higher stool frequency in CC patients [<xref rid="ueg270156-bib-0041" ref-type="bibr">41</xref>]. However, we need to explore the link between cell polarity and microvilli impairment as a primary event (generated by an autoimmune response, e.g.) or a consequence of the inflammatory response in the colonic mucosa.</p><p>Despite novel and promising findings, our study has limitations, including a small cohort (although a strictly homogeneous cohort) and the transcriptomic/proteomic analyses performed on whole biopsies, containing multiple cell types, not exclusively epithelial cells. However, we applied unbiased, sensitive genome‐wide transcriptome and proteome approaches to identify key molecular signatures. Future steps will include single‐cell analyses for individual cell type characterization. Additionally, only post‐budesonide treatment ultrastructural analysis was performed here; however, we will explore molecular and ultrastructural changes in larger longitudinal cohorts in the future, including responders and refractory patients.</p><p>In conclusion, MC is characterized by a distinctive molecular signature associated with brush border atrophy, which can be reversed by oral budesonide. For the first time, a specific IMAC impairment was described in CC as a new key pathophysiological mechanism. Owing to the fundamental role of the brush border in the maintenance of intestinal homoeostasis and the regulation of epithelial barrier function, additional studies are warranted to investigate the drivers and consequences of its impairment in MCs. This study paves the way for the identification of new diagnostic and/or prognostic biomarkers as well as promising therapeutic targets aimed at reinforcing the defencive role of the colonic epithelium in MC and potentially other diarrhoeal diseases.</p></sec><sec id="ueg270156-sec-0120"><title>Author Contributions</title><p>D.G., A.M.G.C. and M.V. were responsible for the conceptualization and administration of the project. D.G., A.M.G.C., M.V., S.L., E.E., E.T., J.J.L. and J.S. executed experiments (biological sample collection, omic, ultrastructural, histological and statistical analysis). D.G., B.L., C.A.C., J.S., R.L.C., A.B., M.D.C., J.D., A.M., F.F.B., Y.Z. and A.J.L. were responsible for the patient recruitment, clinical data collection, and endoscopy realization. D.G., A.M.G., M.V., A.M., A.J.L., J.S. and F.F.B. were responsible for the research activity planning, execution and supervision. D.G., A.M.V., M.V. and J.J.L. performed formal analysis and prepared figures. D.G., A.M.G. and A.M. wrote the initial draft of the manuscript. All authors reviewed and approved the submitted version of this manuscript.</p></sec><sec id="ueg270156-sec-0140"><title>Funding</title><p>This work was supported by: ‘<italic toggle="yes">Gonzalo Miño</italic>’ grant (to D.G.) from the Spanish Association of Gastroenterology (AEG): ‘Multicentre study: involvement of the colonic epithelium in the pathophysiology of microscopic colitis’ (2018–2020); Project [PI17/01443 to DG] funded by <italic toggle="yes">Instituto de Salud Carlos III</italic> and co‐funded by the European Union (ERDF/ESF): ‘Identification of an integrated panel of non‐invasive predictive biomarkers for the diagnosis of microscopic colitis’ (2018–2021); [ACCES‐16 Phase III to M.V.]: ‘Ultrastructural analysis of the colonic epithelium in microscopic colitis’ (CIBEREHD‐ISCIII) (2016); Framework collaboration agreement (to D.G., A.M., M.V.) with Linköping Hospital with economic contributions in the field of ‘Microvilli in microscopic colitis’. Project [PI19/01643 to M.V.] funded by <italic toggle="yes">Instituto de Salud Carlos III</italic> and co‐funded by the European Union (ERDF/ESF): ‘Distinctive contribution of the intestinal epithelium to the pathophysiology of chronic diarrhoea in irritable bowel syndrome and microscopic colitis. Integromic profiling for differential diagnosis’ (2020–2023). The founders of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the manuscript.</p></sec><sec id="ueg270156-sec-0150"><title>Ethics Statement</title><p>The study protocol was approved by the local Ethics Committee of all participant centres (PR(AG)475/2017 and PR(AG)164/2018) in accordance with the Helsinki Declaration.</p></sec><sec id="ueg270156-sec-0160"><title>Consent</title><p>Written informed consent was obtained from each participant.</p></sec><sec sec-type="COI-statement" id="ueg270156-sec-0170"><title>Conflicts of Interest</title><p>No directly relevant conflicts of interest for the authors to the submitted work. Other potential conflict of interest: <italic toggle="yes">D.Guagnozzi.</italic> has received support for conference attendance and speaker fees from Tillots Pharma, Falk, Takeda, Sanofi Biotechnology, Dr. Falk‐Pharma, Laboratorio Salvat; <italic toggle="yes">A.J.Lucendo.</italic> receives research funding from Adare/Ellodi, AstraZeneca, Dr. Falk Pharma, EsoCap, and Regeneron. He serves as a consultant for Alfasigma, Arena/Pfizer, EsoCap, Dr. Falk Pharma, EsoCap, and Sanofi; <italic toggle="yes">J.Santos.</italic> declares having served as medical advisor for Noventure, Devintecpharma, Reckitt, Ipsen, Hipra, Aboca, Pileje, Lainco, Sequentia, and Viatris in the last three years and has otherwise collaborated with Salvat, Norgine, Alfa‐Sigma, Cosmo‐Adare, Danone, Farmasierra, Italfarmaco, Venter, Ordesa, Takeda and Menarini; <italic toggle="yes">Y.Zabana.</italic> has received support for conference attendance, speaker fees, research support and consulting fees from: AbbVie, Adacyte, Alfa‐Sigma, Almirall, Amgen, Boehringer Ingelheim, Dr Falk Pharma, FAES Pharma, Fresenius Kabi, Ferring, Galapagos, Janssen, J&amp;J, Kem, Lilly, MSD, Otsuka, Pfizer, Sanofi, Shire, Takeda, Tillots; <italic toggle="yes">C.Alonso‐Cotoner</italic> has received support for scientific collaboration with Norgine, Menarini; <italic toggle="yes">A.Münch</italic>. has received funding (grants/honoraria) from Ferring and speaker/consulting fees from Tillots, Ferring, Eli Lilly, Falk Foundation, Jansson, Vifor; <italic toggle="yes">M.D.Castillo Cejas</italic> has received support for conference attendance from Bromatech, Norgine, Medtronic; <italic toggle="yes">R.Llerena‐Castro</italic> has received support for conference attendance from Pileje, Sanofi, Falk Foundation, Shwabe Farma Iberica, Alfasigma, Salvat; <italic toggle="yes">B. Lobo</italic> has received funding for conference attendance and speaker fees from: Ferring pharaceuticals, Salvat, Aboca S.P.A. Schwabe Farma Ibérica; <italic toggle="yes">F.Fernandez Bañares</italic> has received financial support for conference attendance and research support from AbbVie, Biogen, Faes Farma, Ferring, Jannsen, MSD, Pfizer, Takeda and Tillotts. <italic toggle="yes">M.Vicario.</italic> is an employee of Société des Produits Nestlé S.A., Switzerland since October 2019. The remaining authors report no conflicts of interest.</p></sec><sec id="ueg270156-sec-0200"><title>Transcript Profiling</title><p>The transcript profiling data have been deposited in the Gene Expression Omnibus (GEO) database under accession number: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE282696">GSE282696</ext-link> and repository URL: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282696" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282696</ext-link>.</p></sec><sec id="ueg270156-sec-0210"><title>Writing Assistance</title><p>No writing assistance has been used for this article.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="ueg270156-sup-0001" position="float" content-type="local-data" orientation="portrait"><caption><p>
Supporting Information S1
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s002.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ueg270156-sup-0002" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S1</bold>: Study design.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ueg270156-sup-0003" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S2</bold>: Visualization of functional enrichment results by CNETPLOTS for CC vs. H, CC vs. IBS‐D and LC vs. CC comparisons, depicting the linkages of genes and biological concepts as networks in which nodes represent GO pathways of the apical plasma membrane, actin and cluster of actin‐based projection and brush border (normalized enriched scores).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s006.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ueg270156-sup-0004" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S3</bold>: Visualization of functional enrichment results by CNETPLOTS for CC vs. H, CC vs. IBS‐D and LC vs. CC comparisons, depicting the linkages of proteins and biological concepts as networks in which nodes represent GO pathways of the apical plasma membrane, actin and cluster of actinbased projection and brush border (normalized enriched scores).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s007.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ueg270156-sup-0005" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Figure S4</bold>: (A) Bubble Plots of AUC for all 28 proteins identified comparing CC or LC patients with IBS‐D patients. (B) Multi‐ROC analysis comparing the diagnostic performance of selected proteins in distinguishing MC and IBS‐D.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s003.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ueg270156-sup-0006" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table S1</bold>: Demographic characteristics of all participants and experimental procedures performed.</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s004.docx" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="ueg270156-sup-0007" position="float" content-type="local-data" orientation="portrait"><caption><p>
<bold>Table S2</bold>: The correlation between gene and protein expression of the 28 genes/proteins identified in the brush border signature (strong correlation: <italic toggle="yes">r</italic> &gt; 0.7; <italic toggle="yes">p</italic> &lt; 0.05 with dark green color; moderate correlation: 0.3 &lt; <italic toggle="yes">r</italic> &lt; 0.7; <italic toggle="yes">p</italic> &lt; 0.05 with light green color).</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="UEG2-14-e70156-s005.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ueg270156-sec-0130"><title>Acknowledgements</title><p>F.Fernandez Bañares passed away before the paper was accepted for publication. He was involved in patient recruitment, clinical data collection, and research activity planning. He was an outstanding clinician and researcher in the study of microscopic colitis. He pioneered clinical and translational research in microscopic colitis, leading the European and Spanish groups of microscopic colitis. We thank all the physicians and nurses of the Gastroenterology Department of each centre for their help in sample collection and appointment schedule. We thank the nurses (Gisela Gili Serrat and Carla Aguilar Blancafort) of the Support Unit for Clinical Research in the Vall d’Hebron Research Institute for their invaluable help with biological sample collection and <italic toggle="yes">Servei de Microscòpia of Universitat Autònoma</italic> de Barcelona for excellent technical support. Figure <xref rid="ueg270156-fig-0009" ref-type="fig">9</xref> partially created in Biorender (Guagnozzi d).</p><fig position="float" fig-type="FIGURE" id="ueg270156-fig-0009" orientation="portrait"><label>FIGURE 9</label><caption><p>The molecular impairment of microvilli structures and its ultrastructure modification in LC and CC compared to H and IBS‐D groups. Representative transmission electron microscopy images of colonocyte microvilli from control groups and LC and CC groups (magnification at 15–20K). Each microvillus contains a core bundle of parallel actin filaments, maintaining consistent length and width. Actin filaments in microvilli are organized by bundling proteins such as VIL1, ESPN, PLS1 and MISP. Formation of the tripartite IMAC complex requires activation of ANKS4B and MYO7B by the USH1C protein. The IMAC complex regulates microvillar organization, ensuring uniform microvillus length, and forms a physical barrier against bacterial invasion by linking adjacent microvilli. The core actin bundle is anchored to the enveloping plasma membrane by membrane‐actin linking proteins essential for brush border integrity, including ERM family proteins (moesin) and class I (MYO1A and MYO1D). ANKS4B: Ankyrin repeat and sterile alpha motif domain containing 4B, CC: collagenous colitis, CDHR2: Cadherin Related Family Member 2, CDHR5: Cadherin Related Family Member 5, EPS8: Epidermal growth factor receptor pathway substrate 8, EPCAM: Epithelial cellular adhesion molecule, ESPN: Espin, EZR: Ezrin, MSN: Moesin, F‐actin: Filament actin, H: healthy subjects, IBS‐D: irritable bowel syndrome with a predominance of diarrhoea, IF: Intermediate filaments, KRT8‐20: Keratin 8‐20, LC: lymphocytic colitis, MISP: Mitotic interactor and substrate of Plk1, MYO1A: Myosin 1A, MYO1D: Myosin 1D, MYO1F: Myosin‐1F, MYO7B: Myosin 7B, PLS1: Plastin‐1, SLC9A3R1 (EBP50): Ezrin‐Radixin‐Moesin‐Binding Phosphoprotein 50, SPTAN1: Monerythrocytic alpha‐spectrin‐1, TPM: Tropomyosin, USH1C: Hamonin, VIL1: Villin‐1. Image created using slideTeam.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-17" orientation="portrait" xlink:href="UEG2-14-e70156-g004.jpg"/></fig></ack><sec sec-type="data-availability" id="ueg270156-sec-0190"><title>Data Availability Statement</title><p>The data, analytical methods, and study materials will be made available to other researchers. Proposals should be directed to <email>danila.guagnoazzi@vallhebron.cat</email>.</p></sec><ref-list content-type="cited-references" id="ueg270156-bibl-0001"><title>References</title><ref id="ueg270156-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="ueg270156-cit-0001">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Miehlke</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Guagnozzi</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Zabana</surname>
</string-name>, et al., “<article-title>European Guidelines on Microscopic Colitis: United European Gastroenterology and European Microscopic Colitis Group Statements and Recommendations</article-title>,” <source>United European Gastroenterol J</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>13</fpage>–<lpage>37</lpage>, <pub-id pub-id-type="doi">10.1177/2050640620951905</pub-id>.<pub-id pub-id-type="pmcid">PMC8259259</pub-id><pub-id pub-id-type="pmid">33619914</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="ueg270156-cit-0002">
<string-name name-style="western">
<given-names>C.</given-names>
<surname>Langner</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Aust</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Ensari</surname>
</string-name>, et al., “<article-title>Histology of Microscopic Colitis – Review With a Practical Approach for Pathologists</article-title>,” <source>Histopathology</source>
<volume>66</volume>, no. <issue>5</issue> (<year>2015</year>): <fpage>613</fpage>–<lpage>626</lpage>, <pub-id pub-id-type="doi">10.1111/his.12592</pub-id>.<pub-id pub-id-type="pmid">25381724</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="ueg270156-cit-0003">
<string-name name-style="western">
<given-names>C. G.</given-names>
<surname>Lindström</surname>
</string-name>, “<article-title>Collagenous Colitis With Watery Diarrhoea – A New Entity</article-title>,” <source>Pathologia Europaea</source>
<volume>11</volume>, no. <issue>1</issue> (<year>1976</year>): <fpage>87</fpage>–<lpage>89</lpage>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/934705/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/934705/</ext-link>.<pub-id pub-id-type="pmid">934705</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="ueg270156-cit-0004">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Guagnozzi</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Arias</surname>
</string-name>, and <string-name name-style="western">
<given-names>A. J.</given-names>
<surname>Lucendo</surname>
</string-name>, “<article-title>Systematic Review With Meta‐Analysis: Diagnostic Overlap of Microscopic Colitis and Functional Bowel Disorders</article-title>,” <source>Alimentary Pharmacology &amp; Therapeutics</source>
<volume>43</volume>, no. <issue>8</issue> (<year>2016</year>): <fpage>851</fpage>–<lpage>862</lpage>, <pub-id pub-id-type="doi">10.1111/apt.13573</pub-id>.<pub-id pub-id-type="pmid">26913568</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="ueg270156-cit-0005">
<string-name name-style="western">
<given-names>F.</given-names>
<surname>Fernández‐Bañares</surname>
</string-name>, <string-name name-style="western">
<given-names>M. J.</given-names>
<surname>Casanova</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Arguedas</surname>
</string-name>, et al., “<article-title>Current Concept on Microscopic Colitis: Evidence‐Based Statements and Recommendations of the Spanish Microscopic Colitis Group</article-title>,” <source>Alimentary Pharmacology &amp; Therapeutics</source>
<volume>43</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>400</fpage>–<lpage>426</lpage>, <pub-id pub-id-type="doi">10.1111/apt.13477</pub-id>.<pub-id pub-id-type="pmid">26597122</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="ueg270156-cit-0006">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Zabana</surname>
</string-name>, <string-name name-style="western">
<given-names>G. E.</given-names>
<surname>Tontini</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Hultgren‐Hörnquist</surname>
</string-name>, et al., “<article-title>Pathogenesis of Microscopic Colitis: A Systematic Review</article-title>,” <source>Journal of Crohn's and Colitis</source>
<volume>16</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>143</fpage>–<lpage>161</lpage>, <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjab123</pub-id>.<pub-id pub-id-type="pmid">34272945</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="ueg270156-cit-0007">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Proctic</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Jojic</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Bojic</surname>
</string-name>, et al., “<article-title>Mechanism of Diarrhea in Microscopic Colitis</article-title>,” <source>World Journal of Gastroenterology</source>
<volume>11</volume>, no. <issue>35</issue> (<year>2005</year>): <fpage>5535</fpage>–<lpage>5539</lpage>, <pub-id pub-id-type="doi">10.3748/wjg.v11.i35.5535</pub-id>.<pub-id pub-id-type="pmid">16222750</pub-id>
<pub-id pub-id-type="pmcid">PMC4320367</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="ueg270156-cit-0008">
<string-name name-style="western">
<given-names>C.</given-names>
<surname>Barmeyer</surname>
</string-name>, <string-name name-style="western">
<given-names>I.</given-names>
<surname>Erko</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Awad</surname>
</string-name>, et al., “<article-title>Epithelial Barrier Dysfunction in Lymphocytic Colitis Through Cytokine‐Dependent Internalization of Claudin‐5 and ‐8</article-title>,” <source>Journal of Gastroenterology</source>
<volume>52</volume>, no. <issue>10</issue> (<year>2017</year>): <fpage>1090</fpage>–<lpage>1100</lpage>, <pub-id pub-id-type="doi">10.1007/s00535-017-1309-2</pub-id>.<pub-id pub-id-type="pmid">28138755</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="ueg270156-cit-0009">
<string-name name-style="western">
<given-names>G.</given-names>
<surname>Roda</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Sartini</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Zambon</surname>
</string-name>, et al., “<article-title>Intestinal Epithelia Cells in Inflammatory Bowel Disease</article-title>,” <source>World Journal of Gastroenterology</source>
<volume>16</volume>, no. <issue>34</issue> (<year>2010</year>): <fpage>4264</fpage>–<lpage>4271</lpage>, <pub-id pub-id-type="doi">10.3748/wjg.v16.i34.4264</pub-id>.<pub-id pub-id-type="pmid">20818809</pub-id>
<pub-id pub-id-type="pmcid">PMC2937106</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="ueg270156-cit-0010">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Delacour</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Salomon</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Robine</surname>
</string-name>, and <string-name name-style="western">
<given-names>D.</given-names>
<surname>Louvard</surname>
</string-name>, “<article-title>Plasticity of the Brush Border – The Yin and Yang of Intestinal Homeostasis</article-title>,” <source>Nature Reviews Gastroenterology &amp; Hepatology</source>
<volume>13</volume>, no. <issue>3</issue> (<year>2016</year>): <fpage>161</fpage>–<lpage>174</lpage>, <pub-id pub-id-type="doi">10.1038/nrgastro.2016.5</pub-id>.<pub-id pub-id-type="pmid">26837713</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="ueg270156-cit-0011">
<string-name name-style="western">
<given-names>A. J.</given-names>
<surname>Lazenby</surname>
</string-name>, <string-name name-style="western">
<given-names>J. H.</given-names>
<surname>Yardley</surname>
</string-name>, <string-name name-style="western">
<given-names>F. M.</given-names>
<surname>Giardiello</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Jessurun</surname>
</string-name>, and <string-name name-style="western">
<given-names>T. M.</given-names>
<surname>Bayless</surname>
</string-name>, “<article-title>Lymphocytic (Microscopic) Colitis: A Comparative Histopathologic Study With Particular Reference to Collagenous Colitis</article-title>,” <source>Human Pathology</source>
<volume>20</volume>, no. <issue>1</issue> (<year>1989</year>): <fpage>18</fpage>–<lpage>28</lpage>, <pub-id pub-id-type="doi">10.1016/0046-8177(89)90198-6</pub-id>.<pub-id pub-id-type="pmid">2912870</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="ueg270156-cit-0012">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Jessurun</surname>
</string-name>, <string-name name-style="western">
<given-names>J. H.</given-names>
<surname>Yardley</surname>
</string-name>, <string-name name-style="western">
<given-names>F. M.</given-names>
<surname>Giardiello</surname>
</string-name>, <string-name name-style="western">
<given-names>S. R.</given-names>
<surname>Hamilton</surname>
</string-name>, and <string-name name-style="western">
<given-names>T. M.</given-names>
<surname>Bayless</surname>
</string-name>, “<article-title>Chronic Colitis With Thickening of the Subepithelial Collagen Layer (Collagenous Colitis): Histopathologic Findings in 15 Patients</article-title>,” <source>Human Pathology</source>
<volume>18</volume>, no. <issue>8</issue> (<year>1987</year>): <fpage>839</fpage>–<lpage>848</lpage>, <pub-id pub-id-type="doi">10.1016/s0046-8177(87)80059-x</pub-id>.<pub-id pub-id-type="pmid">3610134</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0013"><label>13</label><mixed-citation publication-type="book" id="ueg270156-cit-0013">
<string-name name-style="western">
<given-names>D. A.</given-names>
<surname>Drossman</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Chang</surname>
</string-name>, <string-name name-style="western">
<given-names>W. D.</given-names>
<surname>Chey</surname>
</string-name>, et al., <source>The Rome IV Committees. Rome IV Functional Gastrointestinal Disorders – Disorders of gut‐brain Interactions</source>, <edition>4th ed. I.</edition> (<publisher-name>Rome Foundation</publisher-name>, <year>2016</year>), <fpage>549</fpage>–<lpage>577</lpage>.</mixed-citation></ref><ref id="ueg270156-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="ueg270156-cit-0014">
<string-name name-style="western">
<given-names>S. J.</given-names>
<surname>Lewis</surname>
</string-name> and <string-name name-style="western">
<given-names>K. W.</given-names>
<surname>Heaton</surname>
</string-name>, “<article-title>Stool Form Scale as a Useful Guide to Intestinal Transit Time</article-title>,” <source>Scandinavian Journal of Gastroenterology</source>
<volume>32</volume>, no. <issue>9</issue> (<year>1997</year>): <fpage>920</fpage>–<lpage>924</lpage>, <pub-id pub-id-type="doi">10.3109/00365529709011203</pub-id>.<pub-id pub-id-type="pmid">9299672</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="ueg270156-cit-0015">
<string-name name-style="western">
<given-names>H.</given-names>
<surname>Hjortswang</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Tysk</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Bohr</surname>
</string-name>, et al., “<article-title>Defining Clinical Criteria for Clinical Remission and Disease Activity in Collagenous Colitis</article-title>,” <source>Inflammatory Bowel Diseases</source>
<volume>15</volume>, no. <issue>12</issue> (<year>2009</year>): <fpage>1875</fpage>–<lpage>1881</lpage>, <pub-id pub-id-type="doi">10.1002/ibd.20977</pub-id>.<pub-id pub-id-type="pmid">19504614</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="ueg270156-cit-0016">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Arbaizar‐Rovirosa</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Pedragosa</surname>
</string-name>, <string-name name-style="western">
<given-names>J. J.</given-names>
<surname>Lozano</surname>
</string-name>, et al., “<article-title>Aged Lipid‐Laden Microglia Display Impaired Responses to Stroke</article-title>,” <source>EMBO Molecular Medicine</source>
<volume>15</volume>, no. <issue>2</issue> (<year>2023</year>): <elocation-id>e17175</elocation-id>, <pub-id pub-id-type="doi">10.15252/emmm.202217175</pub-id>.<pub-id pub-id-type="pmid">36541061</pub-id>
<pub-id pub-id-type="pmcid">PMC9906381</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="ueg270156-cit-0017">
<string-name name-style="western">
<given-names>M. I.</given-names>
<surname>Love</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Huber</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Anders</surname>
</string-name>, “<article-title>Moderated Estimation of Fold Change and Dispersion for RNA‐Seq Data With DESeq2</article-title>,” <source>Genome Biology</source>
<volume>15</volume>, no. <issue>12</issue> (<year>2014</year>): <elocation-id>550</elocation-id>, <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>.<pub-id pub-id-type="pmid">25516281</pub-id>
<pub-id pub-id-type="pmcid">PMC4302049</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0018"><label>18</label><mixed-citation publication-type="book" id="ueg270156-cit-0018">
<string-name name-style="western">
<given-names>G. K.</given-names>
<surname>Smyth</surname>
</string-name>, “<part-title>Limma: Linear Models for Microarray Data</part-title>,” in <source>Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Statistics for Biology and Health</source> (<publisher-name>Springer</publisher-name>, <year>2005</year>), <fpage>397</fpage>–<lpage>420</lpage>.</mixed-citation></ref><ref id="ueg270156-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="ueg270156-cit-0019">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Guangchuang</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Li‐Gen</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Yanyan</surname>
</string-name>, and <string-name name-style="western">
<given-names>Q. Y.</given-names>
<surname>He</surname>
</string-name>, “<article-title>Cluster Profiler: An R Package for Comparing Biological Themes Among Gene Clusters</article-title>,” <source>OMICS</source>
<volume>16</volume>, no. <issue>5</issue> (<year>2012</year>): <fpage>284</fpage>–<lpage>287</lpage>, <pub-id pub-id-type="doi">10.1089/omi.2011.0118</pub-id>.<pub-id pub-id-type="pmid">22455463</pub-id>
<pub-id pub-id-type="pmcid">PMC3339379</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="ueg270156-cit-0020">
<string-name name-style="western">
<given-names>D. A.</given-names>
<surname>Barbie</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Tamayo</surname>
</string-name>, <string-name name-style="western">
<given-names>J. S.</given-names>
<surname>Boehm</surname>
</string-name>, et al., “<article-title>Systematic RNA Interference Reveals That Oncogenic KRAS‐Driven Cancers Require TBK1</article-title>,” <source>Nature</source>
<volume>462</volume>, no. <issue>7269</issue> (<year>2009</year>): <fpage>108</fpage>–<lpage>112</lpage>, <pub-id pub-id-type="doi">10.1038/nature08460</pub-id>.<pub-id pub-id-type="pmid">19847166</pub-id>
<pub-id pub-id-type="pmcid">PMC2783335</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="ueg270156-cit-0021">
<string-name name-style="western">
<given-names>D. A.</given-names>
<surname>Giron‐Perez</surname>
</string-name>, <string-name name-style="western">
<given-names>Z. L.</given-names>
<surname>Piedra‐Quintero</surname>
</string-name>, and <string-name name-style="western">
<given-names>L.</given-names>
<surname>Santos‐Argumedo</surname>
</string-name>, “<article-title>Class I Myosins: Highly Versatile Proteins With Specific Functions in the Immune System</article-title>,” <source>Journal of Leukocyte Biology</source>
<volume>105</volume>, no. <issue>5</issue> (<year>2019</year>): <fpage>973</fpage>–<lpage>981</lpage>, <pub-id pub-id-type="doi">10.1002/jlb.1mr0918-350rrr</pub-id>.<pub-id pub-id-type="pmid">30821871</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="ueg270156-cit-0022">
<string-name name-style="western">
<given-names>D. R.</given-names>
<surname>Burgess</surname>
</string-name>, <string-name name-style="western">
<given-names>K. O.</given-names>
<surname>Broschat</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. M.</given-names>
<surname>Hayden</surname>
</string-name>, “<article-title>Tropomyosin Distinguishes Between the Two Actin‐Binding Sites of Villin and Affects Actin‐Binding Properties of Other Brush Border Proteins</article-title>,” <source>Journal of Cell Biology</source>
<volume>104</volume>, no. <issue>1</issue> (<year>1987</year>): <fpage>29</fpage>–<lpage>40</lpage>, <pub-id pub-id-type="doi">10.1083/jcb.104.1.29</pub-id>.<pub-id pub-id-type="pmid">3793760</pub-id>
<pub-id pub-id-type="pmcid">PMC2117036</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="ueg270156-cit-0023">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Matoo</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Graves</surname>
</string-name>, <string-name name-style="western">
<given-names>M. S.</given-names>
<surname>Choi</surname>
</string-name>, et al., “<article-title>The Microvillar Protocadherin CDHR5 Associates With EBP50 to Promote Brush Border Assembly</article-title>,” <source>Molecular Biology of the Cell</source>
<volume>35</volume>, no. <issue>3</issue> (<year>2024</year>): <elocation-id>ar36</elocation-id>, <pub-id pub-id-type="doi">10.1091/mbc.e23-02-0065</pub-id>.<pub-id pub-id-type="pmid">38170579</pub-id>
<pub-id pub-id-type="pmcid">PMC10916864</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="ueg270156-cit-0024">
<string-name name-style="western">
<given-names>G.</given-names>
<surname>Carpentieri</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Cecchetti</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Bocchinfuso</surname>
</string-name>, et al., “<article-title>Dominantly Acting Variants in ATP6V1C1 and ATP6V1B2 Cause a Multisystem Phenotypic Spectrum by Altering Lysosomal and/or Autophagosome Function</article-title>,” <source>HGG Adv</source>
<volume>5</volume>, no. <issue>4</issue> (<year>2024</year>): <elocation-id>100349</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.xhgg.2024.100349</pub-id>.<pub-id pub-id-type="pmid">39210597</pub-id>
<pub-id pub-id-type="pmcid">PMC11465052</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="ueg270156-cit-0025">
<string-name name-style="western">
<given-names>A. E.</given-names>
<surname>Morales</surname>
</string-name>, <string-name name-style="western">
<given-names>I.</given-names>
<surname>Gaeta</surname>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Tyska</surname>
</string-name>, “<article-title>Building the Brush Border, One Microvillus at a Time</article-title>,” <source>Current Opinion in Cell Biology</source>
<volume>80</volume> (<year>2023</year>): <elocation-id>102153</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.ceb.2023.102153</pub-id>.<pub-id pub-id-type="pmid">36827850</pub-id>
<pub-id pub-id-type="pmcid">PMC10033394</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="ueg270156-cit-0026">
<string-name name-style="western">
<given-names>I.</given-names>
<surname>Gaeta</surname>
</string-name>, <string-name name-style="western">
<given-names>L. M.</given-names>
<surname>Meenderink</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Postema</surname>
</string-name>, <string-name name-style="western">
<given-names>C. S.</given-names>
<surname>Cencer</surname>
</string-name>, and <string-name name-style="western">
<given-names>M. J.</given-names>
<surname>Tyska</surname>
</string-name>, “<article-title>Direct Visualization of Epithelial Microvilli Biogenesis</article-title>,” <source>Current Biology</source>
<volume>31</volume>, no. <issue>12</issue> (<year>2021</year>): <fpage>2561</fpage>–<lpage>2575</lpage>, <pub-id pub-id-type="doi">10.1016/j.cub.2021.04.012</pub-id>.<pub-id pub-id-type="pmid">33951456</pub-id>
<pub-id pub-id-type="pmcid">PMC8222192</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="ueg270156-cit-0027">
<string-name name-style="western">
<given-names>K. L.</given-names>
<surname>VanDussen</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Stojmirovic</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Li</surname>
</string-name>, et al., “<article-title>Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn’s Disease</article-title>,” <source>Gastroenterology</source>
<volume>155</volume>, no. <issue>3</issue> (<year>2018</year>): <fpage>815</fpage>–<lpage>828</lpage>, <pub-id pub-id-type="doi">10.1053/j.gastro.2018.05.028</pub-id>.<pub-id pub-id-type="pmid">29782846</pub-id>
<pub-id pub-id-type="pmcid">PMC6378688</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="ueg270156-cit-0028">
<string-name name-style="western">
<given-names>B.</given-names>
<surname>Mödi</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Awad</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Zwolanek</surname>
</string-name>, et al., “<article-title>Defects in Microvillus Crosslinking Sensitize to Colitis and Inflammatory Bowel Disease</article-title>,” <source>EMBO Reports</source>
<volume>24</volume> (<year>2020</year>): <elocation-id>e57084</elocation-id>, <pub-id pub-id-type="doi">10.15252/embr.202357084</pub-id>.<pub-id pub-id-type="pmcid">PMC10561180</pub-id><pub-id pub-id-type="pmid">37691494</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="ueg270156-cit-0029">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Sharkova</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Chow</surname>
</string-name>, <string-name name-style="western">
<given-names>T.</given-names>
<surname>Erickson</surname>
</string-name>, and <string-name name-style="western">
<given-names>J. C.</given-names>
<surname>Hocking</surname>
</string-name>, “<article-title>The Morphological and Functional Diversity of Apical Microvilli</article-title>,” <source>Journal of Anatomy</source>
<volume>242</volume>, no. <issue>3</issue> (<year>2023</year>): <fpage>327</fpage>–<lpage>353</lpage>, <pub-id pub-id-type="doi">10.1111/joa.13781</pub-id>.<pub-id pub-id-type="pmid">36281951</pub-id>
<pub-id pub-id-type="pmcid">PMC9919547</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="ueg270156-cit-0030">
<string-name name-style="western">
<given-names>T. D.</given-names>
<surname>Pollard</surname>
</string-name> and <string-name name-style="western">
<given-names>M. S.</given-names>
<surname>Mooseker</surname>
</string-name>, “<article-title>Direct Measurement of Actin Polymerization Rate Constants by Electron Microscopy of Actin Polymerization Rate Constants by Electron Microscopy of Actin Filaments Nucleated by Isolated Microvilli Cores</article-title>,” <source>Journal of Cell Biology</source>
<volume>88</volume>, no. <issue>3</issue> (<year>1981</year>): <fpage>654</fpage>–<lpage>659</lpage>, <pub-id pub-id-type="doi">10.1083/jcb.88.3.654</pub-id>.<pub-id pub-id-type="pmid">6894301</pub-id>
<pub-id pub-id-type="pmcid">PMC2112767</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="ueg270156-cit-0031">
<string-name name-style="western">
<given-names>M. S.</given-names>
<surname>Moosker</surname>
</string-name> and <string-name name-style="western">
<given-names>L. G.</given-names>
<surname>Tilney</surname>
</string-name>, “<article-title>Organization of an Actin Filament Membrane Complex. Filament Polarity and Membrane Attachment in the Microvilli of Intestinal Epithelial Cells</article-title>,” <source>Journal of Cell Biology</source>
<volume>67</volume>, no. <issue>3</issue> (<year>1975</year>): <fpage>725</fpage>–<lpage>743</lpage>, <pub-id pub-id-type="doi">10.1083/jcb.67.3.725</pub-id>.<pub-id pub-id-type="pmid">1202021</pub-id>
<pub-id pub-id-type="pmcid">PMC2111646</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="ueg270156-cit-0032">
<string-name name-style="western">
<given-names>E.</given-names>
<surname>Grimm‐Gunter</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Revenu</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Ramos</surname>
</string-name>, et al., “<article-title>Plastin 1 Binds to Keratin and Is Required for Terminal Web Assembly in the Intestinal Epithelium</article-title>,” <source>Molecular Biology of the Cell</source>
<volume>20</volume>, no. <issue>10</issue> (<year>2009</year>): <fpage>2549</fpage>–<lpage>2562</lpage>, <pub-id pub-id-type="doi">10.1091/mbc.e08-10-1030</pub-id>.<pub-id pub-id-type="pmid">19321664</pub-id>
<pub-id pub-id-type="pmcid">PMC2682596</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="ueg270156-cit-0033">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Khurana</surname>
</string-name> and <string-name name-style="western">
<given-names>S. P.</given-names>
<surname>George</surname>
</string-name>, “<article-title>Regulation of Cell Structure and Function by‐Actin‐Binding Proteins: Villin’s Perspective</article-title>,” <source>FEBS Letters</source>
<volume>582</volume>, no. <issue>14</issue> (<year>2008</year>): <fpage>2128</fpage>–<lpage>2139</lpage>, <pub-id pub-id-type="doi">10.1016/j.febslet.2008.02.040</pub-id>.<pub-id pub-id-type="pmid">18307996</pub-id>
<pub-id pub-id-type="pmcid">PMC2680319</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="ueg270156-cit-0034">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Kersting</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Bruewer</surname>
</string-name>, <string-name name-style="western">
<given-names>G.</given-names>
<surname>Schuermann</surname>
</string-name>, et al., “<article-title>Antigen Transport and Cytoskeletal Characteristics of a Distinct Enterocyte Population in Inflammatory Bowel Diseases</article-title>,” <source>American journal of pathology</source>
<volume>165</volume>, no. <issue>2</issue> (<year>2004</year>): <fpage>425</fpage>–<lpage>437</lpage>, <pub-id pub-id-type="doi">10.1016/s0002-9440(10)63308-1</pub-id>.<pub-id pub-id-type="pmid">15277217</pub-id>
<pub-id pub-id-type="pmcid">PMC1618561</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="ueg270156-cit-0035">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Roy</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Esmaeilniakooshkghazi</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Patnaik</surname>
</string-name>, et al., “<article-title>Villin‐1 and Gelsolin Regulate Changes in Actin Dynamics That Affect Cell Survival Signaling Pathways and Intestinal Inflammation</article-title>,” <source>Gastroenterology</source>
<volume>154</volume>, no. <issue>5</issue> (<year>2018</year>): <fpage>1405</fpage>–<lpage>1420</lpage>, <pub-id pub-id-type="doi">10.1053/j.gastro.2017.12.016</pub-id>.<pub-id pub-id-type="pmid">29274870</pub-id>
<pub-id pub-id-type="pmcid">PMC7808315</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="ueg270156-cit-0036">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Li</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>He</surname>
</string-name>, <string-name name-style="western">
<given-names>Q.</given-names>
<surname>Lu</surname>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Zhang</surname>
</string-name>, “<article-title>Mechanistic Basis of Organization of the Harmonin USH1‐Mediated Brush Border Microvilli Tip‐Link Complex</article-title>,” <source>Developmental Cell</source>
<volume>36</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>179</fpage>–<lpage>189</lpage>, <pub-id pub-id-type="doi">10.1016/j.devcel.2015.12.020</pub-id>.<pub-id pub-id-type="pmid">26812017</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="ueg270156-cit-0037">
<string-name name-style="western">
<given-names>S. W.</given-names>
<surname>Crawley</surname>
</string-name>, <string-name name-style="western">
<given-names>M. L.</given-names>
<surname>Weck</surname>
</string-name>, <string-name name-style="western">
<given-names>N. E.</given-names>
<surname>Grega‐Larson</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Shifrin</surname>
<suffix>Jr.</suffix>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Tyska</surname>
</string-name>, “<article-title>ANKS4B Is Essential for Intermicrovillar Adhesion Complex Formation</article-title>,” <source>Developmental Cell</source>
<volume>36</volume>, no. <issue>2</issue> (<year>2016</year>): <fpage>190</fpage>–<lpage>200</lpage>, <pub-id pub-id-type="doi">10.1016/j.devcel.2015.12.022</pub-id>.<pub-id pub-id-type="pmid">26812018</pub-id>
<pub-id pub-id-type="pmcid">PMC4730382</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="ueg270156-cit-0038">
<string-name name-style="western">
<given-names>B.</given-names>
<surname>Modl</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Schmidt</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Moser</surname>
</string-name>, and <string-name name-style="western">
<given-names>R.</given-names>
<surname>Eferi</surname>
</string-name>, “<article-title>The Intermicrovillar Adhesion Complex in Gut Barrier Function and Inflammation</article-title>,” <source>Explor Dig Dis</source>
<volume>1</volume> (<year>2022</year>): <fpage>72</fpage>–<lpage>79</lpage>, <pub-id pub-id-type="doi">10.37349/edd.2022.00006</pub-id>.<pub-id pub-id-type="pmid">39092422</pub-id>
<pub-id pub-id-type="pmcid">PMC7616328</pub-id></mixed-citation></ref><ref id="ueg270156-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="ueg270156-cit-0039">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Münch</surname>
</string-name>, <string-name name-style="western">
<given-names>J. D.</given-names>
<surname>Soderholm</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Öst</surname>
</string-name>, and <string-name name-style="western">
<given-names>M.</given-names>
<surname>Ström</surname>
</string-name>, “<article-title>Increased Transmucosal Uptake of E. coli K12 in Collagenous Colitis Persists After Budesonide Treatment</article-title>,” <source>American Journal of Gastroenterology</source>
<volume>104</volume>, no. <issue>3</issue> (<year>2009</year>): <fpage>679</fpage>–<lpage>685</lpage>, <pub-id pub-id-type="doi">10.14309/00000434-200903000-00028</pub-id>.<pub-id pub-id-type="pmid">19209166</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="ueg270156-cit-0040">
<string-name name-style="western">
<given-names>P.</given-names>
<surname>Verhulst</surname>
</string-name>, <string-name name-style="western">
<given-names>L. M.</given-names>
<surname>Van Der Velden</surname>
</string-name>, <string-name name-style="western">
<given-names>V.</given-names>
<surname>Oaeschot</surname>
</string-name>, et al., “<article-title>A Flipase‐independent Function of ATP8B1 the Protein Affected in Familial Intrahepatic Cholestasis Type 1 Is Required for Apical Protein Expression and Microvillus Formation in Polarized Epithelial Cells</article-title>,” <source>Hepatology</source>
<volume>51</volume> (<year>2010</year>): <fpage>2049</fpage>–<lpage>2060</lpage>, <pub-id pub-id-type="doi">10.1002/hep.23586</pub-id>.<pub-id pub-id-type="pmid">20512993</pub-id>
</mixed-citation></ref><ref id="ueg270156-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="ueg270156-cit-0041">
<string-name name-style="western">
<given-names>C.</given-names>
<surname>Escudero‐Hernandez</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Münch</surname>
</string-name>, <string-name name-style="western">
<given-names>A. E.</given-names>
<surname>Ostvik</surname>
</string-name>, <string-name name-style="western">
<given-names>AvB.</given-names>
<surname>Granlund</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Koch</surname>
</string-name>, “<article-title>The Water Channel Aquaporin 8 Is a Critical Regulator of Intestinal Fluid Homeostasis in Collagenous Colitis</article-title>,” <source>Journal of Crohn's and Colitis</source>
<volume>14</volume>, no. <issue>7</issue> (<year>2020</year>): <fpage>962</fpage>–<lpage>973</lpage>, <pub-id pub-id-type="doi">10.1093/ecco-jcc/jjaa020</pub-id>.<pub-id pub-id-type="pmcid">PMC7393183</pub-id><pub-id pub-id-type="pmid">32016376</pub-id></mixed-citation></ref></ref-list></back></article><article id="prp270197" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="pmc-domain-id">2563</journal-id><journal-id journal-id-type="pmc-domain">pharmrespersp</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &amp; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12664903</article-id><article-id pub-id-type="pmcid-ver">PMC12664903.1</article-id><article-id pub-id-type="pmcaid">12664903</article-id><article-id pub-id-type="pmcaiid">12664903</article-id><article-id pub-id-type="pmid">41318994</article-id><article-id pub-id-type="doi">10.1002/prp2.70197</article-id><article-id pub-id-type="publisher-id">PRP270197</article-id><article-id pub-id-type="other">PRP2-2025-04-0190</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects</article-title></title-group><contrib-group><contrib id="prp270197-cr-0001" contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="K">Kai</given-names></name><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270197-cr-0002" contrib-type="author"><name name-style="western"><surname>Yin</surname><given-names initials="S">Shaohong</given-names></name><xref rid="prp270197-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp270197-cr-0003" contrib-type="author"><name name-style="western"><surname>Huang</surname><given-names initials="W">Weiguo</given-names></name><xref rid="prp270197-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp270197-cr-0004" contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="L">Lairong</given-names></name><xref rid="prp270197-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp270197-cr-0005" contrib-type="author"><name name-style="western"><surname>Qin</surname><given-names initials="W">Wei</given-names></name><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270197-cr-0006" contrib-type="author"><name name-style="western"><surname>Qian</surname><given-names initials="Z">Zhenzhong</given-names></name><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270197-cr-0007" contrib-type="author"><name name-style="western"><surname>Ding</surname><given-names initials="Y">Ying</given-names></name><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270197-cr-0008" contrib-type="author"><name name-style="western"><surname>Que</surname><given-names initials="L">Linling</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3380-8105</contrib-id><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270197-cr-0009" contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="Y">Yunfei</given-names></name><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270197-cr-0010" contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="J">Jinxia</given-names></name><xref rid="prp270197-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="prp270197-cr-0011" contrib-type="author" corresp="yes"><name name-style="western"><surname>Zhao</surname><given-names initials="Y">Yi</given-names></name><xref rid="prp270197-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>xunt_1@yeah.net</email></address></contrib></contrib-group><aff id="prp270197-aff-0001">
<label>
<sup>1</sup>
</label>
<institution>Drug Clinical Trial Institution, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University</institution>
<city>Wuxi</city>
<country country="CN">China</country>
</aff><aff id="prp270197-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Lunan Better Pharmaceutical Co. LTD</institution>
<named-content content-type="country-part">Shandong</named-content>
<country country="CN">China</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Yi Zhao (<email>xunt_1@yeah.net</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>13</volume><issue seq="200">6</issue><issue-id pub-id-type="pmc-issue-id">499133</issue-id><issue-id pub-id-type="doi">10.1002/prp2.v13.6</issue-id><elocation-id>e70197</elocation-id><history><date date-type="rev-recd"><day>16</day><month>9</month><year>2025</year></date><date date-type="received"><day>23</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>10</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-12-01 14:25:13.187"><day>01</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">© 2025 The Author(s). <italic toggle="yes">Pharmacology Research &amp; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &amp; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="PRP2-13-e70197.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:PRP2-13-e70197.pdf"/><abstract><title>ABSTRACT</title><p>Budesonide is a first‐line inhaled glucocorticoid (ICS) for asthma treatment in adults and children. The purpose of this study was to compare the pharmacokinetics and assess the bioequivalence between two budesonide pressurized metered‐dose inhalers (pMDIs, 200 μg/actuation × 1 actuation) in healthy Chinese subjects. The study was conducted in 32 healthy Chinese subjects using a single‐center, randomized, open‐label, four‐period and crossover design with a 3‐day washout between periods. Blood samples were collected up to 16 h post‐dose. Plasma concentrations of budesonide were quantified using liquid chromatography–tandem mass spectrometry (LC–MS/MS). Reference‐scaled average bioequivalence (RSABE) or average bioequivalence (ABE) method was applied to evaluate the bioequivalence, on the basis of the within‐subject standard deviation (<italic toggle="no">S</italic>
<sub>WR</sub>) of the reference product (Budiair), and the safety was also assessed. Eventually, 31 subjects completed this study. For the maximum concentration (<italic toggle="no">C</italic>
<sub>max</sub>) (within‐subject standard deviation, <italic toggle="no">S</italic>
<sub>WR</sub> ≥ 0.294), the RSABE method showed a geometric mean ratio (GMR) of 97.13% with a 95% upper confidence bound of &lt; 0. For the area under plasma concentration‐time curve from time zero to the last measurable concentration (AUC<sub>0−t</sub>) and the area under plasma concentration‐time curve extrapolated to infinity (AUC<sub>0−∞</sub>) (<italic toggle="no">S</italic>
<sub>WR</sub> &lt; 0.294), ABE yielded GMRs of 104.81% and 104.61%, with 90% confidence intervals (CIs) of 99.98%–109.86% and 99.81%–109.63%, respectively. All adverse events (AEs) were mild to moderate and transient, with no serious adverse events (SAEs) reported. The two budesonide pMDIs (200 μg) were bioequivalent and well tolerated in healthy Chinese subjects.</p><p>
<bold>Trial Registration:</bold> Chinese Clinical Trial Registry, Registration No. CTR20244600; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://clinicaltrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06924190">NCT06924190</ext-link></p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="prp270197-kwd-0001">bioequivalence</kwd><kwd id="prp270197-kwd-0002">budesonide</kwd><kwd id="prp270197-kwd-0003">pharmacokinetics</kwd><kwd id="prp270197-kwd-0004">pressurized metered dose inhaler</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>
<institution-wrap><institution>Lunan Better Pharmaceutical Co., LTD</institution></institution-wrap>
</funding-source></award-group></funding-group><counts><fig-count count="3"/><table-count count="4"/><page-count count="8"/><word-count count="5400"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.6 mode:remove_FC converted:30.11.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="prp270197-cit-1001">
<string-name name-style="western">
<given-names>K.</given-names>
<surname>Huang</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Yin</surname>
</string-name>, <string-name name-style="western">
<given-names>W.</given-names>
<surname>Huang</surname>
</string-name>, et al., “<article-title>A Single Dose, Randomized, Open‐Label, Cross‐Over Bioequivalence Study of Budesonide Pressurized Metered‐Dose Inhaler in Healthy Chinese Subjects</article-title>,” <source>Pharmacology Research &amp; Perspectives</source>
<volume>13</volume>, no. <issue>6</issue> (<year>2025</year>): <elocation-id>e70197</elocation-id>, <pub-id pub-id-type="doi">10.1002/prp2.70197</pub-id>.<pub-id pub-id-type="pmid">41318994</pub-id></mixed-citation>
</p><fn-group id="prp270197-ntgp-0001"><fn fn-type="funding" id="prp270197-note-0001"><p>
<bold>Funding:</bold> This study was funded by Lunan Better Pharmaceutical Co. LTD.</p></fn><fn fn-type="equal" id="prp270197-note-0002"><p>Kai Huang and Shaohong Yin contributed equally to the study and should be regarded as co‐first authors.</p></fn></fn-group></notes></front><body id="prp270197-body-0001"><def-list list-content="abbreviations" id="prp270197-dl-0001"><title>Abbreviations</title><def-item><term id="prp270197-li-0001">ABE</term><def id="prp270197-li-0002"><p>average bioequivalence</p></def></def-item><def-item><term id="prp270197-li-0003">AE</term><def id="prp270197-li-0004"><p>adverse events</p></def></def-item><def-item><term id="prp270197-li-0005">AUC<sub>0−∞</sub>
</term><def id="prp270197-li-0006"><p>area under plasma concentration‐time curve extrapolated to infinity</p></def></def-item><def-item><term id="prp270197-li-0007">AUC<sub>0−T</sub>
</term><def id="prp270197-li-0008"><p>area under plasma concentration‐time curve from time zero to the last measurable concentration</p></def></def-item><def-item><term id="prp270197-li-0009">BES</term><def id="prp270197-li-0010"><p>bioequivalence set</p></def></def-item><def-item><term id="prp270197-li-0011">BMI</term><def id="prp270197-li-0012"><p>body mass index</p></def></def-item><def-item><term id="prp270197-li-0013">CI</term><def id="prp270197-li-0014"><p>confidence intervals</p></def></def-item><def-item><term id="prp270197-li-0015">
<italic toggle="yes">C</italic>
<sub>max</sub>
</term><def id="prp270197-li-0016"><p>maximum concentration</p></def></def-item><def-item><term id="prp270197-li-0017">CV</term><def id="prp270197-li-0018"><p>coefficient of variation</p></def></def-item><def-item><term id="prp270197-li-0019">CV<sub>W</sub>
</term><def id="prp270197-li-0020"><p>within‐subject coefficient of variation</p></def></def-item><def-item><term id="prp270197-li-0021">ECG</term><def id="prp270197-li-0022"><p>electrocardiograph</p></def></def-item><def-item><term id="prp270197-li-0023">FAS</term><def id="prp270197-li-0024"><p>full analysis set</p></def></def-item><def-item><term id="prp270197-li-0025">FDA</term><def id="prp270197-li-0026"><p>food and drug administration</p></def></def-item><def-item><term id="prp270197-li-0027">GMR</term><def id="prp270197-li-0028"><p>geometric mean ratio</p></def></def-item><def-item><term id="prp270197-li-0029">ICS</term><def id="prp270197-li-0030"><p>inhaled glucocorticoids</p></def></def-item><def-item><term id="prp270197-li-0031">IS</term><def id="prp270197-li-0032"><p>internal standard</p></def></def-item><def-item><term id="prp270197-li-0033">LC–MS/MS</term><def id="prp270197-li-0034"><p>liquid chromatography–tandem mass spectrometry</p></def></def-item><def-item><term id="prp270197-li-0035">Meddra</term><def id="prp270197-li-0036"><p>medical dictionary for regulatory activities</p></def></def-item><def-item><term id="prp270197-li-0037">MRM</term><def id="prp270197-li-0038"><p>multiple‐reaction‐monitoring</p></def></def-item><def-item><term id="prp270197-li-0039">NCI‐CTCAE</term><def id="prp270197-li-0040"><p>National Cancer Institute‐Common Terminology Criteria for Adverse Events</p></def></def-item><def-item><term id="prp270197-li-0041">NMPA</term><def id="prp270197-li-0042"><p>National Medical Products Administration</p></def></def-item><def-item><term id="prp270197-li-0043">Oips</term><def id="prp270197-li-0044"><p>orally inhaled products</p></def></def-item><def-item><term id="prp270197-li-0045">PK</term><def id="prp270197-li-0046"><p>pharmacokinetics</p></def></def-item><def-item><term id="prp270197-li-0047">PKCS</term><def id="prp270197-li-0048"><p>pharmacokinetics concentration set</p></def></def-item><def-item><term id="prp270197-li-0049">PKPS</term><def id="prp270197-li-0050"><p>pharmacokinetics parameter set</p></def></def-item><def-item><term id="prp270197-li-0051">Pmdi</term><def id="prp270197-li-0052"><p>pressurized metered‐dose inhalers</p></def></def-item><def-item><term id="prp270197-li-0053">RSABE</term><def id="prp270197-li-0054"><p>reference‐scaled average bioequivalence</p></def></def-item><def-item><term id="prp270197-li-0055">SAE</term><def id="prp270197-li-0056"><p>serious adverse events</p></def></def-item><def-item><term id="prp270197-li-0057">SS</term><def id="prp270197-li-0058"><p>safety analysis set</p></def></def-item><def-item><term id="prp270197-li-0059">
<italic toggle="yes">S</italic>
<sub>WR</sub>
</term><def id="prp270197-li-0060"><p>within‐subject standard deviation</p></def></def-item><def-item><term id="prp270197-li-0061">
<italic toggle="yes">T</italic>
<sub>1/2</sub>
</term><def id="prp270197-li-0062"><p>terminal elimination half‐life</p></def></def-item></def-list><sec id="prp270197-sec-0001"><label>1</label><title>Introduction</title><p>Asthma, a common chronic respiratory disease, is recognized as a major global public health problem [<xref rid="prp270197-bib-0001" ref-type="bibr">1</xref>]. Currently, over 300 million people are affected worldwide, with a continuously rising prevalence [<xref rid="prp270197-bib-0002" ref-type="bibr">2</xref>]. Asthma is characterized by chronic airway inflammation and hyperresponsiveness, manifesting as wheeze, cough, chest tightness, and/or dyspnea [<xref rid="prp270197-bib-0003" ref-type="bibr">3</xref>, <xref rid="prp270197-bib-0004" ref-type="bibr">4</xref>]. It imposes significant burdens on both individual health and the socioeconomic system [<xref rid="prp270197-bib-0005" ref-type="bibr">5</xref>]. Therefore, how to effectively treat and manage asthma has become an important goal for the prevention of asthma in recent years.</p><p>Inhaled glucocorticoids (ICSs) are the first‐line treatment for asthma because of their potent anti‐inflammatory effects and favorable safety profiles [<xref rid="prp270197-bib-0006" ref-type="bibr">6</xref>]. Budesonide, one of the most widely prescribed ICSs, is used in both adults and pediatric patients owing to its potent anti‐inflammatory activity, high airway selectivity, low systemic bioavailability, and minimal side side effects [<xref rid="prp270197-bib-0007" ref-type="bibr">7</xref>, <xref rid="prp270197-bib-0008" ref-type="bibr">8</xref>]. Following inhalation, budesonide is rapidly absorbed into the lungs because of its moderate lipophilicity, approximately 15% deposits in the airways from a pressurized metered dose inhaler (pMDI), only 10% of ingested budesonide reaches the systemic circulation, with excretion via the urine and feces [<xref rid="prp270197-bib-0009" ref-type="bibr">9</xref>, <xref rid="prp270197-bib-0010" ref-type="bibr">10</xref>]. Additionally, budesonide is extensively metabolized by cytochrome P450 (CYP) isoenzyme 3A4 into two inactive metabolites, 16α‐hydroxyprednisolone and 6β‐hydroxybudesonide, which exhibit low glucocorticoid receptor affinity [<xref rid="prp270197-bib-0011" ref-type="bibr">11</xref>]. CYP3A4 inhibitors may potentially impact the metabolism of budesonide [<xref rid="prp270197-bib-0012" ref-type="bibr">12</xref>].</p><p>Budesonide pMDI (Budiair) is manufactured by Chiesi S.A.S (Colombes, France). A new generic budesonide pMDI has been developed by Lunan Better Pharmaceutical Co. LTD (Shandong, China). To comply with China's National Medical Products Administration (NMPA) regulations for generic inhaled products approval, the bioequivalence study was required [<xref rid="prp270197-bib-0013" ref-type="bibr">13</xref>]. Despite variations in international bioequivalence guidelines, pharmacokinetics (PK) studies remain the gold standard for demonstrating the bioequivalence between test and reference products in vivo [<xref rid="prp270197-bib-0014" ref-type="bibr">14</xref>]. The study aimed to evaluate the bioequivalence and safety of a generic budesonide pMDI compared with the marketed budesonide pMDI (Budiair) in healthy Chinese subjects under fasting conditions.</p></sec><sec sec-type="methods" id="prp270197-sec-0002"><label>2</label><title>Methods</title><p>This study was conducted at the phase I center of Wuxi People's Hospital between December 2024 and January 2025 in compliance with the International Council for Harmonisation Good Clinical Practice, the principle of the Declaration of Helsinki and the applicable local regulatory requirements. The study protocol and informed consent form were approved by the Independent Ethics Committee of Wuxi People's Hospital (Ethics Approval No: 2024LLPJ‐I‐123).</p><sec id="prp270197-sec-0003"><label>2.1</label><title>Subjects</title><p>Healthy Chinese males and females aged 18–60 years with a body mass index (BMI) of 19.0–26.0 kg/m<sup>2</sup> were eligible for inclusion. Subjects were determined to be healthy on the basis of vital signs, physical examination, medical history, laboratory tests (including blood chemistry, hematology, and urinalysis), virological examinations (human immunodeficiency virus antibody, hepatitis B antigen, hepatitis C antibody, and <styled-content style="fixed-case" toggle="no">
<italic toggle="no">treponema pallidum</italic>
</styled-content> antibody), chest X‐ray, electrocardiograph (ECG), pulmonary function test, urine nicotine test, alcohol breath analysis, and urine drug screening test within 2 weeks prior to the study. Subjects were excluded if they were allergic to any biologic agents, took any medicine within 30 days prior to the study or attempted to become pregnant or breastfeed. More importantly, subjects should be able to use the metered‐dose inhaler correctly.</p><p>Eligible subjects were admitted to the Phase I Clinical Trial Center. They were required to fast for at least 10 h before dosing and maintain a light diet during the study. Consumption of any food or beverages containing methylxanthines (e.g., coffee, tea, cola, and cocoa), alcohol, or grapefruit, as well as the use of any other forbidden medications, was strictly forbidden.</p><p>All subjects were informed about the objectives, procedures, and potential risks of the study before signing the written informed consent. Subjects retained the right to withdraw from the study at any time without providing justification or incurring penalties.</p></sec><sec id="prp270197-sec-0004"><label>2.2</label><title>Clinical Study Design</title><p>This was a single‐center, randomized, open‐label, four‐period, crossover study. 32 healthy Chinese subjects were randomly assigned to the TRTR group (<italic toggle="yes">n</italic> = 16) and RTRT group (<italic toggle="yes">n</italic> = 16) in a 1:1 ratio according to the random table before dosing.</p><p>Subjects received the test product (Budesonide pMDI, 200 μg per actuation × 1 actuation, lot no. 558240501; Lunan Better Pharmaceutical Co. LTD., Shandong, China) or reference product (Budiair, 200 μg per actuation × 1 puff, lot no. 1186054; Chiesi S.A.S, Colombes, France) under fasting conditions in each period (Figure <xref rid="prp270197-fig-0001" ref-type="fig">1</xref>), with a 3‐day washout between periods.</p><fig position="float" fig-type="FIGURE" id="prp270197-fig-0001" orientation="portrait"><label>FIGURE 1</label><caption><p>Study design.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-1" orientation="portrait" xlink:href="PRP2-13-e70197-g002.jpg"/></fig><p>For standardized administration, subjects inhaled slowly through their mouths while actuating the budesonide pMDI, immediately held their breath for 10 s, and then exhaled slowly. They were instructed to rinse their mouths thoroughly with water post‐administration. All subjects remained fasting for 4 h post‐dose. With water restriction 1 h before and after dosing.</p><p>The pharmacokinetic (PK) samples (5.0 mL) were collected in K<sub>2−</sub>EDTA vacuum tubes at 0 (pre‐dose) and 0.03, 0.07, 0.10, 0.13, 0.17, 0.20, 0.25, 0.33, 0.42, 0.50, 0.75, 1, 2, 4, 6, 8, 10, 12, and 16 h after administration. Samples were centrifuged at 1700× <italic toggle="yes">g</italic> for 10 min at 4°C and then divided into two portions (test and backup) and stored at ≤ −60°C until analysis.</p><p>The plasma budesonide concentrations were quantified by a validated liquid chromatography–tandem mass spectrometry (LC–MS/MS) method [<xref rid="prp270197-bib-0011" ref-type="bibr">11</xref>]. Budesonide (purity: 98.27%) and budesonide‐d8 (internal standard, IS; purity: 98.70%) were purchased from CATO Research Chemical Inc. (Guangdong, China) and TLC Pharmaceutical Standards Ltd. (Ontario, Canada), respectively. Budesonide was extracted from the plasma sample using liquid–liquid extraction with methyl tertiary butyl ether, and a 20.0 μL extracted sample was injected into the LC–MS/MS with gradient elution. Budesonide and budesonide‐d8 were detected by the AB SCIEX Triple Quad 7500 system in multiple‐reaction‐monitoring (MRM) with negative‐ion electrospray ionization. The mass transition ion pairs were m/z 489.2 → 357.2 for budesonide and m/z 497.2 → 357.2 for budesonide‐d8 (IS). The calibration curve of budesonide was validated over the concentration range of 4.0–3000 pg/mL with the lower limit of quantification of 4.0 pg/mL. The inter‐ and intra‐batch precisions were less than 10% and the accuracies were all within ±15%. Budesonide in the extracted plasma samples was stable for 285 h at 2°C–8°C and 25 h at 20°C–30°C, and budesonide in plasma was stable for 57 days at −80°C.</p></sec><sec id="prp270197-sec-0005"><label>2.3</label><title>Safety Assessment</title><p>Safety was assessed by clinical observation and spontaneous reporting of adverse events (AEs). Clinical laboratory tests (blood chemistry, hematology, and urinalysis), ECG, physical examination, and vital signs were also performed at the end of the study. The seriousness and severity of AEs and the relationship to the investigational products were recorded and reported faithfully. All AEs were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) (version 27.1), with the seriousness and severity recorded according to the National Cancer Institute–Common Terminology Criteria for Adverse Events (NCI‐CTCAE) (version 5.0).</p></sec><sec id="prp270197-sec-0006"><label>2.4</label><title>Statistical Analysis</title><p>The calculation of sample size for a bioequivalence study is mainly based on the power value, the intra‐individual coefficient of variation (CV%), and the test/reference ratio [<xref rid="prp270197-bib-0015" ref-type="bibr">15</xref>]. The intra‐subject CV% for the maximum concentration (<italic toggle="yes">C</italic>
<sub>max</sub>) of budesonide was assumed to be 30% according to the previous literature [<xref rid="prp270197-bib-0016" ref-type="bibr">16</xref>]. The geometric mean ratio (GMR) of the test/reference for <italic toggle="yes">C</italic>
<sub>max</sub> was set at 95% to achieve 90% power (1‐β) at the significance level (two‐sided <italic toggle="yes">α</italic> = 5%). The initial sample size was 26, calculated by PASS software (version 22). Considering the 20% drop‐out rate, the final sample size was determined to be 32.</p><p>PK analysis was performed by the non‐compartmental method with WinNonlin software (version 8.3). The main PK parameters included <italic toggle="yes">C</italic>
<sub>max</sub>, the time to maximum concentration (<italic toggle="yes">T</italic>
<sub>max</sub>), the area under the plasma concentration‐time curve from time zero to the last measurable concentration (AUC<sub>0−<italic toggle="yes">t</italic>
</sub>), the area under the plasma concentration‐time curve extrapolated to infinity (AUC<sub>0−<italic toggle="yes">∞</italic>
</sub>), and the terminal elimination half‐life (<italic toggle="yes">t</italic>
<sub>1/2</sub>).</p><p>The reference‐scaled average bioequivalence (RSABE) and average bioequivalence (ABE) methods were used for bioequivalence evaluation, with the within‐subject standard deviation (<italic toggle="yes">S</italic>
<sub>WR</sub>) of the reference product calculated first. The RSABE method was applied if <italic toggle="yes">S</italic>
<sub>WR</sub> ≥ 0.294 (the within‐subject coefficient of variation, CV<sub>W</sub>% ≥ 30%) for any primary PK parameters (<italic toggle="yes">C</italic>
<sub>max</sub>, AUC<sub>0−<italic toggle="yes">t</italic>
</sub> or AUC<sub>0−∞</sub>). Bioequivalence was concluded when the geometric mean ratios (GMRs) for <italic toggle="yes">C</italic>
<sub>max</sub>, AUC<sub>0−<italic toggle="yes">t</italic>
</sub>, and AUC<sub>0−<italic toggle="yes">∞</italic>
</sub> fell within 80%–125%, and the 95% upper confidence bound for (<italic toggle="yes">Y</italic>
<sub>T</sub> − <italic toggle="yes">Y</italic>
<sub>R</sub>)<sup>2</sup>—<italic toggle="yes">θ</italic> × (<italic toggle="yes">S</italic>
<sub>WR</sub>)<sup>2</sup> was ≤ 0. <italic toggle="yes">Y</italic>
<sub>R</sub> and <italic toggle="yes">Y</italic>
<sub>T</sub> are the mean values of the natural log‐transformed AUC or <italic toggle="yes">C</italic>
<sub>max</sub> for test and reference products, respectively. <italic toggle="yes">θ</italic> = (ln (1.25)<sup>2</sup>/<italic toggle="yes">σ</italic>
<sub>W0</sub>)<sup>2</sup> is the bioequivalence limit, and <italic toggle="yes">σ</italic>
<sub>W0</sub> = 0.25 is the regulatory constant specified in guidance. The ABE method was used if <italic toggle="yes">S</italic>
<sub>WR</sub> &lt; 0.294 (CV<sub>W</sub>% &lt; 30%). Bioequivalence was concluded when the 90% confidence intervals (CIs) for the GMR of <italic toggle="yes">C</italic>
<sub>max</sub>, AUC<sub>0−<italic toggle="yes">t</italic>
</sub>, and AUC<sub>0−∞</sub> were all within 80%–125% [<xref rid="prp270197-bib-0017" ref-type="bibr">17</xref>].</p><p>The normality of PK parameters was assessed using the Shapiro–Wilk test. Data were analyzed using the paired <italic toggle="yes">t</italic>‐test for normally distributed parameters and the Wilcoxon signed‐rank test for non‐normally distributed parameters. All statistical analyses were performed using SAS software (version 9.4). <italic toggle="yes">p</italic> &lt; 0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="prp270197-sec-0007"><label>3</label><title>Results</title><sec id="prp270197-sec-0008"><label>3.1</label><title>Demographic Data of Subjects</title><p>A total of 121 subjects were screened, of which 32 subjects (28 males and four females) met the inclusion criteria and were enrolled. Ultimately, 31 subjects completed this study, whereas one subject discontinued after the first treatment period because of an AE (fever) (Figure <xref rid="prp270197-fig-0002" ref-type="fig">2</xref>). The mean age of subjects was 29.53 years (range: 18–39 years), mean body weight was 65.77 kg (range: 54.1–81.5 kg), mean height was 169.74 cm (range: 151.1–181.6 cm), and the mean BMI was 22.80 kg/m<sup>2</sup> (range: 19.8–25.9 kg/m<sup>2</sup>) (Table <xref rid="prp270197-tbl-0001" ref-type="table">1</xref>).</p><fig position="float" fig-type="FIGURE" id="prp270197-fig-0002" orientation="portrait"><label>FIGURE 2</label><caption><p>Study flow diagram.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-3" orientation="portrait" xlink:href="PRP2-13-e70197-g001.jpg"/></fig><table-wrap position="float" id="prp270197-tbl-0001" content-type="TABLE" orientation="portrait"><label>TABLE 1</label><caption><p>The demographic data of enrolled subjects.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Age (y)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Weight (kg)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Height (cm)</th><th align="center" valign="bottom" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Mean ± SD</td><td align="center" valign="top" rowspan="1" colspan="1">29.5 ± 5.7</td><td align="center" valign="top" rowspan="1" colspan="1">65.8 ± 7.0</td><td align="center" valign="top" rowspan="1" colspan="1">169.7 ± 7.4</td><td align="center" valign="top" rowspan="1" colspan="1">22.8 ± 1.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Median</td><td align="center" valign="top" rowspan="1" colspan="1">31.0</td><td align="center" valign="top" rowspan="1" colspan="1">65.8</td><td align="center" valign="top" rowspan="1" colspan="1">170.4</td><td align="center" valign="top" rowspan="1" colspan="1">22.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Minimum</td><td align="center" valign="top" rowspan="1" colspan="1">18.0</td><td align="center" valign="top" rowspan="1" colspan="1">54.1</td><td align="center" valign="top" rowspan="1" colspan="1">151.1</td><td align="center" valign="top" rowspan="1" colspan="1">19.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Maximum</td><td align="center" valign="top" rowspan="1" colspan="1">39.0</td><td align="center" valign="top" rowspan="1" colspan="1">81.5</td><td align="center" valign="top" rowspan="1" colspan="1">181.6</td><td align="center" valign="top" rowspan="1" colspan="1">25.9</td></tr></tbody></table><table-wrap-foot id="prp270197-ntgp-0002"><fn id="prp270197-note-0003"><p>Abbreviations: BMI, body mass index; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><p>All subjects were included in the full analysis set (FAS), safety analysis set (SS), pharmacokinetics concentration set (PKCS), pharmacokinetics parameter set (PKPS), and bioequivalence set (BES).</p></sec><sec id="prp270197-sec-0009"><label>3.2</label><title>Pharmacokinetic Analyses</title><p>PK parameters of the test product (budesonide pMDI) and the reference product (Budiair) are summarized in Table <xref rid="prp270197-tbl-0002" ref-type="table">2</xref>. <italic toggle="yes">C</italic>
<sub>max</sub> was 1782.11 ± 1266.01 and 1688.02 ± 960.69 pg/mL, AUC<sub>0–t</sub> was 1286.63 ± 427.53 and 1219.33 ± 376.96 h pg/mL, AUC<sub>0–∞</sub> was 1324.51 ± 437.15 and 1259.22 ± 395.27 h pg/mL, and <italic toggle="yes">t</italic>
<sub>1/2</sub> was 3.13 ± 0.59 and 3.26 ± 0.69 h. No significant differences were observed in any of the above measured PK parameters (<italic toggle="yes">p</italic> &gt; 0.05). The mean plasma concentration‐time curves of budesonide were similar and overlapping after inhalation of 200 μg of budesonide pMDI or Budiair in healthy Chinese subjects (Figure <xref rid="prp270197-fig-0003" ref-type="fig">3</xref>).</p><table-wrap position="float" id="prp270197-tbl-0002" content-type="TABLE" orientation="portrait"><label>TABLE 2</label><caption><p>The primary pharmacokinetic parameters after inhalation of 200 μg of Budesonide pMDI in healthy Chinese subjects.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="center" valign="bottom" rowspan="1" colspan="1">Test (<italic toggle="yes">n</italic> = 31)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reference (<italic toggle="yes">n</italic> = 32)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">P</italic> values</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">C</italic>
<sub>max</sub> (pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">1782.11 ± 1266.01</td><td align="center" valign="top" rowspan="1" colspan="1">1688.02 ± 960.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.5271</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–t</sub> (h pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">1286.63 ± 427.53</td><td align="center" valign="top" rowspan="1" colspan="1">1219.33 ± 376.96</td><td align="center" valign="top" rowspan="1" colspan="1">0.1171</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–∞</sub> (h pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">1324.51 ± 437.15</td><td align="center" valign="top" rowspan="1" colspan="1">1259.22 ± 395.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.1392</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">T</italic>
<sub>max</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (0.03, 2.00)</td><td align="center" valign="top" rowspan="1" colspan="1">0.03 (0.03, 0.13)</td><td align="center" valign="top" rowspan="1" colspan="1">0.1198</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub> (h)</td><td align="center" valign="top" rowspan="1" colspan="1">3.13 ± 0.59</td><td align="center" valign="top" rowspan="1" colspan="1">3.26 ± 0.69</td><td align="center" valign="top" rowspan="1" colspan="1">0.0919</td></tr></tbody></table><table-wrap-foot id="prp270197-ntgp-0003"><fn id="prp270197-note-0004"><p>
<italic toggle="yes">Note:</italic> No statistically significant differences were found between the above parameters (<italic toggle="yes">p</italic> &gt; 0.05). <italic toggle="yes">T</italic>
<sub>max</sub> represented with Median (Minimum, Maximum) and others represented with mean ± standard deviation.</p></fn><fn id="prp270197-note-0005"><p>Abbreviations: AUC<sub>0–∞</sub>, the area under plasma concentration–time curve extrapolated to infinity (AUC<sub>0–∞</sub>); AUC<sub>0–t</sub>, the area under plasma concentration–time curve from time zero to the last measurable concentration; <italic toggle="yes">C</italic>
<sub>max</sub>, the maximum concentration; <italic toggle="yes">t</italic>
<sub>1/2</sub>, the terminal elimination half‐life; <italic toggle="yes">T</italic>
<sub>max</sub>, the time to maximum concentration.</p></fn></table-wrap-foot></table-wrap><fig position="float" fig-type="FIGURE" id="prp270197-fig-0003" orientation="portrait"><label>FIGURE 3</label><caption><p>Mean plasma concentration‐time curves (A) and semilogarithmic curves (B) of the test and reference products of budesonide pMDI in Chinese healthy subjects (mean ± standard deviation [SD]). <italic toggle="yes">N</italic> = 62 for the test product and <italic toggle="yes">N</italic> = 63 for the reference product; 31 subjects successfully completed the study, whereas only 1 subject completed the first period and withdrew from the study.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" id="jats-graphic-5" orientation="portrait" xlink:href="PRP2-13-e70197-g003.jpg"/></fig><p>As shown in Table <xref rid="prp270197-tbl-0003" ref-type="table">3</xref>, the <italic toggle="yes">C</italic>
<sub>max</sub> of Budiair had a <italic toggle="yes">S</italic>
<sub>WR</sub> of 0.4229, which meant CV<sub>W</sub>% of 44.26% was greater than 30%. Therefore, the RSABE method was used to evaluate the bioequivalence of <italic toggle="yes">C</italic>
<sub>max</sub>, and the 95% upper confidence bound was −0.0922. The GMR for <italic toggle="yes">C</italic>
<sub>max</sub> between the test and reference products was 97.13%, which fell within 80.00%–125.00%. For AUC<sub>0−<italic toggle="yes">t</italic>
</sub> and AUC<sub>0−∞</sub> of Budiair, the <italic toggle="yes">S</italic>
<sub>WR</sub> was less than 0.294, which meant CV<sub>W</sub>% was less than 30%; the ABE method was used. The GMRs and their 90% CIs for AUC<sub>0−<italic toggle="yes">t</italic>
</sub> and AUC<sub>0−∞</sub> were 104.81% (99.98%–109.86%) and 104.61% (99.81%–109.63%), respectively, both falling within the range of 80.00%–125.00%.</p><table-wrap position="float" id="prp270197-tbl-0003" content-type="TABLE" orientation="portrait"><label>TABLE 3</label><caption><p>Bioequivalence Evaluation of test and reference products of budesonide pMDI in healthy Chinese subjects.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Parameter</th><th align="center" valign="bottom" rowspan="1" colspan="1">GMR (T/R)</th><th align="center" valign="bottom" rowspan="1" colspan="1">90% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">Power</th><th align="center" valign="bottom" rowspan="1" colspan="1">Intra‐subject CV</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">S</italic>
<sub>WR</sub>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Upper 95% CI</th><th align="center" valign="bottom" rowspan="1" colspan="1">Evaluation method</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Cmax (pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">97.13%</td><td align="center" valign="top" rowspan="1" colspan="1">84.71%–111.36%</td><td align="center" valign="top" rowspan="1" colspan="1">99.54%</td><td align="center" valign="top" rowspan="1" colspan="1">44.26%</td><td align="center" valign="top" rowspan="1" colspan="1">0.4229</td><td align="center" valign="top" rowspan="1" colspan="1">−0.0922</td><td align="center" valign="top" rowspan="1" colspan="1">RSABE</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–<italic toggle="yes">t</italic>
</sub> (h pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">104.81%</td><td align="center" valign="top" rowspan="1" colspan="1">99.98%–109.86%</td><td align="center" valign="top" rowspan="1" colspan="1">&gt; 99.99%</td><td align="center" valign="top" rowspan="1" colspan="1">16.72%</td><td align="center" valign="top" rowspan="1" colspan="1">0.1661</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">ABE</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AUC<sub>0–∞</sub> (h pg/mL)</td><td align="center" valign="top" rowspan="1" colspan="1">104.61%</td><td align="center" valign="top" rowspan="1" colspan="1">99.81%–109.63%</td><td align="center" valign="top" rowspan="1" colspan="1">&gt; 99.99%</td><td align="center" valign="top" rowspan="1" colspan="1">16.74%</td><td align="center" valign="top" rowspan="1" colspan="1">0.1663</td><td align="center" valign="top" rowspan="1" colspan="1">—</td><td align="center" valign="top" rowspan="1" colspan="1">ABE</td></tr></tbody></table><table-wrap-foot id="prp270197-ntgp-0004"><fn id="prp270197-note-0006"><p>Abbreviations: AUC<sub>0–∞</sub>, the area under plasma concentration‐time curve extrapolated to infinity; AUC<sub>0–t</sub>, the area under plasma concentration‐time curve from time zero to the last measurable concentration; CI, confidence interval; <italic toggle="yes">C</italic>
<sub>max</sub>, the maximum concentration; CV, the intra‐individual coefficient of variation; GMR, the geometric mean ratio; R, reference; <italic toggle="yes">S</italic>
<sub>WR</sub>, the within‐subject standard deviation; T, test; <italic toggle="yes">t</italic>
<sub>1/2</sub>, the terminal elimination half‐life; <italic toggle="yes">T</italic>
<sub>max</sub>, the time to maximum concentration.</p></fn></table-wrap-foot></table-wrap></sec><sec id="prp270197-sec-0010"><label>3.3</label><title>Safety Analysis</title><p>In our study, four subjects (12.5%) experienced five AEs. Table <xref rid="prp270197-tbl-0004" ref-type="table">4</xref> details the AEs reported in healthy Chinese subjects following inhalation of either the test or reference product. Both products demonstrated acceptable tolerability profiles in 32 enrolled healthy Chinese subjects who were all included in SS.</p><table-wrap position="float" id="prp270197-tbl-0004" content-type="TABLE" orientation="portrait"><label>TABLE 4</label><caption><p>Summary of adverse events reported in healthy Chinese subjects inhaling 200 μg of budesonide pMDI.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">AEs</th><th align="center" valign="bottom" rowspan="1" colspan="1">Test (<italic toggle="yes">n</italic> = 31)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Reference (<italic toggle="yes">n</italic> = 32)</th><th align="center" rowspan="2" valign="bottom" colspan="1">Severity</th><th align="center" rowspan="2" valign="bottom" colspan="1">Overall (<italic toggle="yes">n</italic> = 32)</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Blood glucose decreased</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">Mild</td><td align="center" valign="top" rowspan="1" colspan="1">2 (6.3)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Aspartate aminotransferase increased</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">Mild</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" style="padding-left:10%" valign="top" rowspan="1" colspan="1">Alanine aminotransferase increased</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">Mild</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fever</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">Moderate</td><td align="center" valign="top" rowspan="1" colspan="1">1 (3.1)</td></tr></tbody></table><table-wrap-foot id="prp270197-ntgp-0005"><fn id="prp270197-note-0007"><p>Abbreviations: AEs, adverse events; <italic toggle="yes">N</italic> (%), number (%) of subjects reporting adverse events.</p></fn></table-wrap-foot></table-wrap><p>Three AEs occurred in two subjects (6.5%) after inhalation of the test product during the end‐of‐study safety examinations, including blood glucose decrease (<italic toggle="yes">n</italic> = 1, 3.2%), AST increase (<italic toggle="yes">n</italic> = 1, 3.2%), and ALT increase (<italic toggle="yes">n</italic> = 1, 3.2%). The AST and ALT elevations were assessed as possibly drug‐related, whereas blood glucose decrease was considered unlikely related. All AEs were mild and resolved spontaneously within 1 week.</p><p>During the end‐of‐study safety examinations, one subject experienced one AE, blood glucose decreased (<italic toggle="yes">n</italic> = 1, 3.1%), following inhalation of the reference product. It was deemed unlikely to be drug‐related and mild in severity, and resolved spontaneously within 2 days. Fever (<italic toggle="yes">n</italic> = 1, 3.1%) occurred in one subject at the first treatment period following inhalation of the reference product, which was deemed unrelated to the drug and moderate; the subject recovered within 1 week after receiving a single 0.2 mg ibuprofen tablet.</p><p>No serious adverse events (SAEs) and deaths occurred during the study. Compared with baseline no clinically significant changes were found in vital signs, physical examinations, ECG results or laboratory findings. All AEs were reported to the Ethics Committee of Wuxi People's Hospital.</p></sec></sec><sec id="prp270197-sec-0011"><label>4</label><title>Dicussion</title><p>The bioequivalence of budesonide pMDI and Budiair was first reported in healthy Chinese subjects in our study. Both the test/reference GMR for <italic toggle="yes">C</italic>
<sub>max</sub> and 90% CIs of GMRs for AUC<sub>0−<italic toggle="yes">t</italic>
</sub> and AUC<sub>0–∞</sub> were all within 80.00%–125.00%, confirming that the bioequivalence of the two products; additionally, both products also exhibited a favorable safety profile. Although this bioequivalence study was used to evaluate PK characteristics and systemic safety of budesonide in accordance with NMPA guidance [<xref rid="prp270197-bib-0013" ref-type="bibr">13</xref>], several key factors should also be considered in the design.</p><p>First of all, the crossover design is the most robust and valid method for comparing the PK profiles of test and reference products. It eliminates the inter‐subject variability in the comparison of average bioavailability and reduces the required sample size [<xref rid="prp270197-bib-0018" ref-type="bibr">18</xref>].</p><p>The reported within‐subject CVs for <italic toggle="yes">C</italic>
<sub>max</sub> of budesonide ranged from 50.0% to 92.2% [<xref rid="prp270197-bib-0012" ref-type="bibr">12</xref>]. High CV values reflect not only the drug's inherent variability but also variability arising from inhalation technique. On the basis of these CV values, the required sample size for a fully replicated crossover design would be approximately 68–184 subjects. Such huge sample sizes are not feasible in healthy volunteer studies because of ethical constraints and operational limitations. To minimize operational variability in drug administration, our study was conducted at an experienced inhaled‐product research center, and a CV of 30% has been proven to be adequate for powering the bioequivalence assessment [<xref rid="prp270197-bib-0019" ref-type="bibr">19</xref>]. Post hoc analysis using the observed parameters (CV = 44.26% and GMR = 0.97) with 80% power yielded a sample size of 38 subjects, closely matching the planned enrollment. The sample size of 32 subjects is statistically adequate and does not affect the bioequivalence conclusion.</p><p>Therefore, the four‐period crossover study conducted with 32 healthy subjects was methodologically appropriate, achieving optimal statistical power while minimizing the required sample size. In addition, in view of the short terminal elimination half‐life of budesonide [<xref rid="prp270197-bib-0010" ref-type="bibr">10</xref>], a 3‐day washout period was sufficient to eliminate the potential carryover effect.</p><p>In addition, healthy subjects are the most sensitive and suitable population for the bioequivalence study. Long‐term smoking impairs lung function, leading to airways and alveoli tissue damage, so smokers exhibit a higher risk of respiratory [<xref rid="prp270197-bib-0020" ref-type="bibr">20</xref>, <xref rid="prp270197-bib-0021" ref-type="bibr">21</xref>]. Asthma patients often present with various complications and concomitant medications [<xref rid="prp270197-bib-0022" ref-type="bibr">22</xref>, <xref rid="prp270197-bib-0023" ref-type="bibr">23</xref>], which may alter the PK profiles of budesonide. Conversely, healthy adults exhibit normal lung function and enhanced peripheral lung deposition, thereby increasing the sensitivity for detecting potential differences between test and reference products if present [<xref rid="prp270197-bib-0024" ref-type="bibr">24</xref>]. For this reason, the healthy, non‐smoking subjects were exclusively enrolled in our study.</p><p>What is more, the selection of the inhaled dose is crucial to the PK profiles of budesonide. Both FDA and NMPA guidelines for orally inhaled products (OIPs) emphasized that the minimum number of inhalations should be used to characterize the PK profiles [<xref rid="prp270197-bib-0013" ref-type="bibr">13</xref>, <xref rid="prp270197-bib-0014" ref-type="bibr">14</xref>], 200 μg (200 μg/actuation × 1 actuation) is the recommended minimum single dose of Budiair. However, the extremely low plasma concentration of budesonide poses a significant challenge because of the poor systemic absorption. Thus, developing a sensitive analytical method is essential to accurately determine the PK profiles of budesonide. In order to minimize drug exposure in healthy subjects and accurately assess the PK differences between two products, a 200 μg dose of budesonide pMDI combined with the sensitive LC–MS/MS method was therefore adopted. This approach ensured that the PK profiles of budesonide in vivo could be accurately exhibited and distinguished at such a low dose. To our knowledge, this is the first study to reveal the PK profiles of 200 μg inhaled budesonide pMDI in healthy Chinese subjects, providing valuable insights for future research and regulatory evaluations.</p><p>Finally, proper use of the inhalation device is critical for subjects. Clinical studies have shown that over 77% of patients have experience in misusing inhaler devices, highlighting the importance of training and correct inhalation technique to ensure optimal therapeutic outcomes [<xref rid="prp270197-bib-0025" ref-type="bibr">25</xref>]. In our study, all subjects received standardized training before and after enrollment to achieve appropriate, consistent inspiratory flow rates and durations, which was also the requirement of the guidance [<xref rid="prp270197-bib-0013" ref-type="bibr">13</xref>, <xref rid="prp270197-bib-0026" ref-type="bibr">26</xref>]. It should be noted that rigorous and individualized inhaler technique training is essential in all patient‐based clinical trials and is also the critical step to reduce operational deviations in pulmonary drug delivery. Only if patients correctly operate the inhalation device and strictly adhere to the prescribed regimen during long‐term therapy can the interindividual variability in pharmacodynamics be significantly reduced.</p><p>Notably, though the <italic toggle="yes">t</italic>
<sub>1/2</sub> of budesonide pMDI in our study was consistent with previously reported values, the median <italic toggle="yes">T</italic>
<sub>max</sub> was markedly shorter than before (0.03 h vs. 0.17–0.67 h) [<xref rid="prp270197-bib-0010" ref-type="bibr">10</xref>, <xref rid="prp270197-bib-0012" ref-type="bibr">12</xref>, <xref rid="prp270197-bib-0027" ref-type="bibr">27</xref>, <xref rid="prp270197-bib-0028" ref-type="bibr">28</xref>]. Several factors may account for this discrepancy. First, the previous study used higher inhalation dosages [<xref rid="prp270197-bib-0010" ref-type="bibr">10</xref>, <xref rid="prp270197-bib-0012" ref-type="bibr">12</xref>, <xref rid="prp270197-bib-0027" ref-type="bibr">27</xref>, <xref rid="prp270197-bib-0028" ref-type="bibr">28</xref>], which inherently required longer administration time; thereby the <italic toggle="yes">T</italic>
<sub>max</sub> was potentially prolonged. Second, the initial blood sampling timepoint (0.03 h post‐dose) was not designed in some PK studies because of the difficulty in sampling [<xref rid="prp270197-bib-0028" ref-type="bibr">28</xref>, <xref rid="prp270197-bib-0029" ref-type="bibr">29</xref>]. Third, some PK data were derived from patient populations rather than healthy subjects [<xref rid="prp270197-bib-0027" ref-type="bibr">27</xref>, <xref rid="prp270197-bib-0030" ref-type="bibr">30</xref>]. Additionally, variations in aerosol particle properties (size, distribution, morphology, etc.) were also determinants of pulmonary deposition and absorption rate of OIPs [<xref rid="prp270197-bib-0031" ref-type="bibr">31</xref>, <xref rid="prp270197-bib-0032" ref-type="bibr">32</xref>], further influencing the PK parameters and systemic drug concentration.</p><p>Regarding the safety of budesonide, four subjects experienced at least 1 AE in our study. All AEs were mild to moderate and eventually resolved; no SAEs and deaths were reported. Both the test and reference products demonstrated excellent tolerability in healthy Chinese subjects after four single‐dose administrations. However, the limited sample size restricts adequate safety profile comparison between the test and reference products in healthy subjects. Thus, a comprehensive safety comparison of these two budesonides requires further evaluation in a larger‐scale patient trial with a long‐term dosing regimen.</p></sec><sec sec-type="conclusions" id="prp270197-sec-0012"><label>5</label><title>Conclusion</title><p>The test product of budesonide pMDI (200 μg/actuation × 1 actuation) demonstrated the reference product (Budiair) and exhibited a favorable safety profile with good tolerability in healthy Chinese subjects.</p></sec><sec id="prp270197-sec-0015"><title>Author Contributions</title><p>Kai Huang, Shaohong Yin, and Weiguo Huang designed this clinical trial. Kai Huang, Wei Qin, Zhenzhong Qian, Ying Ding, Linling Que, and Yunfei Shi performed this clinical trial. Lairong Ding and Jinxia Gao analyzed and interpreted the data. All authors wrote, reviewed, and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="prp270197-sec-0013"><title>Conflicts of Interest</title><p>Shaohong Yin, Weiguo Huang, Lairong Ding, and Jinxia Gao are employees of Lunan Better Pharmaceutical Co. LTD. Other authors declare no conflicts of interest.</p></sec></body><back><ack id="prp270197-sec-0014"><title>Acknowledgments</title><p>We are grateful to all subjects in this trial. This study was funded by Lunan Better Pharmaceutical Co. LTD.</p></ack><sec sec-type="data-availability" id="prp270197-sec-0017"><title>Data Availability Statement</title><p>The data that support the findings of this study are available on request from the corresponding author.</p></sec><ref-list content-type="cited-references" id="prp270197-bibl-0001"><title>References</title><ref id="prp270197-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="prp270197-cit-0001">
<string-name name-style="western">
<given-names>J.</given-names>
<surname>Ora</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>De Marco</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Gabriele</surname>
</string-name>, et al., “<article-title>Exercise‐Induced Asthma: Managing Respiratory Issues in Athletes</article-title>,” <source>Journal of Functional Morphology and Kinesiology</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2024</year>): <elocation-id>15</elocation-id>, <pub-id pub-id-type="doi">10.3390/jfmk9010015</pub-id>.<pub-id pub-id-type="pmid">38249092</pub-id>
<pub-id pub-id-type="pmcid">PMC10801521</pub-id></mixed-citation></ref><ref id="prp270197-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp270197-cit-0002">
<string-name name-style="western">
<given-names>F.</given-names>
<surname>Schleich</surname>
</string-name>, <string-name name-style="western">
<given-names>N.</given-names>
<surname>Bougard</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Moermans</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Sabbe</surname>
</string-name>, and <string-name name-style="western">
<given-names>R.</given-names>
<surname>Louis</surname>
</string-name>, “<article-title>Cytokine‐Targeted Therapies for Asthma and COPD</article-title>,” <source>European Respiratory Review</source>
<volume>32</volume>, no. <issue>168</issue> (<year>2023</year>): <elocation-id>220193</elocation-id>, <pub-id pub-id-type="doi">10.1183/16000617.0193-2022</pub-id>.<pub-id pub-id-type="pmid">37076177</pub-id>
<pub-id pub-id-type="pmcid">PMC10113955</pub-id></mixed-citation></ref><ref id="prp270197-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp270197-cit-0003">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Hussain</surname>
</string-name> and <string-name name-style="western">
<given-names>G.</given-names>
<surname>Liu</surname>
</string-name>, “<article-title>Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons</article-title>,” <source>Cells</source>
<volume>13</volume>, no. <issue>5</issue> (<year>2024</year>): <elocation-id>384</elocation-id>, <pub-id pub-id-type="doi">10.3390/cells13050384</pub-id>.<pub-id pub-id-type="pmid">38474348</pub-id>
<pub-id pub-id-type="pmcid">PMC10931088</pub-id></mixed-citation></ref><ref id="prp270197-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="prp270197-cit-0004">
<string-name name-style="western">
<given-names>E.</given-names>
<surname>Melén</surname>
</string-name>, <string-name name-style="western">
<given-names>H. J.</given-names>
<surname>Zar</surname>
</string-name>, <string-name name-style="western">
<given-names>V.</given-names>
<surname>Siroux</surname>
</string-name>, et al., “<article-title>Asthma Inception: Epidemiologic Risk Factors and Natural History Across the Life Course</article-title>,” <source>American Journal of Respiratory and Critical Care Medicine</source>
<volume>210</volume>, no. <issue>6</issue> (<year>2024</year>): <fpage>737</fpage>–<lpage>754</lpage>.<pub-id pub-id-type="pmid">38981012</pub-id>
<pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202312-2249SO</pub-id><pub-id pub-id-type="pmcid">PMC11418887</pub-id></mixed-citation></ref><ref id="prp270197-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="prp270197-cit-0005">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Ding</surname>
</string-name> and <string-name name-style="western">
<given-names>C.</given-names>
<surname>Zhong</surname>
</string-name>, “<article-title>Exercise and Asthma</article-title>,” <source>Advances in Experimental Medicine and Biology</source>
<volume>1228</volume> (<year>2020</year>): <fpage>369</fpage>–<lpage>380</lpage>, <pub-id pub-id-type="doi">10.1164/rccm.202312-2249SO</pub-id>.<pub-id pub-id-type="pmid">32342471</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp270197-cit-0006">
<string-name name-style="western">
<given-names>T.</given-names>
<surname>Srichana</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Juthong</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>Thawithong</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Supaiboonpipat</surname>
</string-name>, and <string-name name-style="western">
<given-names>S.</given-names>
<surname>Soorapan</surname>
</string-name>, “<article-title>Clinical Equivalence of Budesonide Dry Powder Inhaler and Pressurized Metered Dose Inhaler</article-title>,” <source>Clinical Respiratory Journal</source>
<volume>10</volume>, no. <issue>1</issue> (<year>2016</year>): <fpage>74</fpage>–<lpage>82</lpage>, <pub-id pub-id-type="doi">10.1111/crj.12188</pub-id>.<pub-id pub-id-type="pmid">25043636</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp270197-cit-0007">
<string-name name-style="western">
<given-names>E. J.</given-names>
<surname>O'Connell</surname>
</string-name>, “<article-title>Review of the Unique Properties of Budesonide</article-title>,” <source>Clinical Therapeutics</source>
<volume>25</volume>, no. <issue>Suppl C</issue> (<year>2003</year>): <fpage>C42</fpage>–<lpage>C60</lpage>, <pub-id pub-id-type="doi">10.1016/s0149-2918(03)80305-3</pub-id>.<pub-id pub-id-type="pmid">14642803</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp270197-cit-0008">
<string-name name-style="western">
<given-names>W.</given-names>
<surname>Jin</surname>
</string-name>, <string-name name-style="western">
<given-names>Z.</given-names>
<surname>Zhao</surname>
</string-name>, and <string-name name-style="western">
<given-names>D.</given-names>
<surname>Zhou</surname>
</string-name>, “<article-title>Effect of Montelukast Sodium Combined With Budesonide Aerosol on Airway Function and T Lymphocytes in Asthmatic Children</article-title>,” <source>Pakistan Journal of Medical Sciences</source>
<volume>38</volume>, no. <issue>5</issue> (<year>2022</year>): <fpage>1265</fpage>–<lpage>1270</lpage>, <pub-id pub-id-type="doi">10.12669/pjms.38.5.5749</pub-id>.<pub-id pub-id-type="pmid">35799724</pub-id>
<pub-id pub-id-type="pmcid">PMC9247798</pub-id></mixed-citation></ref><ref id="prp270197-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp270197-cit-0009">
<string-name name-style="western">
<given-names>K. A.</given-names>
<surname>Lyseng‐Williamson</surname>
</string-name> and <string-name name-style="western">
<given-names>D.</given-names>
<surname>Simpson</surname>
</string-name>, “<article-title>Budesonide/Formoterol Pressurized Metered‐Dose Inhaler</article-title>,” <source>Drugs</source>
<volume>68</volume>, no. <issue>13</issue> (<year>2008</year>): <fpage>1855</fpage>–<lpage>1864</lpage>, <pub-id pub-id-type="doi">10.2165/00003495-200868130-00005</pub-id>.<pub-id pub-id-type="pmid">18729536</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp270197-cit-0010">
<string-name name-style="western">
<given-names>R.</given-names>
<surname>Donnelly</surname>
</string-name> and <string-name name-style="western">
<given-names>J. P.</given-names>
<surname>Seale</surname>
</string-name>, “<article-title>Clinical Pharmacokinetics of Inhaled Budesonide</article-title>,” <source>Clinical Pharmacokinetics</source>
<volume>40</volume>, no. <issue>6</issue> (<year>2001</year>): <fpage>427</fpage>–<lpage>440</lpage>, <pub-id pub-id-type="doi">10.2165/00003088-200140060-00004</pub-id>.<pub-id pub-id-type="pmid">11475468</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp270197-cit-0011">
<string-name name-style="western">
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name name-style="western">
<given-names>B.</given-names>
<surname>Xu</surname>
</string-name>, et al., “<article-title>Pharmacokinetics and Bioequivalence of a Generic and a Branded Budesonide Nasal Spray in Healthy Chinese Subjects</article-title>,” <source>Clinical Pharmacology in Drug Development</source>
<volume>11</volume>, no. <issue>4</issue> (<year>2022</year>): <fpage>516</fpage>–<lpage>522</lpage>, <pub-id pub-id-type="doi">10.1002/cpdd.1036</pub-id>.<pub-id pub-id-type="pmid">34783456</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp270197-cit-0012">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Maes</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>DePetrillo</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Siddiqui</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Reisner</surname>
</string-name>, and <string-name name-style="western">
<given-names>P.</given-names>
<surname>Dorinsky</surname>
</string-name>, “<article-title>Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults</article-title>,” <source>Clinical Pharmacology in Drug Development</source>
<volume>8</volume>, no. <issue>2</issue> (<year>2019</year>): <fpage>223</fpage>–<lpage>233</lpage>, <pub-id pub-id-type="doi">10.1002/cpdd.585</pub-id>.<pub-id pub-id-type="pmid">29901860</pub-id>
<pub-id pub-id-type="pmcid">PMC6585691</pub-id></mixed-citation></ref><ref id="prp270197-bib-0013"><label>13</label><mixed-citation publication-type="miscellaneous" id="prp270197-cit-0013">
<collab collab-type="authors">National Medical Products Administration</collab>
, <article-title>“Guidelines for Bioequivalence Studies of Generic Oral Inhaled Products,”</article-title>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cde.org.cn/zdyz/downloadAtt?idCODE=77dd20dfcf61c41b2eb5b59e14bdd9dc" ext-link-type="uri">https://www.cde.org.cn/zdyz/downloadAtt?idCODE=77dd20dfcf61c41b2eb5b59e14bdd9dc</ext-link>.</mixed-citation></ref><ref id="prp270197-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp270197-cit-0014">
<string-name name-style="western">
<given-names>D.</given-names>
<surname>Lu</surname>
</string-name>, <string-name name-style="western">
<given-names>S. L.</given-names>
<surname>Lee</surname>
</string-name>, <string-name name-style="western">
<given-names>R. A.</given-names>
<surname>Lionberger</surname>
</string-name>, et al., “<article-title>International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences</article-title>,” <source>AAPS Journal</source>
<volume>17</volume>, no. <issue>3</issue> (<year>2015</year>): <fpage>546</fpage>–<lpage>557</lpage>, <pub-id pub-id-type="doi">10.1208/s12248-015-9733-9</pub-id>.<pub-id pub-id-type="pmid">25758352</pub-id>
<pub-id pub-id-type="pmcid">PMC4406956</pub-id></mixed-citation></ref><ref id="prp270197-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="prp270197-cit-0015">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Ring</surname>
</string-name>, <string-name name-style="western">
<given-names>B.</given-names>
<surname>Lang</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Kazaroho</surname>
</string-name>, <string-name name-style="western">
<given-names>D.</given-names>
<surname>Labes</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Schall</surname>
</string-name>, and <string-name name-style="western">
<given-names>H.</given-names>
<surname>Schütz</surname>
</string-name>, “<article-title>Sample Size Determination in Bioequivalence Studies Using Statistical Assurance</article-title>,” <source>British Journal of Clinical Pharmacology</source>
<volume>85</volume>, no. <issue>10</issue> (<year>2019</year>): <fpage>2369</fpage>–<lpage>2377</lpage>, <pub-id pub-id-type="doi">10.1111/bcp.14055</pub-id>.<pub-id pub-id-type="pmid">31276603</pub-id>
<pub-id pub-id-type="pmcid">PMC6783617</pub-id></mixed-citation></ref><ref id="prp270197-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="prp270197-cit-0016">
<string-name name-style="western">
<given-names>P.</given-names>
<surname>Darken</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>DePetrillo</surname>
</string-name>, <string-name name-style="western">
<given-names>C.</given-names>
<surname>Reisner</surname>
</string-name>, <string-name name-style="western">
<given-names>E.</given-names>
<surname>St Rose</surname>
</string-name>, and <string-name name-style="western">
<given-names>P.</given-names>
<surname>Dorinsky</surname>
</string-name>, “<article-title>The Pharmacokinetics of Three Doses of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhaler Compared With Active Controls: A Phase I Randomized, Single‐Dose, Crossover Study in Healthy Adults</article-title>,” <source>Pulmonary Pharmacology &amp; Therapeutics</source>
<volume>50</volume> (<year>2018</year>): <fpage>11</fpage>–<lpage>18</lpage>, <pub-id pub-id-type="doi">10.1016/j.pupt.2018.03.001</pub-id>.<pub-id pub-id-type="pmid">29544728</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="prp270197-cit-0017">
<string-name name-style="western">
<given-names>Y.</given-names>
<surname>Chen</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Ye</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Mei</surname>
</string-name>, et al., “<article-title>Pharmacokinetics and Bioequivalence of Two Formulations of Azithromycin Tablets: A Randomized, Single‐Dose, Three‐Period, Crossover Study in Healthy Chinese Volunteers Under Fasting and Fed Conditions</article-title>,” <source>Drugs in R&amp;D</source>
<volume>24</volume>, no. <issue>2</issue> (<year>2024</year>): <fpage>201</fpage>–<lpage>209</lpage>, <pub-id pub-id-type="doi">10.1007/s40268-024-00464-8</pub-id>.<pub-id pub-id-type="pmid">38811485</pub-id>
<pub-id pub-id-type="pmcid">PMC11315817</pub-id></mixed-citation></ref><ref id="prp270197-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp270197-cit-0018">
<string-name name-style="western">
<given-names>C. M.</given-names>
<surname>Metzler</surname>
</string-name>, “<article-title>Bioavailability/Bioequivalence: Study Design and Statistical Issues</article-title>,” <source>Journal of Clinical Pharmacology</source>
<volume>29</volume>, no. <issue>4</issue> (<year>1989</year>): <fpage>289</fpage>–<lpage>292</lpage>, <pub-id pub-id-type="doi">10.1002/j.1552-4604.1989.tb03329.x</pub-id>.<pub-id pub-id-type="pmid">2656773</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp270197-cit-0019">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Arısoy</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Saydam</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Ekin Dolaksız</surname>
</string-name>, et al., “<article-title>A Study to Compare Bioequivalence Approach Between FDA and EMA in a Highly Variable Drug: Pinaverium Bromide Film Tablets</article-title>,” <source>Journal of Pharmaceutical Sciences</source>
<volume>111</volume>, no. <issue>11</issue> (<year>2022</year>): <fpage>3149</fpage>–<lpage>3154</lpage>, <pub-id pub-id-type="doi">10.1016/j.xphs.2022.08.010</pub-id>.<pub-id pub-id-type="pmid">35981633</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp270197-cit-0020">
<string-name name-style="western">
<given-names>J. D.</given-names>
<surname>Thacher</surname>
</string-name>, <string-name name-style="western">
<given-names>E. S.</given-names>
<surname>Schultz</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Hallberg</surname>
</string-name>, et al., “<article-title>Tobacco Smoke Exposure in Early Life and Adolescence in Relation to Lung Function</article-title>,” <source>European Respiratory Journal</source>
<volume>51</volume>, no. <issue>6</issue> (<year>2018</year>): <elocation-id>1702111</elocation-id>, <pub-id pub-id-type="doi">10.1183/13993003.02111-2017</pub-id>.<pub-id pub-id-type="pmid">29748304</pub-id>
<pub-id pub-id-type="pmcid">PMC6003782</pub-id></mixed-citation></ref><ref id="prp270197-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="prp270197-cit-0021">
<string-name name-style="western">
<given-names>H.</given-names>
<surname>Zuo</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Faiz</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>van den Berge</surname>
</string-name>, et al., “<article-title>Cigarette Smoke Exposure Alters Phosphodiesterases in Human Structural Lung Cells</article-title>,” <source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source>
<volume>318</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>L59</fpage>–<lpage>L64</lpage>, <pub-id pub-id-type="doi">10.1152/ajplung.00319.2019</pub-id>.<pub-id pub-id-type="pmid">31664853</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="prp270197-cit-0022">
<string-name name-style="western">
<given-names>N. Y.</given-names>
<surname>Kim</surname>
</string-name>, <string-name name-style="western">
<given-names>C. H.</given-names>
<surname>Lee</surname>
</string-name>, <string-name name-style="western">
<given-names>K. N.</given-names>
<surname>Jin</surname>
</string-name>, et al., “<article-title>Clinical Deterioration and Lung Function Change in Patients With Concomitant Asthma and Bronchiectasis</article-title>,” <source>Journal of Allergy and Clinical Immunology. In Practice</source>
<volume>10</volume>, no. <issue>10</issue> (<year>2022</year>): <fpage>2607</fpage>–<lpage>2613</lpage>, <pub-id pub-id-type="doi">10.1016/j.jaip.2022.05.026</pub-id>.<pub-id pub-id-type="pmid">35690367</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="prp270197-cit-0023">
<string-name name-style="western">
<given-names>H. K.</given-names>
<surname>Reddel</surname>
</string-name>, <string-name name-style="western">
<given-names>L. B.</given-names>
<surname>Bacharier</surname>
</string-name>, <string-name name-style="western">
<given-names>E. D.</given-names>
<surname>Bateman</surname>
</string-name>, et al., “<article-title>Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes</article-title>,” <source>American Journal of Respiratory and Critical Care Medicine</source>
<volume>205</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>17</fpage>–<lpage>35</lpage>, <pub-id pub-id-type="doi">10.1164/rccm.202109-2205PP</pub-id>.<pub-id pub-id-type="pmid">34658302</pub-id>
<pub-id pub-id-type="pmcid">PMC8865583</pub-id></mixed-citation></ref><ref id="prp270197-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="prp270197-cit-0024">
<string-name name-style="western">
<given-names>L.</given-names>
<surname>Weisfeld</surname>
</string-name>, <string-name name-style="western">
<given-names>Y.</given-names>
<surname>Shu</surname>
</string-name>, and <string-name name-style="western">
<given-names>T. P.</given-names>
<surname>Shah</surname>
</string-name>, “<article-title>Bioequivalence of Budesonide Plus Formoterol (BF) Spiromax and BF Turbohaler (With and Without Charcoal Block) in Healthy Volunteers</article-title>,” <source>International Journal of Clinical Pharmacology and Therapeutics</source>
<volume>53</volume>, no. <issue>7</issue> (<year>2015</year>): <fpage>593</fpage>–<lpage>602</lpage>, <pub-id pub-id-type="doi">10.5414/CP202238</pub-id>.<pub-id pub-id-type="pmid">26042485</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="prp270197-cit-0025">
<string-name name-style="western">
<given-names>S.</given-names>
<surname>Çakmaklı</surname>
</string-name>, <string-name name-style="western">
<given-names>A.</given-names>
<surname>Özdemir</surname>
</string-name>, <string-name name-style="western">
<given-names>H.</given-names>
<surname>Fırat</surname>
</string-name>, and <string-name name-style="western">
<given-names>C.</given-names>
<surname>Aypak</surname>
</string-name>, “<article-title>An Evaluation of the Use of Inhalers in Asthma and Chronic Obstructive Pulmonary Disease</article-title>,” <source>Journal of Taibah University Medical Sciences</source>
<volume>18</volume>, no. <issue>4</issue> (<year>2023</year>): <fpage>860</fpage>–<lpage>867</lpage>, <pub-id pub-id-type="doi">10.1016/j.jtumed.2023.01.001</pub-id>.<pub-id pub-id-type="pmid">36852239</pub-id>
<pub-id pub-id-type="pmcid">PMC9957742</pub-id></mixed-citation></ref><ref id="prp270197-bib-0026"><label>26</label><mixed-citation publication-type="miscellaneous" id="prp270197-cit-0026">
<collab collab-type="authors">U.S. Food and Drug Administration</collab>
, <article-title>“Draft Guidance on Budesonide; Formoterol Fumarate Dihydrate,”</article-title>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021929.pdf" ext-link-type="uri">https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_021929.pdf</ext-link>.</mixed-citation></ref><ref id="prp270197-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="prp270197-cit-0027">
<string-name name-style="western">
<given-names>L. J.</given-names>
<surname>Dunn</surname>
</string-name>, <string-name name-style="western">
<given-names>E. M.</given-names>
<surname>Kerwin</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>DeAngelis</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Darken</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Gillen</surname>
</string-name>, and <string-name name-style="western">
<given-names>P.</given-names>
<surname>Dorinsky</surname>
</string-name>, “<article-title>Pharmacokinetics of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co‐Suspension Delivery Technology After Single and Chronic Dosing in Patients With COPD</article-title>,” <source>Pulmonary Pharmacology &amp; Therapeutics</source>
<volume>60</volume> (<year>2020</year>): <elocation-id>101873</elocation-id>, <pub-id pub-id-type="doi">10.1016/j.pupt.2019.101873</pub-id>.<pub-id pub-id-type="pmid">31841699</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="prp270197-cit-0028">
<string-name name-style="western">
<given-names>K. L.</given-names>
<surname>Clearie</surname>
</string-name>, <string-name name-style="western">
<given-names>P. A.</given-names>
<surname>Williamson</surname>
</string-name>, <string-name name-style="western">
<given-names>K.</given-names>
<surname>Meldrum</surname>
</string-name>, et al., “<article-title>Pharmacokinetic and Pharmacodynamic Comparison of Hydrofluoroalkane and Chlorofluorocarbon Formulations of Budesonide</article-title>,” <source>British Journal of Clinical Pharmacology</source>
<volume>71</volume>, no. <issue>4</issue> (<year>2011</year>): <fpage>504</fpage>–<lpage>513</lpage>, <pub-id pub-id-type="doi">10.1111/j.1365-2125.2010.03857.x</pub-id>.<pub-id pub-id-type="pmid">21395643</pub-id>
<pub-id pub-id-type="pmcid">PMC3080637</pub-id></mixed-citation></ref><ref id="prp270197-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="prp270197-cit-0029">
<string-name name-style="western">
<given-names>M.</given-names>
<surname>Gillen</surname>
</string-name>, <string-name name-style="western">
<given-names>P.</given-names>
<surname>Forte</surname>
</string-name>, <string-name name-style="western">
<given-names>J. O.</given-names>
<surname>Svensson</surname>
</string-name>, et al., “<article-title>Effect of a Spacer on Total Systemic and Lung Bioavailability in Healthy Volunteers and In Vitro Performance of the Symbicort (Budesonide/Formoterol) Pressurized Metered Dose Inhaler</article-title>,” <source>Pulmonary Pharmacology &amp; Therapeutics</source>
<volume>52</volume> (<year>2018</year>): <fpage>7</fpage>–<lpage>17</lpage>, <pub-id pub-id-type="doi">10.1016/j.pupt.2018.08.001</pub-id>.<pub-id pub-id-type="pmid">30077809</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="prp270197-cit-0030">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Tronde</surname>
</string-name>, <string-name name-style="western">
<given-names>M.</given-names>
<surname>Gillen</surname>
</string-name>, <string-name name-style="western">
<given-names>L.</given-names>
<surname>Borgström</surname>
</string-name>, <string-name name-style="western">
<given-names>J.</given-names>
<surname>Lötvall</surname>
</string-name>, and <string-name name-style="western">
<given-names>J.</given-names>
<surname>Ankerst</surname>
</string-name>, “<article-title>Pharmacokinetics of Budesonide and Formoterol Administered via 1 Pressurized Metered‐Dose Inhaler in Patients With Asthma and COPD</article-title>,” <source>Journal of Clinical Pharmacology</source>
<volume>48</volume>, no. <issue>11</issue> (<year>2008</year>): <fpage>1300</fpage>–<lpage>1308</lpage>, <pub-id pub-id-type="doi">10.1177/0091270008322122</pub-id>.<pub-id pub-id-type="pmid">18974284</pub-id>
</mixed-citation></ref><ref id="prp270197-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="prp270197-cit-0031">
<string-name name-style="western">
<given-names>B. B.</given-names>
<surname>Eedara</surname>
</string-name>, <string-name name-style="western">
<given-names>R.</given-names>
<surname>Bastola</surname>
</string-name>, and <string-name name-style="western">
<given-names>S. C.</given-names>
<surname>Das</surname>
</string-name>, “<article-title>Dissolution and Absorption of Inhaled Drug Particles in the Lungs</article-title>,” <source>Pharmaceutics</source>
<volume>14</volume>, no. <issue>12</issue> (<year>2022</year>): <elocation-id>2667</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics14122667</pub-id>.<pub-id pub-id-type="pmid">36559160</pub-id>
<pub-id pub-id-type="pmcid">PMC9781681</pub-id></mixed-citation></ref><ref id="prp270197-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="prp270197-cit-0032">
<string-name name-style="western">
<given-names>A.</given-names>
<surname>Nokhodchi</surname>
</string-name>, <string-name name-style="western">
<given-names>S.</given-names>
<surname>Chavan</surname>
</string-name>, and <string-name name-style="western">
<given-names>T.</given-names>
<surname>Ghafourian</surname>
</string-name>, “<article-title>In Vitro Dissolution and Permeability Testing of Inhalation Products: Challenges and Advances</article-title>,” <source>Pharmaceutics</source>
<volume>15</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>983</elocation-id>, <pub-id pub-id-type="doi">10.3390/pharmaceutics15030983</pub-id>.<pub-id pub-id-type="pmid">36986844</pub-id>
<pub-id pub-id-type="pmcid">PMC10059005</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Respir Dis</journal-id><journal-id journal-id-type="pmc-domain-id">3335</journal-id><journal-id journal-id-type="pmc-domain">tardis</journal-id><journal-id journal-id-type="publisher-id">TAR</journal-id><journal-title-group><journal-title>Therapeutic Advances in Respiratory Disease</journal-title></journal-title-group><issn pub-type="ppub">1753-4658</issn><issn pub-type="epub">1753-4666</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9340410</article-id><article-id pub-id-type="pmcid-ver">PMC9340410.1</article-id><article-id pub-id-type="pmcaid">9340410</article-id><article-id pub-id-type="pmcaiid">9340410</article-id><article-id pub-id-type="pmid">35815354</article-id><article-id pub-id-type="doi">10.1177/17534666221107312</article-id><article-id pub-id-type="publisher-id">10.1177_17534666221107312</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effect of inhaled budesonide/formoterol fumarate dihydrate delivered
via two different devices on lung function in patients with COPD and low peak
inspiratory flow</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Huber</surname><given-names initials="B">Bärbel</given-names></name><aff id="aff1-17534666221107312">Clinical Unit, Inamed GmbH, Gauting,
Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Project_administration">Project administration</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Keller</surname><given-names initials="C">Claus</given-names></name><aff id="aff2-17534666221107312">Lung and Bronchial Medicine, Praxis Dr. Claus
Keller, Frankfurt, Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jenkins</surname><given-names initials="M">Martin</given-names></name><aff id="aff3-17534666221107312">Late Respiratory and Immunology Biometrics,
AstraZeneca, Cambridge, UK</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name name-style="western"><surname>Raza</surname><given-names initials="A">Abid</given-names></name><aff id="aff4-17534666221107312">Medsearch UK Limited, Slough, UK</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4660-5040</contrib-id><name name-style="western"><surname>Aurivillius</surname><given-names initials="M">Magnus</given-names></name><xref rid="corresp1-17534666221107312" ref-type="corresp"/><aff id="aff5-17534666221107312">AstraZeneca Research and Development,
Pepparedsleden 1, Gothenburg 43183, Sweden</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Supervision">Supervision</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-17534666221107312">
<email>magnus.aurivillius@astrazeneca.com</email>
</corresp></author-notes><pub-date pub-type="epub"><day>9</day><month>7</month><year>2022</year></pub-date><pub-date pub-type="collection"><season>Jan-Dec</season><year>2022</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">398032</issue-id><elocation-id>17534666221107312</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>30</day><month>5</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>07</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>02</day><month>08</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-08-02 04:18:07.157"><day>02</day><month>08</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>© The Author(s), 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_17534666221107312.pdf"/><abstract><sec id="section1-17534666221107312"><title>Background and aims:</title><p>Low peak inspiratory flow (PIF) is common following severe exacerbations of
chronic obstructive pulmonary disease (COPD). Patients with COPD and low PIF
may be at risk of suboptimal delivery of inhaled therapies to the airways,
especially when using devices such as dry powder inhalers (DPIs), which
require greater inspiratory effort than metered dose inhalers (MDIs). We
report the results from a 2-week crossover study evaluating the effects of
inhaled dual therapy with budesonide/formoterol fumarate dihydrate with an
MDI with a spacer <italic toggle="yes">versus</italic> a DPI in patients with COPD and
low PIF.</p></sec><sec id="section2-17534666221107312"><title>Methods:</title><p>This randomized, open-label, two-period (each 1 week in duration) crossover
efficacy and safety study included patients with severe-to-very severe COPD
and PIF &lt; 50 L/min (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04078126">NCT04078126</ext-link>). Patients were randomized 1:1 to
twice-daily budesonide/formoterol fumarate dihydrate MDI (BFF MDI) 320/10 µg
with a spacer for 1 week followed by twice-daily budesonide/formoterol
fumarate dihydrate DPI (BUD/FORM DPI) 320/9 µg for 1 week, or the inverse.
The primary endpoint was peak change from baseline in forced expiratory
volume in 1 s (FEV<sub>1</sub>) within 4 h post-dose following 1 week of
treatment. Other assessments included pre-dose lung function,
pharmacokinetics, and safety, as assessed by adverse events.</p></sec><sec id="section3-17534666221107312"><title>Results:</title><p>The modified intention-to-treat analysis set comprised 30 patients (mean age:
66.9 years; mean baseline FEV<sub>1</sub>: 766 mL; mean COPD assessment test
score: 22.20). Following 1 week of treatment, both BFF MDI and BUD/FORM DPI
improved mean [95% confidence interval (CI)] peak FEV<sub>1</sub> 4 h
post-dose [256 (190, 322) mL and 274 (208, 340) mL, respectively]. No
clinically meaningful difference between treatments was observed for any
lung function endpoint. There were no unexpected safety findings.</p></sec><sec id="section4-17534666221107312"><title>Conclusion:</title><p>Dual therapy with BFF MDI and with BUD/FORM DPI led to improvements in lung
function in patients with severe-to-very severe COPD and low PIF.</p></sec></abstract><kwd-group><kwd>budesonide</kwd><kwd>chronic obstructive pulmonary disease</kwd><kwd>dry powder inhaler</kwd><kwd>formoterol fumarate dihydrate</kwd><kwd>inhaled dual therapy</kwd><kwd>metered dose inhaler</kwd><kwd>peak inspiratory flow</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-17534666221107312"><funding-source id="funding1-17534666221107312">
<institution-wrap><institution>AstraZeneca</institution><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100004325</institution-id></institution-wrap>
</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2022</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section5-17534666221107312"><title>Introduction</title><p>Exacerbations of chronic obstructive pulmonary disease (COPD) are characterized by an
acute worsening of respiratory symptoms and negatively impact the rates of
hospitalization and readmission.<sup>
<xref rid="bibr1-17534666221107312" ref-type="bibr">1</xref>
</sup> Low (i.e. ⩽ 60 L/min) peak inspiratory flow (PIF) has been reported in 31.7<sup>
<xref rid="bibr2-17534666221107312" ref-type="bibr">2</xref>
</sup>–52%<sup>
<xref rid="bibr3-17534666221107312" ref-type="bibr">3</xref>
</sup> of patients following severe exacerbations of COPD (i.e. exacerbations
requiring hospitalization or a visit to the emergency room<sup>
<xref rid="bibr1-17534666221107312" ref-type="bibr">1</xref>
</sup>) and can result in a shorter time to hospital readmission.<sup>
<xref rid="bibr3-17534666221107312" ref-type="bibr">3</xref>
</sup> Patients with COPD and low PIF may also be at risk of suboptimal delivery of
inhaled medications to the airways, particularly when using devices with high
inspiratory airflow resistance.<sup>
<xref rid="bibr4-17534666221107312" ref-type="bibr">4</xref>
</sup></p><p>Importantly, the flow dependency of fine particle mass is greater for dry powder
inhalers (DPIs) than metered dose inhalers (MDIs), which could impact medication
delivery and subsequent lung function.<sup>
<xref rid="bibr5-17534666221107312" ref-type="bibr">5</xref>
</sup> DPIs require the patient to produce sufficient airflow (typically ⩾ 60 L/min),<sup>
<xref rid="bibr4-17534666221107312" ref-type="bibr">4</xref>
</sup> but their airflow resistance [0.060–0.163 cmH<sub>2</sub>O<sup>0.5</sup>
(L/min)<sup>−<xref rid="bibr1-17534666221107312" ref-type="bibr">1</xref></sup>] and the resulting PIF rate (49–108 L/min) can vary widely by device.<sup>
<xref rid="bibr6-17534666221107312" ref-type="bibr">6</xref>
</sup> Although MDIs are less dependent on a patient’s ability to produce airflow
than DPIs, some patients have difficulty appropriately using MDIs, including
coordinating device activation and inhalation.<sup><xref rid="bibr6-17534666221107312" ref-type="bibr">6</xref>,<xref rid="bibr7-17534666221107312" ref-type="bibr">7</xref></sup> To improve coordination of
inhaler actuation and inspiration, a spacer (a valved holding chamber) may be used
with an MDI.<sup>
<xref rid="bibr7-17534666221107312" ref-type="bibr">7</xref>
</sup> Studies have shown that drug delivery may be improved using a spacer when MDI
inhalation technique is suspected to be suboptimal.<sup><xref rid="bibr8-17534666221107312" ref-type="bibr">8</xref>,<xref rid="bibr9-17534666221107312" ref-type="bibr">9</xref></sup> This may result in part from a
reduced amount of drug being deposited in the oropharynx.<sup>
<xref rid="bibr7-17534666221107312" ref-type="bibr">7</xref>
</sup></p><p>Fixed-dose inhaled corticosteroid (ICS)/long-acting β<sub>2</sub>-agonist (LABA) dual
therapy is effective in improving lung function and reducing exacerbations in
patients with moderate-to-very severe COPD and a history of exacerbations.<sup>
<xref rid="bibr1-17534666221107312" ref-type="bibr">1</xref>
</sup> This study evaluated whether lung function outcomes would be differentially
improved by delivering dual combination maintenance therapy with the ICS budesonide
and the LABA formoterol fumarate dihydrate via an MDI with a spacer
<italic toggle="yes">versus</italic> a DPI in patients with severe-to-very severe COPD and
low PIF. Budesonide and formoterol fumarate steady-state pharmacokinetics were also
measured to enable an assessment of exposure following administration with an MDI or
DPI. In addition, safety was assessed, as measured by the occurrence of adverse
events (AEs).</p></sec><sec sec-type="methods" id="section6-17534666221107312"><title>Methods</title><sec id="section7-17534666221107312"><title>Study design</title><p>This was a phase IIIb, randomized, open-label, two-period (each 1 week in
duration) crossover efficacy and safety pilot study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04078126">NCT04078126</ext-link>) conducted at
four sites in Germany that compared the delivery of inhaled
budesonide/formoterol fumarate dihydrate dual therapy with two different
devices: twice-daily budesonide/formoterol fumarate dihydrate MDI 320/10 µg (BFF
MDI) administered with a spacer <italic toggle="yes">versus</italic> twice-daily
budesonide/formoterol fumarate dihydrate DPI 320/9 µg (BUD/FORM DPI;
Symbicort<sup>®</sup> Turbuhaler<sup>®</sup>; AstraZeneca, Cambridge, UK).
An overview of the study design is shown in <xref rid="fig1-17534666221107312" ref-type="fig">Figure 1</xref>. Based on the previously
published data, a 1-week treatment duration was considered sufficient to reach
steady-state exposure of budesonide and formoterol fumarate dihydrate in both
treatment arms<sup>
<xref rid="bibr10-17534666221107312" ref-type="bibr">10</xref>
</sup> and to evaluate resulting increases in peak expiratory volume in 1 s
(FEV<sub>1</sub>) within 4 h post-dose.<sup><xref rid="bibr11-17534666221107312" ref-type="bibr">11</xref>,<xref rid="bibr12-17534666221107312" ref-type="bibr">12</xref></sup> The lung function and
pharmacokinetic endpoints were objective measures not expected to be impacted by
the open-label nature of the comparison, and the crossover design allowed
within-patient comparisons to be made.</p><fig position="float" id="fig1-17534666221107312" orientation="portrait"><label>Figure 1.</label><caption><p>Study design.</p><p>BFF MDI, budesonide/formoterol fumarate dihydrate metered dose inhaler;
BUD/FORM DPI, budesonide/formoterol fumarate dihydrate DPI.</p><p><sup>a</sup>Administered twice daily.</p><p><sup>b</sup>Administered four times daily.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-fig1.jpg"/></fig><p>This study was performed in accordance with ethical principles that have their
origin in the Declaration of Helsinki and that are consistent with International
Council on Harmonisation/Good Clinical Practice and applicable regulatory
requirements. The study protocol and its amendments, the informed consent form,
and other relevant documents were reviewed and approved by an institutional
review board/independent ethics committee before the study was initiated. Each
patient or their legally authorized representative was required to provide
written informed consent before participation.</p><p>This study was conducted between September 2019 and December 2020. On 17 March
2020, due to circumstances related to the coronavirus disease 2019 (COVID-19)
pandemic, patients who were in screening or run-in, or who had been randomized
but had not completed the study were considered screen failures and discontinued
when the study was paused. On the study recommencing on 17 September 2020, all
patients impacted by the study hold were reinvited and started with informed
consent procedures before initiating study assessments as appropriate.</p></sec><sec id="section8-17534666221107312"><title>Patients</title><p>Patients eligible for study participation were current or former smokers (history
of ⩾ 10 pack-years) aged 40–80 years (inclusive) who were diagnosed with COPD
and receiving ⩾ 2 inhaled maintenance therapies for COPD in the 4 weeks before
the first visit, including ⩾ 1 long-acting bronchodilator. All patients were
required to demonstrate acceptable MDI with a spacer and DPI administration
technique and to be able to correctly perform the PIF measurement.</p><p>At visit 2, eligible patients had a pre-bronchodilator PIF of &lt; 50 L/min, as
measured by an In-Check inspiratory flow measurement device (In-Check™ DIAL G16;
Clement Clarke International, Harlow, UK) at Turbuhaler Symbicort (S)
resistance; the In-Check device measures PIF in increments equal to 5 L/min and
data were recorded to the nearest increment. Eligible patients also had a
post-bronchodilator ratio of the FEV<sub>1</sub> to forced vital capacity
of &lt; 0.70, and a post-bronchodilator FEV<sub>1</sub> of &lt; 50% of the
predicted normal value. Because a PIF rate of 60 L/min is considered optimal for
DPIs, we selected patients who had a PIF rate of ⩽ 50 L/min at Turbuhaler S
resistance to evaluate for a clinically meaningful difference.</p><p>Key exclusion criteria included a current diagnosis of asthma, COPD due to
α<sub>1</sub>-antitrypsin deficiency, sleep apnea, other respiratory
disorders, or any other significant disease or disorder that could put the
patient at risk or influence the results of the study. Patients were also
ineligible if they had a moderate or severe exacerbation of COPD within 6 weeks
before randomization, had lung resection or lung-volume-reduction surgery in the
6 months before the first visit, or required mechanical ventilation in the
3 months before visit 1.</p></sec><sec id="section9-17534666221107312"><title>Procedures and treatments</title><p>At visit 1, eligible patients discontinued their COPD maintenance therapies and
entered a 2- to 3-week run-in period receiving ipratropium bromide/fenoterol
hydrobromide 20/50 µg (Berodual<sup>®</sup> Respimat<sup>®</sup>; Boehringer
Ingelheim International GmbH, Ingelheim am Rhein, Germany) four times daily.
Patients receiving ICSs at screening also received budesonide MDI 320 µg twice
daily. Albuterol sulfate [Ventolin<sup>®</sup> hydrofluoroalkane (HFA);
GlaxoSmithKline, Brentford, UK] was provided as rescue therapy throughout the
study and could be used as needed; however, rescue therapy was withheld for at
least 6 h prior to spirometry measurements on study visit days. At visit 2, PIF
was measured with the In-Check inspiratory flow measurement device, set to no
resistance, Turbuhaler S resistance, and Ellipta device (GlaxoSmithKline,
Brentford, UK) resistance; reversibility and COPD assessment test (CAT) scores
were also measured.</p><p>Following the run-in period, patients who remained eligible and who had baseline
FEV<sub>1</sub> stability at visit 3 (i.e. within 20% or 200 mL of the
pre-bronchodilator assessment at visit 2) discontinued run-in treatments and
were randomized 1:1 to one of the two treatment sequences: open-label BFF MDI
320/10 µg administered with a spacer twice daily for 1 week followed by a 2-week
washout period, then followed by open-label BUD/FORM DPI 320/9 µg administered
twice daily for 1 week, or the inverse (<xref rid="fig1-17534666221107312" ref-type="fig">Figure 1</xref>). During the 2-week washout
period, patients discontinued their randomized treatment and resumed their
run-in treatments. Randomization was stratified by PIF values at visit 3
(&lt; 40 <italic toggle="yes">versus</italic> ⩾ 40 L/min at Turbuhaler S resistance).</p><p>Patients were admitted to the clinic prior to the evening doses of study
treatment on the days before visits 3, 4, 5, and 6; pre- and post-dose
spirometry assessments were conducted at each of these visits. Ipratropium
bromide/fenoterol hydrobromide and budesonide were withheld after evening dosing
before visits 3 and 5 to allow for a washout period of at least 12 h prior to
spirometry on the visit day. At visits 4 and 6, the time of dosing was
standardized to be &gt; 11 h and &lt; 12 h from the previous evening dose so as
to remove any confounding based on prior doses.</p><p>Samples of approximately 10 mL of whole blood were drawn for pharmacokinetic
analyses 30 min pre-dose and 2, 5, 20, 30, 40, 60, 120, 180, and 240 min
post-dose on the morning of visits 4 and 6. Budesonide and formoterol plasma
concentrations were determined by Covance, Inc. (Salt Lake City, UT, USA), as
previously described.<sup>
<xref rid="bibr13-17534666221107312" ref-type="bibr">13</xref>
</sup></p><p>Patients were considered to have completed the study when they had finished the
last scheduled procedure and the follow-up telephone call, which was scheduled
to take place 7–14 days after the last dose.</p></sec><sec id="section10-17534666221107312"><title>Endpoints</title><p>The primary endpoint was the peak change from baseline in FEV<sub>1</sub> within
4 h following 1 week of treatment. Secondary efficacy endpoints following the
first dose of each treatment on day 1 were change from baseline in 2-h
FEV<sub>1</sub> and change from baseline in 2-h inspiratory capacity (IC).
Additional secondary efficacy endpoints following 1 week of treatment were the
area under the curve for change from baseline in FEV<sub>1</sub> from 0 to 4 h
(FEV<sub>1</sub> AUC<sub>0–4</sub>), change from baseline in pre-dose
FEV<sub>1</sub>, change from baseline in 2-h post-dose IC, and change from
baseline in pre-dose PIF (In-Check device set to no resistance, Turbuhaler S
resistance, or Ellipta resistance).</p><p>Key pharmacokinetic endpoints for budesonide and formoterol fumarate included
area under the concentration–time curve from 0 to 4 h post-dose
(AUC<sub>0–4</sub>), maximum observed plasma concentration
(C<sub>max</sub>), time to C<sub>max</sub> (t<sub>max</sub>), and concentration
at the end of the dosing interval (C<sub>trough</sub>).</p><p>Safety endpoints were AEs, serious AEs, and AEs leading to treatment
discontinuation.</p></sec><sec id="section11-17534666221107312"><title>Statistical analysis</title><p>It was planned for approximately 30 patients to be randomized (15 per treatment
sequence) for 26 patients to complete the study. Sample size was selected based
on practical considerations to obtain reasonable point estimates of treatment
effects related to each device.</p><p>No formal hypothesis testing was conducted in this pilot study; only exploratory
hypotheses were evaluated, and there were no corrections for multiplicity.
Statistical analyses were conducted using SAS<sup>®</sup> version 9.4 (SAS
Institute, Cary, NC).</p><p>The intention-to-treat (ITT) analysis set comprised all randomized patients who
received ⩾ 1 dose of study treatment.</p><p>To isolate differences due to device only, a per-protocol estimand was used,
defined as the effect of the randomized treatments in all patients who were
compliant with the protocol and not impacted by other factors, such as
adherence, technique, or dosing time. Thus, analyses for the per-protocol
estimand used the modified ITT (mITT) analysis set that included patients in the
ITT analysis set who had post-baseline spirometry data from both treatments at
visits 4 and 6 and no significant protocol violations. Patients who did not
restart the study after it was paused due to the COVID-19 pandemic were included
in the ITT analysis set but not in the mITT analysis set; those who restarted
the study were included in the ITT or mITT analysis set only for the instance of
enrollment after restarting, providing they met the definition for the analysis
set as described.</p></sec><sec id="section12-17534666221107312"><title>Efficacy analysis</title><p>The primary endpoint was analyzed using an analysis of covariance (ANCOVA) model
with baseline FEV<sub>1</sub>, PIF at screening (at Turbuhaler S resistance),
and reversibility to albuterol sulfate HFA as continuous covariates; treatment
and period were included as categorical covariates. The model included patient
as a random effect and did not include patient sequence unless it was determined
to be statistically important (<italic toggle="yes">p</italic> &lt; 0.1). Estimates of the
difference between treatments with 95% confidence intervals (CIs) are reported
with <italic toggle="yes">p</italic> values provided to aid interpretation. Secondary
efficacy endpoints in the mITT analysis set and peak change from baseline
FEV<sub>1</sub> 4 h post-dose in the ITT analysis set were analyzed using a
similar model.</p><p>The primary and secondary endpoints were also analyzed in subgroups based on PIF
(&lt; 40 and ⩾ 40 L/min) at screening based on Turbuhaler S resistance.
Scatterplots and Pearson’s correlation coefficients were used to investigate
associations between baseline PIF on a continuous scale and within-patient
differences in device effect for the primary endpoint.</p></sec><sec id="section13-17534666221107312"><title>Pharmacokinetics analysis</title><p>Pharmacokinetics were analyzed in the pharmacokinetics analysis set, which
included all patients in the mITT analysis set with C<sub>max</sub> defined in
both treatment periods and no significant protocol violations that influenced
the pharmacokinetic analyses; patients were analyzed according to treatment
received.</p><p>Pharmacokinetic parameters were derived using noncompartmental methods in
Phoenix<sup>®</sup> WinNonlin<sup>®</sup> version 8.1 or higher software
(Certara, Inc., Princeton, NJ, USA). C<sub>max</sub>, C<sub>trough</sub>, and
t<sub>max</sub> were obtained from the concentration–time profiles, with the
concentration at the end of the dosing interval defined as the pre-dose
concentration at visits 4 and 6. Logarithmic transformations of
C<sub>trough</sub>, C<sub>max</sub>, and AUC<sub>0–4</sub> were analyzed
with an ANCOVA model, using treatment and period as categorical covariates and
patient as a random effect; treatment sequence was only included in the model if
determined to be statistically important (<italic toggle="yes">p &lt; </italic>0.10). Ratios
and 90% CIs for C<sub>max</sub>, C<sub>trough</sub>, and AUC<sub>0–4</sub> were
generated and produced by back-transformation. Descriptive statistics for
untransformed t<sub>max</sub> are presented.</p></sec><sec id="section14-17534666221107312"><title>Safety analysis</title><p>Safety was analyzed in the safety analysis set, which comprised patients who were
randomized and received at least one dose of study treatment; patients were
analyzed by the treatment received. Patients who restarted the study after it
was paused were included in the safety analysis set only for the instance of
enrollment after restarting. AEs were coded using the Medical Dictionary for
Regulatory Activities (MedDRA) version 23.1.</p></sec></sec><sec sec-type="results" id="section15-17534666221107312"><title>Results</title><sec id="section16-17534666221107312"><title>Patient disposition</title><p>The first patient was enrolled on 10 September 2019; the last patient had their
last visit on 30 December, 2020. Patient disposition is summarized in <xref rid="fig2-17534666221107312" ref-type="fig">Figure 2</xref>. In brief, 77
patients were enrolled and 35 were randomized to receive treatment
(<italic toggle="yes">n = </italic>18 to receive BFF MDI followed by BUD/FORM DPI;
<italic toggle="yes">n = </italic>17 to receive BUD/FORM DPI followed by BFF MDI). As it
is difficult to predict a low PIF in a patient based on other clinical
characteristics or lung function measurements, a relatively high number of
patients needed to be screened to randomize this study. Overall, 30/35 (85.7%)
of randomized patients were included in the mITT population. The pharmacokinetic
analysis set included 28 patients. Four patients [4/35 (11.4%)] discontinued the
study early due to the COVID-19 pandemic-related study hold.</p><fig position="float" id="fig2-17534666221107312" orientation="portrait"><label>Figure 2.</label><caption><p>Patient disposition.</p><p>BFF MDI, budesonide/formoterol fumarate dihydrate metered dose inhaler;
BUD/FORM DPI, budesonide/formoterol fumarate dihydrate dry powder
inhaler; C<sub>max</sub>, maximum concentration; COVID-19, coronavirus
disease 2019; mITT, modified intention-to-treat.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-fig2.jpg"/></fig></sec><sec id="section17-17534666221107312"><title>Demographics and baseline characteristics</title><p>Patient demographics and baseline clinical characteristics in the mITT analysis
set are reported in <xref rid="table1-17534666221107312" ref-type="table">Table
1</xref>. In brief, all patients were White and not of Hispanic or Latino
ethnicity; 50% of the patients were female; and the mean [standard deviation
(SD)] age was 66.9 (4.8) years. Overall, the median time since diagnosis with
COPD was 11.7 (minimum 2.8, maximum 30.7) years; the majority of patients had
severe COPD and the mean (SD) post-bronchodilator FEV<sub>1</sub> was 32.52%
(8.15%) of the predicted normal value. The mean (SD) FEV<sub>1</sub> at baseline
was 766 (212) mL, and the mean (SD) CAT score was 22.20 (6.13). Approximately
half [14/30 (46.7%)] of the patients had ⩾ 1 COPD exacerbation in 12 months
before the study. Mean (SD) baseline PIF values with the In-Check Device set to
no resistance, Turbuhaler S resistance, and Ellipta resistance were 78.86
(25.81), 38.56 (9.60), and 47.53 (13.60) L/min, respectively.</p><table-wrap position="float" id="table1-17534666221107312" orientation="portrait"><label>Table 1.</label><caption><p>Patient demographics and baseline COPD characteristics (mITT analysis
set).</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-table1.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1">All
patients<break/>(<italic toggle="yes">n = </italic>30)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Age in years, M (SD)</td><td rowspan="1" colspan="1">66.9 (4.8)</td></tr><tr><td colspan="2" rowspan="1">Age group in years, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">40–65</td><td rowspan="1" colspan="1">6 (20.0)</td></tr><tr><td rowspan="1" colspan="1">65–80</td><td rowspan="1" colspan="1">24 (80.0)</td></tr><tr><td colspan="2" rowspan="1">Sex, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1"> Female</td><td rowspan="1" colspan="1">15 (50.0)</td></tr><tr><td colspan="2" rowspan="1">Race, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1"> White</td><td rowspan="1" colspan="1">30 (100)</td></tr><tr><td rowspan="1" colspan="1">Time since COPD diagnosis<sup>
<xref rid="table-fn2-17534666221107312" ref-type="table-fn">a</xref>
</sup> in years, median (range)</td><td rowspan="1" colspan="1">11.7 (2.8–30.7)</td></tr><tr><td colspan="2" rowspan="1">GOLD COPD severity, <italic toggle="yes">n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1"> Severe</td><td rowspan="1" colspan="1">27 (90.0)</td></tr><tr><td rowspan="1" colspan="1"> Very severe</td><td rowspan="1" colspan="1">3 (10.0)</td></tr><tr><td rowspan="1" colspan="1">FEV<sub>1</sub> at baseline<sup>
<xref rid="table-fn3-17534666221107312" ref-type="table-fn">b</xref>
</sup> in mL, M (SD)</td><td rowspan="1" colspan="1">766 (212)</td></tr><tr><td rowspan="1" colspan="1">Post-bronchodilator FEV<sub>1</sub>% predicted, M (SD)</td><td rowspan="1" colspan="1">32.52 (8.15)</td></tr><tr><td colspan="2" rowspan="1">PIF at baseline<sup>
<xref rid="table-fn3-17534666221107312" ref-type="table-fn">b</xref>
</sup> in liters, M (SD)</td></tr><tr><td rowspan="1" colspan="1"> At no resistance</td><td rowspan="1" colspan="1">78.86 (25.81)</td></tr><tr><td rowspan="1" colspan="1"> At Turbuhaler S resistance</td><td rowspan="1" colspan="1">38.56 (9.60)</td></tr><tr><td rowspan="1" colspan="1"> At Ellipta resistance</td><td rowspan="1" colspan="1">47.53 (13.60)</td></tr><tr><td rowspan="1" colspan="1">Total CAT score, M (SD)</td><td rowspan="1" colspan="1">22.20 (6.13)</td></tr><tr><td rowspan="1" colspan="1">Patients with ⩾ 1 COPD exacerbation in the past 12 months,
<italic toggle="yes">n</italic> (%)</td><td rowspan="1" colspan="1">14 (46.7)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-17534666221107312"><p>CAT, COPD assessment test; COPD, chronic obstructive pulmonary
disease; FEV<sub>1</sub>, forced expiratory volume in 1 s;
FEV<sub>1</sub>% predicted, FEV<sub>1</sub> percentage of the
predicted normal value; GOLD, Global Initiative for Chronic
Obstructive Lung Disease; mITT, modified intention-to-treat; PIF,
peak inspiratory flow; SD, standard deviation; Turbuhaler S,
Turbuhaler Symbicort.</p></fn><fn id="table-fn2-17534666221107312"><label>a</label><p>Relative to day 1 of the first treatment period.</p></fn><fn id="table-fn3-17534666221107312"><label>b</label><p>Defined as the mean of the last pre-dose values at visits 3 and 5. If
both values were missing, the last pre-dose assessment during
screening visits was used.</p></fn></table-wrap-foot></table-wrap></sec><sec id="section18-17534666221107312"><title>Efficacy</title><p>Similar improvements in peak FEV<sub>1</sub> within 4 h post-dose following
1 week of treatment were observed for both BFF MDI and BUD/FORM DPI (<xref rid="fig3-17534666221107312" ref-type="fig">Figure 3</xref>). Adjusted mean
[95% confidence interval (CI)] changes from baseline in peak FEV<sub>1</sub>
were 256 (190, 322) mL for BFF MDI and 274 (208, 340) mL for BUD/FORM DPI,
corresponding to a between-group difference of −17 (−54, 20) mL
(<italic toggle="yes">p = </italic>0.3450). Similarly, the adjusted mean difference (95%
CI) in the ITT analysis set was −16 (−51, 19) mL. Patients with PIF ⩾ 40 L/min
at screening (<italic toggle="yes">n = </italic>18) had numerically greater improvements in
peak FEV<sub>1</sub> within 4 h post-dose following 1 week of treatment compared
with those with PIF &lt; 40 L/min (<italic toggle="yes">n = </italic>12) for both BFF MDI and
BUD/FORM DPI (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666221107312" ext-link-type="uri">Supplemental Table S1</ext-link>). Between-treatment differences for
changes in peak FEV<sub>1</sub> within 4 h post-dose in individual patients were
not correlated with baseline PIF at any resistance level tested (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666221107312" ext-link-type="uri">Supplemental Figure S1</ext-link>).</p><fig position="float" id="fig3-17534666221107312" orientation="portrait"><label>Figure 3.</label><caption><p>Peak change from baseline in FEV<sub>1</sub> within 4 h post-dose
following 1 week of treatment (mITT analysis set).</p><p>Data are presented as adjusted means; error bars depict 95% CI.</p><p>The adjusted mean difference is calculated as BFF MDI minus BUD/FORM
DPI.</p><p>BFF MDI, budesonide/formoterol fumarate dihydrate metered dose inhaler;
BUD/FORM DPI, budesonide/formoterol fumarate dihydrate dry powder
inhaler; CI, confidence interval; FEV<sub>1</sub>, forced expiratory
volume in 1 s; mITT, modified intention-to-treat.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-fig3.jpg"/></fig><p>Following the first dose, improvements in 2-h post-dose FEV<sub>1</sub> were
numerically greater with BFF MDI compared with BUD/FORM DPI, but improvements in
2-h post-dose IC were similar between treatments (<xref rid="table2-17534666221107312" ref-type="table">Table 2</xref>). After 1 week of treatment,
improvements of similar magnitude were observed for FEV<sub>1</sub>
AUC<sub>0–4</sub>, pre-dose FEV<sub>1</sub>, and 2-h post-dose IC with both
BFF MDI and BUD/FORM DPI (<xref rid="table2-17534666221107312" ref-type="table">Table 2</xref>). Improvements in secondary efficacy endpoints were
generally larger in patients with PIF ⩾ 40 L/min at screening compared with
those with PIF &lt; 40 L/min for both BFF MDI and BUD/FORM DPI (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666221107312" ext-link-type="uri">Supplemental Table S1</ext-link>).</p><table-wrap position="float" id="table2-17534666221107312" orientation="portrait"><label>Table 2.</label><caption><p>Secondary efficacy endpoints (mITT analysis set).</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-table2.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Endpoint, adjusted mean (95% CI)</th><th align="left" rowspan="1" colspan="1">BFF
MDI<break/>320/10 µg<break/>(<italic toggle="yes">N = </italic>30)</th><th align="left" rowspan="1" colspan="1">BUD/FORM
DPI<break/>320/9 µg<break/>(<italic toggle="yes">N = </italic>30)</th></tr></thead><tbody><tr><td colspan="3" rowspan="1">Following the first dose</td></tr><tr><td rowspan="1" colspan="1"> 2-h post-dose FEV<sub>1</sub> change from baseline,<sup>
<xref rid="table-fn6-17534666221107312" ref-type="table-fn">a</xref>
</sup> mL</td><td rowspan="1" colspan="1">136 (100, 173)</td><td rowspan="1" colspan="1">93 (57, 130)</td></tr><tr><td rowspan="1" colspan="1">  Difference from BUD/FORM DPI, mL</td><td rowspan="1" colspan="1">43 (3, 84)</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1">  <italic toggle="yes">p</italic> value</td><td rowspan="1" colspan="1">0.0375</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1"> 2-h post-dose IC change from baseline,<sup>
<xref rid="table-fn6-17534666221107312" ref-type="table-fn">a</xref>
</sup> mL</td><td rowspan="1" colspan="1">264 (164, 363)</td><td rowspan="1" colspan="1">258 (161, 356)</td></tr><tr><td rowspan="1" colspan="1">  Difference from BUD/FORM DPI, mL</td><td rowspan="1" colspan="1">5 (−86, 96)</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1">  <italic toggle="yes">p</italic> value</td><td rowspan="1" colspan="1">0.9089</td><td rowspan="1" colspan="1">–</td></tr><tr><td colspan="3" rowspan="1">Following 1 week of treatment</td></tr><tr><td rowspan="1" colspan="1"> FEV<sub>1</sub> AUC<sub>0–4</sub> change from baseline,<sup>
<xref rid="table-fn6-17534666221107312" ref-type="table-fn">a</xref>
</sup> mL</td><td rowspan="1" colspan="1">194 (133, 254)</td><td rowspan="1" colspan="1">210 (149, 271)</td></tr><tr><td rowspan="1" colspan="1">  Difference from BUD/FORM DPI, mL</td><td rowspan="1" colspan="1">−17 (−54 to 21)</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1">  <italic toggle="yes">p</italic> value</td><td rowspan="1" colspan="1">0.3675</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1"> Pre-dose FEV<sub>1</sub> change from baseline,<sup>
<xref rid="table-fn6-17534666221107312" ref-type="table-fn">a</xref>
</sup> mL</td><td rowspan="1" colspan="1">81 (30, 131)</td><td rowspan="1" colspan="1">87 (37, 137)</td></tr><tr><td rowspan="1" colspan="1">  Difference from BUD/FORM DPI, mL</td><td rowspan="1" colspan="1">−6 (−47, 34)</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1">  <italic toggle="yes">p</italic> value</td><td rowspan="1" colspan="1">0.7563</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1"> 2-h post-dose IC change from baseline,<sup>
<xref rid="table-fn6-17534666221107312" ref-type="table-fn">a</xref>
</sup> mL</td><td rowspan="1" colspan="1">379 (242, 517)</td><td rowspan="1" colspan="1">411 (275, 548)</td></tr><tr><td rowspan="1" colspan="1">  Difference from BUD/FORM DPI, mL</td><td rowspan="1" colspan="1">−32 (−139, 75)</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1">  <italic toggle="yes">p</italic> value</td><td rowspan="1" colspan="1">0.5419</td><td rowspan="1" colspan="1">–</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn4-17534666221107312"><p>AUC<sub>0–4</sub>, area under the curve from 0 to 4 h post-dose; BFF
MDI, budesonide/formoterol fumarate dihydrate metered dose inhaler;
BUD/FORM DPI, budesonide/formoterol fumarate dihydrate dry powder
inhaler; CI, confidence interval; FEV<sub>1</sub>, forced expiratory
volume in 1 s; IC, inspiratory capacity; mITT, modified
intention-to-treat.</p></fn><fn id="table-fn5-17534666221107312"><p>Adjusted means (95% CI) are from an analysis of covariance; reported
<italic toggle="yes">p</italic> values were not adjusted for
multiplicity.</p></fn><fn id="table-fn6-17534666221107312"><label>a</label><p>Baseline is defined as the mean of the last pre-dose values at visits
3 and 5. If both were missing, the last pre-dose assessment during
screening visits was used.</p></fn></table-wrap-foot></table-wrap><p>Across the resistances tested, improvements in pre-dose PIF were generally less
than one increment on the measurement scale (5 L/min) on the In-Check device for
both BUD/FORM DPI and BFF MDI, irrespective of PIF at screening, and were not
considered clinically meaningful (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://journals.sagepub.com/doi/suppl/10.1177/17534666221107312" ext-link-type="uri">Supplemental Table S2</ext-link>).</p></sec><sec id="section19-17534666221107312"><title>Pharmacokinetics</title><p>Plasma concentration–time profiles for budesonide were similar between BFF MDI
and BUD/FORM DPI (<xref rid="fig4-17534666221107312" ref-type="fig">Figure
4(a)</xref>). The rate and extent of budesonide absorption between BFF MDI
and BUD/FORM DPI were similar based on median t<sub>max</sub> and geometric mean
C<sub>max</sub>, AUC<sub>0–4</sub>, and C<sub>trough</sub> (<xref rid="table3-17534666221107312" ref-type="table">Table 3</xref>); however,
there was high between-patient variability in budesonide exposure with both
treatments. Adjusted geometric mean treatment ratios for AUC<sub>0–4</sub> and
C<sub>max</sub> were approximately 1, with the 90% CI falling within the
range of 0.8–1.25 (<xref rid="table3-17534666221107312" ref-type="table">Table
3</xref>). For C<sub>trough</sub>, the adjusted geometric mean ratio for
was &lt; 1 with a wide 90% CI, indicating that budesonide trough concentrations
were lower with BFF MDI compared with BUD/FORM DPI (<xref rid="table3-17534666221107312" ref-type="table">Table 3</xref>).</p><fig position="float" id="fig4-17534666221107312" orientation="portrait"><label>Figure 4.</label><caption><p>Geometric mean (a) budesonide and (b) formoterol fumarate plasma
concentrations over time (pharmacokinetics analysis set).BFF MDI,
budesonide/formoterol fumarate dihydrate metered dose inhaler; BUD/FORM
DPI, budesonide/formoterol fumarate dihydrate dry powder inhaler.</p><p>Data are presented as geometric mean; error bars depict the geometric
standard deviation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-fig4.jpg"/></fig><table-wrap position="float" id="table3-17534666221107312" orientation="portrait"><label>Table 3.</label><caption><p>Budesonide and formoterol fumarate pharmacokinetic parameters
(pharmacokinetics analysis set).</p></caption><alternatives><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="10.1177_17534666221107312-table3.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">BFF
MDI<break/>320/10 µg<break/>(<italic toggle="yes">N = </italic>28)</th><th align="left" rowspan="1" colspan="1">BUD/FORM
DPI<break/>320/9 µg<break/>(<italic toggle="yes">N = </italic>28)</th><th align="left" rowspan="1" colspan="1">Adjusted geometric mean ratio (90% CI)</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Budesonide</td></tr><tr><td rowspan="1" colspan="1"> t<sub>max</sub>, h, median (range)</td><td rowspan="1" colspan="1">0.525 (0.033–2.000)</td><td rowspan="1" colspan="1">0.417 (0.033–1.000)</td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1"> C<sub>max</sub>, pg/mL, adjusted geometric mean</td><td rowspan="1" colspan="1">752.8</td><td rowspan="1" colspan="1">743.9</td><td rowspan="1" colspan="1">1.012 (0.842, 1.216)</td></tr><tr><td rowspan="1" colspan="1"> C<sub>trough</sub>, pg/mL, adjusted geometric mean</td><td rowspan="1" colspan="1">72.6</td><td rowspan="1" colspan="1">85.8<sup>
<xref rid="table-fn9-17534666221107312" ref-type="table-fn">a</xref>
</sup></td><td rowspan="1" colspan="1">0.846 (0.618, 1.160)</td></tr><tr><td rowspan="1" colspan="1"> AUC<sub>0–4</sub>, h*pg/mL, adjusted geometric mean</td><td rowspan="1" colspan="1">1841.6</td><td rowspan="1" colspan="1">1796.7</td><td rowspan="1" colspan="1">1.025 (0.868, 1.210)</td></tr><tr><td colspan="4" rowspan="1">Formoterol fumarate dihydrate</td></tr><tr><td rowspan="1" colspan="1"> t<sub>max</sub>, h, median (range)</td><td rowspan="1" colspan="1">0.500 (0.033–2.000)<sup>
<xref rid="table-fn10-17534666221107312" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">0.667 (0.033–4.000)<sup>
<xref rid="table-fn10-17534666221107312" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">–</td></tr><tr><td rowspan="1" colspan="1"> C<sub>max</sub>, pg/mL, adjusted geometric mean</td><td rowspan="1" colspan="1">15.46<sup>
<xref rid="table-fn10-17534666221107312" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">12.68<sup>
<xref rid="table-fn10-17534666221107312" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">1.219 (1.003, 1.483)</td></tr><tr><td rowspan="1" colspan="1"> C<sub>trough</sub>, pg/mL, adjusted geometric mean</td><td rowspan="1" colspan="1">4.86<sup>
<xref rid="table-fn10-17534666221107312" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">4.02<sup>
<xref rid="table-fn11-17534666221107312" ref-type="table-fn">c</xref>
</sup></td><td rowspan="1" colspan="1">1.209 (0.939, 1.555)</td></tr><tr><td rowspan="1" colspan="1"> AUC<sub>0–4</sub>, h*pg/mL, adjusted geometric mean</td><td rowspan="1" colspan="1">46.14<sup>
<xref rid="table-fn11-17534666221107312" ref-type="table-fn">c</xref>
</sup></td><td rowspan="1" colspan="1">37.88<sup>
<xref rid="table-fn10-17534666221107312" ref-type="table-fn">b</xref>
</sup></td><td rowspan="1" colspan="1">1.218 (1.016, 1.460)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn7-17534666221107312"><p>AUC<sub>0–4</sub>, area under the concentration–time curve from 0 to
4 h post-dose; BFF MDI, budesonide/formoterol fumarate dihydrate
metered dose inhaler; BUD/FORM DPI, budesonide/formoterol fumarate
dihydrate dry powder inhaler; CI, confidence interval;
C<sub>max</sub>, maximum observed plasma concentration;
C<sub>trough</sub>, concentration at the end of the dosing
interval; t<sub>max</sub>, time to C<sub>max</sub>.</p></fn><fn id="table-fn8-17534666221107312"><p>Adjusted geometric means were computed from an analysis of covariance
on the logarithmic transformation of the pharmacokinetic parameter
with treatment and period as categorical covariates. Adjusted
geometric mean ratios and 90% CIs were computed through
back-transformation.</p></fn><fn id="table-fn9-17534666221107312"><label>a</label><p>Based on <italic toggle="yes">n</italic> = 25.</p></fn><fn id="table-fn10-17534666221107312"><label>b</label><p>Based on <italic toggle="yes">n</italic> = 26.</p></fn><fn id="table-fn11-17534666221107312"><label>c</label><p>Based on <italic toggle="yes">n</italic> = 27.</p></fn></table-wrap-foot></table-wrap><p>For formoterol fumarate, plasma concentration–time profiles were slightly higher
with BFF MDI with a spacer <italic toggle="yes">versus</italic> BUD/FORM DPI, although
standard deviation estimates overlapped at all time points (<xref rid="fig4-17534666221107312" ref-type="fig">Figure 4(b)</xref>). Despite formoterol
fumarate absorption rates being similar across treatments, as evidenced by
comparable median t<sub>max</sub> values, the extent of absorption was greater
with BFF MDI based on geometric mean treatment ratios for AUC<sub>0–4</sub>
(26.3% higher with BFF MDI), C<sub>max</sub> (24.5% higher with BFF MDI), and
C<sub>trough</sub> values (18.5% higher with BFF MDI; <xref rid="table3-17534666221107312" ref-type="table">Table 3</xref>). As with budesonide,
between-patient variability in formoterol fumarate exposure was high with both
treatments. Adjusted geometric mean treatment ratios from the overall
statistical analysis exceeded 1 for AUC<sub>0–4</sub>, C<sub>max</sub>, and
C<sub>trough</sub>, indicating that exposure to formoterol fumarate was
higher with BFF MDI than BUD/FORM DPI (<xref rid="table3-17534666221107312" ref-type="table">Table 3</xref>).</p></sec><sec id="section20-17534666221107312"><title>Safety</title><p>Two patients, one in each treatment arm, had a single treatment-emergent AE
during the study. One patient had a moderate nonserious AE of angina, and one
had a mild nonserious AE of abdominal discomfort. Both AEs were considered
unrelated to study treatment by the investigator, and patients recovered with no
changes to the administration of study treatment.</p><p>There were no deaths, no serious AEs, no AEs considered related to the study
drug, and no AEs leading to discontinuation of the study drug during the
study.</p></sec></sec><sec sec-type="discussion" id="section21-17534666221107312"><title>Discussion</title><p>In this phase IIIb pilot study, treatment with either BFF MDI or BUD/FORM DPI for
1 week was associated with clinically meaningful improvements compared with baseline
in peak FEV<sub>1</sub> within 4 h post-dose in patients with severe-to-very severe
COPD and low PIF (&lt; 50 L/min at Turbuhaler S resistance). Notably, these
improvements in FEV<sub>1</sub> of &gt; 250 mL were observed in a study population
with markedly limited lung function, as evidenced by the mean baseline
FEV<sub>1</sub> of 766 mL. In subgroups defined by PIF (&lt;40 or ⩾40 L/min) at
screening, improvements in FEV<sub>1</sub> were also similar across treatments. In
addition, correlational analyses showed that there was no association between
baseline PIF and the differences in FEV<sub>1</sub> improvements between treatments.
Both treatments resulted in improved lung function, but a clinically meaningful
difference was not observed in peak change from baseline in FEV<sub>1</sub> between
BFF MDI and BUD/FORM DPI.</p><p>Given the high inspiratory airflow resistance offered by DPIs compared with MDIs, it
was hypothesized that the delivery of maintenance medication via an MDI with a
spacer would be more effective in patients with low PIF than delivery via a DPI,
thereby resulting in greater improvements in lung function with the use of an MDI.
The current findings do not support this hypothesis, and both devices were effective
in this patient population. Improvements were also observed for secondary lung
function endpoints with each treatment. As for the primary endpoint, there were
generally no clinically meaningful differences between BFF MDI and BUD/FORM DPI.
Although a numerically greater improvement in 2-h post-dose FEV<sub>1</sub> was
observed following the first dose of treatment with BFF MDI <italic toggle="yes">versus</italic>
BUD/FORM DPI, this finding was not sustained following 1 week of treatment and is
not likely to be clinically meaningful. Similarly, both the absolute changes from
baseline in pre-dose PIF and differences observed between BFF MDI and BUD/FORM DPI
were small and not considered clinically meaningful across all tested
resistances.</p><p>Improvements in lung function were generally numerically greater across endpoints in
patients with PIF at screening ⩾ 40 L/min <italic toggle="yes">versus</italic> those with
PIF &lt; 40 L/min. However, this was observed for both treatments, and the
differences were not clinically meaningful in either subgroup for any endpoint.
Furthermore, correlational analysis of the difference between the treatments for the
primary endpoint and PIF at screening revealed no association. Taken together, there
was no evidence to suggest that the conclusions of the study would have differed,
had a lower PIF threshold been used for inclusion in the study.</p><p>The rate of absorption of budesonide and formoterol fumarate was generally similar
between BFF MDI and BUD/FORM DPI, with similar t<sub>max</sub> observed for both
treatments with each device. Although the extent of budesonide exposure was similar
with BFF MDI and BUD/FORM DPI, formoterol fumarate exposure was slightly higher with
BFF MDI compared with BUD/FORM DPI. The higher formoterol fumarate exposure observed
with BFF MDI may be partially attributed to the higher dose administered
<italic toggle="yes">versus</italic> BUD/FORM DPI (10 <italic toggle="yes">versus</italic> 9 µg,
respectively) and is consistent with at least one previously published study.<sup>
<xref rid="bibr13-17534666221107312" ref-type="bibr">13</xref>
</sup> However, the roughly 11% higher dose may not account for the entire 22%
difference in C<sub>max</sub> and AUC<sub>0–4</sub>. Differences between the devices
may potentially contribute, although the small sample size and high variability
between patients limit the ability to determine if the difference in formoterol
fumarate exposure is related to delivery device. In either case, this difference was
not associated with any meaningful difference with respect to lung function by week
1.</p><p>Despite the study being interrupted by the COVID-19 pandemic, there were no apparent
issues related to the COVID-19 pandemic that impacted on the evaluation of efficacy
in the study.</p><p>Both BFF MDI and BUD/FORM DPI were well tolerated. Only two AEs were reported in the
study, and neither impacted the administration of study treatment. No AEs were known
to be related to COVID-19. Although the small number of events precludes drawing
firm conclusions, there were no unexpected safety findings.</p><p>Limitations of this pilot study include its small sample size and short treatment
duration. It is also unclear whether the study results would have differed if the
recruited population had low PIF due to an immediately preceding exacerbation rather
than recruitment of patients with naturally low PIF away from the time of an
exacerbation (&lt;50% of this study’s population had an exacerbation in the last
year, and having a moderate or severe exacerbation within 6 weeks of randomization
was exclusionary). Although the baseline mean PIF values at Turbuhaler S and Ellipta
resistances in the current population (38.56 and 47.53 L/min) approximated
suboptimal PIF levels observed in hospitalized patients with COPD,<sup><xref rid="bibr3-17534666221107312" ref-type="bibr">3</xref>,<xref rid="bibr14-17534666221107312" ref-type="bibr">14</xref></sup> low PIF in hospitalized
patients is also associated with low grip strength<sup>
<xref rid="bibr14-17534666221107312" ref-type="bibr">14</xref>
</sup> (a measure of general muscle weakness<sup>
<xref rid="bibr15-17534666221107312" ref-type="bibr">15</xref>
</sup>), which could impact the patient’s ability to effectively use their inhaler
device. Thus, it is possible that in a peri-hospitalized population with low PIF the
findings could have differed and that benefits of the use of an MDI with a spacer
might have been observed.</p></sec><sec sec-type="conclusions" id="section22-17534666221107312"><title>Conclusion</title><p>In conclusion, both BFF MDI and BUD/FORM DPI improved lung function in patients with
severe-to-very severe COPD and low PIF, without differential effects being observed
based on the delivery device.</p></sec><sec sec-type="supplementary-material" id="section23-17534666221107312" specific-use="figshare"><title>Supplemental Material</title><supplementary-material id="suppl1-17534666221107312" position="float" content-type="local-data" orientation="portrait"><caption><title>sj-docx-1-tar-10.1177_17534666221107312 – Supplemental material for
Effect of inhaled budesonide/formoterol fumarate dihydrate delivered via two
different devices on lung function in patients with COPD and low peak
inspiratory flow</title></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sj-docx-1-tar-10.1177_17534666221107312.docx" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media><p>Supplemental material, sj-docx-1-tar-10.1177_17534666221107312 for Effect of
inhaled budesonide/formoterol fumarate dihydrate delivered via two different
devices on lung function in patients with COPD and low peak inspiratory flow by
Bärbel Huber, Claus Keller, Martin Jenkins, Abid Raza and Magnus Aurivillius in
Therapeutic Advances in Respiratory Disease</p></supplementary-material></sec></body><back><ack><p>The authors would like to thank Debasree Purkayastha (for assistance with statistical
analyses), Sara Asimus (for assistance with pharmacokinetic analyses), Wolfgang
Timmer (for study investigation and oversight), Martin Hoffman (for study
investigation), Heiner Steffen (for study investigation), Patrick Darken (for study
conceptualization and interpretation), and Paul Dorinsky (for study
conceptualization and interpretation) for their contributions to this study.</p></ack><fn-group><fn fn-type="other"><p><bold>Ethics approval and consent to participate:</bold> This study was performed in accordance with ethical principles having their
origin in the Declaration of Helsinki and that are consistent with International
Council on Harmonisation/Good Clinical Practice and applicable regulatory
requirements. The study protocol and its amendments, the informed consent form,
and other relevant documents were reviewed and approved by an institutional
review board/independent ethics committee before the study was initiated. Each
patient or their legally authorized representative was required to provide
written informed consent before participation.</p></fn><fn fn-type="other"><p><bold>Consent for publication:</bold> As part of the informed consent process, patients consented to publication of
these data.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Bärbel Huber:</bold> Investigation; Project administration; Writing –
review &amp; editing.</p><p><bold>Claus Keller:</bold> Investigation; Writing – review &amp; editing.</p><p><bold>Martin Jenkins:</bold> Conceptualization; Methodology; Writing – review
&amp; editing.</p><p><bold>Abid Raza:</bold> Investigation; Methodology; Writing – review &amp;
editing.</p><p><bold>Magnus Aurivillius:</bold> Conceptualization; Methodology; Supervision;
Writing – review &amp; editing.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Magnus Aurivillius <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1177_17534666221107312-img1.jpg"/>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://orcid.org/0000-0003-4660-5040" ext-link-type="uri">https://orcid.org/0000-0003-4660-5040</ext-link></p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This study was
sponsored by AstraZeneca. Medical writing support, under the guidance of the
authors, was provided by Brian Woolums, PhD of CMC Connect, McCann Health
Medical Communications, and was funded by AstraZeneca, in accordance with Good
Publication Practice (GPP3) guidelines (Battisti WP, Wager E, Baltzer L,
<italic toggle="yes">et al. Ann Intern Med</italic> 2015;163: 461–464).</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> The authors declared the following potential conflicts of interest with respect
to the research, authorship, and/or publication of this article: B.H. is an
employee of Inamed Gmbh (part of Nuvisan Gmbh), which was contracted by
AstraZeneca for this study. C.K. has a lung and bronchial medicine practice,
including a study center in Frankfurt am Main, Germany and was contracted by
AstraZeneca as a consultant research physician for this study. A.R. is an
employee of Medsearch UK Limited and was contracted by AstraZeneca as a
consultant research physician for this study. M.A. and M.J. are employees of
AstraZeneca and own stock or stock options in the company.</p></fn><fn fn-type="other"><p><bold>Availability of data and materials:</bold> Data underlying the findings described in this article may be obtained in
accordance with AstraZeneca’s data sharing policy described at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure" ext-link-type="uri">https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ext-link>.</p></fn><fn fn-type="supplementary-material"><p><bold>Supplemental material:</bold> Supplemental material for this article is available online.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-17534666221107312"><label>1</label><mixed-citation publication-type="webpage">
<collab>Global Initiative for Chronic Obstructive Lung Disease</collab>.
<article-title>Global strategy for the diagnosis, management, and prevention
of chronic obstructive pulmonary disease</article-title>. <year>2021</year>
Report. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf" ext-link-type="uri">https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf</ext-link>.</mixed-citation></ref><ref id="bibr2-17534666221107312"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Sharma</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Mahler</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Mayorga</surname><given-names>VM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Prevalence of low peak
inspiratory flow rate at discharge in patients hospitalized for COPD
exacerbation</article-title>. <source>Chronic Obstr Pulm Dis</source>
<year>2017</year>; <volume>4</volume>:
<fpage>217</fpage>–<lpage>224</lpage>.<pub-id pub-id-type="pmid">28848933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15326/jcopdf.4.3.2017.0183</pub-id><pub-id pub-id-type="pmcid">PMC5556913</pub-id></mixed-citation></ref><ref id="bibr3-17534666221107312"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Loh</surname><given-names>CH</given-names></name>
<name name-style="western"><surname>Peters</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Lovings</surname><given-names>TM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Suboptimal inspiratory flow
rates are associated with chronic obstructive pulmonary disease and
all-cause readmissions</article-title>. <source>Ann Am Thorac Soc</source>
<year>2017</year>; <volume>14</volume>:
<fpage>1305</fpage>–<lpage>1311</lpage>.<pub-id pub-id-type="pmid">28406710</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.201611-903OC</pub-id></mixed-citation></ref><ref id="bibr4-17534666221107312"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Mahler</surname><given-names>DA.</given-names></name>
</person-group>
<article-title>Peak inspiratory flow rate as a criterion for dry powder inhaler
use in chronic obstructive pulmonary disease</article-title>. <source>Ann Am
Thorac Soc</source>
<year>2017</year>; <volume>14</volume>:
<fpage>1103</fpage>–<lpage>1107</lpage>.<pub-id pub-id-type="pmid">28481631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1513/AnnalsATS.201702-156PS</pub-id></mixed-citation></ref><ref id="bibr5-17534666221107312"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Feddah</surname><given-names>MR</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Gipps</surname><given-names>EM</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>In-vitro characterisation of
metered dose inhaler versus dry powder inhaler glucocorticoid products:
influence of inspiratory flow rates</article-title>. <source>J Pharm
Pharmaceut Sci</source>
<year>2000</year>; <volume>3</volume>:
<fpage>318</fpage>–<lpage>324</lpage>.<pub-id pub-id-type="pmid">11177650</pub-id></mixed-citation></ref><ref id="bibr6-17534666221107312"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Altman</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Wehbe</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Dederichs</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Comparison of peak
inspiratory flow rate via the Breezhaler®, Ellipta® and HandiHaler® dry
powder inhalers in patients with moderate to very severe COPD: a randomized
cross-over trial</article-title>. <source>BMC Pulm Med</source>
<year>2018</year>; <volume>18</volume>: <fpage>100</fpage>.<pub-id pub-id-type="pmid">29898702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12890-018-0662-0</pub-id><pub-id pub-id-type="pmcid">PMC6001060</pub-id></mixed-citation></ref><ref id="bibr7-17534666221107312"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Vincken</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Levy</surname><given-names>ML</given-names></name>
<name name-style="western"><surname>Scullion</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Spacer devices for inhaled
therapy: why use them, and how?</article-title>
<source>ERJ Open Res</source>
<year>2018</year>; <volume>4</volume>:
<fpage>00065</fpage>-<lpage>02018</lpage>.<pub-id pub-id-type="pmid">29928649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/23120541.00065-2018</pub-id><pub-id pub-id-type="pmcid">PMC6004521</pub-id></mixed-citation></ref><ref id="bibr8-17534666221107312"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dorinsky</surname><given-names>P</given-names></name>
<name name-style="western"><surname>DePetrillo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>DeAngelis</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Relative bioavailability of
budesonide/glycopyrrolate/formoterol fumarate dihydrate metered dose inhaler
administered with and without a spacer: results of a phase I, randomized,
crossover trial in healthy adults</article-title>. <source>Clin
Ther</source>
<year>2020</year>; <volume>42</volume>:
<fpage>634</fpage>–<lpage>648</lpage>.<pub-id pub-id-type="pmid">32253054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2020.02.012</pub-id></mixed-citation></ref><ref id="bibr9-17534666221107312"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Gillen</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Forte</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Svensson</surname><given-names>JO</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Effect of a spacer on total
systemic and lung bioavailability in healthy volunteers and in vitro
performance of the Symbicort® (budesonide/formoterol) pressurized metered
dose inhaler</article-title>. <source>Pulm Pharmacol Ther</source>
<year>2018</year>; <volume>52</volume>:
<fpage>7</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">30077809</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2018.08.001</pub-id></mixed-citation></ref><ref id="bibr10-17534666221107312"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Dunn</surname><given-names>LJ</given-names></name>
<name name-style="western"><surname>Kerwin</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>DeAngelis</surname><given-names>K</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pharmacokinetics of
budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler
formulated using co-suspension delivery technology after single and chronic
dosing in patients with COPD</article-title>. <source>Pulm Pharmacol
Ther</source>
<year>2020</year>; <volume>60</volume>: <fpage>101873</fpage>.<pub-id pub-id-type="pmid">31841699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.pupt.2019.101873</pub-id></mixed-citation></ref><ref id="bibr11-17534666221107312"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Ferguson</surname><given-names>GT</given-names></name>
<name name-style="western"><surname>Rabe</surname><given-names>KF</given-names></name>
<name name-style="western"><surname>Martinez</surname><given-names>FJ</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>KRONOS: 24-week study of
triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI
via co-suspension delivery technology vs glycopyrronium/formoterol (GFF)
MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in
COPD</article-title>. <source>Eur Respir J</source>
<year>2018</year>; <volume>52</volume>(<issue>Suppl. 62</issue>):
OA1661.</mixed-citation></ref><ref id="bibr12-17534666221107312"><label>12</label><mixed-citation publication-type="confproc">
<person-group person-group-type="author">
<name name-style="western"><surname>Ferguson</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Rabe</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Bourne</surname><given-names>E</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>12-hour lung function
assessment of budesonide/glycopyrrolate/formoterol fumarate metered dose
inhaler delivered by co-suspension delivery technology in patients with
COPD</article-title>. <conf-name>Presented at the American Thoracic Society
2019 International Conference (May 17–22; Dallas, TX, USA)</conf-name>,
Poster number 540.</mixed-citation></ref><ref id="bibr13-17534666221107312"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Maes</surname><given-names>A</given-names></name>
<name name-style="western"><surname>DePetrillo</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Siddiqui</surname><given-names>S</given-names></name>
</person-group>, <etal>et al</etal>. <article-title>Pharmacokinetics of
co-suspension delivery technology budesonide/glycopyrronium/formoterol
fumarate dihydrate (BGF MDI) and budesonide/formoterol fumarate dihydrate
(BFF MDI) fixed-dose combinations compared with an active control: a Phase
1, randomized, single dose, crossover study in healthy
adults</article-title>. <source>Clin Pharmacol Drug Dev</source>
<year>2019</year>; <volume>8</volume>:
<fpage>223</fpage>–<lpage>233</lpage>.<pub-id pub-id-type="pmid">29901860</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpdd.585</pub-id><pub-id pub-id-type="pmcid">PMC6585691</pub-id></mixed-citation></ref><ref id="bibr14-17534666221107312"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Samarghandi</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ioachimescu</surname><given-names>OC</given-names></name>
<name name-style="western"><surname>Qayyum</surname><given-names>R.</given-names></name>
</person-group>
<article-title>Association between peak inspiratory flow rate and hand grip
muscle strength in hospitalized patients with acute exacerbation of chronic
obstructive pulmonary disease</article-title>. <source>PLOS ONE</source>
<year>2020</year>; <volume>15</volume>: e0227737.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0227737</pub-id><pub-id pub-id-type="pmcid">PMC6994102</pub-id><pub-id pub-id-type="pmid">32004333</pub-id></mixed-citation></ref><ref id="bibr15-17534666221107312"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name name-style="western"><surname>Bohannon</surname><given-names>RW.</given-names></name>
</person-group>
<article-title>Grip strength: an indispensable biomarker for older
adults</article-title>. <source>Clin Interv Aging</source>
<year>2019</year>; <volume>14</volume>:
<fpage>1681</fpage>–<lpage>1691</lpage>.<pub-id pub-id-type="pmid">31631989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/CIA.S194543</pub-id><pub-id pub-id-type="pmcid">PMC6778477</pub-id></mixed-citation></ref></ref-list></back></article><article xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="pmc-domain-id">2103</journal-id><journal-id journal-id-type="pmc-domain">pharmamdpi</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10535222</article-id><article-id pub-id-type="pmcid-ver">PMC10535222.1</article-id><article-id pub-id-type="pmcaid">10535222</article-id><article-id pub-id-type="pmcaiid">10535222</article-id><article-id pub-id-type="pmid">37765205</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics15092237</article-id><article-id pub-id-type="publisher-id">pharmaceutics-15-02237</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn’s Disease Patients through PBPK Modeling</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-7304-0336</contrib-id><name name-style="western"><surname>Han</surname><given-names initials="C">Chunyan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-pharmaceutics-15-02237" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-15-02237" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-15-02237" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sun</surname><given-names initials="T">Tiancheng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af2-pharmaceutics-15-02237" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5026-8369</contrib-id><name name-style="western"><surname>Chirumamilla</surname><given-names initials="SK">Siri Kalyan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af3-pharmaceutics-15-02237" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4154-0391</contrib-id><name name-style="western"><surname>Bois</surname><given-names initials="FY">Frederic Y.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af3-pharmaceutics-15-02237" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xu</surname><given-names initials="M">Mandy</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing – original draft</role><xref rid="af2-pharmaceutics-15-02237" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3917-844X</contrib-id><name name-style="western"><surname>Rostami-Hodjegan</surname><given-names initials="A">Amin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing – review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing – review &amp; editing</role><xref rid="af1-pharmaceutics-15-02237" ref-type="aff">1</xref><xref rid="af3-pharmaceutics-15-02237" ref-type="aff">3</xref><xref rid="c1-pharmaceutics-15-02237" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Paixão</surname><given-names initials="P">Paulo</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-15-02237"><label>1</label>Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester M13 9PL, UK</aff><aff id="af2-pharmaceutics-15-02237"><label>2</label>Pharmaron Inc., Beijing 100176, China; <email>tiancheng.sun@pharmaron.com</email> (T.S.); <email>mandy.xu@pharmaron.com</email> (M.X.)</aff><aff id="af3-pharmaceutics-15-02237"><label>3</label>Simcyp Division, Certara, Sheffield S1 2BJ, UK; <email>sirikalyan.chirumamilla@certara.com</email> (S.K.C.); <email>frederic.bois@certara.com</email> (F.Y.B.)</aff><author-notes><corresp id="c1-pharmaceutics-15-02237"><label>*</label>Correspondence: <email>chunyan.han@pharmaron.com</email> (C.H.); <email>amin.rostami@manchester.ac.uk</email> (A.R.-H.); Tel.: +86-010-5791-5816 (C.H.)</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2023</year></pub-date><volume>15</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">446233</issue-id><elocation-id>2237</elocation-id><history><date date-type="received"><day>01</day><month>8</month><year>2023</year></date><date date-type="rev-recd"><day>25</day><month>8</month><year>2023</year></date><date date-type="accepted"><day>28</day><month>8</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>30</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>09</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-28 15:25:15.177"><day>28</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>© 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceutics-15-02237.pdf"/><abstract><p>The most common method for establishing bioequivalence (BE) is to demonstrate similarity of concentration–time profiles in the systemic circulation, as a surrogate to the site of action. However, similarity of profiles from two formulations in the systemic circulation does not imply similarity in the gastrointestinal tract (GIT) nor local BE. We have explored the concordance of BE conclusions for a set of hypothetical formulations based on budesonide concentration profiles in various segments of gut vs. those in systemic circulation using virtual trials powered by physiologically based pharmacokinetic (PBPK) models. The impact of Crohn’s disease on the BE conclusions was explored by changing physiological and biological GIT attributes. Substantial ‘discordance’ between local and systemic outcomes of VBE was observed. Upper GIT segments were much more sensitive to formulation changes than systemic circulation, where the latter led to false conclusions for BE. The ileum and colon showed a lower frequency of discordance. In the case of Crohn’s disease, a product-specific similarity factor might be needed for products such as Entocort<sup>®</sup> EC to ensure local BE. Our results are specific to budesonide, but we demonstrate potential discordances between the local gut vs. systemic BE for the first time.</p></abstract><kwd-group><kwd>local bioequivalence</kwd><kwd>local BE</kwd><kwd>
<italic toggle="yes">f</italic>
<sub>2</sub>
</kwd><kwd>virtual bioequivalence</kwd><kwd>gut-wall exposure</kwd><kwd>Entocort EC</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-15-02237"><title>1. Introduction</title><p>The lifecycle management of drugs involves conduct of bioequivalence (BE) studies throughout various phases of drug development, necessitated by unforeseen factors such as changes in formulation or manufacturing process. These BE studies offer the possibility of comparing clinical outcomes by ensuring the similarity of the essential data for products going through various phases of development. Since the initial publication of the bioequivalence regulation by FDA in 1977, bioequivalence standards have undergone substantial evolution, incorporating increasing levels of complexity in drug discovery. However, pharmacokinetic endpoint studies remain the most commonly employed approach due to their sensitivity and repeatability, in contrast to pharmacodynamics or clinical endpoint studies [<xref rid="B1-pharmaceutics-15-02237" ref-type="bibr">1</xref>]. The underlying assumption is that systemic exposure is directly linked to the therapeutic effect. When two pharmaceutically equivalent drug products (e.g., two formulations of the drug or two drug products) are demonstrated to be bioequivalent, it is inferred that their active ingredient(s) are absorbed at the same rate and extent, generating comparable safety and efficacy profiles when administered to patients under the specified conditions in the product labeling. Consequently, these two drug products are deemed therapeutically equivalent and can be interchanged without restrictions [<xref rid="B2-pharmaceutics-15-02237" ref-type="bibr">2</xref>].</p><p>For locally acting gastrointestinal (GI) products, unlike other drugs, plasma concentration is downstream from the site of clinical effect, resulting in a disparity between the pharmacokinetic (PK) profile and effectiveness. After administration, the active drug ingredient would be released from the drug product, undergoes dissolution in the GI tract, and subsequently becomes available at the site of action for therapeutic purposes. The rate and extent of drug presentation at the site of action are governed by dissolution and the transit along the GI tract rather than plasma concentration [<xref rid="B3-pharmaceutics-15-02237" ref-type="bibr">3</xref>]. In the case of such drugs, in vivo dissolution testing plays a critical role in identifying potential formulation difference between generic and reference products of GI locally acting drug products, assuming the formulation has no impact on the GIT itself, whereas plasma concentration actually disconnects from the action site drug concentration. Any changes in intestinal microbiota, absorption rate and the expression level of intestinal transporters, intestinal metabolism, hepatic metabolism and plasma protein caused by interindividual differences or patients’ disease state could bias the detected plasma concentration profiles and widen the gap between local GI concentration and in vivo PK profiles [<xref rid="B3-pharmaceutics-15-02237" ref-type="bibr">3</xref>].</p><p>Considering the polarity between GI local concentration and systemic PK profile of GI products, developing physiologically relevant dissolution methods and the high cost of clinical endpoint BE studies pose significant challenges. In this context, physiologically based pharmacokinetic (PBPK) models emerge as an ideal investigative tool for exploring the correlation between dissolution in the GI tract and plasma concentration profiles. These in silico PBPK models can integrate existing knowledge of physiological parameters (and population distribution) and drug properties that influence oral drug absorption together, which allows theoretical investigation into the interplay between the system and the drug properties, shedding light on the main driving forces of drug absorption, transport and metabolism [<xref rid="B4-pharmaceutics-15-02237" ref-type="bibr">4</xref>]. Verified PBPK models are also capable of predicting potential pharmacokinetics difference between test and reference drugs in virtual populations and thus assess the BE risks by virtual bioequivalence simulations [<xref rid="B5-pharmaceutics-15-02237" ref-type="bibr">5</xref>].</p><p>In this study, the controlled-release (CR) formulation of budesonide, known as Entocort<sup>®</sup> EC, was utilized as an illustrative example to compare local and systemic PK profiles in both healthy volunteers and Crohn’s disease (CD) patients. There are many different dosage forms of budesonide on the market today, i.g., nasal spray, rectal tablet, oral capsule, etc. [<xref rid="B6-pharmaceutics-15-02237" ref-type="bibr">6</xref>]. Oral budesonide serves as the first-line therapy for inducing remission in mild to moderate CD patients [<xref rid="B7-pharmaceutics-15-02237" ref-type="bibr">7</xref>]. It is a corticosteroid drug with high potency while experiencing limited systemic exposure due to extensive first-pass metabolism [<xref rid="B8-pharmaceutics-15-02237" ref-type="bibr">8</xref>]. The permeability of budesonide is high (BCS class II), and if the compound is dosed in the form of micronized solid, it could dissolve quickly and be absorbed mainly in the upper GI sections [<xref rid="B9-pharmaceutics-15-02237" ref-type="bibr">9</xref>]. The approved product Entocort<sup>®</sup> EC is an orange/white-colored gelatin capsule containing 3 mg of budesonide in the form of small pellets. Each pellet consists of multiple layers, including an enteric coating on the exterior that initiates dissolution at a pH &gt; 5.5 after the budesonide pellets enter the duodenum, and under the coating an ethylcellulose polymer–budesonide layer that can control the rate of budesonide release. This multiple-unit formulation can combine the favorable pharmacological properties of budesonide (high potency and extensive first-pass metabolism) with localized, time-dependent release targeting the ileum and ascending colon, the most common sites of inflammation in patients with Crohn’s disease.</p><p>Despite the extensive first-pass metabolism and low bioavailability of budesonide, it is feasible to accurately quantify its plasma concentration following the oral administration of Entocort<sup>®</sup> EC capsules. Abundant clinical data collected with different dosage of Entocort<sup>®</sup> EC capsule in a healthy population and CD patients are available in publications. Additionally, literature reports provide information on the dissolution profile of Entocort<sup>®</sup> EC at fed- and fasted-state biorelevant buffer for healthy volunteer and CD patients at different disease levels. These resources render Entocort<sup>®</sup> EC an ideal model drug/formulation for investigation in the current study.</p><p>In this study, PBPK models were built for Entocort<sup>®</sup> EC in both healthy subjects and in Crohn’s disease populations. Local GI tract exposures in eight segments from duodenum to colon and two layers (lumen and enterocyte) in each segment were simulated for virtual generic formulations and Entocort<sup>®</sup> EC. Local bioequivalence was calculated and compared with systemic bioequivalence. For each virtual simulation, correlation between <italic toggle="yes">f</italic><sub>2</sub> value, local bioequivalence and systematic bioequivalence was examined. Validity of <italic toggle="yes">f</italic><sub>2</sub> value to indicate local or systematic BE, or adequacy of systemic BE to demonstrate local BE was analyzed for all virtual formulations. Suitability of incorporating healthy volunteers in BE studies for formulations used in treating GI tract diseases was investigated. Through this current study, we simulated various scenarios representing actual BE studies, trying to formulate some guiding principles regarding the most appropriate methods for BE studies of drugs acting locally in GIT.</p></sec><sec id="sec2-pharmaceutics-15-02237"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-15-02237"><title>2.1. Workflow</title><p>The workflow of the study is as depicted in <xref rid="pharmaceutics-15-02237-f001" ref-type="fig">Figure 1</xref>. PPBK models for budesonide and Entocort<sup>®</sup> EC were developed and validated against clinical PK data in HV and CD patients. Then, virtual bioequivalence studies were conducted with appropriate within-subject variances so that the results are closer to actual situations. Based on BE results, bar charts for 10 trials were generated and analyzed, and BE heatmaps were depicted.</p></sec><sec id="sec2dot2-pharmaceutics-15-02237"><title>2.2. Software</title><p>The Simcyp PBPK Simulator (Version 22 Release 1; Certara UK Limited, Sheffield, UK) was used to build the model for Entocort<sup>®</sup> EC formulation in healthy subjects and Crohn’s disease patients. VBE module embedded in the simulator was used in simulations of virtual bioequivalence between Entocort<sup>®</sup> EC and virtual generic formulations in eight sections of local GI tracts along with plasma in both populations. Clinical plasma concentration–time data from the literature were digitized with Digit (version 1.0.4, Simulation Plus). Noncompartmental analysis and bioequivalence analysis were performed using Phoenix WinNonlin 8.3 (Certara L.P., Princeton, NJ, USA).</p></sec><sec id="sec2dot3-pharmaceutics-15-02237"><title>2.3. Data Package Used in Modeling</title><p>Physicochemical, in vitro ADME parameters and clinical PK data collected from health volunteers and CD patients are available from literature sources. Budesonide clinical PK profiles in 10 clinical trials conducted with injections, solutions (orally and GI locally dosed) and Entocort<sup>®</sup> EC capsules in healthy subjects and in two studies conducted with Entocort<sup>®</sup> EC in CD patients were collected and used in the model development and validation. The summary of basic subject demographics information of these clinical trials is presented in <xref rid="pharmaceutics-15-02237-t001" ref-type="table">Table 1</xref>. Since individual data were not provided in these papers, the mean concentrations from each trial were extracted instead. Clinical studies 1–4 were used in stepwise model building and parameter fitting. Others were used for external validation. For each simulation, the trial design was adapted to match the dose, age range and proportion of females in the reported clinical study under preprandial state. The number of subjects in each trial was set as 100, following the default setting in Simcyp.</p></sec><sec id="sec2dot4-pharmaceutics-15-02237"><title>2.4. Model Development and Validation</title><sec id="sec2dot4dot1-pharmaceutics-15-02237"><title>2.4.1. Physicochemical Data</title><p>Budesonide is a moderately lipophilic (logP<sub>o:w</sub> 2.62) neutral small molecule compound. Physicochemical and binding data were collected from Effinger’s paper [<xref rid="B22-pharmaceutics-15-02237" ref-type="bibr">22</xref>]. The plasma protein binding was assigned to HSA and the K<sub>D</sub> was calculated by Simcyp.</p></sec><sec id="sec2dot4dot2-pharmaceutics-15-02237"><title>2.4.2. Distribution</title><p>The full PBPK model was selected as the PK model. The Rodgers and Rowland equations (Method 2) were used to calculate tissue-specific K<sub>p</sub> values and the volume of distribution. The K<sub>p</sub> scalar was adjusted manually to 1.065 so that predicted K<sub>p</sub> values for all tissues could be scaled and the predicted V<sub>ss</sub> could resemble the reported volume of distribution in clinical PK study with IV dose, which is 2.69 L/kg [<xref rid="B10-pharmaceutics-15-02237" ref-type="bibr">10</xref>]. After incorporation of clearance, the fitted IV plasma concentration showed overestimation of exposure (underestimation of IV plasma concentration profile). The K<sub>p</sub> scalar was then adjusted to 0.8 to better fit the observed PK profiles.</p></sec><sec id="sec2dot4dot3-pharmaceutics-15-02237"><title>2.4.3. Metabolism</title><p>Numerous studies have reported that budesonide undergoes extensive first-pass metabolism, primarily mediated by the enzyme CYP3A4. Additionally, there is minor renal clearance involved in the elimination process. The renal clearance was calculated by Equation (1), where f<sub>u</sub> was equal to 0.15, and the glomerular filtration rate (GFR) of the population representative (a 24-year-old Caucasian male), 172.42 mL/min/1.73 m<sup>2</sup>, was used in the calculation. Consequently, <italic toggle="yes">CL<sub>R</sub></italic>, the typical renal clearance of budesonide for a 20–30-year-old healthy male, was calculated to be 1.55 L/h. Biliary clearance and additional systemic clearance were set to be 0 since no biliary excretion or other elimination route was reported for budesonide.
<disp-formula id="FD1-pharmaceutics-15-02237"><label>(1)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mi>R</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>f</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mo>×</mml:mo><mml:mi>G</mml:mi><mml:mi>F</mml:mi><mml:mi>R</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Regarding to metabolic clearance, CYP3A4 was added to Enzyme Kinetics pane as the only metabolic pathway. Recombinant was selected as the source of kinetic data, and the intrinsic clearance (CL<sub>int</sub>) mediated by CYP3A4 was estimated by fitting the IV plasma concentration profile. A CL<sub>int</sub> of 4.1 μL/min/pmol of isoform was estimated by PE function.</p></sec><sec id="sec2dot4dot4-pharmaceutics-15-02237"><title>2.4.4. Absorption</title><p>Multilayer gut wall within the ADAM (M-ADAM) model was used to simulate the absorption of Entocort<sup>®</sup> EC. The model parameters were adjusted to mimic the behavior of the time-dependent release and absorption of the enteric-coated formulation along the intestinal tract.</p><list list-type="simple"><list-item><label>1.</label><p>Permeability</p></list-item></list><p>Apical P<sub>trans,0</sub> was calculated by method 2 in Simcyp using Equation (2), where <italic toggle="yes">a</italic> = 2.36 × 10<sup>−6</sup> and <italic toggle="yes">b</italic> = 1.1. The estimated Apical <italic toggle="yes">P<sub>trans,</sub></italic><sub>0</sub> of budesonide was 1798.5 × 10<sup>−6</sup> cm/s.
<disp-formula id="FD2-pharmaceutics-15-02237"><label>(2)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:mo>×</mml:mo><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mi>o</mml:mi><mml:mo>:</mml:mo><mml:mi>w</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mrow/><mml:mi>b</mml:mi></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p>Basolateral <italic toggle="yes">P<sub>trans,</sub></italic><sub>0</sub> was manually adjusted to 6000 × 10<sup>−6</sup> cm/s to cover first pass metabolism and AUC. P-gp CL<sub>int,T</sub> (μL/min) was calculated by the software from J<sub>max</sub> of 93 and K<sub>m</sub> of 9.4, which were collected from the literature [<xref rid="B23-pharmaceutics-15-02237" ref-type="bibr">23</xref>]. P<sub>para</sub> was set as 0.05506 × 10<sup>−6</sup> cm/s, which was the default value in the simulator.</p><p>In Simcyp, the gastrointestinal tract is divided into eight sections, including one section for duodenum, two sections for jejunum, four sections for ileum and one section for colon. To better reflect reginal absorption along the GI tract, absorption rate scalars for colon, ileum and jejunum were adjusted in turn to recover PK profiles of locally dosed budesonide solutions. To simulate the administration to corresponding GI sections, ‘Fluid MRT’ and ‘Transit Time (Total%)’ were adjusted accordingly. In the case of colon dosing, as the minimum transit time for small intestine in Simcyp is 0.5 h, the 0.5 h was added to the time axis of the colon-dosed PK profile to compensate for the discrepancy in time course. The absorption rate scalar for duodenum was adjusted to recover the PK profile of orally dosed budesonide solution. As the formulation of locally dosed solution is ethanol/water (1:1), in which the ethanol could substantially increase the permeability [<xref rid="B24-pharmaceutics-15-02237" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-15-02237" ref-type="bibr">25</xref>], locally fitted absorption rate scalars across the whole GI tract were adjusted by a cofactor of 0.6 to offset the increase. The final set of absorption scalars used in the model for the duodenum, jejunum, ileum and colon were 0.06, 0.12, 0.54 and 1.44, respectively.</p><list list-type="simple"><list-item><label>2.</label><p>Formulation</p></list-item></list><p>Controlled/modified release-dispersible system was selected in Simcyp as the formulation type, which tracks the entity of fluid and dissolved drug and also the Pellets with activated Segregated transit time model (STTM) function. Stomach lag time and mean residence time (MRT) of pellet in stomach was set to 0 h and 0.8 h, respectively. MRT of pellet in SI was set to 3 h based on previous clinical investigation on the movement of the particle [<xref rid="B13-pharmaceutics-15-02237" ref-type="bibr">13</xref>]. Retention time of fluid and dissolved drug was left as default values in the software.</p><p>The dissolution profile for Entocort<sup>®</sup> EC was collected from reference [<xref rid="B22-pharmaceutics-15-02237" ref-type="bibr">22</xref>] and used as the dissolution behavior of budesonide pellets. As the dissolution percentage in the experiment did not reach 100% at the last incubation time point, 100% dissolution was assumed at 12 h. Then, the dissolution profile was modified manually by adjusting the % release or altering the trigger pH to generate dissolution profiles for eight virtual formulations. These formulations were named by corresponding changes in dissolution profiles, i.e., ‘+5%’ is the formulations with trigger pH of 5.5 (the same as Entocort<sup>®</sup> EC) and a 5% increase in the release% at every sampling time point; ‘pH threshold = 5’ is the formulation with a modified trigger pH of 5 and an unchanged release profile compared with reference formulation Entocort<sup>®</sup> EC. To facilitate subsequent <italic toggle="yes">f</italic><sub>2</sub> calculation, the time for achieving 100% dissolution was standardized to 12 h for all formulations except for the +20% formulation, for which 100% dissolution was reached at 7 h. Dissolution profiles for the reference and six virtual formulations modified by changing the release% are shown in <xref rid="pharmaceutics-15-02237-f002" ref-type="fig">Figure 2</xref>.</p><p>Similarity factor (<italic toggle="yes">f</italic><sub>2</sub>) between the reference formulation and each virtual formulation were calculated using the bootstrap method [<xref rid="B26-pharmaceutics-15-02237" ref-type="bibr">26</xref>]. The parameter is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent (%) dissolution between the two curves, as illustrated in Equation (3).
<disp-formula id="FD3-pharmaceutics-15-02237"><label>(3)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mi>f</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>50</mml:mn><mml:mo>×</mml:mo><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mstyle mathsize="140%" displaystyle="true"><mml:mo>∑</mml:mo></mml:mstyle><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mi>n</mml:mi></mml:mfrac></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">n</italic> is the number of sampling time points, <italic toggle="yes">R<sub>t</sub></italic> is the dissolution percentage of reference product at time point t, <italic toggle="yes">T<sub>t</sub></italic> is the dissolution of test product at time point t. <italic toggle="yes">f</italic><sub>2</sub> values greater than 50 are indicative of the sameness or equivalence of the two dissolution curves and, thus, of the performance of the test and reference products [<xref rid="B27-pharmaceutics-15-02237" ref-type="bibr">27</xref>]. Based on the equation, an <italic toggle="yes">f</italic><sub>2</sub> of 50 could be achieved by a formulation with 10% change at every time point of the dissolution profile compared with the reference formulation. The smaller the change, the greater the <italic toggle="yes">f</italic><sub>2</sub> value, until up to 100.</p><p>Dissolution profiles for reference and six virtual formulations were then fitted to the Weibull function using Equation (4). Corresponding <italic toggle="yes">F<sub>max</sub></italic>, α and β for Entocort<sup>®</sup> EC and virtual formulations are listed in <xref rid="pharmaceutics-15-02237-t002" ref-type="table">Table 2</xref>.
<disp-formula id="FD4-pharmaceutics-15-02237"><label>(4)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="mm4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">F</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">t</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">T</mml:mi><mml:mrow><mml:mi>lag</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi mathvariant="sans-serif">β</mml:mi></mml:msup></mml:mrow><mml:mi mathvariant="sans-serif">α</mml:mi></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec sec-type="subjects" id="sec2dot4dot5-pharmaceutics-15-02237"><title>2.4.5. PBPK Model for Entocort<sup>®</sup> EC in Crohn’s Disease Patients</title><list list-type="simple"><list-item><label>3.</label><p>Local sensitivity analysis (LSA)</p></list-item></list><p>As Crohn’s disease could lead to significant anatomical and physiological changes that might alter the pharmacokinetic property of drugs, LSA was conducted to assess the influence of changes in physiological parameters to the PK profiles of Entocort<sup>®</sup> EC, and to build CD patient population by modifying key parameters. The selection of parameters for sensitivity analysis was based on the properties of budesonide and reported changes in CD patients, including mean retention time (MRT) in gut and small intestine; CYP3A4 abundance in liver, small intestine (SI) and colon; HSA concentration; and transporter abundance. Ranges of these parameters were set to cover the range for both healthy subjects and CD patients. Details are listed in <xref rid="pharmaceutics-15-02237-t003" ref-type="table">Table 3</xref>. Oral C<sub>max</sub> and AUC<sub>last</sub> were selected as the analysis endpoints.</p><list list-type="simple"><list-item><label>4.</label><p>Demographic parameters for healthy volunteers and Crohn’s disease patients</p></list-item></list><p>The default setting for healthy volunteers in the Simcyp database was used in the PBPK model of Entocort<sup>®</sup> EC in healthy subjects. CD population was built by changing key parameters identified in LSA. Values of these parameters in CD patients were collected from literature. The list of parameters and values are listed in <xref rid="pharmaceutics-15-02237-t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec id="sec2dot5-pharmaceutics-15-02237"><title>2.5. Virtual Bioequivalence (VBE)</title><p>The bioequivalence between Entocort<sup>®</sup> EC and virtual formulations were simulated by VBE module in Simcyp software (version 22). The study design for all simulations was the typical design for BE study, i.e., two-sequence, two-treatment, two-period, crossover study. All simulations were performed with 10 trials with 12 subjects in each trial. Healthy subjects age from 20 to 50, with 50% of female. Virtual subjects were generated from demographic information by the simulator using the Monte Carlo method. The default between-subject variability for HV population built in the software internal database was applied to each parameter. Within-subject variances (WSV) for some parameters were included to better recover the actual variance, as listed in <xref rid="pharmaceutics-15-02237-t005" ref-type="table">Table 5</xref>.</p><p>After simulation, concentration–time profiles in the system/plasma and two layers (lumen and enterocyte) of eight sections of GI tract (duodenum, Jejunum 1 and 2, ileum 1–4, and colon) for each subject after each treatment were generated and exported to Excel and then imported to WinNonlin for bioequivalence analysis. PK parameters (AUC<sub>last</sub> and C<sub>max</sub>) for each subject were calculated by noncompartmental analysis. A linear mixed-effect model was used to analyze the variance in log-transformed PK parameters between formulations. Sequence, treatment and period were selected as fixed effects, and subjects-within-sequence was regarded as random effect.</p><p>The 90% confidence interval (CI) of the ratio of geometric mean (test/reference) of PK parameters was calculated. Two formulations were considered bioequivalent if the 90% CI of the ratio of geometric means of C<sub>max</sub> and AUC<sub>last</sub> fell within the bioequivalence limits of 80% to 125%. BE bar charts were prepared based on BE results in the enterocyte or lumen layer of 8 GI sections, and plasma in one trial (<xref rid="pharmaceutics-15-02237-f003" ref-type="fig">Figure 3</xref>).</p><p>For simulations with 10 trials, if ≥8 trials show bioequivalence, the formulation was defined as bioequivalent to Entocort<sup>®</sup> EC. BE heatmaps were then generated based on bioequivalence or nonbioequivalence (NBE) results between 8 virtual formulations and Entocort<sup>®</sup> EC in plasma and the local GI tract in 10 trials (<xref rid="pharmaceutics-15-02237-f004" ref-type="fig">Figure 4</xref>). If a formulation was BE with Entocort<sup>®</sup> EC in plasma, the result was defined as positive; otherwise, the result is negative. If the BE in certain GI segment was consistent with that in plasma, i.e., plasma BE could represent local BE result, then the result was defined as true and colored in green (true positive or true negative); otherwise, the result was considered false and colored in red and pink (false positive or false negative).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-15-02237"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-pharmaceutics-15-02237"><title>3.1. PBPK Models for Entocort<sup>®</sup> EC in Healthy Volunteers and CD Patients</title><p>Detailed parameters for Entocort<sup>®</sup> EC PBPK models for healthy volunteers are summarized in <xref rid="app1-pharmaceutics-15-02237" ref-type="app">Table S1</xref>. Simulations for both healthy volunteers and CD patients met the criterion for internal (0.8- to 1.25-fold) and external validation (within 2-fold) (<xref rid="pharmaceutics-15-02237-t006" ref-type="table">Table 6</xref>), indicating the success of models in predicting the exposure of budesonide after the administration of solutions and the formulation. Regarding the shape of the simulated concentration–time profile, as shown in <xref rid="app1-pharmaceutics-15-02237" ref-type="app">Figure S1</xref>, disposition and clearance of budesonide was successfully recovered by the PBPK model with IV bolus dose in healthy volunteers. Furthermore, the PK profiles of budesonide after local and oral administration of 2.6 mg (1 mL) solution, 3 mg (10 mL) solution and Entocort<sup>®</sup> EC were also captured well (<xref rid="app1-pharmaceutics-15-02237" ref-type="app">Figures S2–S5 and S9</xref>). Details about local sensitivity analysis can be found in <xref rid="app1-pharmaceutics-15-02237" ref-type="app">Figures S7 and S8</xref>).</p><p>Regarding local absorption in the GI tract, the ileo-colonic region accounts for approximately 70% of absorption% of budesonide, and the simulated value (82.2%) has no significant difference from the reported value (76.1%), as shown in <xref rid="app1-pharmaceutics-15-02237" ref-type="app">Table S2</xref>. The fraction of absorption in each segment was simulated well except for transverse and descending colon (reported: 6.9% vs. simulated: 1.9%).</p><p>Simulated concentration–time profiles for different sections and layers of the GI tract were checked visually in <xref rid="app1-pharmaceutics-15-02237" ref-type="app">Figure S6</xref>, and simulated t<sub>max</sub> and C<sub>max</sub> were compared, as listed in <xref rid="pharmaceutics-15-02237-t007" ref-type="table">Table 7</xref>. Plasma concentration reached C<sub>max</sub> at 3 h while the upper small intestine reached C<sub>max</sub> earlier, which was at 1–2 h for the duodenum and jejunum. The time for the local GI tract to reach C<sub>max</sub> was longer for distal intestinal sections. T<sub>max</sub> for the ileum and colon were 2–3 and 6 h, respectively. The shape of the concentration–time profile (in semilog scale) in the colon is quite similar to that in plasma. In contrast, the concentration profile of the duodenum to ileum segments exhibited a completely different shape. It might be caused by the long retention time and thus prolonged absorption of the drug in the colon. For the same section of the gastrointestinal tract, concentrations in lumen and enterocyte showed a consistent trend of changes. Enterocyte concentrations are around 1% of the lumen concentrations in the same segment. Furthermore, concentrations in lumen and enterocytes are 2–5 orders of magnitude higher than the plasma concentration at the same sampling time point.</p></sec><sec id="sec3dot2-pharmaceutics-15-02237"><title>3.2. Virtual BE Heatmaps for Healthy Subjects</title><p>Systematic and local BE results were organized into heatmaps for further analysis. To facilitate classification and identification, heatmaps were modified based on local BE results. Local BE cells remained flat, while 3D bevel effects were added to local NBE cells. After modification, local BE could be identified by the 3D effects of cells. Flat green cells represent the most favorable scenario for drug discovery companies, i.e., BE in both plasma and local GI segments. Light green bevel cells depict situations that show systemically and locally NBE. In both green cases, local BE could be expected through comparative PK studies. However, light green is less desirable since it may indicate the failure of the generic drug. Two red colors were used in the heatmap to represent unfavorable situations. Red bevel cells mean systematically BE, but locally NBE. In this case, substandard products could be released through PK-based BE studies and that would be unfavorable for patients. Flat pink cells represented the situation of systematic NBE while achieving BE in the corresponding GI segment, implying that one might lose generic drugs that could potentially work appropriately.</p><p>BE heatmap for the enterocyte and plasma of the healthy volunteer population is shown in <xref rid="pharmaceutics-15-02237-f005" ref-type="fig">Figure 5</xref>. Regarding the sensitivity of the two parameters, i.e., AUC and C<sub>max</sub>, the latter provided more negative results in plasma, whereas AUC identified more negative cases in local GI tracts. Regardless of the parameter used to identify NBE result, it is challenging to identify BE results in upper intestinal sections, including the duodenum and jejunum. It suggests that these regions are sensitive to changes in the dissolution rate and trigger pH, which could be attributed to variations in the formulation manufacturing process.</p><p>In <xref rid="pharmaceutics-15-02237-f005" ref-type="fig">Figure 5</xref>, BE results based on AUC<sub>0–last</sub> and C<sub>max</sub> were listed separately to compare the sensitivity of these two parameters. In plasma, all the test formulations were bioequivalent to the reference formulation based on AUC<sub>0–last</sub>, while three formulations (+20%, +10% and −10%) were identified to be not bioequivalent based on plasma C<sub>max</sub>. It suggests that plasma AUC<sub>0–last</sub> is less sensitive to formulation changes than plasma C<sub>max</sub>. On the other hand, in the local GI tracts, AUC<sub>0-last</sub> is more sensitive than C<sub>max</sub> since the former identified more local NBE results. Due to the discrepancy in parameter sensitivity, it is necessary to combine AUC<sub>0–last</sub> and C<sub>max</sub> together when checking the discordance in local and systemic bioequivalence.</p><p>Based on the combined BE results derived from both AUC and C<sub>max</sub> (<xref rid="pharmaceutics-15-02237-f006" ref-type="fig">Figure 6</xref>), nearly all the formulations show NBE results based in the upper intestines (duodenum and jejunum), which means upper intestines are very sensitive to formulation changes. Both ends of the GI tract (duodenum, jejunum, ileum 1 and colon) were observed to be sensitive to changes in the dissolution rate, and the ileum section tends to be conservative to formulation changes and showed more BE results than other sections. Based on simulation results of eight formulations, in most cases plasma BE could represent the local GI BE in the ileum 2–4 sections and colon, except for the +5% formulation, which was bioequivalent in plasma but not in the ileum 2–3 or colon.</p><p>Regarding the performance of similarity factor <italic toggle="yes">f</italic><sub>2</sub> in predicting plasma and local BE, the study suggested that the commonly used cutoff of 50 is insufficient to ensure either systemic BE or local GI BE. Bioequivalence of plasma BE could be achieved for formulations when <italic toggle="yes">f</italic><sub>2</sub> is increased to 65.5. Regarding bioequivalence in local GI sections, the duodenum, jejunum and ileum 1 segments are so sensitive to formulation changes that all formulations in the current study were found to be not bioequivalent in these sections. Regarding to the more conservative ileum 2–4 and colon sections, which are also the target sections for Entocort<sup>®</sup> EC, bioequivalence could be achieved when <italic toggle="yes">f</italic><sub>2</sub> reaches 65.5, i.e., the +3% formulation (<italic toggle="yes">f</italic><sub>2</sub> = 75.8) and −5% formulation (<italic toggle="yes">f</italic><sub>2</sub> = 65.5). But for another formulation with <italic toggle="yes">f</italic><sub>2</sub> of 65.5, i.e., the +5% formulation, local BE in the ileum 2–3 and colon was not achieved. In summary, based on the BE heatmap, <italic toggle="yes">f</italic><sub>2</sub> of 50 is inadequate to ensure local or plasma bioequivalence in the case of the formulation Entercort<sup>®</sup> EC. Higher <italic toggle="yes">f</italic><sub>2</sub> values (&gt;65.5) should be considered as quality control for GI locally acting products.</p><p>For two formulations with altered trigger pH, which could be achieved by altered coating material or thickness of coating, BE performance is generally comparable or even superior to that of formulations with high <italic toggle="yes">f</italic><sub>2</sub> values (65.5 or 73.8). NBE results were observed in the upper sections (duodenum to ileum 1), whereas the ileum 2–4 and colon were conservative to formulation changes. Increasing the trigger pH from 5.5 to 6.0 could potentially delay the release of the drug after administration, and thus lead to more significant change compared with the performance-to-formulation with a trigger pH of 5.0.</p><p>As NBE results could be attributed to the shift in the geometric mean, or wide confidence interval related to high interindividual variance, BE bar charts for two formulations with faster and slower dissolution rates were examined. As depicted in <xref rid="pharmaceutics-15-02237-f007" ref-type="fig">Figure 7</xref> and <xref rid="pharmaceutics-15-02237-f008" ref-type="fig">Figure 8</xref>, the 90% confidence interval range in local GI tracts are wider than that in plasma, suggesting higher interindividual interval. However, the interval is not excessively wide to cause negative outcomes in bioequivalence analysis. Regarding the trend of concentration change, a faster dissolution rate leads to higher concentration in the upper gastrointestinal tracts as well as in plasma in all trials; slower dissolution could lead to a lower concentration in the upper gastrointestinal tract as well as in plasma. The concentration in colon tends to move in the opposite direction compared with plasma. The magnitude and direction of concentration change in the ileum sections are generally the same as that in plasma, possibly accounting for synchronization between plasma BE and ileum local BE.</p><p>As lumen concentration is important to other GI local action drugs treating Crohn’s disease, such as metronidazole and ciprofloxacin, etc., BE results based on lumen concentrations and PK parameters were also examined for eight formulations and were compared with BE results simulated in plasma. As shown in <xref rid="pharmaceutics-15-02237-f009" ref-type="fig">Figure 9</xref>, comparison between the lumen and enterocyte heatmaps did not uncover any significant difference, especially when one considers the sensitive parameter C<sub>max</sub>. Similar phenomenon concerning discrepancy between local and systemic BE and the discrimination effect of <italic toggle="yes">f</italic><sub>2</sub> could be observed. Although the concentrations in the lumen layer is around 100 fold that of the enterocyte concentration in same GI section (<xref rid="pharmaceutics-15-02237-t007" ref-type="table">Table 7</xref>), they generally respond to the formulation modifications in the same manner and to the same extent.</p></sec><sec sec-type="subjects" id="sec3dot3-pharmaceutics-15-02237"><title>3.3. Virtual BE Heatmaps for CD Patients</title><p>The ultimate goal of a bioequivalence study is to achieve the same local concentration profile and thus therapeutic effect in Crohn’s disease patients. Although investigating local and systemic BE in the CD patient population can be challenging, valuable insights can be obtained through the power of PBPK modeling. In this study, BE in local GI tracts and plasma simulated in CD patients based on lumen and enterocyte were examined. As with healthy volunteers, the lumen layer tends to give similar BE results with the enterocyte compartment; a BE heatmap for the enterocyte layer was prepared and depicted in <xref rid="pharmaceutics-15-02237-f010" ref-type="fig">Figure 10</xref>.</p><p>Similar to the observations in the healthy population, C<sub>max</sub> tends to yield more negative BE results in plasma, whereas AUC<sub>0-last</sub> is associated with higher negative rate in local GI tracts. However, for CD patients, almost all virtual formulations showed bioequivalence in plasma. In the systemic BE point of view, <italic toggle="yes">f</italic><sub>2</sub> of 50 seems to be a reliable indicator of bioequivalence. Nevertheless, more simulations with formulations having <italic toggle="yes">f</italic><sub>2</sub> values lower than 50 need to be conducted to confirm the conclusion.</p><p>Regarding sensitivity along the GI tract, as observed in healthy subjects, the upper intestinal tract (duodenum, jejunum and ileum 1) in CD patients was observed to be more sensitive to changes in formulation, compared with plasma and colon. The observations in ileum sections of patients are significantly different from that in healthy populations. For CD patients, the conservative area restricted to ileum 4, where three formulations with <italic toggle="yes">f</italic><sub>2</sub> &gt; 65.5 showed local bioequivalence. Most parts of the ileum (ileum 1–3) are sensitive to the formulations. To achieve local bioequivalence in almost the entire ileum, an <italic toggle="yes">f</italic><sub>2</sub> higher than 75.8 might be required, which means only a 3% increase at each sampling time point is tolerated in the dissolution profile. As for another important target area, the colon, it seems to be the most conservative GI segment in patients. All three formulations with <italic toggle="yes">f</italic><sub>2</sub> &gt; 65.5 (+5%, +3% and −5%) and one formulation with <italic toggle="yes">f</italic><sub>2</sub> = 50.8 (−10%) showed bioequivalence in this area.</p><p>Concerning formulations with altered trigger pH, it seems that such changes could be well tolerated in the ileum and colon sections of CD patients, since all these segments showed bioequivalence results.</p><p>Based on these simulation results on altered dissolution rate and trigger pH, local concentrations in the ileum and colon sections were very sensitive to changes in the dissolution rate of formulations, which could not be reflected by clinical BE study based on PK profiles. To ensure qualified products being provided to patients, attention should be given to carefully characterize the dissolution profile; a product-specific higher <italic toggle="yes">f</italic><sub>2</sub> (75.8) might be needed for QC of Entocort<sup>®</sup> EC to ensure an appropriate BE in CD patients.</p></sec></sec><sec sec-type="discussion" id="sec4-pharmaceutics-15-02237"><title>4. Discussion</title><p>This current work describes the development and validation of PBPK models for Entocort<sup>®</sup> EC, which is a locally acting GI formulation treating Crohn’s disease in the ileum and ascending colon. Model parameters were carefully adjusted to reflect the actual movement of budesonide pellets along the GI tract, as well as regional absorption in local GI sections. The final model successfully recovered regional absorption in the colon, ileum and jejunum, along with the systemic exposure after oral administration. After validation against clinical PK profiles in healthy subjects and CD patients, virtual bioequivalence between Entocort<sup>®</sup> EC and eight virtual formulations was simulated, and BE heatmaps based on systematic and local exposure were prepared. Through advanced modeling methods, bioequivalence at the site of action and its correlation with the upstream dissolution and downstream system exposure under various scenarios were simulated and explored.</p><p>For GI local action drugs with measurable systemic exposure (like Entocort<sup>®</sup> EC), the quality of products or qualification of generic drugs are controlled by the in vitro dissolution profile and by a clinical BE trial. A minimum <italic toggle="yes">f</italic><sub>2</sub> of 50 is required for the dissolution of the new batch or generic drug under investigation [<xref rid="B27-pharmaceutics-15-02237" ref-type="bibr">27</xref>]. Our simulation results suggested that an <italic toggle="yes">f</italic><sub>2</sub> of 50 is not sufficient to ensure systemic BE in healthy volunteers, but it appears to be an appropriate cutoff value to ensure BE in the plasma of CD patients. For the correlation between <italic toggle="yes">f</italic><sub>2</sub> and local BE, due to the varied sensitivity of GI sections to formulation change, different <italic toggle="yes">f</italic><sub>2</sub> standards should be applied based on the target GI sections. For drugs targeting the ileum and colon sections, an <italic toggle="yes">f</italic><sub>2</sub> of 65 seems required to ensure BE in these two sections in healthy volunteers. In contrast, the ileum of CD patients showed very high sensitivity to changes in dissolution rate, and an <italic toggle="yes">f</italic><sub>2</sub> of 75 should be met to achieve ileum BE. The colon section in CD patients showed better tolerance to formulation change compared with the ileum, and an <italic toggle="yes">f</italic><sub>2</sub> of 50 could relate to a certain possibly of colon BE. Combining observations in the ileum and colon together, an <italic toggle="yes">f</italic><sub>2</sub> of 75 might be a better cutoff to ensure local BE in the ileum and colon sections.</p><p>Concerning the validity of clinical bioequivalence studies in demonstrating bioequivalence in local GI tracts, our results suggest that these studies may be useful in identifying formulations that are NBE in the whole GI tract, i.e., formulations show NBE result in systemic circulation are probably NBE in all gastrointestinal segments. However, on the other hand, formulations that show BE results based on systemic exposure could be BE or NBE in GI tracts, depending on the location of the segment of intestine that is of interest. Thus, a clinical BE result should only be the minimum standard for products that tend to be BE in GI segments.</p><p>The major pitfall for the current simulation is that, based on the product specific guidance of Entocort<sup>®</sup> EC, in vitro dissolution studies should cover a series of pH values including pH 4.5 in citric acid and pHs 6.0, 6.5, 6.8, 7.2 and 7.5 in PBS [<xref rid="B29-pharmaceutics-15-02237" ref-type="bibr">29</xref>]. In contrast, the dissolution profiles for budesonide pellets used in the model were collected with FaSSIF medium. The calculated <italic toggle="yes">f</italic><sub>2</sub> for virtual formulations under investigation might be different if the dissolution profiles were collected according to product-specific guidance. But we believe the dissolution profile in FaSSIF could better mimic the actual dissolution behavior of budesonide pellets in the gastrointestinal tract. Moreover, establishing BE in the case of drugs where a metabolite contributes to pharmacological or safety aspects requires further considerations beyond what we have demonstrated here.</p></sec><sec sec-type="conclusions" id="sec5-pharmaceutics-15-02237"><title>5. Conclusions</title><p>Despite such shortcomings for generalization, our results provide a proof-of-concept that local BE does not necessarily parallel systemic BE in the case of drug/formulations acting locally in the GIT. Establishing local BE remains a challenging area that probably requires full and complete clinical studies with pharmacological endpoints in target patients. Our work also suggests that virtual bioequivalence studies conducted with appropriate PBPK models could be used to decide on local BE effectively.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors sincerely acknowledge Daniel Scotcher (Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK) for valuable suggestions on the paper and for his kind help with setting the simulations, access to software and solving various problems. The author is also grateful to Kayode Ogungbenro (Centre for Applied Pharmacokinetic Research, University of Manchester, Manchester, UK) for the kind help with setting the simulations and access to software. Heartfelt thanks to Certara UK Limited (Simcyp Division) that granted access to the Simcyp Simulators through a sponsored academic license (subject to conditions).</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher’s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-15-02237"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics15092237/s1">https://www.mdpi.com/article/10.3390/pharmaceutics15092237/s1</uri>, Model verification using systemic and locally measured concentration profiles.</p><supplementary-material id="pharmaceutics-15-02237-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="pharmaceutics-15-02237-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.R.-H. and C.H.; methodology, A.R.-H., C.H., S.K.C., F.Y.B. and T.S.; software, A.R.-H. and C.H.; validation, C.H. and T.S.; writing—original draft preparation, C.H., T.S. and M.X.; writing—review and editing, A.R.-H., C.H., F.Y.B. and T.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data can be shared up on request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>C.H., T.S. and M.X. are employees of Pharmaron Inc., an R&amp;D service provider for the life sciences industry. S.C., F.Y.B. and A.R.H. are employees of Certara Ltd., a provider of modeling and simulation platforms in the quantitative systems pharmacology sector to academic and industrial institutions. The company had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, and in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-15-02237"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name name-style="western"><surname>Yu</surname><given-names>L.X.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>B.V.</given-names></name>
</person-group><source>FDA Bioequivalence Standards</source><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2014</year></element-citation></ref><ref id="B2-pharmaceutics-15-02237"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>CFR</collab>
</person-group><source>Codes of Federal Regulations</source><comment>Chapter 21, Part 314</comment><publisher-name>CFR</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2021</year></element-citation></ref><ref id="B3-pharmaceutics-15-02237"><label>3.</label><element-citation publication-type="confproc"><person-group person-group-type="author">
<name name-style="western"><surname>Amidon</surname><given-names>G.L.</given-names></name>
</person-group><article-title>Bioequivalence Testing for Locally Acting Gastrointestinal Drugs: Scientific Principles</article-title><source>Proceedings of the FDA Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology</source><conf-loc>Rockville, MD, USA</conf-loc><conf-date>14 April 2004</conf-date></element-citation></ref><ref id="B4-pharmaceutics-15-02237"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Olivares-Morales</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Kamiyama</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Darwich</surname><given-names>A.S.</given-names></name>
<name name-style="western"><surname>Aarons</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>
</person-group><article-title>Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model</article-title><source>Eur. J. Pharm. Sci.</source><year>2015</year><volume>67</volume><fpage>32</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2014.10.018</pub-id><pub-id pub-id-type="pmid">25444842</pub-id></element-citation></ref><ref id="B5-pharmaceutics-15-02237"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Loisios-Konstantinidis</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Cristofoletti</surname><given-names>R.</given-names></name>
<name name-style="western"><surname>Fotaki</surname><given-names>N.</given-names></name>
<name name-style="western"><surname>Turner</surname><given-names>D.B.</given-names></name>
<name name-style="western"><surname>Dressman</surname><given-names>J.</given-names></name>
</person-group><article-title>Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen</article-title><source>Eur. J. Pharm. Sci.</source><year>2020</year><volume>143</volume><fpage>105170</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.105170</pub-id><pub-id pub-id-type="pmid">31783158</pub-id></element-citation></ref><ref id="B6-pharmaceutics-15-02237"><label>6.</label><element-citation publication-type="webpage"><article-title>DrugBank Online</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://go.drugbank.com/drugs/DB01222" ext-link-type="uri">https://go.drugbank.com/drugs/DB01222</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2022-04-12">(accessed on 12 April 2022)</date-in-citation></element-citation></ref><ref id="B7-pharmaceutics-15-02237"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Nunes</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Acosta</surname><given-names>M.B.</given-names></name>
<name name-style="western"><surname>Marin-Jiménez</surname><given-names>I.</given-names></name>
<name name-style="western"><surname>Nos</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Sans</surname><given-names>M.</given-names></name>
</person-group><article-title>Oral locally active steroids in inflammatory bowel disease</article-title><source>J. Crohn’s Colitis</source><year>2013</year><volume>7</volume><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.crohns.2012.06.010</pub-id><pub-id pub-id-type="pmid">22784947</pub-id></element-citation></ref><ref id="B8-pharmaceutics-15-02237"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Andersson</surname><given-names>T.</given-names></name>
</person-group><article-title>Pharmacokinetics of budesonide (Entocort™ EC) capsules for Crohn’s disease</article-title><source>Clin. Pharmacokinet.</source><year>2004</year><volume>43</volume><fpage>803</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">15355126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/00003088-200443120-00003</pub-id></element-citation></ref><ref id="B9-pharmaceutics-15-02237"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wikberg</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ulmius</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Ragnarsson</surname><given-names>G.</given-names></name>
</person-group><article-title>Review article: Targeted drug delivery in treatment of intestinal diseases</article-title><source>Aliment. Pharmacol. Ther.</source><year>1997</year><volume>11</volume><fpage>109</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.1997.tb00815.x</pub-id><pub-id pub-id-type="pmid">9467985</pub-id></element-citation></ref><ref id="B10-pharmaceutics-15-02237"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Thorsson</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Conradson</surname><given-names>T.B.</given-names></name>
</person-group><article-title>Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI</article-title><source>Eur. Respir. J.</source><year>1994</year><volume>7</volume><fpage>1839</fpage><lpage>1844</lpage><pub-id pub-id-type="doi">10.1183/09031936.94.07101839</pub-id><pub-id pub-id-type="pmid">7828694</pub-id></element-citation></ref><ref id="B11-pharmaceutics-15-02237"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Seidegård</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Nyberg</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Borgå</surname><given-names>O.</given-names></name>
</person-group><article-title>Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole</article-title><source>Eur. J. Pharm. Sci.</source><year>2008</year><volume>35</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2008.07.005</pub-id><pub-id pub-id-type="pmid">18706998</pub-id></element-citation></ref><ref id="B12-pharmaceutics-15-02237"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Dilger</surname><given-names>K.</given-names></name>
<name name-style="western"><surname>Halter</surname><given-names>J.R.</given-names></name>
<name name-style="western"><surname>Bertz</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Lopez-Lazaro</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Gratwohl</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Finke</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease</article-title><source>Biol. Blood Marrow Transplant.</source><year>2009</year><volume>15</volume><fpage>336</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2008.12.001</pub-id><pub-id pub-id-type="pmid">19203724</pub-id></element-citation></ref><ref id="B13-pharmaceutics-15-02237"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bengtsson</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Larsson</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Lundin</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Nilsson</surname><given-names>Å.</given-names></name>
<name name-style="western"><surname>Ulmius</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Wollmer</surname><given-names>P.</given-names></name>
</person-group><article-title>A pharmacoscintigraphic evaluation of oral budesonide given as controlled-release (Entocort) capsules</article-title><source>Aliment. Pharmacol. Ther.</source><year>2003</year><volume>17</volume><fpage>525</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01426.x</pub-id><pub-id pub-id-type="pmid">12622761</pub-id></element-citation></ref><ref id="B14-pharmaceutics-15-02237"><label>14.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>FDA</collab>
</person-group><source>New Drug Application Entocort (21-324): Clinical Pharmacology and Biopharmaceutics Review</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2000</year></element-citation></ref><ref id="B15-pharmaceutics-15-02237"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lundin</surname><given-names>P.D.P.</given-names></name>
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Bergstrand</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Ejderhamn</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Linander</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Högberg</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Persson</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Escher</surname><given-names>J.C.</given-names></name>
<name name-style="western"><surname>Lindquist</surname><given-names>B.</given-names></name>
</person-group><article-title>Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn’s disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2003</year><volume>17</volume><fpage>85</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01386.x</pub-id><pub-id pub-id-type="pmid">12492736</pub-id></element-citation></ref><ref id="B16-pharmaceutics-15-02237"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Larsson</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Bergstrand</surname><given-names>M.</given-names></name>
</person-group><article-title>Pharmacokinetics of budesonide controlled-release capsules when taken with omeprazole</article-title><source>Aliment. Pharmacol. Ther.</source><year>2003</year><volume>17</volume><fpage>403</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2003.01431.x</pub-id><pub-id pub-id-type="pmid">12562453</pub-id></element-citation></ref><ref id="B17-pharmaceutics-15-02237"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Seidegård</surname><given-names>J.</given-names></name>
</person-group><article-title>Reduction of the inhibitory effect of ketoconazole on budesonide pharmacokinetics by separation of their time of administration</article-title><source>Clin. Pharmacol. Ther.</source><year>2000</year><volume>68</volume><fpage>13</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.106895</pub-id><pub-id pub-id-type="pmid">10945311</pub-id></element-citation></ref><ref id="B18-pharmaceutics-15-02237"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Seidegård</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Simonsson</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
</person-group><article-title>Effect of an oral contraceptive on the plasma levels of budesonide and prednisolone and the influence on plasma cortisol</article-title><source>Clin. Pharmacol. Ther.</source><year>2000</year><volume>67</volume><fpage>373</fpage><lpage>381</lpage><pub-id pub-id-type="doi">10.1067/mcp.2000.105762</pub-id><pub-id pub-id-type="pmid">10801246</pub-id></element-citation></ref><ref id="B19-pharmaceutics-15-02237"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Seidegård</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Randvall</surname><given-names>G.</given-names></name>
<name name-style="western"><surname>Nyberg</surname><given-names>L.</given-names></name>
<name name-style="western"><surname>Borga</surname><given-names>O.</given-names></name>
</person-group><article-title>Grapefruit juice interaction with oral budesonide: Equal effect on immediate-release and delayed-release formulations</article-title><source>Pharmazie</source><year>2009</year><volume>64</volume><fpage>461</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">19694184</pub-id></element-citation></ref><ref id="B20-pharmaceutics-15-02237"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Lundin</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Naber</surname><given-names>T.</given-names></name>
<name name-style="western"><surname>Nilsson</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Edsbäcker</surname><given-names>S.</given-names></name>
</person-group><article-title>Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn’s disease</article-title><source>Aliment. Pharmacol. Ther.</source><year>2001</year><volume>15</volume><fpage>45</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2001.00910.x</pub-id><pub-id pub-id-type="pmid">11136277</pub-id></element-citation></ref><ref id="B21-pharmaceutics-15-02237"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Wilson</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Tirona</surname><given-names>R.G.</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>R.B.</given-names></name>
</person-group><article-title>CYP3A4 activity is markedly lower in patients with Crohn’s disease</article-title><source>Inflamm. Bowel Dis.</source><year>2017</year><volume>23</volume><fpage>804</fpage><lpage>813</lpage><pub-id pub-id-type="doi">10.1097/MIB.0000000000001062</pub-id><pub-id pub-id-type="pmid">28301431</pub-id></element-citation></ref><ref id="B22-pharmaceutics-15-02237"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Effinger</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>O’Driscoll</surname><given-names>C.M.</given-names></name>
<name name-style="western"><surname>McAllister</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Fotaki</surname><given-names>N.</given-names></name>
</person-group><article-title>Predicting budesonide performance in healthy subjects and patients with Crohn’s disease using biorelevant in vitro dissolution testing and PBPK modeling</article-title><source>Eur. J. Pharm. Sci.</source><year>2021</year><volume>157</volume><fpage>105617</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2020.105617</pub-id><pub-id pub-id-type="pmid">33164838</pub-id></element-citation></ref><ref id="B23-pharmaceutics-15-02237"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Alrubia</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Mao</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Barber</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>
</person-group><article-title>Altered bioavailability and pharmacokinetics in Crohn’s disease: Capturing systems parameters for PBPK to assist with predicting the fate of orally administered drugs</article-title><source>Clin. Pharmacokinet.</source><year>2022</year><volume>61</volume><fpage>1365</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1007/s40262-022-01169-4</pub-id><pub-id pub-id-type="pmid">36056298</pub-id><pub-id pub-id-type="pmcid">PMC9553790</pub-id></element-citation></ref><ref id="B24-pharmaceutics-15-02237"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Fagerberg</surname><given-names>J.H.</given-names></name>
<name name-style="western"><surname>Sjögren</surname><given-names>E.</given-names></name>
<name name-style="western"><surname>Bergström</surname><given-names>C.A.S.</given-names></name>
</person-group><article-title>Concomitant intake of alcohol may increase the absorption of poorly soluble drugs</article-title><source>Eur. J. Pharm. Sci.</source><year>2015</year><volume>67</volume><fpage>12</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2014.10.017</pub-id><pub-id pub-id-type="pmid">25444841</pub-id></element-citation></ref><ref id="B25-pharmaceutics-15-02237"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Robinson</surname><given-names>G.M.</given-names></name>
<name name-style="western"><surname>Orrego</surname><given-names>H.</given-names></name>
<name name-style="western"><surname>Israel</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Devenyi</surname><given-names>P.</given-names></name>
<name name-style="western"><surname>Kapur</surname><given-names>B.M.</given-names></name>
</person-group><article-title>Low-molecular-weight polyethylene glycol as a probe of gastrointestinal permeability after alcohol ingestion</article-title><source>Dig. Dis. Sci.</source><year>1981</year><volume>26</volume><fpage>971</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1007/BF01314757</pub-id><pub-id pub-id-type="pmid">7297377</pub-id></element-citation></ref><ref id="B26-pharmaceutics-15-02237"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name>
<name name-style="western"><surname>Huo</surname><given-names>M.</given-names></name>
<name name-style="western"><surname>Zhou</surname><given-names>J.</given-names></name>
<name name-style="western"><surname>Zou</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Li</surname><given-names>W.</given-names></name>
<name name-style="western"><surname>Yao</surname><given-names>C.</given-names></name>
<name name-style="western"><surname>Xie</surname><given-names>S.</given-names></name>
</person-group><article-title>DDSolver: An add-In program for modeling and comparison of drug dissolution profiles</article-title><source>AAPS J.</source><year>2010</year><volume>12</volume><fpage>263</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1208/s12248-010-9185-1</pub-id><pub-id pub-id-type="pmid">20373062</pub-id><pub-id pub-id-type="pmcid">PMC2895453</pub-id></element-citation></ref><ref id="B27-pharmaceutics-15-02237"><label>27.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>FDA</collab>
</person-group><source>SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>1995</year></element-citation></ref><ref id="B28-pharmaceutics-15-02237"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name name-style="western"><surname>Alrubia</surname><given-names>S.</given-names></name>
<name name-style="western"><surname>Al-Majdoub</surname><given-names>Z.M.</given-names></name>
<name name-style="western"><surname>Achour</surname><given-names>B.</given-names></name>
<name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A.</given-names></name>
<name name-style="western"><surname>Barber</surname><given-names>J.</given-names></name>
</person-group><article-title>Quantitative assessment of the impact of Crohn’s disease on protein abundance of human intestinal drug-metabolising enzymes and transporters</article-title><source>J. Pharm. Sci.</source><year>2022</year><volume>111</volume><fpage>2917</fpage><lpage>2929</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2022.07.012</pub-id><pub-id pub-id-type="pmid">35872023</pub-id></element-citation></ref><ref id="B29-pharmaceutics-15-02237"><label>29.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>FDA</collab>
</person-group><source>Draft Guidance on Budesonide</source><publisher-name>FDA</publisher-name><publisher-loc>Silver Spring, MD, USA</publisher-loc><year>2021</year></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-15-02237-f001" orientation="portrait"><label>Figure 1</label><caption><p>Workflow of the PBPK model and virtual bioequivalence in this study. PE: parameter estimation; MW: molecular weight; f<sub>u</sub>: unbound fraction; BP: blood plasma; IV: intravenous; Pgp: P-glycoprotein; PO: by mouth; LSA: local sensitivity analysis; SI: small intestine; HSA: human serum albumin; BE: bioequivalence; NCA: noncompartmental analysis; HV: healthy volunteer; CD: Crohn’s disease; BP: blood plasma, PPB: plasma.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g001.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f002" orientation="portrait"><label>Figure 2</label><caption><p>Dissolution profiles for the reference and virtual test formulations. Blue thick line with dot: dissolution profile of reference formulation collected from reference [<xref rid="B22-pharmaceutics-15-02237" ref-type="bibr">22</xref>]; thin line: formulations showing faster dissolution rate compared with reference; dotted line: formulations with slower dissolution rate; +20%: formulation with 20% more dissolution than reference at every sampling time point, and so on; <italic toggle="yes">f</italic><sub>2:</sub> similarity factor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g002.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f003" orientation="portrait"><label>Figure 3</label><caption><p>Example bioequivalence bar chart based on C<sub>max</sub>. Gray dotted line: 80% and 125%; black dots: geometric mean of test versus reference in GI segments; red square: geometric mean of test versus reference in plasma; bar: 90% confidence of the geometric mean of test over reference. GMR: geometric mean of test/reference; CI: confidence interval. Duo: duodenum; Jej1 and Jej2: jejunum sections 1 and 2; Ile1, Ile2, Ile3 and Ile4: ileum sections 1 to 4; Col: colon.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g003.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f004" orientation="portrait"><label>Figure 4</label><caption><p>Coloring and naming rule for the heatmap. Positive: bioequivalent; negative: not bioequivalent; true: local GI segment consistent with plasma, colored in green; false: local GI in consistent with plasma, colored in red.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g004.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f005" orientation="portrait"><label>Figure 5</label><caption><p>BE heatmap of 8 virtual formulations based on AUC and C<sub>max</sub> in the enterocyte layer of GI sections and plasma in the healthy population. Percentage in the box indicates the incidence of BE result in 10 trials. Y indicates BE in plasma. N means NBE in plasma. Green: local BE result consistent with that in plasma. Red: local BE result inconsistent with plasma. Cells with 3D bevel effect: not BE in local GI section. Flat cells: BE locally.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g005.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f006" orientation="portrait"><label>Figure 6</label><caption><p>BE heatmap of 8 virtual formulations based on the combined results of AUC and C<sub>max</sub> in the enterocyte layer of GI sections and plasma in the healthy population. Y indicates BE in GI segments and plasma. N means NBE in GI segments and plasma. Green: local BE result consistent with that in plasma. Red: local BE result inconsistent with plasma. Cells with 3D bevel effect: not BE in local GI section. Flat cells: BE locally.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g006.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f007" orientation="portrait"><label>Figure 7</label><caption><p>BE bar charts (based on C<sub>max</sub>) of the +10% formulation in 10 trials. Gray dotted line: 80% and 125%; black dots: geometric mean of test versus reference in GI segments; red square: geometric mean of test versus reference in plasma; bar: 90% confidence of the geometric mean of test over reference. GMR: geometric mean of test/reference; CI: confidence interval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g007.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f008" orientation="portrait"><label>Figure 8</label><caption><p>BE bar charts (based on C<sub>max</sub>) of the −10% formulation in 10 trials. Gray dotted line: 80% and 125%; black dots: geometric mean of test versus reference in GI segments; red square: geometric mean of test versus reference in plasma; bar: 90% confidence of the geometric mean of test over reference. GMR: geometric mean of test/reference; CI: confidence interval.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g008.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f009" orientation="portrait"><label>Figure 9</label><caption><p>BE heatmap of 8 virtual formulations based on AUC and C<sub>max</sub> in the lumen layer of GI sections and plasma in the healthy population. Percentage in the box indicates the incidence of BE result in 10 trials. Y indicates BE in plasma. N means NBE in plasma. Green: local BE result consistent with that in plasma. Red: local BE result inconsistent with plasma. Cells with 3D bevel effect: not BE in local GI section. Flat cells: BE locally.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g009.jpg"/></fig><fig position="float" id="pharmaceutics-15-02237-f010" orientation="portrait"><label>Figure 10</label><caption><p>BE heatmap of 8 virtual formulations based on AUC and C<sub>max</sub> in the enterocyte layer of GI sections and plasma in Crohn’s disease patients. Percentage in the box indicates the incidence of a BE result in 10 trials. Y indicates BE in plasma. N means NBE in plasma. Green: local BE result consistent with that in plasma. Red: local BE result inconsistent with plasma. Cells with 3D bevel effect: not BE in local GI section. Flat cells: BE locally.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceutics-15-02237-g010.jpg"/></fig><table-wrap position="float" id="pharmaceutics-15-02237-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of clinical studies used for model development (1–4) and validation (5–10) in healthy subjects and validation (11, 12) in CD patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">No. of Subjects (Gender) <sup>a</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Age</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weight (Kg)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">IV</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (M); 12 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">22–53</td><td align="center" valign="middle" rowspan="1" colspan="1">45–92</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B10-pharmaceutics-15-02237" ref-type="bibr">10</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution (local)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 mg (1 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (M)</td><td align="center" valign="middle" rowspan="1" colspan="1">20–44</td><td align="center" valign="middle" rowspan="1" colspan="1">63–111</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B11-pharmaceutics-15-02237" ref-type="bibr">11</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution</td><td align="center" valign="middle" rowspan="1" colspan="1">3 mg (10 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (M); 6 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">43.7 ± 7.1</td><td align="center" valign="middle" rowspan="1" colspan="1">71.5 ± 10.3</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B12-pharmaceutics-15-02237" ref-type="bibr">12</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">18 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (M)</td><td align="center" valign="middle" rowspan="1" colspan="1">40–53</td><td align="center" valign="middle" rowspan="1" colspan="1">77–94</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B13-pharmaceutics-15-02237" ref-type="bibr">13</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">3, 9, 15 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (M); 8 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B14-pharmaceutics-15-02237" ref-type="bibr">14</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (M)</td><td align="center" valign="middle" rowspan="1" colspan="1">43–56</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B15-pharmaceutics-15-02237" ref-type="bibr">15</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">9 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (M); 6 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">21–42</td><td align="center" valign="middle" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B16-pharmaceutics-15-02237" ref-type="bibr">16</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">3 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (M)</td><td align="center" valign="middle" rowspan="1" colspan="1">22–40</td><td align="center" valign="middle" rowspan="1" colspan="1">85 (66–107)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B17-pharmaceutics-15-02237" ref-type="bibr">17</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">19–38</td><td align="center" valign="middle" rowspan="1" colspan="1">61.5 (46–86)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B18-pharmaceutics-15-02237" ref-type="bibr">18</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">3 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">8 (M)</td><td align="center" valign="middle" rowspan="1" colspan="1">20–42</td><td align="center" valign="middle" rowspan="1" colspan="1">75 (60–91)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B19-pharmaceutics-15-02237" ref-type="bibr">19</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">9 mg</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (M); 4 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">24–50</td><td align="center" valign="middle" rowspan="1" colspan="1">BMI 24.9 (18.5–29.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B20-pharmaceutics-15-02237" ref-type="bibr">20</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (M); 7 (F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25–70</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">57.4–104</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B21-pharmaceutics-15-02237" ref-type="bibr">21</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> M: male; F: female.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-02237-t002" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t002_Table 2</object-id><label>Table 2</label><caption><p>Similarity factor and Weibull function parameters for Entocort<sup>®</sup> EC and virtual formulations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Formulation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">f</italic>
<sub>2</sub>
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Similarity between R and T</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">F<sub>max</sub></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">α</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">β</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Trigger pH</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">3.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">+20%</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">36.1</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">N</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">1.53</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">0.87</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+10%</td><td align="center" valign="middle" rowspan="1" colspan="1">50.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Y</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.14</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+5%</td><td align="center" valign="middle" rowspan="1" colspan="1">65.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Y</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.56</td><td align="center" valign="middle" rowspan="1" colspan="1">0.91</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">+3%</td><td align="center" valign="middle" rowspan="1" colspan="1">75.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Y</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">2.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.92</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">−5%</td><td align="center" valign="middle" rowspan="1" colspan="1">65.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Y</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">3.90</td><td align="center" valign="middle" rowspan="1" colspan="1">1.01</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">−10%</td><td align="center" valign="middle" rowspan="1" colspan="1">50.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Y</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">5.01</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09</td><td align="center" valign="middle" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">pH threshold = 5</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">100</td><td align="center" valign="middle" rowspan="1" colspan="1">3.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pH threshold = 6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.94</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-15-02237-t003" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t003_Table 3</object-id><label>Table 3</label><caption><p>Parameters included in LSA and corresponding ranges.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Parameters</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ranges Covered by LSA</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Range in HV</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Reported Ranges in CD Patients</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B22-pharmaceutics-15-02237" ref-type="bibr">22</xref>]</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-15-02237" ref-type="bibr">23</xref>]</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-15-02237" ref-type="bibr">28</xref>]</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gastric MRT (h)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27–2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0–2.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.26 (Active); 0.3 (Inactive)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI MRT (h)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4–6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3–6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.2 (Active); 3.2 (Inactive)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver CYP3A4 abundance<break/>(pmol/mg protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34.35–137</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">137</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.5 (M), 45.75 (F) (low); <break/>38.49 (M), 55.91 (F) (high)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55.4 (M); 80.5 (F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SI CYP3A4 abundance (nmol/SI)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6–65.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60.53 (low);<break/>98.53 (high)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.6 (Inflamed);<break/>15.6 (Noninflamed)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSA (g/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30–50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.34 (M);<break/>49.38 (F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31.72 (M), 27.2 (F) (low);<break/>41 (high)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Study one: 30.13 (M); 25.2 (F)<break/>Study two: 44.8 (M); 43.9 (F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon CYP3A4 abundance<break/>(nmol/colon)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2–1.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2 (Inflamed);<break/>0.5 (Noninflamed)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Transporter abundance<break/>(pmol/mg total membrane protein)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jejunum I:<break/>0.075–0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jejunum I:<break/>0.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ileum I–IV:1.2<break/>Colon: 0.17 (Active);<break/>0.55 (Inactive)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jejunum I:<break/>0.12 (Inflamed); 0.075 (Noninflamed)</td></tr></tbody></table><table-wrap-foot><fn><p>M: male; F: female; MRT: mean residence time; SI: small intestine; HSA: human serum albumin. HV: healthy volunteers; CD: Crohn’s disease. High: Crohn’s disease high level population reflecting the high level for each parameter. Low: Crohn’s disease low level population reflecting the low level for each parameter. Active: Crohn’s disease is active and lead to symptoms like pain, diarrhea or fatigue. Inactive: Crohn’s disease is in remission and no more symptoms. Inflamed: Inflamed intestinal segments taken from active CD patients undergoing ileocolonic resection. Noninflamed: histologically normal intestinal segments taken from active CD patients undergoing ileocolonic resection.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-02237-t004" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t004_Table 4</object-id><label>Table 4</label><caption><p>Demographic parameters that were adjusted to build the CD population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">HV</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">CD</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Liver CYP3A4 abundance (pmol/mg protein)</td><td align="center" valign="middle" rowspan="1" colspan="1">137</td><td align="center" valign="middle" rowspan="1" colspan="1">55.4 (M); 80.5 (F)</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-15-02237" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">SI CYP3A4 abundance (nmol/SI)</td><td align="center" valign="middle" rowspan="1" colspan="1">65.4</td><td align="center" valign="middle" rowspan="1" colspan="1">8.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-15-02237" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Colon CYP3A4 abundance (nmol/colon)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.99</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-15-02237" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSA (g/L)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50.34 (M); 49.38 (F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30.13 (M); 25.2 (F)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-pharmaceutics-15-02237" ref-type="bibr">23</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: HV: healthy volunteers. CD: Crohn’s disease patients. HV data were default settings in Simcyp database.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-02237-t005" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t005_Table 5</object-id><label>Table 5</label><caption><p>Within-subject variability used in VBE studies of Entocort<sup>®</sup> EC.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameters</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Variation (CV%)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Minimum Limit</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Parameter Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Maximum Limit</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fasted MRT Stomach Fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">38.217</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01</td><td align="center" valign="middle" rowspan="1" colspan="1">0.27</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fasted MRT SI Fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">21.132</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">3.4</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male WColon MRT Fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">44.962</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">37.5</td><td align="center" valign="middle" rowspan="1" colspan="1">240</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male AColon MRT Fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">44.962</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">18.91</td><td align="center" valign="middle" rowspan="1" colspan="1">72</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Female WColon MRT Fluid</td><td align="center" valign="middle" rowspan="1" colspan="1">44.962</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">55.75</td><td align="center" valign="middle" rowspan="1" colspan="1">240</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female AColon MRT Fluid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.962</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23.11</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">72</td></tr></tbody></table><table-wrap-foot><fn><p>MRT: mean residence time; WColon: whole colon; AColon: ascending colon.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-02237-t006" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t006_Table 6</object-id><label>Table 6</label><caption><p>Overview of predicted and observed PK parameters and calculated fold error.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Clinical <break/>Study</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Subject</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Formulation</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Dose<break/>(mg)</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Observed Values</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Simulated Values</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Ratio: sim/obs</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0–t</sub><break/>(nM × h)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub><break/>(nM)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0-t</sub><break/>(nM × h)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub><break/>(nM)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AUC<sub>0–t</sub></th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max</sub></th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">IV bolus</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">15.27</td><td align="center" valign="middle" rowspan="1" colspan="1">11.1</td><td align="center" valign="middle" rowspan="1" colspan="1">12.66</td><td align="center" valign="middle" rowspan="1" colspan="1">9.12</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2-1</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution (Jejunum) *</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 (1 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.52</td><td align="center" valign="middle" rowspan="1" colspan="1">3.14</td><td align="center" valign="middle" rowspan="1" colspan="1">8.19</td><td align="center" valign="middle" rowspan="1" colspan="1">3.38</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">1.08</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2-2</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution (Ileum) *</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 (1 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">11.77</td><td align="center" valign="middle" rowspan="1" colspan="1">5.31</td><td align="center" valign="middle" rowspan="1" colspan="1">11.18</td><td align="center" valign="middle" rowspan="1" colspan="1">5.19</td><td align="center" valign="middle" rowspan="1" colspan="1">0.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.98</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2-3</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution (Colon) *</td><td align="center" valign="middle" rowspan="1" colspan="1">2.6 (1 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.56</td><td align="center" valign="middle" rowspan="1" colspan="1">2.36</td><td align="center" valign="middle" rowspan="1" colspan="1">10.05</td><td align="center" valign="middle" rowspan="1" colspan="1">2.44</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17</td><td align="center" valign="middle" rowspan="1" colspan="1">1.03</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Solution (Oral)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (10 mL)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.58</td><td align="center" valign="middle" rowspan="1" colspan="1">2.15</td><td align="center" valign="middle" rowspan="1" colspan="1">8.30</td><td align="center" valign="middle" rowspan="1" colspan="1">1.84</td><td align="center" valign="middle" rowspan="1" colspan="1">1.26</td><td align="center" valign="middle" rowspan="1" colspan="1">0.86</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">51.49</td><td align="center" valign="middle" rowspan="1" colspan="1">5.92</td><td align="center" valign="middle" rowspan="1" colspan="1">54.78</td><td align="center" valign="middle" rowspan="1" colspan="1">5.74</td><td align="center" valign="middle" rowspan="1" colspan="1">1.06</td><td align="center" valign="middle" rowspan="1" colspan="1">0.97</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5-1</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">12.98</td><td align="center" valign="middle" rowspan="1" colspan="1">1.77</td><td align="center" valign="middle" rowspan="1" colspan="1">9.17</td><td align="center" valign="middle" rowspan="1" colspan="1">0.96</td><td align="center" valign="middle" rowspan="1" colspan="1">0.71</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5-2</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">38.65</td><td align="center" valign="middle" rowspan="1" colspan="1">3.74</td><td align="center" valign="middle" rowspan="1" colspan="1">27.68</td><td align="center" valign="middle" rowspan="1" colspan="1">2.95</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72</td><td align="center" valign="middle" rowspan="1" colspan="1">0.79</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5-3</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">59.37</td><td align="center" valign="middle" rowspan="1" colspan="1">7.08</td><td align="center" valign="middle" rowspan="1" colspan="1">45.83</td><td align="center" valign="middle" rowspan="1" colspan="1">4.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77</td><td align="center" valign="middle" rowspan="1" colspan="1">0.68</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">18.72</td><td align="center" valign="middle" rowspan="1" colspan="1">2.21</td><td align="center" valign="middle" rowspan="1" colspan="1">14.06</td><td align="center" valign="middle" rowspan="1" colspan="1">1.47</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">26.41</td><td align="center" valign="middle" rowspan="1" colspan="1">4.18</td><td align="center" valign="middle" rowspan="1" colspan="1">21.47</td><td align="center" valign="middle" rowspan="1" colspan="1">2.80</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">12.24</td><td align="center" valign="middle" rowspan="1" colspan="1">1.16</td><td align="center" valign="middle" rowspan="1" colspan="1">8.23</td><td align="center" valign="middle" rowspan="1" colspan="1">0.87</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67</td><td align="center" valign="middle" rowspan="1" colspan="1">0.75</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">4.5</td><td align="center" valign="middle" rowspan="1" colspan="1">13.15</td><td align="center" valign="middle" rowspan="1" colspan="1">1.39</td><td align="center" valign="middle" rowspan="1" colspan="1">14.03</td><td align="center" valign="middle" rowspan="1" colspan="1">1.45</td><td align="center" valign="middle" rowspan="1" colspan="1">1.07</td><td align="center" valign="middle" rowspan="1" colspan="1">1.04</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">HV</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">11.75</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28</td><td align="center" valign="middle" rowspan="1" colspan="1">8.23</td><td align="center" valign="middle" rowspan="1" colspan="1">0.88</td><td align="center" valign="middle" rowspan="1" colspan="1">0.70</td><td align="center" valign="middle" rowspan="1" colspan="1">0.69</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">CD patients</td><td align="center" valign="middle" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">27.27</td><td align="center" valign="middle" rowspan="1" colspan="1">4.32</td><td align="center" valign="middle" rowspan="1" colspan="1">45.35</td><td align="center" valign="middle" rowspan="1" colspan="1">5.39</td><td align="center" valign="middle" rowspan="1" colspan="1">1.66</td><td align="center" valign="middle" rowspan="1" colspan="1">1.25</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Entocort<sup>®</sup> EC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.35</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.99</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.93</td></tr></tbody></table><table-wrap-foot><fn><p>* Simulated with regional absorption scalars before applying a coefficient of 0.6.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="pharmaceutics-15-02237-t007" orientation="portrait"><object-id pub-id-type="pii">pharmaceutics-15-02237-t007_Table 7</object-id><label>Table 7</label><caption><p>Simulated t<sub>max</sub> and C<sub>max</sub> in plasma and different sections of the GI tract.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Endpoint</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">t<sub>max</sub> (h)<break/>Lumen/Enterocyte</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max,lumen</sub> (nM)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">C<sub>max,enterocyte</sub> (nM)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Plasma</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Duodenum</td><td align="center" valign="middle" rowspan="1" colspan="1">1/0.5</td><td align="center" valign="middle" rowspan="1" colspan="1">459</td><td align="center" valign="middle" rowspan="1" colspan="1">2.67</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jejunum I</td><td align="center" valign="middle" rowspan="1" colspan="1">1/1</td><td align="center" valign="middle" rowspan="1" colspan="1">10,455</td><td align="center" valign="middle" rowspan="1" colspan="1">43.2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Jejunum II</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">16,745</td><td align="center" valign="middle" rowspan="1" colspan="1">31.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ileum I</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">20,767</td><td align="center" valign="middle" rowspan="1" colspan="1">102</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ileum II</td><td align="center" valign="middle" rowspan="1" colspan="1">3/2</td><td align="center" valign="middle" rowspan="1" colspan="1">17,769</td><td align="center" valign="middle" rowspan="1" colspan="1">91.1</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ileum III</td><td align="center" valign="middle" rowspan="1" colspan="1">3/3</td><td align="center" valign="middle" rowspan="1" colspan="1">17,825</td><td align="center" valign="middle" rowspan="1" colspan="1">83.3</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Ileum IV</td><td align="center" valign="middle" rowspan="1" colspan="1">3/3</td><td align="center" valign="middle" rowspan="1" colspan="1">15,935</td><td align="center" valign="middle" rowspan="1" colspan="1">75.2</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6/6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">152,267</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1092</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>